US20230392215A1 - Biomarkers for cancer immunotherapy outcomes - Google Patents
Biomarkers for cancer immunotherapy outcomes Download PDFInfo
- Publication number
- US20230392215A1 US20230392215A1 US18/325,497 US202318325497A US2023392215A1 US 20230392215 A1 US20230392215 A1 US 20230392215A1 US 202318325497 A US202318325497 A US 202318325497A US 2023392215 A1 US2023392215 A1 US 2023392215A1
- Authority
- US
- United States
- Prior art keywords
- cells
- compared
- cancer
- control
- cell
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000090 biomarker Substances 0.000 title description 3
- 238000002619 cancer immunotherapy Methods 0.000 title 1
- 230000014509 gene expression Effects 0.000 claims abstract description 309
- 238000000034 method Methods 0.000 claims abstract description 149
- 210000001744 T-lymphocyte Anatomy 0.000 claims abstract description 135
- 210000001616 monocyte Anatomy 0.000 claims abstract description 108
- 230000001965 increasing effect Effects 0.000 claims description 182
- 108090000623 proteins and genes Proteins 0.000 claims description 178
- 210000004027 cell Anatomy 0.000 claims description 171
- 206010028980 Neoplasm Diseases 0.000 claims description 114
- 102100036011 T-cell surface glycoprotein CD4 Human genes 0.000 claims description 96
- 201000011510 cancer Diseases 0.000 claims description 88
- 239000012270 PD-1 inhibitor Substances 0.000 claims description 71
- 239000012668 PD-1-inhibitor Substances 0.000 claims description 71
- 229940121655 pd-1 inhibitor Drugs 0.000 claims description 71
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 claims description 39
- 108700018351 Major Histocompatibility Complex Proteins 0.000 claims description 38
- 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 claims description 38
- 230000003247 decreasing effect Effects 0.000 claims description 35
- 238000012174 single-cell RNA sequencing Methods 0.000 claims description 33
- 101000961071 Homo sapiens NF-kappa-B inhibitor alpha Proteins 0.000 claims description 32
- 102100039337 NF-kappa-B inhibitor alpha Human genes 0.000 claims description 32
- 102100023050 Nuclear factor NF-kappa-B p105 subunit Human genes 0.000 claims description 32
- 101001076431 Homo sapiens NF-kappa-B inhibitor zeta Proteins 0.000 claims description 31
- 101150053046 MYD88 gene Proteins 0.000 claims description 31
- 102100026009 NF-kappa-B inhibitor zeta Human genes 0.000 claims description 31
- 101000979342 Homo sapiens Nuclear factor NF-kappa-B p105 subunit Proteins 0.000 claims description 30
- 102100024134 Myeloid differentiation primary response protein MyD88 Human genes 0.000 claims description 30
- 210000005259 peripheral blood Anatomy 0.000 claims description 30
- 239000011886 peripheral blood Substances 0.000 claims description 30
- 238000000684 flow cytometry Methods 0.000 claims description 26
- 210000001266 CD8-positive T-lymphocyte Anatomy 0.000 claims description 22
- 230000030833 cell death Effects 0.000 claims description 21
- 239000012636 effector Substances 0.000 claims description 21
- 238000004519 manufacturing process Methods 0.000 claims description 18
- 206010017993 Gastrointestinal neoplasms Diseases 0.000 claims description 17
- 102100035875 C-C chemokine receptor type 5 Human genes 0.000 claims description 15
- 101710149870 C-C chemokine receptor type 5 Proteins 0.000 claims description 15
- 102100032367 C-C motif chemokine 5 Human genes 0.000 claims description 15
- 101000797762 Homo sapiens C-C motif chemokine 5 Proteins 0.000 claims description 15
- 101000611183 Homo sapiens Tumor necrosis factor Proteins 0.000 claims description 15
- 238000010199 gene set enrichment analysis Methods 0.000 claims description 15
- 230000000638 stimulation Effects 0.000 claims description 14
- 101710149815 C-C chemokine receptor type 2 Proteins 0.000 claims description 13
- 101000916050 Homo sapiens C-X-C chemokine receptor type 3 Proteins 0.000 claims description 13
- 108060006678 I-kappa-B kinase Proteins 0.000 claims description 13
- 102000001284 I-kappa-B kinase Human genes 0.000 claims description 13
- 230000003325 follicular Effects 0.000 claims description 13
- 102100028990 C-X-C chemokine receptor type 3 Human genes 0.000 claims description 12
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims description 12
- 108010050568 HLA-DM antigens Proteins 0.000 claims description 12
- 102100035904 Caspase-1 Human genes 0.000 claims description 11
- 206010009944 Colon cancer Diseases 0.000 claims description 11
- 101000715398 Homo sapiens Caspase-1 Proteins 0.000 claims description 11
- 102100026548 Caspase-8 Human genes 0.000 claims description 10
- 101000983528 Homo sapiens Caspase-8 Proteins 0.000 claims description 10
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 10
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 10
- 238000003757 reverse transcription PCR Methods 0.000 claims description 10
- 238000003196 serial analysis of gene expression Methods 0.000 claims description 10
- GTVAUHXUMYENSK-RWSKJCERSA-N 2-[3-[(1r)-3-(3,4-dimethoxyphenyl)-1-[(2s)-1-[(2s)-2-(3,4,5-trimethoxyphenyl)pent-4-enoyl]piperidine-2-carbonyl]oxypropyl]phenoxy]acetic acid Chemical compound C1=C(OC)C(OC)=CC=C1CC[C@H](C=1C=C(OCC(O)=O)C=CC=1)OC(=O)[C@H]1N(C(=O)[C@@H](CC=C)C=2C=C(OC)C(OC)=C(OC)C=2)CCCC1 GTVAUHXUMYENSK-RWSKJCERSA-N 0.000 claims description 9
- 206010004593 Bile duct cancer Diseases 0.000 claims description 9
- 108090000397 Caspase 3 Proteins 0.000 claims description 9
- 102100029855 Caspase-3 Human genes 0.000 claims description 9
- 102100038902 Caspase-7 Human genes 0.000 claims description 9
- 101000741014 Homo sapiens Caspase-7 Proteins 0.000 claims description 9
- 101001082065 Homo sapiens Interferon-induced protein with tetratricopeptide repeats 1 Proteins 0.000 claims description 9
- 101001136986 Homo sapiens Proteasome subunit beta type-8 Proteins 0.000 claims description 9
- 101001057508 Homo sapiens Ubiquitin-like protein ISG15 Proteins 0.000 claims description 9
- 102100027355 Interferon-induced protein with tetratricopeptide repeats 1 Human genes 0.000 claims description 9
- 102100035760 Proteasome subunit beta type-8 Human genes 0.000 claims description 9
- 102100027266 Ubiquitin-like protein ISG15 Human genes 0.000 claims description 9
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 9
- 201000002528 pancreatic cancer Diseases 0.000 claims description 9
- 229960002621 pembrolizumab Drugs 0.000 claims description 9
- 101001034846 Homo sapiens Interferon-induced transmembrane protein 3 Proteins 0.000 claims description 8
- 101000705759 Homo sapiens Proteasome activator complex subunit 2 Proteins 0.000 claims description 8
- 101001028730 Homo sapiens Transcription factor JunB Proteins 0.000 claims description 8
- 102100040035 Interferon-induced transmembrane protein 3 Human genes 0.000 claims description 8
- 102100031299 Proteasome activator complex subunit 2 Human genes 0.000 claims description 8
- 102100037168 Transcription factor JunB Human genes 0.000 claims description 8
- 108010047933 Tumor Necrosis Factor alpha-Induced Protein 3 Proteins 0.000 claims description 8
- 102100036659 26S proteasome non-ATPase regulatory subunit 9 Human genes 0.000 claims description 7
- 102100028972 HLA class I histocompatibility antigen, A alpha chain Human genes 0.000 claims description 7
- 108010075704 HLA-A Antigens Proteins 0.000 claims description 7
- 101001136710 Homo sapiens 26S proteasome non-ATPase regulatory subunit 9 Proteins 0.000 claims description 7
- 101001082070 Homo sapiens Interferon alpha-inducible protein 6 Proteins 0.000 claims description 7
- 101000959664 Homo sapiens Interferon-induced protein 44-like Proteins 0.000 claims description 7
- 101000595746 Homo sapiens Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform Proteins 0.000 claims description 7
- 101001105486 Homo sapiens Proteasome subunit alpha type-7 Proteins 0.000 claims description 7
- 102100027354 Interferon alpha-inducible protein 6 Human genes 0.000 claims description 7
- 102100039953 Interferon-induced protein 44-like Human genes 0.000 claims description 7
- 102100036056 Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform Human genes 0.000 claims description 7
- 102100021201 Proteasome subunit alpha type-7 Human genes 0.000 claims description 7
- 102100040247 Tumor necrosis factor Human genes 0.000 claims description 7
- 102100028976 HLA class I histocompatibility antigen, B alpha chain Human genes 0.000 claims description 6
- 102100028971 HLA class I histocompatibility antigen, C alpha chain Human genes 0.000 claims description 6
- 102100033079 HLA class II histocompatibility antigen, DM alpha chain Human genes 0.000 claims description 6
- 102100031258 HLA class II histocompatibility antigen, DM beta chain Human genes 0.000 claims description 6
- 102100031618 HLA class II histocompatibility antigen, DP beta 1 chain Human genes 0.000 claims description 6
- 102100036242 HLA class II histocompatibility antigen, DQ alpha 2 chain Human genes 0.000 claims description 6
- 102100036241 HLA class II histocompatibility antigen, DQ beta 1 chain Human genes 0.000 claims description 6
- 102100040505 HLA class II histocompatibility antigen, DR alpha chain Human genes 0.000 claims description 6
- 102100040485 HLA class II histocompatibility antigen, DRB1 beta chain Human genes 0.000 claims description 6
- 108010058607 HLA-B Antigens Proteins 0.000 claims description 6
- 108010052199 HLA-C Antigens Proteins 0.000 claims description 6
- 108010045483 HLA-DPB1 antigen Proteins 0.000 claims description 6
- 108010086786 HLA-DQA1 antigen Proteins 0.000 claims description 6
- 108010065026 HLA-DQB1 antigen Proteins 0.000 claims description 6
- 108010067802 HLA-DR alpha-Chains Proteins 0.000 claims description 6
- 108010039343 HLA-DRB1 Chains Proteins 0.000 claims description 6
- 101000830568 Homo sapiens Tumor necrosis factor alpha-induced protein 2 Proteins 0.000 claims description 6
- 238000000636 Northern blotting Methods 0.000 claims description 6
- 102100024595 Tumor necrosis factor alpha-induced protein 2 Human genes 0.000 claims description 6
- 229940121420 cemiplimab Drugs 0.000 claims description 6
- 238000002509 fluorescent in situ hybridization Methods 0.000 claims description 6
- 238000013394 immunophenotyping Methods 0.000 claims description 6
- 238000002493 microarray Methods 0.000 claims description 6
- 229960003301 nivolumab Drugs 0.000 claims description 6
- 102100029966 HLA class II histocompatibility antigen, DP alpha 1 chain Human genes 0.000 claims description 5
- 108010093061 HLA-DPA1 antigen Proteins 0.000 claims description 5
- 206010062878 Gastrooesophageal cancer Diseases 0.000 claims description 4
- 201000006974 gastroesophageal cancer Diseases 0.000 claims description 4
- 102100031151 C-C chemokine receptor type 2 Human genes 0.000 claims description 3
- 230000002829 reductive effect Effects 0.000 claims description 3
- 230000004614 tumor growth Effects 0.000 claims description 3
- 102000007150 Tumor Necrosis Factor alpha-Induced Protein 3 Human genes 0.000 claims 2
- 210000002443 helper t lymphocyte Anatomy 0.000 claims 2
- 238000011282 treatment Methods 0.000 abstract description 77
- 238000009169 immunotherapy Methods 0.000 abstract description 56
- 210000002865 immune cell Anatomy 0.000 abstract description 31
- 230000004044 response Effects 0.000 abstract description 25
- 230000004043 responsiveness Effects 0.000 abstract description 6
- 230000001976 improved effect Effects 0.000 abstract description 4
- 238000011224 anti-cancer immunotherapy Methods 0.000 abstract 1
- 101000716102 Homo sapiens T-cell surface glycoprotein CD4 Proteins 0.000 description 88
- 101000946843 Homo sapiens T-cell surface glycoprotein CD8 alpha chain Proteins 0.000 description 67
- 102100034922 T-cell surface glycoprotein CD8 alpha chain Human genes 0.000 description 67
- 230000000694 effects Effects 0.000 description 56
- 102000014150 Interferons Human genes 0.000 description 54
- 108010050904 Interferons Proteins 0.000 description 54
- -1 cell death Proteins 0.000 description 54
- 229940079322 interferon Drugs 0.000 description 51
- 238000002512 chemotherapy Methods 0.000 description 48
- 239000000523 sample Substances 0.000 description 48
- 230000037361 pathway Effects 0.000 description 45
- 102000004169 proteins and genes Human genes 0.000 description 45
- 235000018102 proteins Nutrition 0.000 description 40
- 102100040678 Programmed cell death protein 1 Human genes 0.000 description 39
- 230000011664 signaling Effects 0.000 description 38
- 101710089372 Programmed cell death protein 1 Proteins 0.000 description 36
- 201000010099 disease Diseases 0.000 description 34
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 34
- 238000011319 anticancer therapy Methods 0.000 description 29
- 239000003112 inhibitor Substances 0.000 description 25
- 230000004913 activation Effects 0.000 description 19
- 238000001994 activation Methods 0.000 description 19
- 208000024891 symptom Diseases 0.000 description 17
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 16
- 239000003102 growth factor Substances 0.000 description 16
- 230000019491 signal transduction Effects 0.000 description 16
- 230000004069 differentiation Effects 0.000 description 15
- 239000005557 antagonist Substances 0.000 description 13
- 150000001413 amino acids Chemical class 0.000 description 12
- 230000006870 function Effects 0.000 description 12
- 108090000765 processed proteins & peptides Proteins 0.000 description 12
- 238000012545 processing Methods 0.000 description 12
- 238000004458 analytical method Methods 0.000 description 11
- 150000001875 compounds Chemical class 0.000 description 11
- 230000003827 upregulation Effects 0.000 description 11
- 102000004196 processed proteins & peptides Human genes 0.000 description 10
- 238000001990 intravenous administration Methods 0.000 description 9
- 239000003550 marker Substances 0.000 description 9
- 230000009467 reduction Effects 0.000 description 9
- 230000004083 survival effect Effects 0.000 description 9
- 238000012360 testing method Methods 0.000 description 9
- 238000002560 therapeutic procedure Methods 0.000 description 9
- 230000008859 change Effects 0.000 description 8
- 210000004443 dendritic cell Anatomy 0.000 description 8
- 230000005764 inhibitory process Effects 0.000 description 8
- 229920001184 polypeptide Polymers 0.000 description 8
- 238000001959 radiotherapy Methods 0.000 description 8
- 238000003860 storage Methods 0.000 description 8
- 239000000126 substance Substances 0.000 description 8
- 238000001356 surgical procedure Methods 0.000 description 8
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 7
- 101000861454 Homo sapiens Protein c-Fos Proteins 0.000 description 7
- 102100027584 Protein c-Fos Human genes 0.000 description 7
- 239000000556 agonist Substances 0.000 description 7
- 230000000875 corresponding effect Effects 0.000 description 7
- 230000007423 decrease Effects 0.000 description 7
- 229960002949 fluorouracil Drugs 0.000 description 7
- 210000001519 tissue Anatomy 0.000 description 7
- YXTKHLHCVFUPPT-YYFJYKOTSA-N (2s)-2-[[4-[(2-amino-5-formyl-4-oxo-1,6,7,8-tetrahydropteridin-6-yl)methylamino]benzoyl]amino]pentanedioic acid;(1r,2r)-1,2-dimethanidylcyclohexane;5-fluoro-1h-pyrimidine-2,4-dione;oxalic acid;platinum(2+) Chemical compound [Pt+2].OC(=O)C(O)=O.[CH2-][C@@H]1CCCC[C@H]1[CH2-].FC1=CNC(=O)NC1=O.C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 YXTKHLHCVFUPPT-YYFJYKOTSA-N 0.000 description 6
- 108010074328 Interferon-gamma Proteins 0.000 description 6
- 108010044012 STAT1 Transcription Factor Proteins 0.000 description 6
- 102100029904 Signal transducer and activator of transcription 1-alpha/beta Human genes 0.000 description 6
- 101150043341 Socs3 gene Proteins 0.000 description 6
- 108700027337 Suppressor of Cytokine Signaling 3 Proteins 0.000 description 6
- 102100024283 Suppressor of cytokine signaling 3 Human genes 0.000 description 6
- 102100024596 Tumor necrosis factor alpha-induced protein 3 Human genes 0.000 description 6
- 239000002246 antineoplastic agent Substances 0.000 description 6
- 229960000190 bacillus calmette–guérin vaccine Drugs 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- 239000003814 drug Substances 0.000 description 6
- 210000003743 erythrocyte Anatomy 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 230000002496 gastric effect Effects 0.000 description 6
- 238000005259 measurement Methods 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- 210000000822 natural killer cell Anatomy 0.000 description 6
- UQNRTPFLTRZEIM-MRWUDIQNSA-N (2s)-2-amino-3-hydroxy-n-[2-methoxy-5-[(z)-2-(3,4,5-trimethoxyphenyl)ethenyl]phenyl]propanamide;hydrochloride Chemical compound Cl.C1=C(NC(=O)[C@@H](N)CO)C(OC)=CC=C1\C=C/C1=CC(OC)=C(OC)C(OC)=C1 UQNRTPFLTRZEIM-MRWUDIQNSA-N 0.000 description 5
- 108010074708 B7-H1 Antigen Proteins 0.000 description 5
- 102100036301 C-C chemokine receptor type 7 Human genes 0.000 description 5
- 102100039498 Cytotoxic T-lymphocyte protein 4 Human genes 0.000 description 5
- 102000004190 Enzymes Human genes 0.000 description 5
- 108090000790 Enzymes Proteins 0.000 description 5
- 101000716065 Homo sapiens C-C chemokine receptor type 7 Proteins 0.000 description 5
- 101000889276 Homo sapiens Cytotoxic T-lymphocyte protein 4 Proteins 0.000 description 5
- 101000598002 Homo sapiens Interferon regulatory factor 1 Proteins 0.000 description 5
- 206010061218 Inflammation Diseases 0.000 description 5
- 108010014726 Interferon Type I Proteins 0.000 description 5
- 102000002227 Interferon Type I Human genes 0.000 description 5
- 102100036981 Interferon regulatory factor 1 Human genes 0.000 description 5
- 102000008070 Interferon-gamma Human genes 0.000 description 5
- 241001467552 Mycobacterium bovis BCG Species 0.000 description 5
- 102100024216 Programmed cell death 1 ligand 1 Human genes 0.000 description 5
- 101150045565 Socs1 gene Proteins 0.000 description 5
- 108700027336 Suppressor of Cytokine Signaling 1 Proteins 0.000 description 5
- 102100024779 Suppressor of cytokine signaling 1 Human genes 0.000 description 5
- 208000027418 Wounds and injury Diseases 0.000 description 5
- 239000013543 active substance Substances 0.000 description 5
- 238000013459 approach Methods 0.000 description 5
- 239000012472 biological sample Substances 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 230000006378 damage Effects 0.000 description 5
- 238000009826 distribution Methods 0.000 description 5
- 229960004679 doxorubicin Drugs 0.000 description 5
- 229940088598 enzyme Drugs 0.000 description 5
- 230000001747 exhibiting effect Effects 0.000 description 5
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 description 5
- 230000002757 inflammatory effect Effects 0.000 description 5
- 230000004054 inflammatory process Effects 0.000 description 5
- 230000028709 inflammatory response Effects 0.000 description 5
- 230000002401 inhibitory effect Effects 0.000 description 5
- 208000014674 injury Diseases 0.000 description 5
- 230000003993 interaction Effects 0.000 description 5
- 210000003071 memory t lymphocyte Anatomy 0.000 description 5
- 230000005012 migration Effects 0.000 description 5
- 238000013508 migration Methods 0.000 description 5
- 230000007170 pathology Effects 0.000 description 5
- 230000003405 preventing effect Effects 0.000 description 5
- 230000002265 prevention Effects 0.000 description 5
- 238000011870 unpaired t-test Methods 0.000 description 5
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 4
- YMZPQKXPKZZSFV-CPWYAANMSA-N 2-[3-[(1r)-1-[(2s)-1-[(2s)-2-[(1r)-cyclohex-2-en-1-yl]-2-(3,4,5-trimethoxyphenyl)acetyl]piperidine-2-carbonyl]oxy-3-(3,4-dimethoxyphenyl)propyl]phenoxy]acetic acid Chemical compound C1=C(OC)C(OC)=CC=C1CC[C@H](C=1C=C(OCC(O)=O)C=CC=1)OC(=O)[C@H]1N(C(=O)[C@@H]([C@H]2C=CCCC2)C=2C=C(OC)C(OC)=C(OC)C=2)CCCC1 YMZPQKXPKZZSFV-CPWYAANMSA-N 0.000 description 4
- 108010006654 Bleomycin Proteins 0.000 description 4
- 102100031650 C-X-C chemokine receptor type 4 Human genes 0.000 description 4
- 101100113686 Clitocybe nebularis clt4 gene Proteins 0.000 description 4
- 102000004127 Cytokines Human genes 0.000 description 4
- 108090000695 Cytokines Proteins 0.000 description 4
- 102100031480 Dual specificity mitogen-activated protein kinase kinase 1 Human genes 0.000 description 4
- 102100039928 Gamma-interferon-inducible protein 16 Human genes 0.000 description 4
- 102100030595 HLA class II histocompatibility antigen gamma chain Human genes 0.000 description 4
- 101000922348 Homo sapiens C-X-C chemokine receptor type 4 Proteins 0.000 description 4
- 101000960209 Homo sapiens Gamma-interferon-inducible protein 16 Proteins 0.000 description 4
- 101001082627 Homo sapiens HLA class II histocompatibility antigen gamma chain Proteins 0.000 description 4
- 101001011393 Homo sapiens Interferon regulatory factor 2 Proteins 0.000 description 4
- 101000840293 Homo sapiens Interferon-induced protein 44 Proteins 0.000 description 4
- 101001082060 Homo sapiens Interferon-induced protein with tetratricopeptide repeats 3 Proteins 0.000 description 4
- 101001034844 Homo sapiens Interferon-induced transmembrane protein 1 Proteins 0.000 description 4
- 101000733743 Homo sapiens Phorbol-12-myristate-13-acetate-induced protein 1 Proteins 0.000 description 4
- 101001120056 Homo sapiens Phosphatidylinositol 3-kinase regulatory subunit alpha Proteins 0.000 description 4
- 101000933601 Homo sapiens Protein BTG1 Proteins 0.000 description 4
- 101000997835 Homo sapiens Tyrosine-protein kinase JAK1 Proteins 0.000 description 4
- 101000997832 Homo sapiens Tyrosine-protein kinase JAK2 Proteins 0.000 description 4
- 101000617285 Homo sapiens Tyrosine-protein phosphatase non-receptor type 6 Proteins 0.000 description 4
- 101000802101 Homo sapiens mRNA decay activator protein ZFP36L2 Proteins 0.000 description 4
- 102100037850 Interferon gamma Human genes 0.000 description 4
- 102100029838 Interferon regulatory factor 2 Human genes 0.000 description 4
- 102100029607 Interferon-induced protein 44 Human genes 0.000 description 4
- 102100027302 Interferon-induced protein with tetratricopeptide repeats 3 Human genes 0.000 description 4
- 102100040021 Interferon-induced transmembrane protein 1 Human genes 0.000 description 4
- 102000015696 Interleukins Human genes 0.000 description 4
- 108010063738 Interleukins Proteins 0.000 description 4
- 108010000817 Leuprolide Proteins 0.000 description 4
- 229940124647 MEK inhibitor Drugs 0.000 description 4
- 208000032818 Microsatellite Instability Diseases 0.000 description 4
- 108010057466 NF-kappa B Proteins 0.000 description 4
- 102100033716 Phorbol-12-myristate-13-acetate-induced protein 1 Human genes 0.000 description 4
- 102100026169 Phosphatidylinositol 3-kinase regulatory subunit alpha Human genes 0.000 description 4
- 102100026036 Protein BTG1 Human genes 0.000 description 4
- 108010079933 Receptor-Interacting Protein Serine-Threonine Kinase 2 Proteins 0.000 description 4
- 102100022502 Receptor-interacting serine/threonine-protein kinase 2 Human genes 0.000 description 4
- 108010055623 S-Phase Kinase-Associated Proteins Proteins 0.000 description 4
- 108010017324 STAT3 Transcription Factor Proteins 0.000 description 4
- 102100024040 Signal transducer and activator of transcription 3 Human genes 0.000 description 4
- 102100032929 Son of sevenless homolog 1 Human genes 0.000 description 4
- 102100033438 Tyrosine-protein kinase JAK1 Human genes 0.000 description 4
- 102100033444 Tyrosine-protein kinase JAK2 Human genes 0.000 description 4
- 102100021657 Tyrosine-protein phosphatase non-receptor type 6 Human genes 0.000 description 4
- RJURFGZVJUQBHK-UHFFFAOYSA-N actinomycin D Natural products CC1OC(=O)C(C(C)C)N(C)C(=O)CN(C)C(=O)C2CCCN2C(=O)C(C(C)C)NC(=O)C1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)NC4C(=O)NC(C(N5CCCC5C(=O)N(C)CC(=O)N(C)C(C(C)C)C(=O)OC4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-UHFFFAOYSA-N 0.000 description 4
- 230000003213 activating effect Effects 0.000 description 4
- 239000012190 activator Substances 0.000 description 4
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 4
- 239000000427 antigen Substances 0.000 description 4
- 238000003491 array Methods 0.000 description 4
- 210000003719 b-lymphocyte Anatomy 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 230000002255 enzymatic effect Effects 0.000 description 4
- HESCAJZNRMSMJG-HGYUPSKWSA-N epothilone A Natural products O=C1[C@H](C)[C@H](O)[C@H](C)CCC[C@H]2O[C@H]2C[C@@H](/C(=C\c2nc(C)sc2)/C)OC(=O)C[C@H](O)C1(C)C HESCAJZNRMSMJG-HGYUPSKWSA-N 0.000 description 4
- XOZIUKBZLSUILX-GIQCAXHBSA-N epothilone D Chemical compound O1C(=O)C[C@H](O)C(C)(C)C(=O)[C@H](C)[C@@H](O)[C@@H](C)CCC\C(C)=C/C[C@H]1C(\C)=C\C1=CSC(C)=N1 XOZIUKBZLSUILX-GIQCAXHBSA-N 0.000 description 4
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 4
- 229960005277 gemcitabine Drugs 0.000 description 4
- 230000012010 growth Effects 0.000 description 4
- GFIJNRVAKGFPGQ-LIJARHBVSA-N leuprolide Chemical compound CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 GFIJNRVAKGFPGQ-LIJARHBVSA-N 0.000 description 4
- 229960004338 leuprorelin Drugs 0.000 description 4
- 102100034703 mRNA decay activator protein ZFP36L2 Human genes 0.000 description 4
- 238000010801 machine learning Methods 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 238000012544 monitoring process Methods 0.000 description 4
- 210000000581 natural killer T-cell Anatomy 0.000 description 4
- 229960001756 oxaliplatin Drugs 0.000 description 4
- DWAFYCQODLXJNR-BNTLRKBRSA-L oxaliplatin Chemical compound O1C(=O)C(=O)O[Pt]11N[C@@H]2CCCC[C@H]2N1 DWAFYCQODLXJNR-BNTLRKBRSA-L 0.000 description 4
- 210000005134 plasmacytoid dendritic cell Anatomy 0.000 description 4
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 4
- 229920000642 polymer Polymers 0.000 description 4
- DZMVCVHATYROOS-ZBFGKEHZSA-N soblidotin Chemical compound CC(C)[C@H](N(C)C)C(=O)N[C@@H](C(C)C)C(=O)N(C)[C@@H]([C@@H](C)CC)[C@H](OC)CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)NCCC1=CC=CC=C1 DZMVCVHATYROOS-ZBFGKEHZSA-N 0.000 description 4
- 230000009885 systemic effect Effects 0.000 description 4
- WYWHKKSPHMUBEB-UHFFFAOYSA-N tioguanine Chemical compound N1C(N)=NC(=S)C2=C1N=CN2 WYWHKKSPHMUBEB-UHFFFAOYSA-N 0.000 description 4
- 230000002103 transcriptional effect Effects 0.000 description 4
- 229960004528 vincristine Drugs 0.000 description 4
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 4
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 4
- OOKIODJYZSVHDO-QMYFOHRPSA-N (2s)-n-tert-butyl-1-[(2s)-1-[(2s)-2-[[(2s)-2-[[(2s)-2-(dimethylamino)-3-methylbutanoyl]amino]-3-methylbutanoyl]-methylamino]-3-methylbutanoyl]pyrrolidine-2-carbonyl]pyrrolidine-2-carboxamide;hydrochloride Chemical compound Cl.CC(C)[C@H](N(C)C)C(=O)N[C@@H](C(C)C)C(=O)N(C)[C@@H](C(C)C)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(=O)NC(C)(C)C)CCC1 OOKIODJYZSVHDO-QMYFOHRPSA-N 0.000 description 3
- 102100027769 2'-5'-oligoadenylate synthase 1 Human genes 0.000 description 3
- 102100027621 2'-5'-oligoadenylate synthase 2 Human genes 0.000 description 3
- 102100035389 2'-5'-oligoadenylate synthase 3 Human genes 0.000 description 3
- GFMMXOIFOQCCGU-UHFFFAOYSA-N 2-(2-chloro-4-iodoanilino)-N-(cyclopropylmethoxy)-3,4-difluorobenzamide Chemical compound C=1C=C(I)C=C(Cl)C=1NC1=C(F)C(F)=CC=C1C(=O)NOCC1CC1 GFMMXOIFOQCCGU-UHFFFAOYSA-N 0.000 description 3
- GXAFMKJFWWBYNW-OWHBQTKESA-N 2-[3-[(1r)-1-[(2s)-1-[(2s)-3-cyclopropyl-2-(3,4,5-trimethoxyphenyl)propanoyl]piperidine-2-carbonyl]oxy-3-(3,4-dimethoxyphenyl)propyl]phenoxy]acetic acid Chemical compound C1=C(OC)C(OC)=CC=C1CC[C@H](C=1C=C(OCC(O)=O)C=CC=1)OC(=O)[C@H]1N(C(=O)[C@@H](CC2CC2)C=2C=C(OC)C(OC)=C(OC)C=2)CCCC1 GXAFMKJFWWBYNW-OWHBQTKESA-N 0.000 description 3
- NDMPLJNOPCLANR-UHFFFAOYSA-N 3,4-dihydroxy-15-(4-hydroxy-18-methoxycarbonyl-5,18-seco-ibogamin-18-yl)-16-methoxy-1-methyl-6,7-didehydro-aspidospermidine-3-carboxylic acid methyl ester Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 NDMPLJNOPCLANR-UHFFFAOYSA-N 0.000 description 3
- AOJJSUZBOXZQNB-VTZDEGQISA-N 4'-epidoxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-VTZDEGQISA-N 0.000 description 3
- XAUDJQYHKZQPEU-KVQBGUIXSA-N 5-aza-2'-deoxycytidine Chemical compound O=C1N=C(N)N=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 XAUDJQYHKZQPEU-KVQBGUIXSA-N 0.000 description 3
- 102100022089 Acyl-[acyl-carrier-protein] hydrolase Human genes 0.000 description 3
- 102100030346 Antigen peptide transporter 1 Human genes 0.000 description 3
- 101100404726 Arabidopsis thaliana NHX7 gene Proteins 0.000 description 3
- 108700003785 Baculoviral IAP Repeat-Containing 3 Proteins 0.000 description 3
- 102100021662 Baculoviral IAP repeat-containing protein 3 Human genes 0.000 description 3
- 102100027314 Beta-2-microglobulin Human genes 0.000 description 3
- 101150104237 Birc3 gene Proteins 0.000 description 3
- 101000964894 Bos taurus 14-3-3 protein zeta/delta Proteins 0.000 description 3
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 3
- 102100034798 CCAAT/enhancer-binding protein beta Human genes 0.000 description 3
- 102100034799 CCAAT/enhancer-binding protein delta Human genes 0.000 description 3
- 102100032912 CD44 antigen Human genes 0.000 description 3
- FVLVBPDQNARYJU-XAHDHGMMSA-N C[C@H]1CCC(CC1)NC(=O)N(CCCl)N=O Chemical compound C[C@H]1CCC(CC1)NC(=O)N(CCCl)N=O FVLVBPDQNARYJU-XAHDHGMMSA-N 0.000 description 3
- 108010037462 Cyclooxygenase 2 Proteins 0.000 description 3
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 3
- 102100032218 Cytokine-inducible SH2-containing protein Human genes 0.000 description 3
- 108010092160 Dactinomycin Proteins 0.000 description 3
- 102100034289 Deoxynucleoside triphosphate triphosphohydrolase SAMHD1 Human genes 0.000 description 3
- 102100023266 Dual specificity mitogen-activated protein kinase kinase 2 Human genes 0.000 description 3
- 102100027088 Dual specificity protein phosphatase 5 Human genes 0.000 description 3
- 102100027274 Dual specificity protein phosphatase 6 Human genes 0.000 description 3
- 102100035813 E3 ubiquitin-protein ligase CBL Human genes 0.000 description 3
- 102100023991 E3 ubiquitin-protein ligase DTX3L Human genes 0.000 description 3
- HTIJFSOGRVMCQR-UHFFFAOYSA-N Epirubicin Natural products COc1cccc2C(=O)c3c(O)c4CC(O)(CC(OC5CC(N)C(=O)C(C)O5)c4c(O)c3C(=O)c12)C(=O)CO HTIJFSOGRVMCQR-UHFFFAOYSA-N 0.000 description 3
- 101000914063 Eucalyptus globulus Leafy/floricaula homolog FL1 Proteins 0.000 description 3
- 102100028121 Fos-related antigen 2 Human genes 0.000 description 3
- 102100027346 GTP cyclohydrolase 1 Human genes 0.000 description 3
- 102100029974 GTPase HRas Human genes 0.000 description 3
- 102100021736 Galectin-1 Human genes 0.000 description 3
- 102100033067 Growth factor receptor-bound protein 2 Human genes 0.000 description 3
- 102100035688 Guanylate-binding protein 1 Human genes 0.000 description 3
- 102100028538 Guanylate-binding protein 4 Human genes 0.000 description 3
- 102000001554 Hemoglobins Human genes 0.000 description 3
- 108010054147 Hemoglobins Proteins 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 101001008907 Homo sapiens 2'-5'-oligoadenylate synthase 1 Proteins 0.000 description 3
- 101001008910 Homo sapiens 2'-5'-oligoadenylate synthase 2 Proteins 0.000 description 3
- 101000597332 Homo sapiens 2'-5'-oligoadenylate synthase 3 Proteins 0.000 description 3
- 101000824278 Homo sapiens Acyl-[acyl-carrier-protein] hydrolase Proteins 0.000 description 3
- 101000937544 Homo sapiens Beta-2-microglobulin Proteins 0.000 description 3
- 101000945963 Homo sapiens CCAAT/enhancer-binding protein beta Proteins 0.000 description 3
- 101000945965 Homo sapiens CCAAT/enhancer-binding protein delta Proteins 0.000 description 3
- 101000868273 Homo sapiens CD44 antigen Proteins 0.000 description 3
- 101001057612 Homo sapiens Dual specificity protein phosphatase 5 Proteins 0.000 description 3
- 101001057587 Homo sapiens Dual specificity protein phosphatase 6 Proteins 0.000 description 3
- 101000904542 Homo sapiens E3 ubiquitin-protein ligase DTX3L Proteins 0.000 description 3
- 101000877395 Homo sapiens ETS-related transcription factor Elf-1 Proteins 0.000 description 3
- 101000967216 Homo sapiens Eosinophil cationic protein Proteins 0.000 description 3
- 101001059934 Homo sapiens Fos-related antigen 2 Proteins 0.000 description 3
- 101000862581 Homo sapiens GTP cyclohydrolase 1 Proteins 0.000 description 3
- 101000584633 Homo sapiens GTPase HRas Proteins 0.000 description 3
- 101000871017 Homo sapiens Growth factor receptor-bound protein 2 Proteins 0.000 description 3
- 101001001336 Homo sapiens Guanylate-binding protein 1 Proteins 0.000 description 3
- 101001058851 Homo sapiens Guanylate-binding protein 4 Proteins 0.000 description 3
- 101001046870 Homo sapiens Hypoxia-inducible factor 1-alpha Proteins 0.000 description 3
- 101001056180 Homo sapiens Induced myeloid leukemia cell differentiation protein Mcl-1 Proteins 0.000 description 3
- 101001077600 Homo sapiens Insulin receptor substrate 2 Proteins 0.000 description 3
- 101000599852 Homo sapiens Intercellular adhesion molecule 1 Proteins 0.000 description 3
- 101000852865 Homo sapiens Interferon alpha/beta receptor 2 Proteins 0.000 description 3
- 101000599940 Homo sapiens Interferon gamma Proteins 0.000 description 3
- 101001032342 Homo sapiens Interferon regulatory factor 7 Proteins 0.000 description 3
- 101000998500 Homo sapiens Interferon-induced 35 kDa protein Proteins 0.000 description 3
- 101001128393 Homo sapiens Interferon-induced GTP-binding protein Mx1 Proteins 0.000 description 3
- 101001082058 Homo sapiens Interferon-induced protein with tetratricopeptide repeats 2 Proteins 0.000 description 3
- 101001082063 Homo sapiens Interferon-induced protein with tetratricopeptide repeats 5 Proteins 0.000 description 3
- 101001034842 Homo sapiens Interferon-induced transmembrane protein 2 Proteins 0.000 description 3
- 101001057504 Homo sapiens Interferon-stimulated gene 20 kDa protein Proteins 0.000 description 3
- 101001033312 Homo sapiens Interleukin-4 receptor subunit alpha Proteins 0.000 description 3
- 101001043809 Homo sapiens Interleukin-7 receptor subunit alpha Proteins 0.000 description 3
- 101001139126 Homo sapiens Krueppel-like factor 6 Proteins 0.000 description 3
- 101001064870 Homo sapiens Lon protease homolog, mitochondrial Proteins 0.000 description 3
- 101001052493 Homo sapiens Mitogen-activated protein kinase 1 Proteins 0.000 description 3
- 101001052490 Homo sapiens Mitogen-activated protein kinase 3 Proteins 0.000 description 3
- 101001055091 Homo sapiens Mitogen-activated protein kinase kinase kinase 8 Proteins 0.000 description 3
- 101000946889 Homo sapiens Monocyte differentiation antigen CD14 Proteins 0.000 description 3
- 101001030211 Homo sapiens Myc proto-oncogene protein Proteins 0.000 description 3
- 101000844245 Homo sapiens Non-receptor tyrosine-protein kinase TYK2 Proteins 0.000 description 3
- 101000605639 Homo sapiens Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform Proteins 0.000 description 3
- 101000952078 Homo sapiens Probable ATP-dependent RNA helicase DDX60 Proteins 0.000 description 3
- 101000611936 Homo sapiens Programmed cell death protein 1 Proteins 0.000 description 3
- 101000705756 Homo sapiens Proteasome activator complex subunit 1 Proteins 0.000 description 3
- 101001136888 Homo sapiens Proteasome subunit alpha type-3 Proteins 0.000 description 3
- 101001124792 Homo sapiens Proteasome subunit beta type-10 Proteins 0.000 description 3
- 101001136981 Homo sapiens Proteasome subunit beta type-9 Proteins 0.000 description 3
- 101000876829 Homo sapiens Protein C-ets-1 Proteins 0.000 description 3
- 101000898093 Homo sapiens Protein C-ets-2 Proteins 0.000 description 3
- 101000931462 Homo sapiens Protein FosB Proteins 0.000 description 3
- 101001098560 Homo sapiens Proteinase-activated receptor 2 Proteins 0.000 description 3
- 101000779418 Homo sapiens RAC-alpha serine/threonine-protein kinase Proteins 0.000 description 3
- 101000712530 Homo sapiens RAF proto-oncogene serine/threonine-protein kinase Proteins 0.000 description 3
- 101000999079 Homo sapiens Radiation-inducible immediate-early gene IEX-1 Proteins 0.000 description 3
- 101001081220 Homo sapiens RanBP-type and C3HC4-type zinc finger-containing protein 1 Proteins 0.000 description 3
- 101000595531 Homo sapiens Serine/threonine-protein kinase pim-1 Proteins 0.000 description 3
- 101000596334 Homo sapiens TSC22 domain family protein 1 Proteins 0.000 description 3
- 101000881764 Homo sapiens Transcription elongation factor 1 homolog Proteins 0.000 description 3
- 101000766332 Homo sapiens Tribbles homolog 1 Proteins 0.000 description 3
- 101000611023 Homo sapiens Tumor necrosis factor receptor superfamily member 6 Proteins 0.000 description 3
- 101000662026 Homo sapiens Ubiquitin-like modifier-activating enzyme 7 Proteins 0.000 description 3
- 101000761740 Homo sapiens Ubiquitin/ISG15-conjugating enzyme E2 L6 Proteins 0.000 description 3
- 101000808011 Homo sapiens Vascular endothelial growth factor A Proteins 0.000 description 3
- 101000795753 Homo sapiens mRNA decay activator protein ZFP36 Proteins 0.000 description 3
- 102100022875 Hypoxia-inducible factor 1-alpha Human genes 0.000 description 3
- 108010044240 IFIH1 Interferon-Induced Helicase Proteins 0.000 description 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 3
- 102100026539 Induced myeloid leukemia cell differentiation protein Mcl-1 Human genes 0.000 description 3
- 102100025092 Insulin receptor substrate 2 Human genes 0.000 description 3
- 102100037877 Intercellular adhesion molecule 1 Human genes 0.000 description 3
- 102100036718 Interferon alpha/beta receptor 2 Human genes 0.000 description 3
- 102100036157 Interferon gamma receptor 2 Human genes 0.000 description 3
- 102100038070 Interferon regulatory factor 7 Human genes 0.000 description 3
- 102100033273 Interferon-induced 35 kDa protein Human genes 0.000 description 3
- 102100031802 Interferon-induced GTP-binding protein Mx1 Human genes 0.000 description 3
- 102100027353 Interferon-induced helicase C domain-containing protein 1 Human genes 0.000 description 3
- 102100027303 Interferon-induced protein with tetratricopeptide repeats 2 Human genes 0.000 description 3
- 102100027356 Interferon-induced protein with tetratricopeptide repeats 5 Human genes 0.000 description 3
- 102100040020 Interferon-induced transmembrane protein 2 Human genes 0.000 description 3
- 102100027268 Interferon-stimulated gene 20 kDa protein Human genes 0.000 description 3
- 108010002350 Interleukin-2 Proteins 0.000 description 3
- 102000000588 Interleukin-2 Human genes 0.000 description 3
- 102100039078 Interleukin-4 receptor subunit alpha Human genes 0.000 description 3
- 102100021593 Interleukin-7 receptor subunit alpha Human genes 0.000 description 3
- 102100020679 Krueppel-like factor 6 Human genes 0.000 description 3
- 239000005517 L01XE01 - Imatinib Substances 0.000 description 3
- 108010023335 Member 2 Subfamily B ATP Binding Cassette Transporter Proteins 0.000 description 3
- 102100024193 Mitogen-activated protein kinase 1 Human genes 0.000 description 3
- 102100024192 Mitogen-activated protein kinase 3 Human genes 0.000 description 3
- 102100026907 Mitogen-activated protein kinase kinase kinase 8 Human genes 0.000 description 3
- 102100035877 Monocyte differentiation antigen CD14 Human genes 0.000 description 3
- 102100038895 Myc proto-oncogene protein Human genes 0.000 description 3
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 3
- 206010029260 Neuroblastoma Diseases 0.000 description 3
- 102100032028 Non-receptor tyrosine-protein kinase TYK2 Human genes 0.000 description 3
- 102100038332 Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform Human genes 0.000 description 3
- 102100037439 Probable ATP-dependent RNA helicase DDX60 Human genes 0.000 description 3
- 102100038280 Prostaglandin G/H synthase 2 Human genes 0.000 description 3
- 206010060862 Prostate cancer Diseases 0.000 description 3
- 102100031300 Proteasome activator complex subunit 1 Human genes 0.000 description 3
- 102100035908 Proteasome subunit alpha type-3 Human genes 0.000 description 3
- 102100029081 Proteasome subunit beta type-10 Human genes 0.000 description 3
- 102100035764 Proteasome subunit beta type-9 Human genes 0.000 description 3
- 102100035251 Protein C-ets-1 Human genes 0.000 description 3
- 102100021890 Protein C-ets-2 Human genes 0.000 description 3
- 102100020847 Protein FosB Human genes 0.000 description 3
- 102100037132 Proteinase-activated receptor 2 Human genes 0.000 description 3
- 102100033810 RAC-alpha serine/threonine-protein kinase Human genes 0.000 description 3
- 102100033479 RAF proto-oncogene serine/threonine-protein kinase Human genes 0.000 description 3
- 102100036900 Radiation-inducible immediate-early gene IEX-1 Human genes 0.000 description 3
- 102100027716 RanBP-type and C3HC4-type zinc finger-containing protein 1 Human genes 0.000 description 3
- 108700019718 SAM Domain and HD Domain-Containing Protein 1 Proteins 0.000 description 3
- 101150114242 SAMHD1 gene Proteins 0.000 description 3
- 102100022340 SHC-transforming protein 1 Human genes 0.000 description 3
- 102000005155 SKP1 Human genes 0.000 description 3
- 108700022176 SOS1 Proteins 0.000 description 3
- 108010081691 STAT2 Transcription Factor Proteins 0.000 description 3
- 101100379220 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) API2 gene Proteins 0.000 description 3
- 101100197320 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) RPL35A gene Proteins 0.000 description 3
- OTKJDMGTUTTYMP-ROUUACIJSA-N Safingol ( L-threo-sphinganine) Chemical compound CCCCCCCCCCCCCCC[C@H](O)[C@@H](N)CO OTKJDMGTUTTYMP-ROUUACIJSA-N 0.000 description 3
- 102100036077 Serine/threonine-protein kinase pim-1 Human genes 0.000 description 3
- 102100023978 Signal transducer and activator of transcription 2 Human genes 0.000 description 3
- 101150100839 Sos1 gene Proteins 0.000 description 3
- 102100035051 TSC22 domain family protein 1 Human genes 0.000 description 3
- FOCVUCIESVLUNU-UHFFFAOYSA-N Thiotepa Chemical compound C1CN1P(N1CC1)(=S)N1CC1 FOCVUCIESVLUNU-UHFFFAOYSA-N 0.000 description 3
- 208000024770 Thyroid neoplasm Diseases 0.000 description 3
- 102100037116 Transcription elongation factor 1 homolog Human genes 0.000 description 3
- 108010040625 Transforming Protein 1 Src Homology 2 Domain-Containing Proteins 0.000 description 3
- 102100026387 Tribbles homolog 1 Human genes 0.000 description 3
- 102100037938 Ubiquitin-like modifier-activating enzyme 7 Human genes 0.000 description 3
- 102100024843 Ubiquitin/ISG15-conjugating enzyme E2 L6 Human genes 0.000 description 3
- 102100039037 Vascular endothelial growth factor A Human genes 0.000 description 3
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 3
- 229960001220 amsacrine Drugs 0.000 description 3
- XCPGHVQEEXUHNC-UHFFFAOYSA-N amsacrine Chemical compound COC1=CC(NS(C)(=O)=O)=CC=C1NC1=C(C=CC=C2)C2=NC2=CC=CC=C12 XCPGHVQEEXUHNC-UHFFFAOYSA-N 0.000 description 3
- 108091007433 antigens Proteins 0.000 description 3
- 102000036639 antigens Human genes 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 229960001561 bleomycin Drugs 0.000 description 3
- OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 description 3
- 238000004422 calculation algorithm Methods 0.000 description 3
- 230000033077 cellular process Effects 0.000 description 3
- 229960004630 chlorambucil Drugs 0.000 description 3
- JCKYGMPEJWAADB-UHFFFAOYSA-N chlorambucil Chemical compound OC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 JCKYGMPEJWAADB-UHFFFAOYSA-N 0.000 description 3
- 229960004397 cyclophosphamide Drugs 0.000 description 3
- 210000004292 cytoskeleton Anatomy 0.000 description 3
- XOZIUKBZLSUILX-UHFFFAOYSA-N desoxyepothilone B Natural products O1C(=O)CC(O)C(C)(C)C(=O)C(C)C(O)C(C)CCCC(C)=CCC1C(C)=CC1=CSC(C)=N1 XOZIUKBZLSUILX-UHFFFAOYSA-N 0.000 description 3
- OFDNQWIFNXBECV-VFSYNPLYSA-N dolastatin 10 Chemical compound CC(C)[C@H](N(C)C)C(=O)N[C@@H](C(C)C)C(=O)N(C)[C@@H]([C@@H](C)CC)[C@H](OC)CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@H](C=1SC=CN=1)CC1=CC=CC=C1 OFDNQWIFNXBECV-VFSYNPLYSA-N 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 229960001904 epirubicin Drugs 0.000 description 3
- 229940011871 estrogen Drugs 0.000 description 3
- 239000000262 estrogen Substances 0.000 description 3
- 239000000328 estrogen antagonist Substances 0.000 description 3
- KLEPCGBEXOCIGS-XUZZJYLKSA-N ethyl N-[4-[[(2S,4S)-2-(imidazol-1-ylmethyl)-2-(4-methoxyphenyl)-1,3-dioxolan-4-yl]methylsulfanyl]phenyl]carbamate Chemical compound C1=CC(NC(=O)OCC)=CC=C1SC[C@H]1O[C@](CN2C=NC=C2)(C=2C=CC(OC)=CC=2)OC1 KLEPCGBEXOCIGS-XUZZJYLKSA-N 0.000 description 3
- 229960005420 etoposide Drugs 0.000 description 3
- 229960000752 etoposide phosphate Drugs 0.000 description 3
- LIQODXNTTZAGID-OCBXBXKTSA-N etoposide phosphate Chemical compound COC1=C(OP(O)(O)=O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 LIQODXNTTZAGID-OCBXBXKTSA-N 0.000 description 3
- GIUYCYHIANZCFB-FJFJXFQQSA-N fludarabine phosphate Chemical compound C1=NC=2C(N)=NC(F)=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]1O GIUYCYHIANZCFB-FJFJXFQQSA-N 0.000 description 3
- 108020001507 fusion proteins Proteins 0.000 description 3
- 102000037865 fusion proteins Human genes 0.000 description 3
- KTUFNOKKBVMGRW-UHFFFAOYSA-N imatinib Chemical compound C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 KTUFNOKKBVMGRW-UHFFFAOYSA-N 0.000 description 3
- 108010085650 interferon gamma receptor Proteins 0.000 description 3
- 229940047124 interferons Drugs 0.000 description 3
- 229940047122 interleukins Drugs 0.000 description 3
- GURKHSYORGJETM-WAQYZQTGSA-N irinotecan hydrochloride (anhydrous) Chemical compound Cl.C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 GURKHSYORGJETM-WAQYZQTGSA-N 0.000 description 3
- 210000000265 leukocyte Anatomy 0.000 description 3
- 210000004698 lymphocyte Anatomy 0.000 description 3
- 102100031622 mRNA decay activator protein ZFP36 Human genes 0.000 description 3
- 230000003211 malignant effect Effects 0.000 description 3
- 201000001441 melanoma Diseases 0.000 description 3
- 229960001156 mitoxantrone Drugs 0.000 description 3
- KKZJGLLVHKMTCM-UHFFFAOYSA-N mitoxantrone Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO KKZJGLLVHKMTCM-UHFFFAOYSA-N 0.000 description 3
- 229950003600 ombrabulin Drugs 0.000 description 3
- 230000036961 partial effect Effects 0.000 description 3
- 239000013610 patient sample Substances 0.000 description 3
- 230000034190 positive regulation of NF-kappaB transcription factor activity Effects 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 238000011321 prophylaxis Methods 0.000 description 3
- 239000012474 protein marker Substances 0.000 description 3
- 238000007637 random forest analysis Methods 0.000 description 3
- 230000000284 resting effect Effects 0.000 description 3
- 229930002330 retinoic acid Natural products 0.000 description 3
- CYOHGALHFOKKQC-UHFFFAOYSA-N selumetinib Chemical compound OCCONC(=O)C=1C=C2N(C)C=NC2=C(F)C=1NC1=CC=C(Br)C=C1Cl CYOHGALHFOKKQC-UHFFFAOYSA-N 0.000 description 3
- 229960003440 semustine Drugs 0.000 description 3
- 230000001235 sensitizing effect Effects 0.000 description 3
- 108010047846 soblidotin Proteins 0.000 description 3
- 229910052708 sodium Inorganic materials 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 229950006050 spiromustine Drugs 0.000 description 3
- 238000002626 targeted therapy Methods 0.000 description 3
- 108010029464 tasidotin Proteins 0.000 description 3
- NRUKOCRGYNPUPR-QBPJDGROSA-N teniposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@@H](OC[C@H]4O3)C=3SC=CC=3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 NRUKOCRGYNPUPR-QBPJDGROSA-N 0.000 description 3
- 229960001278 teniposide Drugs 0.000 description 3
- 229960001196 thiotepa Drugs 0.000 description 3
- 210000004881 tumor cell Anatomy 0.000 description 3
- 229960004355 vindesine Drugs 0.000 description 3
- UGGWPQSBPIFKDZ-KOTLKJBCSA-N vindesine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(N)=O)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1N=C1[C]2C=CC=C1 UGGWPQSBPIFKDZ-KOTLKJBCSA-N 0.000 description 3
- AKNNEGZIBPJZJG-MSOLQXFVSA-N (-)-noscapine Chemical compound CN1CCC2=CC=3OCOC=3C(OC)=C2[C@@H]1[C@@H]1C2=CC=C(OC)C(OC)=C2C(=O)O1 AKNNEGZIBPJZJG-MSOLQXFVSA-N 0.000 description 2
- HZSBSRAVNBUZRA-RQDPQJJXSA-J (1r,2r)-cyclohexane-1,2-diamine;tetrachloroplatinum(2+) Chemical compound Cl[Pt+2](Cl)(Cl)Cl.N[C@@H]1CCCC[C@H]1N HZSBSRAVNBUZRA-RQDPQJJXSA-J 0.000 description 2
- PFJFPBDHCFMQPN-RGJAOAFDSA-N (1s,3s,7s,10r,11s,12s,16r)-3-[(e)-1-[2-(aminomethyl)-1,3-thiazol-4-yl]prop-1-en-2-yl]-7,11-dihydroxy-8,8,10,12,16-pentamethyl-4,17-dioxabicyclo[14.1.0]heptadecane-5,9-dione Chemical compound C/C([C@@H]1C[C@@H]2O[C@]2(C)CCC[C@@H]([C@@H]([C@@H](C)C(=O)C(C)(C)[C@@H](O)CC(=O)O1)O)C)=C\C1=CSC(CN)=N1 PFJFPBDHCFMQPN-RGJAOAFDSA-N 0.000 description 2
- XSAKVDNHFRWJKS-IIZANFQQSA-N (2s)-n-benzyl-1-[(2s)-1-[(2s)-2-[[(2s)-2-[[(2s)-2-(dimethylamino)-3-methylbutanoyl]amino]-3-methylbutanoyl]-methylamino]-3-methylbutanoyl]pyrrolidine-2-carbonyl]pyrrolidine-2-carboxamide Chemical compound CC(C)[C@H](N(C)C)C(=O)N[C@@H](C(C)C)C(=O)N(C)[C@@H](C(C)C)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(=O)NCC=2C=CC=CC=2)CCC1 XSAKVDNHFRWJKS-IIZANFQQSA-N 0.000 description 2
- FELGMEQIXOGIFQ-CYBMUJFWSA-N (3r)-9-methyl-3-[(2-methylimidazol-1-yl)methyl]-2,3-dihydro-1h-carbazol-4-one Chemical compound CC1=NC=CN1C[C@@H]1C(=O)C(C=2C(=CC=CC=2)N2C)=C2CC1 FELGMEQIXOGIFQ-CYBMUJFWSA-N 0.000 description 2
- SWXOGPJRIDTIRL-DOUNNPEJSA-N (4r,7s,10s,13r,16s,19r)-10-(4-aminobutyl)-n-[(2s)-1-amino-3-(1h-indol-3-yl)-1-oxopropan-2-yl]-19-[[(2r)-2-amino-3-phenylpropanoyl]amino]-16-[(4-hydroxyphenyl)methyl]-13-(1h-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-7-propan-2-yl-1,2-dithia-5,8,11,14,17-pent Chemical compound C([C@H]1C(=O)N[C@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(N[C@@H](CSSC[C@@H](C(=O)N1)NC(=O)[C@H](N)CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(N)=O)=O)C(C)C)C1=CC=C(O)C=C1 SWXOGPJRIDTIRL-DOUNNPEJSA-N 0.000 description 2
- FPVKHBSQESCIEP-UHFFFAOYSA-N (8S)-3-(2-deoxy-beta-D-erythro-pentofuranosyl)-3,6,7,8-tetrahydroimidazo[4,5-d][1,3]diazepin-8-ol Natural products C1C(O)C(CO)OC1N1C(NC=NCC2O)=C2N=C1 FPVKHBSQESCIEP-UHFFFAOYSA-N 0.000 description 2
- FDKXTQMXEQVLRF-ZHACJKMWSA-N (E)-dacarbazine Chemical compound CN(C)\N=N\c1[nH]cnc1C(N)=O FDKXTQMXEQVLRF-ZHACJKMWSA-N 0.000 description 2
- LKJPYSCBVHEWIU-KRWDZBQOSA-N (R)-bicalutamide Chemical compound C([C@@](O)(C)C(=O)NC=1C=C(C(C#N)=CC=1)C(F)(F)F)S(=O)(=O)C1=CC=C(F)C=C1 LKJPYSCBVHEWIU-KRWDZBQOSA-N 0.000 description 2
- CNTMOLDWXSVYKD-PSRNMDMQSA-N (e,4s)-4-[[(2s)-3,3-dimethyl-2-[[(2s)-3-methyl-2-(methylamino)-3-phenylbutanoyl]amino]butanoyl]-methylamino]-2,5-dimethylhex-2-enoic acid Chemical compound OC(=O)C(/C)=C/[C@H](C(C)C)N(C)C(=O)[C@H](C(C)(C)C)NC(=O)[C@@H](NC)C(C)(C)C1=CC=CC=C1 CNTMOLDWXSVYKD-PSRNMDMQSA-N 0.000 description 2
- FONKWHRXTPJODV-DNQXCXABSA-N 1,3-bis[2-[(8s)-8-(chloromethyl)-4-hydroxy-1-methyl-7,8-dihydro-3h-pyrrolo[3,2-e]indole-6-carbonyl]-1h-indol-5-yl]urea Chemical compound C1([C@H](CCl)CN2C(=O)C=3NC4=CC=C(C=C4C=3)NC(=O)NC=3C=C4C=C(NC4=CC=3)C(=O)N3C4=CC(O)=C5NC=C(C5=C4[C@H](CCl)C3)C)=C2C=C(O)C2=C1C(C)=CN2 FONKWHRXTPJODV-DNQXCXABSA-N 0.000 description 2
- 102100025573 1-alkyl-2-acetylglycerophosphocholine esterase Human genes 0.000 description 2
- 102100035473 2'-5'-oligoadenylate synthase-like protein Human genes 0.000 description 2
- OOMDVERDMZLRFX-UHFFFAOYSA-N 2,2-bis(aminomethyl)propane-1,3-diol;cyclobutane-1,1-dicarboxylic acid;platinum Chemical compound [Pt].NCC(CN)(CO)CO.OC(=O)C1(C(O)=O)CCC1 OOMDVERDMZLRFX-UHFFFAOYSA-N 0.000 description 2
- QXLQZLBNPTZMRK-UHFFFAOYSA-N 2-[(dimethylamino)methyl]-1-(2,4-dimethylphenyl)prop-2-en-1-one Chemical compound CN(C)CC(=C)C(=O)C1=CC=C(C)C=C1C QXLQZLBNPTZMRK-UHFFFAOYSA-N 0.000 description 2
- KOQIAZNBAWFSQM-UHFFFAOYSA-N 2-[4-(3-ethynylanilino)-7-(2-methoxyethoxy)quinazolin-6-yl]oxyethanol Chemical compound C=12C=C(OCCO)C(OCCOC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 KOQIAZNBAWFSQM-UHFFFAOYSA-N 0.000 description 2
- WVAKRQOMAINQPU-UHFFFAOYSA-N 2-[4-[2-[5-(2,2-dimethylbutyl)-1h-imidazol-2-yl]ethyl]phenyl]pyridine Chemical compound N1C(CC(C)(C)CC)=CN=C1CCC1=CC=C(C=2N=CC=CC=2)C=C1 WVAKRQOMAINQPU-UHFFFAOYSA-N 0.000 description 2
- 102100023817 26S proteasome complex subunit SEM1 Human genes 0.000 description 2
- UZFPOOOQHWICKY-UHFFFAOYSA-N 3-[13-[1-[1-[8,12-bis(2-carboxyethyl)-17-(1-hydroxyethyl)-3,7,13,18-tetramethyl-21,24-dihydroporphyrin-2-yl]ethoxy]ethyl]-18-(2-carboxyethyl)-8-(1-hydroxyethyl)-3,7,12,17-tetramethyl-22,23-dihydroporphyrin-2-yl]propanoic acid Chemical compound N1C(C=C2C(=C(CCC(O)=O)C(C=C3C(=C(C)C(C=C4N5)=N3)CCC(O)=O)=N2)C)=C(C)C(C(C)O)=C1C=C5C(C)=C4C(C)OC(C)C1=C(N2)C=C(N3)C(C)=C(C(O)C)C3=CC(C(C)=C3CCC(O)=O)=NC3=CC(C(CCC(O)=O)=C3C)=NC3=CC2=C1C UZFPOOOQHWICKY-UHFFFAOYSA-N 0.000 description 2
- QNKJFXARIMSDBR-UHFFFAOYSA-N 3-[2-[bis(2-chloroethyl)amino]ethyl]-1,3-diazaspiro[4.5]decane-2,4-dione Chemical compound O=C1N(CCN(CCCl)CCCl)C(=O)NC11CCCCC1 QNKJFXARIMSDBR-UHFFFAOYSA-N 0.000 description 2
- 102100029103 3-ketoacyl-CoA thiolase Human genes 0.000 description 2
- CLPFFLWZZBQMAO-UHFFFAOYSA-N 4-(5,6,7,8-tetrahydroimidazo[1,5-a]pyridin-5-yl)benzonitrile Chemical compound C1=CC(C#N)=CC=C1C1N2C=NC=C2CCC1 CLPFFLWZZBQMAO-UHFFFAOYSA-N 0.000 description 2
- AKJHMTWEGVYYSE-AIRMAKDCSA-N 4-HPR Chemical compound C=1C=C(O)C=CC=1NC(=O)/C=C(\C)/C=C/C=C(C)C=CC1=C(C)CCCC1(C)C AKJHMTWEGVYYSE-AIRMAKDCSA-N 0.000 description 2
- IDPUKCWIGUEADI-UHFFFAOYSA-N 5-[bis(2-chloroethyl)amino]uracil Chemical compound ClCCN(CCCl)C1=CNC(=O)NC1=O IDPUKCWIGUEADI-UHFFFAOYSA-N 0.000 description 2
- VVIAGPKUTFNRDU-UHFFFAOYSA-N 6S-folinic acid Natural products C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-UHFFFAOYSA-N 0.000 description 2
- STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 description 2
- RTHKPHCVZVYDFN-UHFFFAOYSA-N 9-amino-5-(2-aminopyrimidin-4-yl)pyrido[3',2':4,5]pyrrolo[1,2-c]pyrimidin-4-ol Chemical compound NC1=NC=CC(C=2C3=C(O)C=CN=C3N3C(N)=NC=CC3=2)=N1 RTHKPHCVZVYDFN-UHFFFAOYSA-N 0.000 description 2
- 102100039645 ADP-ribosylation factor-like protein 4A Human genes 0.000 description 2
- 108010004483 APOBEC-3G Deaminase Proteins 0.000 description 2
- 102100030835 AT-rich interactive domain-containing protein 5B Human genes 0.000 description 2
- 102100037435 Antiviral innate immune response receptor RIG-I Human genes 0.000 description 2
- 102100030762 Apolipoprotein L1 Human genes 0.000 description 2
- 102100037325 Apolipoprotein L6 Human genes 0.000 description 2
- 108010024976 Asparaginase Proteins 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 208000023275 Autoimmune disease Diseases 0.000 description 2
- 102100021631 B-cell lymphoma 6 protein Human genes 0.000 description 2
- 102100037152 BAG family molecular chaperone regulator 1 Human genes 0.000 description 2
- MLDQJTXFUGDVEO-UHFFFAOYSA-N BAY-43-9006 Chemical compound C1=NC(C(=O)NC)=CC(OC=2C=CC(NC(=O)NC=3C=C(C(Cl)=CC=3)C(F)(F)F)=CC=2)=C1 MLDQJTXFUGDVEO-UHFFFAOYSA-N 0.000 description 2
- 101150050047 BHLHE40 gene Proteins 0.000 description 2
- 102100021573 Bcl-2-binding component 3, isoforms 3/4 Human genes 0.000 description 2
- 102100037086 Bone marrow stromal antigen 2 Human genes 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- 208000003174 Brain Neoplasms Diseases 0.000 description 2
- CIUUIPMOFZIWIZ-UHFFFAOYSA-N Bropirimine Chemical compound NC1=NC(O)=C(Br)C(C=2C=CC=CC=2)=N1 CIUUIPMOFZIWIZ-UHFFFAOYSA-N 0.000 description 2
- LDZJNMJIPNOYGA-UHFFFAOYSA-N C1=C(OC(C)=O)C(OC)=CC=C1C1=C2C3=CC(OC)=C(OC(C)=O)C=C3C=CN2C2=C1C(C=C(OC)C(OC(C)=O)=C1)=C1OC2=O Chemical compound C1=C(OC(C)=O)C(OC)=CC=C1C1=C2C3=CC(OC)=C(OC(C)=O)C=C3C=CN2C2=C1C(C=C(OC)C(OC(C)=O)=C1)=C1OC2=O LDZJNMJIPNOYGA-UHFFFAOYSA-N 0.000 description 2
- 102100021786 CMP-N-acetylneuraminate-poly-alpha-2,8-sialyltransferase Human genes 0.000 description 2
- 239000012275 CTLA-4 inhibitor Substances 0.000 description 2
- 229940045513 CTLA4 antagonist Drugs 0.000 description 2
- GAGWJHPBXLXJQN-UORFTKCHSA-N Capecitabine Chemical compound C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1[C@H]1[C@H](O)[C@H](O)[C@@H](C)O1 GAGWJHPBXLXJQN-UORFTKCHSA-N 0.000 description 2
- GAGWJHPBXLXJQN-UHFFFAOYSA-N Capecitabine Natural products C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1C1C(O)C(O)C(C)O1 GAGWJHPBXLXJQN-UHFFFAOYSA-N 0.000 description 2
- 201000009030 Carcinoma Diseases 0.000 description 2
- DLGOEMSEDOSKAD-UHFFFAOYSA-N Carmustine Chemical compound ClCCNC(=O)N(N=O)CCCl DLGOEMSEDOSKAD-UHFFFAOYSA-N 0.000 description 2
- 102100040751 Casein kinase II subunit alpha Human genes 0.000 description 2
- 102100021633 Cathepsin B Human genes 0.000 description 2
- JWBOIMRXGHLCPP-UHFFFAOYSA-N Chloditan Chemical compound C=1C=CC=C(Cl)C=1C(C(Cl)Cl)C1=CC=C(Cl)C=C1 JWBOIMRXGHLCPP-UHFFFAOYSA-N 0.000 description 2
- PTOAARAWEBMLNO-KVQBGUIXSA-N Cladribine Chemical compound C1=NC=2C(N)=NC(Cl)=NC=2N1[C@H]1C[C@H](O)[C@@H](CO)O1 PTOAARAWEBMLNO-KVQBGUIXSA-N 0.000 description 2
- 102100026191 Class E basic helix-loop-helix protein 40 Human genes 0.000 description 2
- 208000035473 Communicable disease Diseases 0.000 description 2
- 102100035432 Complement factor H Human genes 0.000 description 2
- 108010043471 Core Binding Factor Alpha 2 Subunit Proteins 0.000 description 2
- 108010076010 Cystathionine beta-lyase Proteins 0.000 description 2
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 description 2
- 102100030497 Cytochrome c Human genes 0.000 description 2
- 102100034560 Cytosol aminopeptidase Human genes 0.000 description 2
- 101710203008 D-galactose-binding periplasmic protein Proteins 0.000 description 2
- 102100025267 DENN domain-containing protein 5A Human genes 0.000 description 2
- 102100038076 DNA dC->dU-editing enzyme APOBEC-3G Human genes 0.000 description 2
- 102100030960 DNA replication licensing factor MCM2 Human genes 0.000 description 2
- 102100027642 DNA-binding protein inhibitor ID-2 Human genes 0.000 description 2
- 102100039303 DNA-directed RNA polymerase II subunit RPB2 Human genes 0.000 description 2
- 101100457345 Danio rerio mapk14a gene Proteins 0.000 description 2
- 101100457347 Danio rerio mapk14b gene Proteins 0.000 description 2
- 206010061818 Disease progression Diseases 0.000 description 2
- 102100029791 Double-stranded RNA-specific adenosine deaminase Human genes 0.000 description 2
- ZQZFYGIXNQKOAV-OCEACIFDSA-N Droloxifene Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=C(O)C=CC=1)\C1=CC=C(OCCN(C)C)C=C1 ZQZFYGIXNQKOAV-OCEACIFDSA-N 0.000 description 2
- 101710146526 Dual specificity mitogen-activated protein kinase kinase 1 Proteins 0.000 description 2
- 101710146529 Dual specificity mitogen-activated protein kinase kinase 2 Proteins 0.000 description 2
- 102100023275 Dual specificity mitogen-activated protein kinase kinase 3 Human genes 0.000 description 2
- 102100023401 Dual specificity mitogen-activated protein kinase kinase 6 Human genes 0.000 description 2
- 102100034428 Dual specificity protein phosphatase 1 Human genes 0.000 description 2
- 102100039922 E3 ISG15-protein ligase HERC5 Human genes 0.000 description 2
- 102100035273 E3 ubiquitin-protein ligase CBL-B Human genes 0.000 description 2
- 102100034893 E3 ubiquitin-protein ligase HUWE1 Human genes 0.000 description 2
- 102100027418 E3 ubiquitin-protein ligase RNF213 Human genes 0.000 description 2
- 102100023431 E3 ubiquitin-protein ligase TRIM21 Human genes 0.000 description 2
- 102100034597 E3 ubiquitin-protein ligase TRIM22 Human genes 0.000 description 2
- 102100034582 E3 ubiquitin/ISG15 ligase TRIM25 Human genes 0.000 description 2
- 102000001301 EGF receptor Human genes 0.000 description 2
- 108060006698 EGF receptor Proteins 0.000 description 2
- 102100032036 EH domain-containing protein 1 Human genes 0.000 description 2
- 102100032057 ETS domain-containing protein Elk-1 Human genes 0.000 description 2
- 102100023792 ETS domain-containing protein Elk-4 Human genes 0.000 description 2
- 102100023226 Early growth response protein 1 Human genes 0.000 description 2
- 102100039369 Epidermal growth factor receptor substrate 15 Human genes 0.000 description 2
- 102100039621 Epithelial-stromal interaction protein 1 Human genes 0.000 description 2
- QXRSDHAAWVKZLJ-OXZHEXMSSA-N Epothilone B Natural products O=C1[C@H](C)[C@H](O)[C@@H](C)CCC[C@@]2(C)O[C@H]2C[C@@H](/C(=C\c2nc(C)sc2)/C)OC(=O)C[C@H](O)C1(C)C QXRSDHAAWVKZLJ-OXZHEXMSSA-N 0.000 description 2
- 108010082945 Eukaryotic Initiation Factor-2B Proteins 0.000 description 2
- 102000002639 Eukaryotic Initiation Factor-2B Human genes 0.000 description 2
- 102100029925 Eukaryotic translation initiation factor 4E type 3 Human genes 0.000 description 2
- 102100022629 Fructose-2,6-bisphosphatase Human genes 0.000 description 2
- 102100040861 G0/G1 switch protein 2 Human genes 0.000 description 2
- 102100040510 Galectin-3-binding protein Human genes 0.000 description 2
- 208000032612 Glial tumor Diseases 0.000 description 2
- 206010018338 Glioma Diseases 0.000 description 2
- 102100039619 Granulocyte colony-stimulating factor Human genes 0.000 description 2
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 2
- 102100030386 Granzyme A Human genes 0.000 description 2
- 102100031153 Growth arrest and DNA damage-inducible protein GADD45 beta Human genes 0.000 description 2
- 102100028541 Guanylate-binding protein 2 Human genes 0.000 description 2
- 102100028539 Guanylate-binding protein 5 Human genes 0.000 description 2
- 102100037174 Helicase MOV-10 Human genes 0.000 description 2
- 101800001649 Heparin-binding EGF-like growth factor Proteins 0.000 description 2
- 102100025190 Histone-binding protein RBBP4 Human genes 0.000 description 2
- 101000597360 Homo sapiens 2'-5'-oligoadenylate synthase-like protein Proteins 0.000 description 2
- 101000684297 Homo sapiens 26S proteasome complex subunit SEM1 Proteins 0.000 description 2
- 101000841262 Homo sapiens 3-ketoacyl-CoA thiolase Proteins 0.000 description 2
- 101000886015 Homo sapiens ADP-ribosylation factor-like protein 4A Proteins 0.000 description 2
- 101100323521 Homo sapiens APOL1 gene Proteins 0.000 description 2
- 101000792947 Homo sapiens AT-rich interactive domain-containing protein 5B Proteins 0.000 description 2
- 101000952099 Homo sapiens Antiviral innate immune response receptor RIG-I Proteins 0.000 description 2
- 101000806784 Homo sapiens Apolipoprotein L6 Proteins 0.000 description 2
- 101000971234 Homo sapiens B-cell lymphoma 6 protein Proteins 0.000 description 2
- 101000740062 Homo sapiens BAG family molecular chaperone regulator 1 Proteins 0.000 description 2
- 101000971203 Homo sapiens Bcl-2-binding component 3, isoforms 1/2 Proteins 0.000 description 2
- 101000971209 Homo sapiens Bcl-2-binding component 3, isoforms 3/4 Proteins 0.000 description 2
- 101000740785 Homo sapiens Bone marrow stromal antigen 2 Proteins 0.000 description 2
- 101000616698 Homo sapiens CMP-N-acetylneuraminate-poly-alpha-2,8-sialyltransferase Proteins 0.000 description 2
- 101000892026 Homo sapiens Casein kinase II subunit alpha Proteins 0.000 description 2
- 101000892015 Homo sapiens Casein kinase II subunit alpha' Proteins 0.000 description 2
- 101000898449 Homo sapiens Cathepsin B Proteins 0.000 description 2
- 101000737574 Homo sapiens Complement factor H Proteins 0.000 description 2
- 101000716088 Homo sapiens Cyclin-L1 Proteins 0.000 description 2
- 101000726355 Homo sapiens Cytochrome c Proteins 0.000 description 2
- 101000943420 Homo sapiens Cytokine-inducible SH2-containing protein Proteins 0.000 description 2
- 101000924389 Homo sapiens Cytosol aminopeptidase Proteins 0.000 description 2
- 101000722275 Homo sapiens DENN domain-containing protein 5A Proteins 0.000 description 2
- 101000583807 Homo sapiens DNA replication licensing factor MCM2 Proteins 0.000 description 2
- 101001081582 Homo sapiens DNA-binding protein inhibitor ID-2 Proteins 0.000 description 2
- 101000669831 Homo sapiens DNA-directed RNA polymerase II subunit RPB2 Proteins 0.000 description 2
- 101000641077 Homo sapiens Diamine acetyltransferase 1 Proteins 0.000 description 2
- 101000865408 Homo sapiens Double-stranded RNA-specific adenosine deaminase Proteins 0.000 description 2
- 101001115394 Homo sapiens Dual specificity mitogen-activated protein kinase kinase 3 Proteins 0.000 description 2
- 101000624426 Homo sapiens Dual specificity mitogen-activated protein kinase kinase 6 Proteins 0.000 description 2
- 101000924017 Homo sapiens Dual specificity protein phosphatase 1 Proteins 0.000 description 2
- 101000881110 Homo sapiens Dual specificity protein phosphatase 12 Proteins 0.000 description 2
- 101001035145 Homo sapiens E3 ISG15-protein ligase HERC5 Proteins 0.000 description 2
- 101000737265 Homo sapiens E3 ubiquitin-protein ligase CBL-B Proteins 0.000 description 2
- 101001019732 Homo sapiens E3 ubiquitin-protein ligase HUWE1 Proteins 0.000 description 2
- 101000650316 Homo sapiens E3 ubiquitin-protein ligase RNF213 Proteins 0.000 description 2
- 101000685877 Homo sapiens E3 ubiquitin-protein ligase TRIM21 Proteins 0.000 description 2
- 101000848629 Homo sapiens E3 ubiquitin-protein ligase TRIM22 Proteins 0.000 description 2
- 101000848655 Homo sapiens E3 ubiquitin/ISG15 ligase TRIM25 Proteins 0.000 description 2
- 101000921221 Homo sapiens EH domain-containing protein 1 Proteins 0.000 description 2
- 101001048716 Homo sapiens ETS domain-containing protein Elk-4 Proteins 0.000 description 2
- 101001049697 Homo sapiens Early growth response protein 1 Proteins 0.000 description 2
- 101000812517 Homo sapiens Epidermal growth factor receptor substrate 15 Proteins 0.000 description 2
- 101000814134 Homo sapiens Epithelial-stromal interaction protein 1 Proteins 0.000 description 2
- 101001011076 Homo sapiens Eukaryotic translation initiation factor 4E type 3 Proteins 0.000 description 2
- 101000823463 Homo sapiens Fructose-2,6-bisphosphatase Proteins 0.000 description 2
- 101000893656 Homo sapiens G0/G1 switch protein 2 Proteins 0.000 description 2
- 101000967904 Homo sapiens Galectin-3-binding protein Proteins 0.000 description 2
- 101001002170 Homo sapiens Glutamine amidotransferase-like class 1 domain-containing protein 3, mitochondrial Proteins 0.000 description 2
- 101001009599 Homo sapiens Granzyme A Proteins 0.000 description 2
- 101001066164 Homo sapiens Growth arrest and DNA damage-inducible protein GADD45 beta Proteins 0.000 description 2
- 101001058858 Homo sapiens Guanylate-binding protein 2 Proteins 0.000 description 2
- 101001058850 Homo sapiens Guanylate-binding protein 5 Proteins 0.000 description 2
- 101001028696 Homo sapiens Helicase MOV-10 Proteins 0.000 description 2
- 101000840551 Homo sapiens Hexokinase-2 Proteins 0.000 description 2
- 101001083553 Homo sapiens Hydroxyacyl-coenzyme A dehydrogenase, mitochondrial Proteins 0.000 description 2
- 101001003233 Homo sapiens Immediate early response gene 2 protein Proteins 0.000 description 2
- 101001003310 Homo sapiens Immediate early response gene 5 protein Proteins 0.000 description 2
- 101001034652 Homo sapiens Insulin-like growth factor 1 receptor Proteins 0.000 description 2
- 101001046677 Homo sapiens Integrin alpha-V Proteins 0.000 description 2
- 101001001420 Homo sapiens Interferon gamma receptor 1 Proteins 0.000 description 2
- 101001011382 Homo sapiens Interferon regulatory factor 3 Proteins 0.000 description 2
- 101001011441 Homo sapiens Interferon regulatory factor 4 Proteins 0.000 description 2
- 101001032341 Homo sapiens Interferon regulatory factor 9 Proteins 0.000 description 2
- 101000926535 Homo sapiens Interferon-induced, double-stranded RNA-activated protein kinase Proteins 0.000 description 2
- 101001003140 Homo sapiens Interleukin-15 receptor subunit alpha Proteins 0.000 description 2
- 101001055145 Homo sapiens Interleukin-2 receptor subunit beta Proteins 0.000 description 2
- 101000599048 Homo sapiens Interleukin-6 receptor subunit alpha Proteins 0.000 description 2
- 101001050577 Homo sapiens Kinesin-like protein KIF2A Proteins 0.000 description 2
- 101001006892 Homo sapiens Krueppel-like factor 10 Proteins 0.000 description 2
- 101000652814 Homo sapiens Lactosylceramide alpha-2,3-sialyltransferase Proteins 0.000 description 2
- 101001051093 Homo sapiens Low-density lipoprotein receptor Proteins 0.000 description 2
- 101001065568 Homo sapiens Lymphocyte antigen 6E Proteins 0.000 description 2
- 101001004953 Homo sapiens Lysosomal acid lipase/cholesteryl ester hydrolase Proteins 0.000 description 2
- 101000669513 Homo sapiens Metalloproteinase inhibitor 1 Proteins 0.000 description 2
- 101001014059 Homo sapiens Metallothionein-2 Proteins 0.000 description 2
- 101000950695 Homo sapiens Mitogen-activated protein kinase 8 Proteins 0.000 description 2
- 101000970017 Homo sapiens NEDD8 ultimate buster 1 Proteins 0.000 description 2
- 101000701614 Homo sapiens Nuclear autoantigen Sp-100 Proteins 0.000 description 2
- 101000979338 Homo sapiens Nuclear factor NF-kappa-B p100 subunit Proteins 0.000 description 2
- 101000973177 Homo sapiens Nuclear factor interleukin-3-regulated protein Proteins 0.000 description 2
- 101000970403 Homo sapiens Nuclear pore complex protein Nup153 Proteins 0.000 description 2
- 101001007909 Homo sapiens Nuclear pore complex protein Nup93 Proteins 0.000 description 2
- 101000974356 Homo sapiens Nuclear receptor coactivator 3 Proteins 0.000 description 2
- 101000974345 Homo sapiens Nuclear receptor coactivator 7 Proteins 0.000 description 2
- 101001109698 Homo sapiens Nuclear receptor subfamily 4 group A member 2 Proteins 0.000 description 2
- 101001082142 Homo sapiens Pentraxin-related protein PTX3 Proteins 0.000 description 2
- 101000702718 Homo sapiens Phosphatidylcholine:ceramide cholinephosphotransferase 1 Proteins 0.000 description 2
- 101000595918 Homo sapiens Phospholipase A and acyltransferase 4 Proteins 0.000 description 2
- 101001067396 Homo sapiens Phospholipid scramblase 1 Proteins 0.000 description 2
- 101000582950 Homo sapiens Platelet factor 4 Proteins 0.000 description 2
- 101001066878 Homo sapiens Polyribonucleotide nucleotidyltransferase 1, mitochondrial Proteins 0.000 description 2
- 101001026214 Homo sapiens Potassium voltage-gated channel subfamily A member 5 Proteins 0.000 description 2
- 101000690940 Homo sapiens Pro-adrenomedullin Proteins 0.000 description 2
- 101001041721 Homo sapiens Probable ATP-dependent RNA helicase DDX17 Proteins 0.000 description 2
- 101000864662 Homo sapiens Probable ATP-dependent RNA helicase DHX58 Proteins 0.000 description 2
- 101001035144 Homo sapiens Probable E3 ubiquitin-protein ligase HERC6 Proteins 0.000 description 2
- 101001117519 Homo sapiens Prostaglandin E2 receptor EP2 subtype Proteins 0.000 description 2
- 101000736929 Homo sapiens Proteasome subunit alpha type-1 Proteins 0.000 description 2
- 101000933604 Homo sapiens Protein BTG2 Proteins 0.000 description 2
- 101001048456 Homo sapiens Protein Hook homolog 2 Proteins 0.000 description 2
- 101000979748 Homo sapiens Protein NDRG1 Proteins 0.000 description 2
- 101000979565 Homo sapiens Protein NLRC5 Proteins 0.000 description 2
- 101001129744 Homo sapiens Protein PHTF2 Proteins 0.000 description 2
- 101000573199 Homo sapiens Protein PML Proteins 0.000 description 2
- 101000613617 Homo sapiens Protein mono-ADP-ribosyltransferase PARP12 Proteins 0.000 description 2
- 101000613615 Homo sapiens Protein mono-ADP-ribosyltransferase PARP14 Proteins 0.000 description 2
- 101000735459 Homo sapiens Protein mono-ADP-ribosyltransferase PARP9 Proteins 0.000 description 2
- 101000611643 Homo sapiens Protein phosphatase 1 regulatory subunit 15A Proteins 0.000 description 2
- 101000878540 Homo sapiens Protein-tyrosine kinase 2-beta Proteins 0.000 description 2
- 101000873438 Homo sapiens Putative protein SEM1, isoform 2 Proteins 0.000 description 2
- 101001099586 Homo sapiens Pyridoxal kinase Proteins 0.000 description 2
- 101000635777 Homo sapiens Receptor-transporting protein 4 Proteins 0.000 description 2
- 101000606535 Homo sapiens Receptor-type tyrosine-protein phosphatase epsilon Proteins 0.000 description 2
- 101000581118 Homo sapiens Rho-related GTP-binding protein RhoC Proteins 0.000 description 2
- 101000945090 Homo sapiens Ribosomal protein S6 kinase alpha-3 Proteins 0.000 description 2
- 101000945096 Homo sapiens Ribosomal protein S6 kinase alpha-5 Proteins 0.000 description 2
- 101000836983 Homo sapiens Secretoglobin family 1D member 1 Proteins 0.000 description 2
- 101000587430 Homo sapiens Serine/arginine-rich splicing factor 2 Proteins 0.000 description 2
- 101000597662 Homo sapiens Serine/threonine-protein phosphatase 2B catalytic subunit alpha isoform Proteins 0.000 description 2
- 101000620653 Homo sapiens Serine/threonine-protein phosphatase 5 Proteins 0.000 description 2
- 101001133085 Homo sapiens Sialomucin core protein 24 Proteins 0.000 description 2
- 101000587455 Homo sapiens Single-stranded DNA-binding protein, mitochondrial Proteins 0.000 description 2
- 101000713305 Homo sapiens Sodium-coupled neutral amino acid transporter 1 Proteins 0.000 description 2
- 101000701625 Homo sapiens Sp110 nuclear body protein Proteins 0.000 description 2
- 101000663635 Homo sapiens Sphingosine kinase 1 Proteins 0.000 description 2
- 101000641015 Homo sapiens Sterile alpha motif domain-containing protein 9 Proteins 0.000 description 2
- 101000822540 Homo sapiens Sterile alpha motif domain-containing protein 9-like Proteins 0.000 description 2
- 101000740523 Homo sapiens Syntenin-1 Proteins 0.000 description 2
- 101000634866 Homo sapiens TRAF-type zinc finger domain-containing protein 1 Proteins 0.000 description 2
- 101000796022 Homo sapiens Thioredoxin-interacting protein Proteins 0.000 description 2
- 101000659879 Homo sapiens Thrombospondin-1 Proteins 0.000 description 2
- 101000796134 Homo sapiens Thymidine phosphorylase Proteins 0.000 description 2
- 101000843556 Homo sapiens Transcription factor HES-1 Proteins 0.000 description 2
- 101000763474 Homo sapiens Transmembrane protein 140 Proteins 0.000 description 2
- 101000848653 Homo sapiens Tripartite motif-containing protein 26 Proteins 0.000 description 2
- 101000640976 Homo sapiens Tryptophan-tRNA ligase, cytoplasmic Proteins 0.000 description 2
- 101000830565 Homo sapiens Tumor necrosis factor ligand superfamily member 10 Proteins 0.000 description 2
- 101001022129 Homo sapiens Tyrosine-protein kinase Fyn Proteins 0.000 description 2
- 101001054878 Homo sapiens Tyrosine-protein kinase Lyn Proteins 0.000 description 2
- 101001087394 Homo sapiens Tyrosine-protein phosphatase non-receptor type 1 Proteins 0.000 description 2
- 101001087416 Homo sapiens Tyrosine-protein phosphatase non-receptor type 11 Proteins 0.000 description 2
- 101001135572 Homo sapiens Tyrosine-protein phosphatase non-receptor type 2 Proteins 0.000 description 2
- 101001115218 Homo sapiens Ubiquitin-40S ribosomal protein S27a Proteins 0.000 description 2
- 101000840051 Homo sapiens Ubiquitin-60S ribosomal protein L40 Proteins 0.000 description 2
- 101000644655 Homo sapiens Ubiquitin-conjugating enzyme E2 E1 Proteins 0.000 description 2
- 101000644682 Homo sapiens Ubiquitin-conjugating enzyme E2 H Proteins 0.000 description 2
- 101000644684 Homo sapiens Ubiquitin-conjugating enzyme E2 N Proteins 0.000 description 2
- 101000644847 Homo sapiens Ubl carboxyl-terminal hydrolase 18 Proteins 0.000 description 2
- 101000982023 Homo sapiens Unconventional myosin-Ic Proteins 0.000 description 2
- 101000760337 Homo sapiens Urokinase plasminogen activator surface receptor Proteins 0.000 description 2
- 101000954434 Homo sapiens V-type proton ATPase 21 kDa proteolipid subunit c'' Proteins 0.000 description 2
- 101000639143 Homo sapiens Vesicle-associated membrane protein 5 Proteins 0.000 description 2
- 101000965719 Homo sapiens Volume-regulated anion channel subunit LRRC8C Proteins 0.000 description 2
- 101000814514 Homo sapiens XIAP-associated factor 1 Proteins 0.000 description 2
- 101000964436 Homo sapiens Z-DNA-binding protein 1 Proteins 0.000 description 2
- 102100030358 Hydroxyacyl-coenzyme A dehydrogenase, mitochondrial Human genes 0.000 description 2
- VSNHCAURESNICA-UHFFFAOYSA-N Hydroxyurea Chemical compound NC(=O)NO VSNHCAURESNICA-UHFFFAOYSA-N 0.000 description 2
- 102000040090 IFIT family Human genes 0.000 description 2
- 108091069905 IFIT family Proteins 0.000 description 2
- 101150062179 II gene Proteins 0.000 description 2
- 108091058560 IL8 Proteins 0.000 description 2
- XDXDZDZNSLXDNA-TZNDIEGXSA-N Idarubicin Chemical compound C1[C@H](N)[C@H](O)[C@H](C)O[C@H]1O[C@@H]1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2C[C@@](O)(C(C)=O)C1 XDXDZDZNSLXDNA-TZNDIEGXSA-N 0.000 description 2
- 102100020702 Immediate early response gene 2 protein Human genes 0.000 description 2
- 102100020688 Immediate early response gene 5 protein Human genes 0.000 description 2
- 229940076838 Immune checkpoint inhibitor Drugs 0.000 description 2
- 108091008026 Inhibitory immune checkpoint proteins Proteins 0.000 description 2
- 102000037984 Inhibitory immune checkpoint proteins Human genes 0.000 description 2
- 102100039688 Insulin-like growth factor 1 receptor Human genes 0.000 description 2
- 102100022337 Integrin alpha-V Human genes 0.000 description 2
- 108010078049 Interferon alpha-2 Proteins 0.000 description 2
- 102100035678 Interferon gamma receptor 1 Human genes 0.000 description 2
- 102100029843 Interferon regulatory factor 3 Human genes 0.000 description 2
- 102100030126 Interferon regulatory factor 4 Human genes 0.000 description 2
- 102100038251 Interferon regulatory factor 9 Human genes 0.000 description 2
- 102000006992 Interferon-alpha Human genes 0.000 description 2
- 108010047761 Interferon-alpha Proteins 0.000 description 2
- 102100034170 Interferon-induced, double-stranded RNA-activated protein kinase Human genes 0.000 description 2
- 108090000172 Interleukin-15 Proteins 0.000 description 2
- 102000003812 Interleukin-15 Human genes 0.000 description 2
- 102100020789 Interleukin-15 receptor subunit alpha Human genes 0.000 description 2
- 102100026879 Interleukin-2 receptor subunit beta Human genes 0.000 description 2
- 102100037792 Interleukin-6 receptor subunit alpha Human genes 0.000 description 2
- 102000004890 Interleukin-8 Human genes 0.000 description 2
- 108090001007 Interleukin-8 Proteins 0.000 description 2
- 102100023426 Kinesin-like protein KIF2A Human genes 0.000 description 2
- 102100027798 Krueppel-like factor 10 Human genes 0.000 description 2
- 108010025026 Ku Autoantigen Proteins 0.000 description 2
- 102000015335 Ku Autoantigen Human genes 0.000 description 2
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 2
- 239000005411 L01XE02 - Gefitinib Substances 0.000 description 2
- 239000005551 L01XE03 - Erlotinib Substances 0.000 description 2
- CZQHHVNHHHRRDU-UHFFFAOYSA-N LY294002 Chemical compound C1=CC=C2C(=O)C=C(N3CCOCC3)OC2=C1C1=CC=CC=C1 CZQHHVNHHHRRDU-UHFFFAOYSA-N 0.000 description 2
- 102100030928 Lactosylceramide alpha-2,3-sialyltransferase Human genes 0.000 description 2
- HLFSDGLLUJUHTE-SNVBAGLBSA-N Levamisole Chemical compound C1([C@H]2CN3CCSC3=N2)=CC=CC=C1 HLFSDGLLUJUHTE-SNVBAGLBSA-N 0.000 description 2
- 102100024640 Low-density lipoprotein receptor Human genes 0.000 description 2
- 102100032131 Lymphocyte antigen 6E Human genes 0.000 description 2
- 102100026001 Lysosomal acid lipase/cholesteryl ester hydrolase Human genes 0.000 description 2
- 108010068342 MAP Kinase Kinase 1 Proteins 0.000 description 2
- 102100034069 MAP kinase-activated protein kinase 2 Human genes 0.000 description 2
- 108010041955 MAP-kinase-activated kinase 2 Proteins 0.000 description 2
- 108700012928 MAPK14 Proteins 0.000 description 2
- 108010018650 MEF2 Transcription Factors Proteins 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 101150003941 Mapk14 gene Proteins 0.000 description 2
- 229930126263 Maytansine Natural products 0.000 description 2
- 102100039364 Metalloproteinase inhibitor 1 Human genes 0.000 description 2
- 102100031347 Metallothionein-2 Human genes 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 102100037989 Mitoferrin-2 Human genes 0.000 description 2
- 102000054819 Mitogen-activated protein kinase 14 Human genes 0.000 description 2
- 102100037808 Mitogen-activated protein kinase 8 Human genes 0.000 description 2
- 229930192392 Mitomycin Natural products 0.000 description 2
- HRHKSTOGXBBQCB-UHFFFAOYSA-N Mitomycin E Natural products O=C1C(N)=C(C)C(=O)C2=C1C(COC(N)=O)C1(OC)C3N(C)C3CN12 HRHKSTOGXBBQCB-UHFFFAOYSA-N 0.000 description 2
- 102100025725 Mothers against decapentaplegic homolog 4 Human genes 0.000 description 2
- 101710143112 Mothers against decapentaplegic homolog 4 Proteins 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 102100039229 Myocyte-specific enhancer factor 2C Human genes 0.000 description 2
- URCVCIZFVQDVPM-UHFFFAOYSA-N N-[2-(4-hydroxyanilino)-3-pyridinyl]-4-methoxybenzenesulfonamide Chemical compound C1=CC(OC)=CC=C1S(=O)(=O)NC1=CC=CN=C1NC1=CC=C(O)C=C1 URCVCIZFVQDVPM-UHFFFAOYSA-N 0.000 description 2
- LYPFDBRUNKHDGX-SOGSVHMOSA-N N1C2=CC=C1\C(=C1\C=CC(=N1)\C(=C1\C=C/C(/N1)=C(/C1=N/C(/CC1)=C2/C1=CC(O)=CC=C1)C1=CC(O)=CC=C1)\C1=CC(O)=CC=C1)C1=CC(O)=CC=C1 Chemical compound N1C2=CC=C1\C(=C1\C=CC(=N1)\C(=C1\C=C/C(/N1)=C(/C1=N/C(/CC1)=C2/C1=CC(O)=CC=C1)C1=CC(O)=CC=C1)\C1=CC(O)=CC=C1)C1=CC(O)=CC=C1 LYPFDBRUNKHDGX-SOGSVHMOSA-N 0.000 description 2
- 102100021741 NEDD8 ultimate buster 1 Human genes 0.000 description 2
- 102000003945 NF-kappa B Human genes 0.000 description 2
- 102100030436 Nuclear autoantigen Sp-100 Human genes 0.000 description 2
- 102100023059 Nuclear factor NF-kappa-B p100 subunit Human genes 0.000 description 2
- 102100022163 Nuclear factor interleukin-3-regulated protein Human genes 0.000 description 2
- 102100021706 Nuclear pore complex protein Nup153 Human genes 0.000 description 2
- 102100027585 Nuclear pore complex protein Nup93 Human genes 0.000 description 2
- 102100022883 Nuclear receptor coactivator 3 Human genes 0.000 description 2
- 102100022930 Nuclear receptor coactivator 7 Human genes 0.000 description 2
- 102100022676 Nuclear receptor subfamily 4 group A member 2 Human genes 0.000 description 2
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 2
- 101150042165 Ogfr gene Proteins 0.000 description 2
- 108091034117 Oligonucleotide Proteins 0.000 description 2
- 102100026949 Opioid growth factor receptor Human genes 0.000 description 2
- 206010033128 Ovarian cancer Diseases 0.000 description 2
- 206010061535 Ovarian neoplasm Diseases 0.000 description 2
- 239000012271 PD-L1 inhibitor Substances 0.000 description 2
- 229930012538 Paclitaxel Natural products 0.000 description 2
- BFHAYPLBUQVNNJ-UHFFFAOYSA-N Pectenotoxin 3 Natural products OC1C(C)CCOC1(O)C1OC2C=CC(C)=CC(C)CC(C)(O3)CCC3C(O3)(O4)CCC3(C=O)CC4C(O3)C(=O)CC3(C)C(O)C(O3)CCC3(O3)CCCC3C(C)C(=O)OC2C1 BFHAYPLBUQVNNJ-UHFFFAOYSA-N 0.000 description 2
- 102100027351 Pentraxin-related protein PTX3 Human genes 0.000 description 2
- 102100030919 Phosphatidylcholine:ceramide cholinephosphotransferase 1 Human genes 0.000 description 2
- 102100035200 Phospholipase A and acyltransferase 4 Human genes 0.000 description 2
- 102100034627 Phospholipid scramblase 1 Human genes 0.000 description 2
- 102100030304 Platelet factor 4 Human genes 0.000 description 2
- 108010064218 Poly (ADP-Ribose) Polymerase-1 Proteins 0.000 description 2
- 102100023712 Poly [ADP-ribose] polymerase 1 Human genes 0.000 description 2
- 102100034410 Polyribonucleotide nucleotidyltransferase 1, mitochondrial Human genes 0.000 description 2
- 101710163352 Potassium voltage-gated channel subfamily H member 4 Proteins 0.000 description 2
- 102100026651 Pro-adrenomedullin Human genes 0.000 description 2
- 102100021409 Probable ATP-dependent RNA helicase DDX17 Human genes 0.000 description 2
- 102100030090 Probable ATP-dependent RNA helicase DHX58 Human genes 0.000 description 2
- 102100039921 Probable E3 ubiquitin-protein ligase HERC6 Human genes 0.000 description 2
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 2
- 102100033762 Proheparin-binding EGF-like growth factor Human genes 0.000 description 2
- 102100024448 Prostaglandin E2 receptor EP2 subtype Human genes 0.000 description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 2
- 102100036042 Proteasome subunit alpha type-1 Human genes 0.000 description 2
- 102100026034 Protein BTG2 Human genes 0.000 description 2
- 102100024980 Protein NDRG1 Human genes 0.000 description 2
- 102100023432 Protein NLRC5 Human genes 0.000 description 2
- 102100031570 Protein PHTF2 Human genes 0.000 description 2
- 102100026375 Protein PML Human genes 0.000 description 2
- 229940123924 Protein kinase C inhibitor Drugs 0.000 description 2
- 102100040845 Protein mono-ADP-ribosyltransferase PARP12 Human genes 0.000 description 2
- 102100040848 Protein mono-ADP-ribosyltransferase PARP14 Human genes 0.000 description 2
- 102100034930 Protein mono-ADP-ribosyltransferase PARP9 Human genes 0.000 description 2
- 102100040714 Protein phosphatase 1 regulatory subunit 15A Human genes 0.000 description 2
- 102100037787 Protein-tyrosine kinase 2-beta Human genes 0.000 description 2
- 102100020949 Putative glutamine amidotransferase-like class 1 domain-containing protein 3B, mitochondrial Human genes 0.000 description 2
- 102100038517 Pyridoxal kinase Human genes 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 101000599776 Rattus norvegicus Insulin-like growth factor 2 mRNA-binding protein 1 Proteins 0.000 description 2
- 102100030854 Receptor-transporting protein 4 Human genes 0.000 description 2
- 102100039665 Receptor-type tyrosine-protein phosphatase epsilon Human genes 0.000 description 2
- 102100021258 Regulator of G-protein signaling 2 Human genes 0.000 description 2
- 101710140412 Regulator of G-protein signaling 2 Proteins 0.000 description 2
- 108010071034 Retinoblastoma-Binding Protein 4 Proteins 0.000 description 2
- 102100027611 Rho-related GTP-binding protein RhoB Human genes 0.000 description 2
- 102100027610 Rho-related GTP-binding protein RhoC Human genes 0.000 description 2
- 101150054980 Rhob gene Proteins 0.000 description 2
- 102100033643 Ribosomal protein S6 kinase alpha-3 Human genes 0.000 description 2
- 102100033645 Ribosomal protein S6 kinase alpha-5 Human genes 0.000 description 2
- 102100025373 Runt-related transcription factor 1 Human genes 0.000 description 2
- 108091006460 SLC25A28 Proteins 0.000 description 2
- 101150058731 STAT5A gene Proteins 0.000 description 2
- 101150063267 STAT5B gene Proteins 0.000 description 2
- 102100029666 Serine/arginine-rich splicing factor 2 Human genes 0.000 description 2
- 102100035348 Serine/threonine-protein phosphatase 2B catalytic subunit alpha isoform Human genes 0.000 description 2
- 102100022346 Serine/threonine-protein phosphatase 5 Human genes 0.000 description 2
- 102100034258 Sialomucin core protein 24 Human genes 0.000 description 2
- 102100022055 Signal recognition particle 9 kDa protein Human genes 0.000 description 2
- 101710131307 Signal recognition particle 9 kDa protein Proteins 0.000 description 2
- 102100024481 Signal transducer and activator of transcription 5A Human genes 0.000 description 2
- 102100024474 Signal transducer and activator of transcription 5B Human genes 0.000 description 2
- 102100029719 Single-stranded DNA-binding protein, mitochondrial Human genes 0.000 description 2
- 102000039471 Small Nuclear RNA Human genes 0.000 description 2
- 102100030435 Sp110 nuclear body protein Human genes 0.000 description 2
- 102100039024 Sphingosine kinase 1 Human genes 0.000 description 2
- 101000857870 Squalus acanthias Gonadoliberin Proteins 0.000 description 2
- 102100034291 Sterile alpha motif domain-containing protein 9 Human genes 0.000 description 2
- 102100022459 Sterile alpha motif domain-containing protein 9-like Human genes 0.000 description 2
- 102100030100 Sulfate anion transporter 1 Human genes 0.000 description 2
- 102100037219 Syntenin-1 Human genes 0.000 description 2
- 108700012411 TNFSF10 Proteins 0.000 description 2
- 102100029451 TRAF-type zinc finger domain-containing protein 1 Human genes 0.000 description 2
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 description 2
- 102100031344 Thioredoxin-interacting protein Human genes 0.000 description 2
- 102000036693 Thrombopoietin Human genes 0.000 description 2
- 108010041111 Thrombopoietin Proteins 0.000 description 2
- 102100036034 Thrombospondin-1 Human genes 0.000 description 2
- 102100031372 Thymidine phosphorylase Human genes 0.000 description 2
- IVTVGDXNLFLDRM-HNNXBMFYSA-N Tomudex Chemical compound C=1C=C2NC(C)=NC(=O)C2=CC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)S1 IVTVGDXNLFLDRM-HNNXBMFYSA-N 0.000 description 2
- 108020004566 Transfer RNA Proteins 0.000 description 2
- 102100027030 Transmembrane protein 140 Human genes 0.000 description 2
- 102100034593 Tripartite motif-containing protein 26 Human genes 0.000 description 2
- 102100040411 Tripeptidyl-peptidase 2 Human genes 0.000 description 2
- 108010050144 Triptorelin Pamoate Proteins 0.000 description 2
- 102100034300 Tryptophan-tRNA ligase, cytoplasmic Human genes 0.000 description 2
- 102100024598 Tumor necrosis factor ligand superfamily member 10 Human genes 0.000 description 2
- 102100026857 Tyrosine-protein kinase Lyn Human genes 0.000 description 2
- 102100033001 Tyrosine-protein phosphatase non-receptor type 1 Human genes 0.000 description 2
- 102100033019 Tyrosine-protein phosphatase non-receptor type 11 Human genes 0.000 description 2
- 102100033141 Tyrosine-protein phosphatase non-receptor type 2 Human genes 0.000 description 2
- 102100023341 Ubiquitin-40S ribosomal protein S27a Human genes 0.000 description 2
- 102100028462 Ubiquitin-60S ribosomal protein L40 Human genes 0.000 description 2
- 102100020711 Ubiquitin-conjugating enzyme E2 E1 Human genes 0.000 description 2
- 102100020698 Ubiquitin-conjugating enzyme E2 H Human genes 0.000 description 2
- 102100020695 Ubiquitin-conjugating enzyme E2 N Human genes 0.000 description 2
- 102100020726 Ubl carboxyl-terminal hydrolase 18 Human genes 0.000 description 2
- 102100026785 Unconventional myosin-Ic Human genes 0.000 description 2
- 102100024689 Urokinase plasminogen activator surface receptor Human genes 0.000 description 2
- 102100037167 V-type proton ATPase 21 kDa proteolipid subunit c'' Human genes 0.000 description 2
- 102100031484 Vesicle-associated membrane protein 5 Human genes 0.000 description 2
- 102100040984 Volume-regulated anion channel subunit LRRC8C Human genes 0.000 description 2
- 102100039488 XIAP-associated factor 1 Human genes 0.000 description 2
- 102100040310 Z-DNA-binding protein 1 Human genes 0.000 description 2
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 2
- BOPGDPNILDQYTO-NDOGXIPWSA-N [[(2r,3r,4r,5r)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [(2r,3r,4r,5r)-5-(3-carbamoyl-4h-pyridin-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl hydrogen phosphate Chemical compound C1=CCC(C(=O)N)=CN1[C@H]1[C@H](O)[C@@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]2[C@@H]([C@@H](O)[C@@H](O2)N2C3=NC=NC(N)=C3N=C2)O)O1 BOPGDPNILDQYTO-NDOGXIPWSA-N 0.000 description 2
- USZYSDMBJDPRIF-SVEJIMAYSA-N aclacinomycin A Chemical compound O([C@H]1[C@@H](O)C[C@@H](O[C@H]1C)O[C@H]1[C@H](C[C@@H](O[C@H]1C)O[C@H]1C[C@]([C@@H](C2=CC=3C(=O)C4=CC=CC(O)=C4C(=O)C=3C(O)=C21)C(=O)OC)(O)CC)N(C)C)[C@H]1CCC(=O)[C@H](C)O1 USZYSDMBJDPRIF-SVEJIMAYSA-N 0.000 description 2
- 229960004176 aclarubicin Drugs 0.000 description 2
- SMPZPKRDRQOOHT-UHFFFAOYSA-N acronycine Chemical compound CN1C2=CC=CC=C2C(=O)C2=C1C(C=CC(C)(C)O1)=C1C=C2OC SMPZPKRDRQOOHT-UHFFFAOYSA-N 0.000 description 2
- RJURFGZVJUQBHK-IIXSONLDSA-N actinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-IIXSONLDSA-N 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 2
- 229950004955 adozelesin Drugs 0.000 description 2
- BYRVKDUQDLJUBX-JJCDCTGGSA-N adozelesin Chemical compound C1=CC=C2OC(C(=O)NC=3C=C4C=C(NC4=CC=3)C(=O)N3C[C@H]4C[C@]44C5=C(C(C=C43)=O)NC=C5C)=CC2=C1 BYRVKDUQDLJUBX-JJCDCTGGSA-N 0.000 description 2
- 229940009456 adriamycin Drugs 0.000 description 2
- 229960001686 afatinib Drugs 0.000 description 2
- ULXXDDBFHOBEHA-CWDCEQMOSA-N afatinib Chemical compound N1=CN=C2C=C(O[C@@H]3COCC3)C(NC(=O)/C=C/CN(C)C)=CC2=C1NC1=CC=C(F)C(Cl)=C1 ULXXDDBFHOBEHA-CWDCEQMOSA-N 0.000 description 2
- 108700025316 aldesleukin Proteins 0.000 description 2
- 229960005310 aldesleukin Drugs 0.000 description 2
- 229960000473 altretamine Drugs 0.000 description 2
- 229950010817 alvocidib Drugs 0.000 description 2
- BIIVYFLTOXDAOV-YVEFUNNKSA-N alvocidib Chemical compound O[C@@H]1CN(C)CC[C@@H]1C1=C(O)C=C(O)C2=C1OC(C=1C(=CC=CC=1)Cl)=CC2=O BIIVYFLTOXDAOV-YVEFUNNKSA-N 0.000 description 2
- 229960003437 aminoglutethimide Drugs 0.000 description 2
- ROBVIMPUHSLWNV-UHFFFAOYSA-N aminoglutethimide Chemical compound C=1C=C(N)C=CC=1C1(CC)CCC(=O)NC1=O ROBVIMPUHSLWNV-UHFFFAOYSA-N 0.000 description 2
- 229960002932 anastrozole Drugs 0.000 description 2
- YBBLVLTVTVSKRW-UHFFFAOYSA-N anastrozole Chemical compound N#CC(C)(C)C1=CC(C(C)(C#N)C)=CC(CN2N=CN=C2)=C1 YBBLVLTVTVSKRW-UHFFFAOYSA-N 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 230000002280 anti-androgenic effect Effects 0.000 description 2
- 229940046836 anti-estrogen Drugs 0.000 description 2
- 230000001833 anti-estrogenic effect Effects 0.000 description 2
- 239000000051 antiandrogen Substances 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 230000030741 antigen processing and presentation Effects 0.000 description 2
- 229940045719 antineoplastic alkylating agent nitrosoureas Drugs 0.000 description 2
- 229940045985 antineoplastic platinum compound Drugs 0.000 description 2
- 230000006907 apoptotic process Effects 0.000 description 2
- 229960003852 atezolizumab Drugs 0.000 description 2
- XFILPEOLDIKJHX-QYZOEREBSA-N batimastat Chemical compound C([C@@H](C(=O)NC)NC(=O)[C@H](CC(C)C)[C@H](CSC=1SC=CC=1)C(=O)NO)C1=CC=CC=C1 XFILPEOLDIKJHX-QYZOEREBSA-N 0.000 description 2
- 229950001858 batimastat Drugs 0.000 description 2
- 229960000997 bicalutamide Drugs 0.000 description 2
- 238000001574 biopsy Methods 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 229950008548 bisantrene Drugs 0.000 description 2
- 229950006844 bizelesin Drugs 0.000 description 2
- 238000004820 blood count Methods 0.000 description 2
- 210000000481 breast Anatomy 0.000 description 2
- 229950009494 bropirimine Drugs 0.000 description 2
- 229960002092 busulfan Drugs 0.000 description 2
- 229950002826 canertinib Drugs 0.000 description 2
- OMZCMEYTWSXEPZ-UHFFFAOYSA-N canertinib Chemical compound C1=C(Cl)C(F)=CC=C1NC1=NC=NC2=CC(OCCCN3CCOCC3)=C(NC(=O)C=C)C=C12 OMZCMEYTWSXEPZ-UHFFFAOYSA-N 0.000 description 2
- 229960004117 capecitabine Drugs 0.000 description 2
- 229960004562 carboplatin Drugs 0.000 description 2
- YAYRGNWWLMLWJE-UHFFFAOYSA-L carboplatin Chemical compound O=C1O[Pt](N)(N)OC(=O)C11CCC1 YAYRGNWWLMLWJE-UHFFFAOYSA-L 0.000 description 2
- 229960005243 carmustine Drugs 0.000 description 2
- BBZDXMBRAFTCAA-AREMUKBSSA-N carzelesin Chemical compound C1=2NC=C(C)C=2C([C@H](CCl)CN2C(=O)C=3NC4=CC=C(C=C4C=3)NC(=O)C3=CC4=CC=C(C=C4O3)N(CC)CC)=C2C=C1OC(=O)NC1=CC=CC=C1 BBZDXMBRAFTCAA-AREMUKBSSA-N 0.000 description 2
- 229950007509 carzelesin Drugs 0.000 description 2
- 230000022131 cell cycle Effects 0.000 description 2
- 230000024245 cell differentiation Effects 0.000 description 2
- 210000002421 cell wall Anatomy 0.000 description 2
- 230000005754 cellular signaling Effects 0.000 description 2
- 108010046713 cemadotin Proteins 0.000 description 2
- BZXULYMZYPRZOG-UHFFFAOYSA-N centaureidin Chemical compound C1=C(O)C(OC)=CC=C1C1=C(OC)C(=O)C2=C(O)C(OC)=C(O)C=C2O1 BZXULYMZYPRZOG-UHFFFAOYSA-N 0.000 description 2
- NQGMIPUYCWIEAW-OVCLIPMQSA-N chembl1834105 Chemical compound O/N=C/C1=C(SC)C(OC)=CC(C=2N=CC=CC=2)=N1 NQGMIPUYCWIEAW-OVCLIPMQSA-N 0.000 description 2
- 238000009104 chemotherapy regimen Methods 0.000 description 2
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 2
- 229960004316 cisplatin Drugs 0.000 description 2
- 229960002436 cladribine Drugs 0.000 description 2
- 229960002271 cobimetinib Drugs 0.000 description 2
- BSMCAPRUBJMWDF-KRWDZBQOSA-N cobimetinib Chemical compound C1C(O)([C@H]2NCCCC2)CN1C(=O)C1=CC=C(F)C(F)=C1NC1=CC=C(I)C=C1F BSMCAPRUBJMWDF-KRWDZBQOSA-N 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 230000002596 correlated effect Effects 0.000 description 2
- 108010083340 cryptophycin 52 Proteins 0.000 description 2
- 229960000684 cytarabine Drugs 0.000 description 2
- LVXJQMNHJWSHET-AATRIKPKSA-N dacomitinib Chemical compound C=12C=C(NC(=O)\C=C\CN3CCCCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 LVXJQMNHJWSHET-AATRIKPKSA-N 0.000 description 2
- 229960000640 dactinomycin Drugs 0.000 description 2
- 229960000975 daunorubicin Drugs 0.000 description 2
- STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 description 2
- 229960003603 decitabine Drugs 0.000 description 2
- 230000007850 degeneration Effects 0.000 description 2
- BEFZAMRWPCMWFJ-UHFFFAOYSA-N desoxyepothilone A Natural products O1C(=O)CC(O)C(C)(C)C(=O)C(C)C(O)C(C)CCCC=CCC1C(C)=CC1=CSC(C)=N1 BEFZAMRWPCMWFJ-UHFFFAOYSA-N 0.000 description 2
- 229960003957 dexamethasone Drugs 0.000 description 2
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 2
- WVYXNIXAMZOZFK-UHFFFAOYSA-N diaziquone Chemical compound O=C1C(NC(=O)OCC)=C(N2CC2)C(=O)C(NC(=O)OCC)=C1N1CC1 WVYXNIXAMZOZFK-UHFFFAOYSA-N 0.000 description 2
- 229950002389 diaziquone Drugs 0.000 description 2
- OTKJDMGTUTTYMP-UHFFFAOYSA-N dihydrosphingosine Natural products CCCCCCCCCCCCCCCC(O)C(N)CO OTKJDMGTUTTYMP-UHFFFAOYSA-N 0.000 description 2
- 230000005750 disease progression Effects 0.000 description 2
- NOPFSRXAKWQILS-UHFFFAOYSA-N docosan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCCCCCO NOPFSRXAKWQILS-UHFFFAOYSA-N 0.000 description 2
- 108010045524 dolastatin 10 Proteins 0.000 description 2
- 229950004203 droloxifene Drugs 0.000 description 2
- HESCAJZNRMSMJG-KKQRBIROSA-N epothilone A Chemical class C/C([C@@H]1C[C@@H]2O[C@@H]2CCC[C@@H]([C@@H]([C@@H](C)C(=O)C(C)(C)[C@@H](O)CC(=O)O1)O)C)=C\C1=CSC(C)=N1 HESCAJZNRMSMJG-KKQRBIROSA-N 0.000 description 2
- BEFZAMRWPCMWFJ-QJKGZULSSA-N epothilone C Chemical compound O1C(=O)C[C@H](O)C(C)(C)C(=O)[C@H](C)[C@@H](O)[C@@H](C)CCC\C=C/C[C@H]1C(\C)=C\C1=CSC(C)=N1 BEFZAMRWPCMWFJ-QJKGZULSSA-N 0.000 description 2
- 229950001426 erbulozole Drugs 0.000 description 2
- 229960001433 erlotinib Drugs 0.000 description 2
- AAKJLRGGTJKAMG-UHFFFAOYSA-N erlotinib Chemical compound C=12C=C(OCCOC)C(OCCOC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 AAKJLRGGTJKAMG-UHFFFAOYSA-N 0.000 description 2
- HCZKYJDFEPMADG-UHFFFAOYSA-N erythro-nordihydroguaiaretic acid Natural products C=1C=C(O)C(O)=CC=1CC(C)C(C)CC1=CC=C(O)C(O)=C1 HCZKYJDFEPMADG-UHFFFAOYSA-N 0.000 description 2
- FRPJXPJMRWBBIH-RBRWEJTLSA-N estramustine Chemical class ClCCN(CCCl)C(=O)OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 FRPJXPJMRWBBIH-RBRWEJTLSA-N 0.000 description 2
- WCDWBPCFGJXFJZ-UHFFFAOYSA-N etanidazole Chemical compound OCCNC(=O)CN1C=CN=C1[N+]([O-])=O WCDWBPCFGJXFJZ-UHFFFAOYSA-N 0.000 description 2
- 229950006566 etanidazole Drugs 0.000 description 2
- JEFPWOBULVSOTM-PPHPATTJSA-N ethyl n-[(2s)-5-amino-2-methyl-3-phenyl-1,2-dihydropyrido[3,4-b]pyrazin-7-yl]carbamate;2-hydroxyethanesulfonic acid Chemical compound OCCS(O)(=O)=O.C=1([C@H](C)NC=2C=C(N=C(N)C=2N=1)NC(=O)OCC)C1=CC=CC=C1 JEFPWOBULVSOTM-PPHPATTJSA-N 0.000 description 2
- 229950011548 fadrozole Drugs 0.000 description 2
- NMUSYJAQQFHJEW-ARQDHWQXSA-N fazarabine Chemical compound O=C1N=C(N)N=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 NMUSYJAQQFHJEW-ARQDHWQXSA-N 0.000 description 2
- 229950005096 fazarabine Drugs 0.000 description 2
- 229950003662 fenretinide Drugs 0.000 description 2
- IKIBJHWXDSKRKV-UHFFFAOYSA-N fijianolide B Natural products CC1CC(=C)CC(O)C2OC2CC(OC(=O)C=C/CC3OC(C)(CC=C3)C1)C(O)C=CC4CC(=CCO4)C IKIBJHWXDSKRKV-UHFFFAOYSA-N 0.000 description 2
- 229960004039 finasteride Drugs 0.000 description 2
- DBEPLOCGEIEOCV-WSBQPABSSA-N finasteride Chemical compound N([C@@H]1CC2)C(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H](C(=O)NC(C)(C)C)[C@@]2(C)CC1 DBEPLOCGEIEOCV-WSBQPABSSA-N 0.000 description 2
- 229960000390 fludarabine Drugs 0.000 description 2
- 235000008191 folinic acid Nutrition 0.000 description 2
- 239000011672 folinic acid Substances 0.000 description 2
- VVIAGPKUTFNRDU-ABLWVSNPSA-N folinic acid Chemical compound C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-ABLWVSNPSA-N 0.000 description 2
- CHPZKNULDCNCBW-UHFFFAOYSA-N gallium nitrate Chemical compound [Ga+3].[O-][N+]([O-])=O.[O-][N+]([O-])=O.[O-][N+]([O-])=O CHPZKNULDCNCBW-UHFFFAOYSA-N 0.000 description 2
- 229960002584 gefitinib Drugs 0.000 description 2
- XGALLCVXEZPNRQ-UHFFFAOYSA-N gefitinib Chemical compound C=12C=C(OCCCN3CCOCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 XGALLCVXEZPNRQ-UHFFFAOYSA-N 0.000 description 2
- 208000005017 glioblastoma Diseases 0.000 description 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
- 210000003714 granulocyte Anatomy 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- UUVWYPNAQBNQJQ-UHFFFAOYSA-N hexamethylmelamine Chemical compound CN(C)C1=NC(N(C)C)=NC(N(C)C)=N1 UUVWYPNAQBNQJQ-UHFFFAOYSA-N 0.000 description 2
- 229960001330 hydroxycarbamide Drugs 0.000 description 2
- 229960001101 ifosfamide Drugs 0.000 description 2
- HOMGKSMUEGBAAB-UHFFFAOYSA-N ifosfamide Chemical compound ClCCNP1(=O)OCCCN1CCCl HOMGKSMUEGBAAB-UHFFFAOYSA-N 0.000 description 2
- 229960002411 imatinib Drugs 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 239000012274 immune-checkpoint protein inhibitor Substances 0.000 description 2
- 229960001438 immunostimulant agent Drugs 0.000 description 2
- 239000003022 immunostimulating agent Substances 0.000 description 2
- 230000003308 immunostimulating effect Effects 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 230000008595 infiltration Effects 0.000 description 2
- 238000001764 infiltration Methods 0.000 description 2
- 208000027866 inflammatory disease Diseases 0.000 description 2
- 230000000977 initiatory effect Effects 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- 229960004768 irinotecan Drugs 0.000 description 2
- 108010021336 lanreotide Proteins 0.000 description 2
- MSBQEQDLFWWWMV-XZZGLLCESA-N laulimalide Chemical compound C(/[C@H](O)[C@H]1OC(=O)\C=C/C[C@@H]2C=CC[C@H](O2)C[C@H](CC(=C)C[C@H](O)[C@@H]2O[C@H]2C1)C)=C\[C@@H]1CC(C)=CCO1 MSBQEQDLFWWWMV-XZZGLLCESA-N 0.000 description 2
- 229960003881 letrozole Drugs 0.000 description 2
- HPJKCIUCZWXJDR-UHFFFAOYSA-N letrozole Chemical compound C1=CC(C#N)=CC=C1C(N1N=CN=C1)C1=CC=C(C#N)C=C1 HPJKCIUCZWXJDR-UHFFFAOYSA-N 0.000 description 2
- 229960001691 leucovorin Drugs 0.000 description 2
- 208000032839 leukemia Diseases 0.000 description 2
- 229960001614 levamisole Drugs 0.000 description 2
- 229960003951 masoprocol Drugs 0.000 description 2
- HCZKYJDFEPMADG-TXEJJXNPSA-N masoprocol Chemical compound C([C@H](C)[C@H](C)CC=1C=C(O)C(O)=CC=1)C1=CC=C(O)C(O)=C1 HCZKYJDFEPMADG-TXEJJXNPSA-N 0.000 description 2
- WKPWGQKGSOKKOO-RSFHAFMBSA-N maytansine Chemical compound CO[C@@H]([C@@]1(O)C[C@](OC(=O)N1)([C@H]([C@@H]1O[C@@]1(C)[C@@H](OC(=O)[C@H](C)N(C)C(C)=O)CC(=O)N1C)C)[H])\C=C\C=C(C)\CC2=CC(OC)=C(Cl)C1=C2 WKPWGQKGSOKKOO-RSFHAFMBSA-N 0.000 description 2
- HAWPXGHAZFHHAD-UHFFFAOYSA-N mechlorethamine Chemical compound ClCCN(C)CCCl HAWPXGHAZFHHAD-UHFFFAOYSA-N 0.000 description 2
- 208000023356 medullary thyroid gland carcinoma Diseases 0.000 description 2
- 229960004296 megestrol acetate Drugs 0.000 description 2
- RQZAXGRLVPAYTJ-GQFGMJRRSA-N megestrol acetate Chemical compound C1=C(C)C2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(C)=O)(OC(=O)C)[C@@]1(C)CC2 RQZAXGRLVPAYTJ-GQFGMJRRSA-N 0.000 description 2
- 229960001924 melphalan Drugs 0.000 description 2
- SGDBTWWWUNNDEQ-LBPRGKRZSA-N melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 description 2
- 210000001806 memory b lymphocyte Anatomy 0.000 description 2
- LWYJUZBXGAFFLP-OCNCTQISSA-N menogaril Chemical compound O1[C@@]2(C)[C@H](O)[C@@H](N(C)C)[C@H](O)[C@@H]1OC1=C3C(=O)C(C=C4C[C@@](C)(O)C[C@H](C4=C4O)OC)=C4C(=O)C3=C(O)C=C12 LWYJUZBXGAFFLP-OCNCTQISSA-N 0.000 description 2
- 229950002676 menogaril Drugs 0.000 description 2
- GLVAUDGFNGKCSF-UHFFFAOYSA-N mercaptopurine Chemical compound S=C1NC=NC2=C1NC=N2 GLVAUDGFNGKCSF-UHFFFAOYSA-N 0.000 description 2
- 229960001428 mercaptopurine Drugs 0.000 description 2
- 206010061289 metastatic neoplasm Diseases 0.000 description 2
- 229960000485 methotrexate Drugs 0.000 description 2
- HRHKSTOGXBBQCB-VFWICMBZSA-N methylmitomycin Chemical compound O=C1C(N)=C(C)C(=O)C2=C1[C@@H](COC(N)=O)[C@@]1(OC)[C@H]3N(C)[C@H]3CN12 HRHKSTOGXBBQCB-VFWICMBZSA-N 0.000 description 2
- BMGQWWVMWDBQGC-IIFHNQTCSA-N midostaurin Chemical compound CN([C@H]1[C@H]([C@]2(C)O[C@@H](N3C4=CC=CC=C4C4=C5C(=O)NCC5=C5C6=CC=CC=C6N2C5=C43)C1)OC)C(=O)C1=CC=CC=C1 BMGQWWVMWDBQGC-IIFHNQTCSA-N 0.000 description 2
- CFCUWKMKBJTWLW-BKHRDMLASA-N mithramycin Chemical compound O([C@@H]1C[C@@H](O[C@H](C)[C@H]1O)OC=1C=C2C=C3C[C@H]([C@@H](C(=O)C3=C(O)C2=C(O)C=1C)O[C@@H]1O[C@H](C)[C@@H](O)[C@H](O[C@@H]2O[C@H](C)[C@H](O)[C@H](O[C@@H]3O[C@H](C)[C@@H](O)[C@@](C)(O)C3)C2)C1)[C@H](OC)C(=O)[C@@H](O)[C@@H](C)O)[C@H]1C[C@@H](O)[C@H](O)[C@@H](C)O1 CFCUWKMKBJTWLW-BKHRDMLASA-N 0.000 description 2
- 229960004857 mitomycin Drugs 0.000 description 2
- 229960000350 mitotane Drugs 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- NJSMWLQOCQIOPE-OCHFTUDZSA-N n-[(e)-[10-[(e)-(4,5-dihydro-1h-imidazol-2-ylhydrazinylidene)methyl]anthracen-9-yl]methylideneamino]-4,5-dihydro-1h-imidazol-2-amine Chemical compound N1CCN=C1N\N=C\C(C1=CC=CC=C11)=C(C=CC=C2)C2=C1\C=N\NC1=NCCN1 NJSMWLQOCQIOPE-OCHFTUDZSA-N 0.000 description 2
- 229950008835 neratinib Drugs 0.000 description 2
- ZNHPZUKZSNBOSQ-BQYQJAHWSA-N neratinib Chemical compound C=12C=C(NC\C=C\CN(C)C)C(OCC)=CC2=NC=C(C#N)C=1NC(C=C1Cl)=CC=C1OCC1=CC=CC=N1 ZNHPZUKZSNBOSQ-BQYQJAHWSA-N 0.000 description 2
- 229960005343 ondansetron Drugs 0.000 description 2
- 229950008017 ormaplatin Drugs 0.000 description 2
- 229960001592 paclitaxel Drugs 0.000 description 2
- 229940121656 pd-l1 inhibitor Drugs 0.000 description 2
- 229960001744 pegaspargase Drugs 0.000 description 2
- 108010001564 pegaspargase Proteins 0.000 description 2
- WVUNYSQLFKLYNI-AATRIKPKSA-N pelitinib Chemical compound C=12C=C(NC(=O)\C=C\CN(C)C)C(OCC)=CC2=NC=C(C#N)C=1NC1=CC=C(F)C(Cl)=C1 WVUNYSQLFKLYNI-AATRIKPKSA-N 0.000 description 2
- 229960002340 pentostatin Drugs 0.000 description 2
- FPVKHBSQESCIEP-JQCXWYLXSA-N pentostatin Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(N=CNC[C@H]2O)=C2N=C1 FPVKHBSQESCIEP-JQCXWYLXSA-N 0.000 description 2
- VPAWVRUHMJVRHU-VGDKGRGNSA-N perfosfamide Chemical compound OO[C@@H]1CCO[P@@](=O)(N(CCCl)CCCl)N1 VPAWVRUHMJVRHU-VGDKGRGNSA-N 0.000 description 2
- 229950009351 perfosfamide Drugs 0.000 description 2
- NDTYTMIUWGWIMO-UHFFFAOYSA-N perillyl alcohol Chemical compound CC(=C)C1CCC(CO)=CC1 NDTYTMIUWGWIMO-UHFFFAOYSA-N 0.000 description 2
- 210000004180 plasmocyte Anatomy 0.000 description 2
- 229910052697 platinum Inorganic materials 0.000 description 2
- 150000003058 platinum compounds Chemical class 0.000 description 2
- 229960003171 plicamycin Drugs 0.000 description 2
- 229960004293 porfimer sodium Drugs 0.000 description 2
- 229950004406 porfiromycin Drugs 0.000 description 2
- 229960004618 prednisone Drugs 0.000 description 2
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 2
- 238000002203 pretreatment Methods 0.000 description 2
- 238000004393 prognosis Methods 0.000 description 2
- 208000037821 progressive disease Diseases 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 230000000069 prophylactic effect Effects 0.000 description 2
- 229940121649 protein inhibitor Drugs 0.000 description 2
- 239000012268 protein inhibitor Substances 0.000 description 2
- 239000003881 protein kinase C inhibitor Substances 0.000 description 2
- RXWNCPJZOCPEPQ-NVWDDTSBSA-N puromycin Chemical compound C1=CC(OC)=CC=C1C[C@H](N)C(=O)N[C@H]1[C@@H](O)[C@H](N2C3=NC=NC(=C3N=C2)N(C)C)O[C@@H]1CO RXWNCPJZOCPEPQ-NVWDDTSBSA-N 0.000 description 2
- 229960004432 raltitrexed Drugs 0.000 description 2
- 230000007115 recruitment Effects 0.000 description 2
- QXKJWHWUDVQATH-UHFFFAOYSA-N rogletimide Chemical compound C=1C=NC=CC=1C1(CC)CCC(=O)NC1=O QXKJWHWUDVQATH-UHFFFAOYSA-N 0.000 description 2
- 229950005230 rogletimide Drugs 0.000 description 2
- MOCVYVBNJQIVOV-TVQRCGJNSA-N rohitukine Chemical compound O[C@@H]1CN(C)CC[C@@H]1C1=C(O)C=C(O)C2=C1OC(C)=CC2=O MOCVYVBNJQIVOV-TVQRCGJNSA-N 0.000 description 2
- 229950008902 safingol Drugs 0.000 description 2
- CGFVUVWMYIHGHS-UHFFFAOYSA-N saintopin Chemical compound C1=C(O)C=C2C=C(C(=O)C=3C(=C(O)C=C(C=3)O)C3=O)C3=C(O)C2=C1O CGFVUVWMYIHGHS-UHFFFAOYSA-N 0.000 description 2
- 229940126586 small molecule drug Drugs 0.000 description 2
- 108091029842 small nuclear ribonucleic acid Proteins 0.000 description 2
- XBUIKNRVGYFSHL-IAVQPKKASA-M sodium;[(1e,3r,4r,6r,7z,9z,11e)-3,6,13-trihydroxy-3-methyl-1-[(2r)-6-oxo-2,3-dihydropyran-2-yl]trideca-1,7,9,11-tetraen-4-yl] hydrogen phosphate Chemical compound [Na+].OC/C=C/C=C\C=C/[C@H](O)C[C@@H](OP(O)([O-])=O)[C@@](O)(C)\C=C\[C@H]1CC=CC(=O)O1 XBUIKNRVGYFSHL-IAVQPKKASA-M 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 229960003787 sorafenib Drugs 0.000 description 2
- ICXJVZHDZFXYQC-UHFFFAOYSA-N spongistatin 1 Natural products OC1C(O2)(O)CC(O)C(C)C2CCCC=CC(O2)CC(O)CC2(O2)CC(OC)CC2CC(=O)C(C)C(OC(C)=O)C(C)C(=C)CC(O2)CC(C)(O)CC2(O2)CC(OC(C)=O)CC2CC(=O)OC2C(O)C(CC(=C)CC(O)C=CC(Cl)=C)OC1C2C ICXJVZHDZFXYQC-UHFFFAOYSA-N 0.000 description 2
- HAOCRCFHEPRQOY-JKTUOYIXSA-N spongistatin-1 Chemical compound C([C@@H]1C[C@@H](C[C@@]2(C[C@@H](O)C[C@@H](C2)\C=C/CCC[C@@H]2[C@H](C)[C@@H](O)C[C@](O2)(O)[C@H]2O)O1)OC)C(=O)[C@@H](C)[C@@H](OC(C)=O)[C@H](C)C(=C)C[C@H](O1)C[C@](C)(O)C[C@@]1(O1)C[C@@H](OC(C)=O)C[C@@H]1CC(=O)O[C@H]1[C@H](O)[C@@H](CC(=C)C(C)[C@H](O)\C=C\C(Cl)=C)O[C@@H]2[C@@H]1C HAOCRCFHEPRQOY-JKTUOYIXSA-N 0.000 description 2
- PVYJZLYGTZKPJE-UHFFFAOYSA-N streptonigrin Chemical compound C=1C=C2C(=O)C(OC)=C(N)C(=O)C2=NC=1C(C=1N)=NC(C(O)=O)=C(C)C=1C1=CC=C(OC)C(OC)=C1O PVYJZLYGTZKPJE-UHFFFAOYSA-N 0.000 description 2
- 229960001052 streptozocin Drugs 0.000 description 2
- ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 229950007866 tanespimycin Drugs 0.000 description 2
- AYUNIORJHRXIBJ-TXHRRWQRSA-N tanespimycin Chemical compound N1C(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@@H](O)[C@@H](OC)C[C@H](C)CC2=C(NCC=C)C(=O)C=C1C2=O AYUNIORJHRXIBJ-TXHRRWQRSA-N 0.000 description 2
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 2
- URLYINUFLXOMHP-HTVVRFAVSA-N tcn-p Chemical compound C=12C3=NC=NC=1N(C)N=C(N)C2=CN3[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]1O URLYINUFLXOMHP-HTVVRFAVSA-N 0.000 description 2
- 229960001674 tegafur Drugs 0.000 description 2
- WFWLQNSHRPWKFK-ZCFIWIBFSA-N tegafur Chemical compound O=C1NC(=O)C(F)=CN1[C@@H]1OCCC1 WFWLQNSHRPWKFK-ZCFIWIBFSA-N 0.000 description 2
- 229960002197 temoporfin Drugs 0.000 description 2
- 201000002510 thyroid cancer Diseases 0.000 description 2
- 229960003087 tioguanine Drugs 0.000 description 2
- 229950002376 tirapazamine Drugs 0.000 description 2
- QVMPZNRFXAKISM-UHFFFAOYSA-N tirapazamine Chemical compound C1=CC=C2[N+]([O-])=NC(=N)N(O)C2=C1 QVMPZNRFXAKISM-UHFFFAOYSA-N 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- 229960000303 topotecan Drugs 0.000 description 2
- UCFGDBYHRUNTLO-QHCPKHFHSA-N topotecan Chemical compound C1=C(O)C(CN(C)C)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 UCFGDBYHRUNTLO-QHCPKHFHSA-N 0.000 description 2
- TVPNFKRGOFJQOO-UHFFFAOYSA-N topsentin b1 Chemical compound C1=CC=C2C(C3=CN=C(N3)C(=O)C=3C4=CC=C(C=C4NC=3)O)=CNC2=C1 TVPNFKRGOFJQOO-UHFFFAOYSA-N 0.000 description 2
- 238000012549 training Methods 0.000 description 2
- 229960004066 trametinib Drugs 0.000 description 2
- LIRYPHYGHXZJBZ-UHFFFAOYSA-N trametinib Chemical compound CC(=O)NC1=CC=CC(N2C(N(C3CC3)C(=O)C3=C(NC=4C(=CC(I)=CC=4)F)N(C)C(=O)C(C)=C32)=O)=C1 LIRYPHYGHXZJBZ-UHFFFAOYSA-N 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 238000013519 translation Methods 0.000 description 2
- 229960001099 trimetrexate Drugs 0.000 description 2
- NOYPYLRCIDNJJB-UHFFFAOYSA-N trimetrexate Chemical compound COC1=C(OC)C(OC)=CC(NCC=2C(=C3C(N)=NC(N)=NC3=CC=2)C)=C1 NOYPYLRCIDNJJB-UHFFFAOYSA-N 0.000 description 2
- 108010039189 tripeptidyl-peptidase 2 Proteins 0.000 description 2
- VXKHXGOKWPXYNA-PGBVPBMZSA-N triptorelin Chemical compound C([C@@H](C(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 VXKHXGOKWPXYNA-PGBVPBMZSA-N 0.000 description 2
- 229960004824 triptorelin Drugs 0.000 description 2
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 description 2
- 229960001055 uracil mustard Drugs 0.000 description 2
- 210000002700 urine Anatomy 0.000 description 2
- 229960002730 vapreotide Drugs 0.000 description 2
- 108700029852 vapreotide Proteins 0.000 description 2
- ZQFGRJWRSLZCSQ-ZSFNYQMMSA-N verteporfin Chemical compound C=1C([C@@]2([C@H](C(=O)OC)C(=CC=C22)C(=O)OC)C)=NC2=CC(C(=C2C=C)C)=NC2=CC(C(=C2CCC(O)=O)C)=NC2=CC2=NC=1C(C)=C2CCC(=O)OC ZQFGRJWRSLZCSQ-ZSFNYQMMSA-N 0.000 description 2
- 229960003895 verteporfin Drugs 0.000 description 2
- 229960003048 vinblastine Drugs 0.000 description 2
- JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 description 2
- AQTQHPDCURKLKT-JKDPCDLQSA-N vincristine sulfate Chemical compound OS(O)(=O)=O.C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C=O)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 AQTQHPDCURKLKT-JKDPCDLQSA-N 0.000 description 2
- 229960002110 vincristine sulfate Drugs 0.000 description 2
- 229960002066 vinorelbine Drugs 0.000 description 2
- GBABOYUKABKIAF-GHYRFKGUSA-N vinorelbine Chemical compound C1N(CC=2C3=CC=CC=C3NC=22)CC(CC)=C[C@H]1C[C@]2(C(=O)OC)C1=CC([C@]23[C@H]([C@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC GBABOYUKABKIAF-GHYRFKGUSA-N 0.000 description 2
- 229960001771 vorozole Drugs 0.000 description 2
- XLMPPFTZALNBFS-INIZCTEOSA-N vorozole Chemical compound C1([C@@H](C2=CC=C3N=NN(C3=C2)C)N2N=CN=C2)=CC=C(Cl)C=C1 XLMPPFTZALNBFS-INIZCTEOSA-N 0.000 description 2
- 229950003017 zeniplatin Drugs 0.000 description 2
- AADVCYNFEREWOS-UHFFFAOYSA-N (+)-DDM Natural products C=CC=CC(C)C(OC(N)=O)C(C)C(O)C(C)CC(C)=CC(C)C(O)C(C)C=CC(O)CC1OC(=O)C(C)C(O)C1C AADVCYNFEREWOS-UHFFFAOYSA-N 0.000 description 1
- OPFTUNCRGUEPRZ-UHFFFAOYSA-N (+)-beta-Elemen Natural products CC(=C)C1CCC(C)(C=C)C(C(C)=C)C1 OPFTUNCRGUEPRZ-UHFFFAOYSA-N 0.000 description 1
- BMKDZUISNHGIBY-ZETCQYMHSA-N (+)-dexrazoxane Chemical compound C([C@H](C)N1CC(=O)NC(=O)C1)N1CC(=O)NC(=O)C1 BMKDZUISNHGIBY-ZETCQYMHSA-N 0.000 description 1
- FCCNKYGSMOSYPV-DEDISHTHSA-N (-)-Epothilone E Natural products O=C1[C@H](C)[C@H](O)[C@@H](C)CCC[C@H]2O[C@H]2C[C@@H](/C(=C\c2nc(CO)sc2)/C)OC(=O)C[C@H](O)C1(C)C FCCNKYGSMOSYPV-DEDISHTHSA-N 0.000 description 1
- UKIMCRYGLFQEOE-RLHMMOOASA-N (-)-Epothilone F Natural products O=C1[C@H](C)[C@H](O)[C@@H](C)CCC[C@@]2(C)O[C@H]2C[C@@H](/C(=C\c2nc(CO)sc2)/C)OC(=O)C[C@H](O)C1(C)C UKIMCRYGLFQEOE-RLHMMOOASA-N 0.000 description 1
- OPFTUNCRGUEPRZ-QLFBSQMISA-N (-)-beta-elemene Chemical compound CC(=C)[C@@H]1CC[C@@](C)(C=C)[C@H](C(C)=C)C1 OPFTUNCRGUEPRZ-QLFBSQMISA-N 0.000 description 1
- KQODQNJLJQHFQV-UHFFFAOYSA-N (-)-hemiasterlin Natural products C1=CC=C2C(C(C)(C)C(C(=O)NC(C(=O)N(C)C(C=C(C)C(O)=O)C(C)C)C(C)(C)C)NC)=CN(C)C2=C1 KQODQNJLJQHFQV-UHFFFAOYSA-N 0.000 description 1
- 229930007631 (-)-perillyl alcohol Natural products 0.000 description 1
- OTWVIYXCRFLDJW-QMVMUTFZSA-N (1-hydroxy-1-phosphonooxyethyl) dihydrogen phosphate;rhenium-186 Chemical compound [186Re].OP(=O)(O)OC(O)(C)OP(O)(O)=O OTWVIYXCRFLDJW-QMVMUTFZSA-N 0.000 description 1
- FNEOHTTZLPHOSX-KZNAEPCWSA-N (1r)-1-[(2r,5r)-5-(hydroxymethyl)oxolan-2-yl]tridecan-1-ol Chemical compound CCCCCCCCCCCC[C@@H](O)[C@H]1CC[C@H](CO)O1 FNEOHTTZLPHOSX-KZNAEPCWSA-N 0.000 description 1
- XJYQGNNBDGDYCE-DXBBTUNJSA-N (1r)-1-[(2r,5r)-5-[(1s)-1-hydroxypent-4-enyl]oxolan-2-yl]tridecan-1-ol Chemical compound CCCCCCCCCCCC[C@@H](O)[C@H]1CC[C@H]([C@@H](O)CCC=C)O1 XJYQGNNBDGDYCE-DXBBTUNJSA-N 0.000 description 1
- GCPUVEMWOWMALU-HZMBPMFUSA-N (1s,3s)-1-hydroxy-8-methoxy-3-methyl-1,2,3,4-tetrahydrobenzo[a]anthracene-7,12-dione Chemical compound C1[C@H](C)C[C@H](O)C2=C1C=CC1=C2C(=O)C(C=CC=C2OC)=C2C1=O GCPUVEMWOWMALU-HZMBPMFUSA-N 0.000 description 1
- MNHVIVWFCMBFCV-AVGNSLFASA-N (2S)-2-[[(2S)-2-[[(4S)-4-amino-4-carboxybutanoyl]amino]-6-diazo-5-oxohexanoyl]amino]-6-diazo-5-oxohexanoic acid Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CCC(=O)C=[N+]=[N-])C(=O)N[C@@H](CCC(=O)C=[N+]=[N-])C(O)=O MNHVIVWFCMBFCV-AVGNSLFASA-N 0.000 description 1
- MXABZXILAJGOTL-AUYMZICSSA-N (2S)-N-[(2S)-1-[(2S)-1-[(2S,3S)-1-[(2S)-1-[2-[(2S)-1,3-dihydroxy-1-[(E)-1-hydroxy-1-[(2S,3S)-1-hydroxy-3-methyl-1-[[(2Z,6S,9S,12R)-5,8,11-trihydroxy-9-(2-methylpropyl)-6-propan-2-yl-1-thia-4,7,10-triazacyclotrideca-2,4,7,10-tetraen-12-yl]imino]pentan-2-yl]iminobut-2-en-2-yl]iminopropan-2-yl]imino-2-hydroxyethyl]imino-1,5-dihydroxy-5-iminopentan-2-yl]imino-1-hydroxy-3-methylpentan-2-yl]imino-1-hydroxy-3-methylbutan-2-yl]imino-1-hydroxy-3-phenylpropan-2-yl]-2-[[(2S)-2-[[(2S)-2-[[(Z)-2-[[(2S)-2-[[(Z)-2-[[(2S)-2-[[[(2S)-1-[(Z)-2-[[(2S)-2-(dimethylamino)-1-hydroxypropylidene]amino]but-2-enoyl]pyrrolidin-2-yl]-hydroxymethylidene]amino]-1-hydroxypropylidene]amino]-1-hydroxybut-2-enylidene]amino]-1-hydroxy-3-phenylpropylidene]amino]-1-hydroxybut-2-enylidene]amino]-1-hydroxy-3-methylbutylidene]amino]-1-hydroxypropylidene]amino]pentanediimidic acid Chemical compound CC[C@H](C)[C@H](\N=C(/O)[C@@H](\N=C(/O)[C@H](Cc1ccccc1)\N=C(/O)[C@H](CCC(O)=N)\N=C(/O)[C@H](C)\N=C(/O)[C@@H](\N=C(/O)\C(=C\C)\N=C(/O)[C@H](Cc1ccccc1)\N=C(/O)\C(=C\C)\N=C(/O)[C@H](C)\N=C(/O)[C@@H]1CCCN1C(=O)\C(=C\C)\N=C(/O)[C@H](C)N(C)C)C(C)C)C(C)C)C(\O)=N\[C@@H](CCC(O)=N)C(\O)=N\C\C(O)=N\[C@@H](CO)C(\O)=N\C(=C\C)\C(\O)=N\[C@@H]([C@@H](C)CC)C(\O)=N\[C@H]1CS\C=C/N=C(O)\[C@@H](\N=C(O)/[C@H](CC(C)C)\N=C1\O)C(C)C MXABZXILAJGOTL-AUYMZICSSA-N 0.000 description 1
- MRJQTLJSMQOFTP-JGTKTWDESA-N (2S)-N-benzyl-1-[(2S)-1-[(2S)-2-[[(2S)-2-[[(2S)-2-(dimethylamino)-3-methylbutanoyl]amino]-3-methylbutanoyl]-methylamino]-3-methylbutanoyl]pyrrolidine-2-carbonyl]pyrrolidine-2-carboxamide hydrochloride Chemical compound Cl.CC(C)[C@H](N(C)C)C(=O)N[C@@H](C(C)C)C(=O)N(C)[C@@H](C(C)C)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(=O)NCC=2C=CC=CC=2)CCC1 MRJQTLJSMQOFTP-JGTKTWDESA-N 0.000 description 1
- KJTPWUVVLPCPJD-VGOFMYFVSA-N (2e)-7-amino-2-[(4-hydroxy-3,5-dimethylphenyl)methylidene]-5,6-dimethoxy-3h-inden-1-one Chemical compound O=C1C=2C(N)=C(OC)C(OC)=CC=2C\C1=C/C1=CC(C)=C(O)C(C)=C1 KJTPWUVVLPCPJD-VGOFMYFVSA-N 0.000 description 1
- BUSGWUFLNHIBPT-XYBORKQMSA-N (2e,4e,6e)-7-[(1r,5r,6s)-3-[[(2e,4e)-5-cyclohexylpenta-2,4-dienoyl]amino]-5-hydroxy-2-oxo-7-oxabicyclo[4.1.0]hept-3-en-5-yl]hepta-2,4,6-trienoic acid Chemical compound C([C@]([C@H]1O[C@H]1C1=O)(O)/C=C/C=C/C=C/C(=O)O)=C1NC(=O)\C=C\C=C\C1CCCCC1 BUSGWUFLNHIBPT-XYBORKQMSA-N 0.000 description 1
- LCADVYTXPLBAGB-AUQKUMLUSA-N (2e,4e,6z,8e,10e,14e)-13-hydroxy-n-(1-hydroxypropan-2-yl)-2,10,12,14,16-pentamethyl-18-phenyloctadeca-2,4,6,8,10,14-hexaenamide Chemical compound OCC(C)NC(=O)C(\C)=C\C=C\C=C/C=C/C(/C)=C/C(C)C(O)C(\C)=C\C(C)CCC1=CC=CC=C1 LCADVYTXPLBAGB-AUQKUMLUSA-N 0.000 description 1
- FKHUGQZRBPETJR-RXSRXONKSA-N (2r)-2-[[(4r)-4-[[(2s)-2-[[(2r)-2-[(3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxypropanoyl]amino]propanoyl]amino]-5-amino-5-oxopentanoyl]amino]-6-(octadecanoylamino)hexanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(=O)NCCCC[C@H](C(O)=O)NC(=O)CC[C@H](C(N)=O)NC(=O)[C@H](C)NC(=O)[C@@H](C)O[C@H]1[C@H](O)[C@@H](CO)OC(O)[C@@H]1NC(C)=O FKHUGQZRBPETJR-RXSRXONKSA-N 0.000 description 1
- SWTGJCNCBUCXSS-ISUZDFFFSA-N (2r)-3,4-dihydroxy-2-[(4s)-2-phenyl-1,3-dioxolan-4-yl]-2h-furan-5-one Chemical compound OC1=C(O)C(=O)O[C@@H]1[C@H]1OC(C=2C=CC=CC=2)OC1 SWTGJCNCBUCXSS-ISUZDFFFSA-N 0.000 description 1
- RCGXNDQKCXNWLO-WLEIXIPESA-N (2r)-n-[(2s)-5-amino-1-[[(2r,3r)-1-[[(3s,6z,9s,12r,15r,18r,19s)-9-benzyl-15-[(2r)-butan-2-yl]-6-ethylidene-19-methyl-2,5,8,11,14,17-hexaoxo-3,12-di(propan-2-yl)-1-oxa-4,7,10,13,16-pentazacyclononadec-18-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-1-oxopent Chemical compound N([C@@H](CCCN)C(=O)N[C@H]([C@H](C)CC)C(=O)N[C@H]1C(N[C@@H](C(=O)N[C@@H](C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)NC(/C(=O)N[C@H](C(=O)O[C@H]1C)C(C)C)=C\C)C(C)C)[C@H](C)CC)=O)C(=O)[C@H]1CCCN1C(=O)[C@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](NC(=O)CCCC(C)C)C(C)C)[C@@H](C)O)C(C)C)C(C)C RCGXNDQKCXNWLO-WLEIXIPESA-N 0.000 description 1
- NOENHWMKHNSHGX-IZOOSHNJSA-N (2s)-1-[(2s)-2-[[(2s)-2-[[(2r)-2-[[(2r)-2-[[(2s)-2-[[(2r)-2-[[(2s)-2-[[(2r)-2-acetamido-3-naphthalen-2-ylpropanoyl]amino]-3-(4-chlorophenyl)propanoyl]amino]-3-pyridin-3-ylpropanoyl]amino]-3-hydroxypropanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-6-(ca Chemical compound C([C@H](C(=O)N[C@H](CCCCNC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCNC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N[C@H](C)C(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](CC=1C=NC=CC=1)NC(=O)[C@H](CC=1C=CC(Cl)=CC=1)NC(=O)[C@@H](CC=1C=C2C=CC=CC2=CC=1)NC(C)=O)C1=CC=C(O)C=C1 NOENHWMKHNSHGX-IZOOSHNJSA-N 0.000 description 1
- ZZKNRXZVGOYGJT-VKHMYHEASA-N (2s)-2-[(2-phosphonoacetyl)amino]butanedioic acid Chemical compound OC(=O)C[C@@H](C(O)=O)NC(=O)CP(O)(O)=O ZZKNRXZVGOYGJT-VKHMYHEASA-N 0.000 description 1
- XDZGQQRZJDKPTG-HBNQUELISA-N (2s)-2-[(3s,6s)-6-[2-[(1r,2r,4as,8as)-1-hydroxy-2,4a,5,5,8a-pentamethyl-2,3,4,6,7,8-hexahydronaphthalen-1-yl]ethyl]-6-methyldioxan-3-yl]propanoic acid Chemical compound O1O[C@H]([C@H](C)C(O)=O)CC[C@@]1(C)CC[C@]1(O)[C@@]2(C)CCCC(C)(C)[C@]2(C)CC[C@H]1C XDZGQQRZJDKPTG-HBNQUELISA-N 0.000 description 1
- CUCSSYAUKKIDJV-FAXBSAIASA-N (2s)-2-[[(2r)-2-[[(2s)-2-[[(2r)-2-[[(2s)-2-amino-5-(diaminomethylideneamino)pentanoyl]amino]-3-(1h-indol-3-yl)propanoyl]-methylamino]-3-phenylpropanoyl]amino]-3-(1h-indol-3-yl)propanoyl]amino]-n-[(2s)-1-amino-4-methylsulfanyl-1-oxobutan-2-yl]-4-methylpent Chemical compound C([C@@H](C(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(N)=O)N(C)C(=O)[C@@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@@H](N)CCCN=C(N)N)C1=CC=CC=C1 CUCSSYAUKKIDJV-FAXBSAIASA-N 0.000 description 1
- ZUQBAQVRAURMCL-DOMZBBRYSA-N (2s)-2-[[4-[2-[(6r)-2-amino-4-oxo-5,6,7,8-tetrahydro-1h-pyrido[2,3-d]pyrimidin-6-yl]ethyl]benzoyl]amino]pentanedioic acid Chemical compound C([C@@H]1CC=2C(=O)N=C(NC=2NC1)N)CC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 ZUQBAQVRAURMCL-DOMZBBRYSA-N 0.000 description 1
- JRBXPUUAYKCCLQ-QMMMGPOBSA-N (2s)-2-amino-2-[3-hydroxy-4-(hydroxymethyl)phenyl]acetic acid Chemical compound OC(=O)[C@@H](N)C1=CC=C(CO)C(O)=C1 JRBXPUUAYKCCLQ-QMMMGPOBSA-N 0.000 description 1
- HJNZCKLMRAOTMA-BRBGIFQRSA-N (2s)-n-[(2s)-1-[[(2s)-1-[[(2s)-1-[[(2s)-1-[[(2r)-1-[[(2s)-1-[[(2s)-5-(diaminomethylideneamino)-1-[(2s)-2-(ethylcarbamoyl)pyrrolidin-1-yl]-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(2-methyl-1h-indol-3-yl)-1-oxopropan-2-yl]amino]-3-(4-hydr Chemical compound CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=C(C)NC2=CC=CC=C12 HJNZCKLMRAOTMA-BRBGIFQRSA-N 0.000 description 1
- NAALWFYYHHJEFQ-ZASNTINBSA-N (2s,5r,6r)-6-[[(2r)-2-[[6-[4-[bis(2-hydroxyethyl)sulfamoyl]phenyl]-2-oxo-1h-pyridine-3-carbonyl]amino]-2-(4-hydroxyphenyl)acetyl]amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid Chemical compound N([C@@H](C(=O)N[C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C=1C=CC(O)=CC=1)C(=O)C(C(N1)=O)=CC=C1C1=CC=C(S(=O)(=O)N(CCO)CCO)C=C1 NAALWFYYHHJEFQ-ZASNTINBSA-N 0.000 description 1
- RDIMTXDFGHNINN-UHFFFAOYSA-N (3R,9R,10R)-1-heptadecen-4,6-diyne-3,9,10-triol Natural products CCCCCCCC(O)C(O)CC#CC#CC(O)C=C RDIMTXDFGHNINN-UHFFFAOYSA-N 0.000 description 1
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
- LSXOBYNBRKOTIQ-RQUBOUMQSA-N (3s,10r,13e,16s)-10-[(3-chloro-4-methoxyphenyl)methyl]-6,6-dimethyl-3-(2-methylpropyl)-16-[(1s)-1-[(2r,3r)-3-phenyloxiran-2-yl]ethyl]-1,4-dioxa-8,11-diazacyclohexadec-13-ene-2,5,9,12-tetrone Chemical compound C1=C(Cl)C(OC)=CC=C1C[C@@H]1C(=O)NCC(C)(C)C(=O)O[C@@H](CC(C)C)C(=O)O[C@H]([C@H](C)[C@@H]2[C@H](O2)C=2C=CC=CC=2)C/C=C/C(=O)N1 LSXOBYNBRKOTIQ-RQUBOUMQSA-N 0.000 description 1
- TVIRNGFXQVMMGB-OFWIHYRESA-N (3s,6r,10r,13e,16s)-16-[(2r,3r,4s)-4-chloro-3-hydroxy-4-phenylbutan-2-yl]-10-[(3-chloro-4-methoxyphenyl)methyl]-6-methyl-3-(2-methylpropyl)-1,4-dioxa-8,11-diazacyclohexadec-13-ene-2,5,9,12-tetrone Chemical compound C1=C(Cl)C(OC)=CC=C1C[C@@H]1C(=O)NC[C@@H](C)C(=O)O[C@@H](CC(C)C)C(=O)O[C@H]([C@H](C)[C@@H](O)[C@@H](Cl)C=2C=CC=CC=2)C/C=C/C(=O)N1 TVIRNGFXQVMMGB-OFWIHYRESA-N 0.000 description 1
- GWMHBVLPNWHWGW-CNYBTUBUSA-N (3s,6z)-3-benzyl-6-[[5-(2-methylbut-3-en-2-yl)-1h-imidazol-4-yl]methylidene]piperazine-2,5-dione Chemical compound N1C=NC(\C=C/2C(N[C@@H](CC=3C=CC=CC=3)C(=O)N\2)=O)=C1C(C)(C=C)C GWMHBVLPNWHWGW-CNYBTUBUSA-N 0.000 description 1
- FRCJDPPXHQGEKS-BCHFMIIMSA-N (4S,5R)-N-[4-[(2,3-dihydroxybenzoyl)amino]butyl]-N-[3-[(2,3-dihydroxybenzoyl)amino]propyl]-2-(2-hydroxyphenyl)-5-methyl-4,5-dihydro-1,3-oxazole-4-carboxamide Chemical compound C[C@H]1OC(=N[C@@H]1C(=O)N(CCCCNC(=O)c1cccc(O)c1O)CCCNC(=O)c1cccc(O)c1O)c1ccccc1O FRCJDPPXHQGEKS-BCHFMIIMSA-N 0.000 description 1
- GTEXXGIEZVKSLH-YPMHNXCESA-N (4as,12br)-8,10-dihydroxy-2,5,5,9-tetramethyl-3,4,4a,12b-tetrahydronaphtho[2,3-c]isochromene-7,12-dione Chemical compound O=C1C2=CC(O)=C(C)C(O)=C2C(=O)C2=C1[C@@H]1C=C(C)CC[C@@H]1C(C)(C)O2 GTEXXGIEZVKSLH-YPMHNXCESA-N 0.000 description 1
- DEQANNDTNATYII-OULOTJBUSA-N (4r,7s,10s,13r,16s,19r)-10-(4-aminobutyl)-19-[[(2r)-2-amino-3-phenylpropanoyl]amino]-16-benzyl-n-[(2r,3r)-1,3-dihydroxybutan-2-yl]-7-[(1r)-1-hydroxyethyl]-13-(1h-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carboxa Chemical compound C([C@@H](N)C(=O)N[C@H]1CSSC[C@H](NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](CC=2C3=CC=CC=C3NC=2)NC(=O)[C@H](CC=2C=CC=CC=2)NC1=O)C(=O)N[C@H](CO)[C@H](O)C)C1=CC=CC=C1 DEQANNDTNATYII-OULOTJBUSA-N 0.000 description 1
- PUDHBTGHUJUUFI-SCTWWAJVSA-N (4r,7s,10s,13r,16s,19r)-10-(4-aminobutyl)-n-[(2s,3r)-1-amino-3-hydroxy-1-oxobutan-2-yl]-19-[[(2r)-2-amino-3-naphthalen-2-ylpropanoyl]amino]-16-[(4-hydroxyphenyl)methyl]-13-(1h-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-7-propan-2-yl-1,2-dithia-5,8,11,14,17-p Chemical compound C([C@H]1C(=O)N[C@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(N[C@@H](CSSC[C@@H](C(=O)N1)NC(=O)[C@H](N)CC=1C=C2C=CC=CC2=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(N)=O)=O)C(C)C)C1=CC=C(O)C=C1 PUDHBTGHUJUUFI-SCTWWAJVSA-N 0.000 description 1
- VTTMWBPZTZHGLU-IVSQCGTASA-N (4s,7r,8s,9s,13z,16s)-4,8-dihydroxy-16-[(e)-1-[2-(hydroxymethyl)-1,3-thiazol-4-yl]prop-1-en-2-yl]-5,5,7,9,13-pentamethyl-1-oxacyclohexadec-13-ene-2,6-dione Chemical compound O1C(=O)C[C@H](O)C(C)(C)C(=O)[C@H](C)[C@@H](O)[C@@H](C)CCC\C(C)=C/C[C@H]1C(\C)=C\C1=CSC(CO)=N1 VTTMWBPZTZHGLU-IVSQCGTASA-N 0.000 description 1
- HLAKJNQXUARACO-ZDUSSCGKSA-N (5'r)-5'-hydroxy-2',5',7'-trimethylspiro[cyclopropane-1,6'-indene]-4'-one Chemical compound O=C([C@@]1(O)C)C2=CC(C)=CC2=C(C)C21CC2 HLAKJNQXUARACO-ZDUSSCGKSA-N 0.000 description 1
- WTSKMKRYHATLLL-UHFFFAOYSA-N (6-benzoyloxy-3-cyanopyridin-2-yl) 3-[3-(ethoxymethyl)-5-fluoro-2,6-dioxopyrimidine-1-carbonyl]benzoate Chemical compound O=C1N(COCC)C=C(F)C(=O)N1C(=O)C1=CC=CC(C(=O)OC=2C(=CC=C(OC(=O)C=3C=CC=CC=3)N=2)C#N)=C1 WTSKMKRYHATLLL-UHFFFAOYSA-N 0.000 description 1
- LKBBOPGQDRPCDS-YAOXHJNESA-N (7s,9r,10r)-7-[(2r,4s,5s,6s)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-9-ethyl-4,6,9,10,11-pentahydroxy-8,10-dihydro-7h-tetracene-5,12-dione Chemical compound O([C@H]1C[C@]([C@@H](C2=C(O)C=3C(=O)C4=CC=CC(O)=C4C(=O)C=3C(O)=C21)O)(O)CC)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 LKBBOPGQDRPCDS-YAOXHJNESA-N 0.000 description 1
- MWWSFMDVAYGXBV-FGBSZODSSA-N (7s,9s)-7-[(2r,4s,5r,6s)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-4-methoxy-8,10-dihydro-7h-tetracene-5,12-dione;hydron;chloride Chemical compound Cl.O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@@H](O)[C@H](C)O1 MWWSFMDVAYGXBV-FGBSZODSSA-N 0.000 description 1
- GYPCWHHQAVLMKO-XXKQIVDLSA-N (7s,9s)-7-[(2r,4s,5s,6s)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-9-[(e)-n-[(1-hydroxy-2,2,6,6-tetramethylpiperidin-4-ylidene)amino]-c-methylcarbonimidoyl]-4-methoxy-8,10-dihydro-7h-tetracene-5,12-dione;hydrochloride Chemical group Cl.O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(\C)=N\N=C1CC(C)(C)N(O)C(C)(C)C1)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 GYPCWHHQAVLMKO-XXKQIVDLSA-N 0.000 description 1
- RCFNNLSZHVHCEK-YGCMNLPTSA-N (7s,9s)-7-[(2s,4r,6s)-4-amino-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-4-methoxy-8,10-dihydro-7h-tetracene-5,12-dione;hydrochloride Chemical compound Cl.O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)C[C@H](C)O1 RCFNNLSZHVHCEK-YGCMNLPTSA-N 0.000 description 1
- VHZXNQKVFDBFIK-NBBHSKLNSA-N (8r,9s,10r,13s,14s,16r)-16-fluoro-10,13-dimethyl-1,2,3,4,7,8,9,11,12,14,15,16-dodecahydrocyclopenta[a]phenanthren-17-one Chemical compound C1CCC[C@]2(C)[C@H]3CC[C@](C)(C([C@H](F)C4)=O)[C@@H]4[C@@H]3CC=C21 VHZXNQKVFDBFIK-NBBHSKLNSA-N 0.000 description 1
- IEXUMDBQLIVNHZ-YOUGDJEHSA-N (8s,11r,13r,14s,17s)-11-[4-(dimethylamino)phenyl]-17-hydroxy-17-(3-hydroxypropyl)-13-methyl-1,2,6,7,8,11,12,14,15,16-decahydrocyclopenta[a]phenanthren-3-one Chemical compound C1=CC(N(C)C)=CC=C1[C@@H]1C2=C3CCC(=O)C=C3CC[C@H]2[C@H](CC[C@]2(O)CCCO)[C@@]2(C)C1 IEXUMDBQLIVNHZ-YOUGDJEHSA-N 0.000 description 1
- DOEWDSDBFRHVAP-KRXBUXKQSA-N (E)-3-tosylacrylonitrile Chemical compound CC1=CC=C(S(=O)(=O)\C=C\C#N)C=C1 DOEWDSDBFRHVAP-KRXBUXKQSA-N 0.000 description 1
- 102100035522 (E3-independent) E2 ubiquitin-conjugating enzyme Human genes 0.000 description 1
- MHFRGQHAERHWKZ-HHHXNRCGSA-N (R)-edelfosine Chemical compound CCCCCCCCCCCCCCCCCCOC[C@@H](OC)COP([O-])(=O)OCC[N+](C)(C)C MHFRGQHAERHWKZ-HHHXNRCGSA-N 0.000 description 1
- KQODQNJLJQHFQV-MKWZWQCGSA-N (e,4s)-4-[[(2s)-3,3-dimethyl-2-[[(2s)-3-methyl-2-(methylamino)-3-(1-methylindol-3-yl)butanoyl]amino]butanoyl]-methylamino]-2,5-dimethylhex-2-enoic acid Chemical compound C1=CC=C2C(C(C)(C)[C@@H](C(=O)N[C@H](C(=O)N(C)[C@H](\C=C(/C)C(O)=O)C(C)C)C(C)(C)C)NC)=CN(C)C2=C1 KQODQNJLJQHFQV-MKWZWQCGSA-N 0.000 description 1
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
- POILWHVDKZOXJZ-ARJAWSKDSA-M (z)-4-oxopent-2-en-2-olate Chemical compound C\C([O-])=C\C(C)=O POILWHVDKZOXJZ-ARJAWSKDSA-M 0.000 description 1
- OJRZEKJECRTBPJ-NGAMADIESA-N (z,5s)-5-acetamido-1-diazonio-6-hydroxy-6-oxohex-1-en-2-olate Chemical compound CC(=O)N[C@H](C(O)=O)CC\C([O-])=C\[N+]#N OJRZEKJECRTBPJ-NGAMADIESA-N 0.000 description 1
- OUPZKGBUJRBPGC-HLTSFMKQSA-N 1,5-bis[[(2r)-oxiran-2-yl]methyl]-3-[[(2s)-oxiran-2-yl]methyl]-1,3,5-triazinane-2,4,6-trione Chemical compound O=C1N(C[C@H]2OC2)C(=O)N(C[C@H]2OC2)C(=O)N1C[C@H]1CO1 OUPZKGBUJRBPGC-HLTSFMKQSA-N 0.000 description 1
- UOAFGUOASVSLPK-UHFFFAOYSA-N 1-(2-chloroethyl)-3-(2,2-dimethylpropyl)-1-nitrosourea Chemical compound CC(C)(C)CNC(=O)N(N=O)CCCl UOAFGUOASVSLPK-UHFFFAOYSA-N 0.000 description 1
- YQYBWJPESSJLTK-HXFLIBJXSA-N 1-(2-chloroethyl)-3-[(2r,3s,4r,6s)-3-hydroxy-2-(hydroxymethyl)-6-methoxyoxan-4-yl]-1-nitrosourea Chemical compound CO[C@@H]1C[C@@H](NC(=O)N(CCCl)N=O)[C@H](O)[C@@H](CO)O1 YQYBWJPESSJLTK-HXFLIBJXSA-N 0.000 description 1
- RCLLNBVPCJDIPX-UHFFFAOYSA-N 1-(2-chloroethyl)-3-[2-(dimethylsulfamoyl)ethyl]-1-nitrosourea Chemical compound CN(C)S(=O)(=O)CCNC(=O)N(N=O)CCCl RCLLNBVPCJDIPX-UHFFFAOYSA-N 0.000 description 1
- JQJSFAJISYZPER-UHFFFAOYSA-N 1-(4-chlorophenyl)-3-(2,3-dihydro-1h-inden-5-ylsulfonyl)urea Chemical compound C1=CC(Cl)=CC=C1NC(=O)NS(=O)(=O)C1=CC=C(CCC2)C2=C1 JQJSFAJISYZPER-UHFFFAOYSA-N 0.000 description 1
- SNYUHPPZINRDSG-UHFFFAOYSA-N 1-(oxiran-2-ylmethyl)-4-[1-(oxiran-2-ylmethyl)piperidin-4-yl]piperidine Chemical compound C1CC(C2CCN(CC3OC3)CC2)CCN1CC1CO1 SNYUHPPZINRDSG-UHFFFAOYSA-N 0.000 description 1
- ZKFNOUUKULVDOB-UHFFFAOYSA-N 1-amino-1-phenylmethyl phosphonic acid Chemical compound OP(=O)(O)C(N)C1=CC=CC=C1 ZKFNOUUKULVDOB-UHFFFAOYSA-N 0.000 description 1
- 102100026205 1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase gamma-1 Human genes 0.000 description 1
- 102100026210 1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase gamma-2 Human genes 0.000 description 1
- 101710175516 14 kDa zinc-binding protein Proteins 0.000 description 1
- 102100021408 14-3-3 protein beta/alpha Human genes 0.000 description 1
- 102100040685 14-3-3 protein zeta/delta Human genes 0.000 description 1
- BFPYWIDHMRZLRN-UHFFFAOYSA-N 17alpha-ethynyl estradiol Natural products OC1=CC=C2C3CCC(C)(C(CC4)(O)C#C)C4C3CCC2=C1 BFPYWIDHMRZLRN-UHFFFAOYSA-N 0.000 description 1
- NUXKIZBEPYVRKP-RWBWKAGLSA-N 1xa5 Chemical compound O([C@]12[C@@H]3N(C)C4=C([C@]53CCN3CC=C[C@@]([C@@H]53)(CC)C2)C=C(C(=C4)OC)[C@]2(C(=O)OC)C3=C(C4=CC=CC=C4N3)CCN3C[C@H](C2)C[C@@](C3)(O)CC)C(=O)N(CCCl)C1=O NUXKIZBEPYVRKP-RWBWKAGLSA-N 0.000 description 1
- LNELBQZKXVASLW-AWEZNQCLSA-N 2,2,2-trifluoro-n-[(7s)-1,2,3-trimethoxy-10-methylsulfanyl-9-oxo-6,7-dihydro-5h-benzo[a]heptalen-7-yl]acetamide Chemical compound C1([C@@H](NC(=O)C(F)(F)F)CC2)=CC(=O)C(SC)=CC=C1C1=C2C=C(OC)C(OC)=C1OC LNELBQZKXVASLW-AWEZNQCLSA-N 0.000 description 1
- VKDGNNYJFSHYKD-UHFFFAOYSA-N 2,5-diamino-2-(difluoromethyl)pentanoic acid;hydron;chloride Chemical compound Cl.NCCCC(N)(C(F)F)C(O)=O VKDGNNYJFSHYKD-UHFFFAOYSA-N 0.000 description 1
- RWEVIPRMPFNTLO-UHFFFAOYSA-N 2-(2-fluoro-4-iodoanilino)-N-(2-hydroxyethoxy)-1,5-dimethyl-6-oxo-3-pyridinecarboxamide Chemical compound CN1C(=O)C(C)=CC(C(=O)NOCCO)=C1NC1=CC=C(I)C=C1F RWEVIPRMPFNTLO-UHFFFAOYSA-N 0.000 description 1
- NJWBUDCAWGTQAS-UHFFFAOYSA-N 2-(chrysen-6-ylmethylamino)-2-methylpropane-1,3-diol;methanesulfonic acid Chemical compound CS(O)(=O)=O.C1=CC=C2C(CNC(CO)(CO)C)=CC3=C(C=CC=C4)C4=CC=C3C2=C1 NJWBUDCAWGTQAS-UHFFFAOYSA-N 0.000 description 1
- 102100027962 2-5A-dependent ribonuclease Human genes 0.000 description 1
- VHVPQPYKVGDNFY-DFMJLFEVSA-N 2-[(2r)-butan-2-yl]-4-[4-[4-[4-[[(2r,4s)-2-(2,4-dichlorophenyl)-2-(1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]piperazin-1-yl]phenyl]-1,2,4-triazol-3-one Chemical compound O=C1N([C@H](C)CC)N=CN1C1=CC=C(N2CCN(CC2)C=2C=CC(OC[C@@H]3O[C@](CN4N=CN=C4)(OC3)C=3C(=CC(Cl)=CC=3)Cl)=CC=2)C=C1 VHVPQPYKVGDNFY-DFMJLFEVSA-N 0.000 description 1
- PDWUPXJEEYOOTR-UHFFFAOYSA-N 2-[(3-iodophenyl)methyl]guanidine Chemical compound NC(=N)NCC1=CC=CC(I)=C1 PDWUPXJEEYOOTR-UHFFFAOYSA-N 0.000 description 1
- KPRFMAZESAKTEJ-UHFFFAOYSA-N 2-[1-amino-4-[2,5-dioxo-4-(1-phenylethyl)pyrrolidin-3-yl]-1-oxobutan-2-yl]-5-carbamoylheptanedioic acid;azane Chemical compound [NH4+].[NH4+].C=1C=CC=CC=1C(C)C1C(CCC(C(CCC(CC([O-])=O)C(N)=O)C([O-])=O)C(N)=O)C(=O)NC1=O KPRFMAZESAKTEJ-UHFFFAOYSA-N 0.000 description 1
- XXVLKDRPHSFIIB-UHFFFAOYSA-N 2-[2-(dimethylamino)ethyl]-5-nitrobenzo[de]isoquinoline-1,3-dione Chemical compound [O-][N+](=O)C1=CC(C(N(CCN(C)C)C2=O)=O)=C3C2=CC=CC3=C1 XXVLKDRPHSFIIB-UHFFFAOYSA-N 0.000 description 1
- MHXVDXXARZCVRK-WCWDXBQESA-N 2-[2-[4-[(e)-3,3,3-trifluoro-1,2-diphenylprop-1-enyl]phenoxy]ethylamino]ethanol Chemical compound C1=CC(OCCNCCO)=CC=C1C(\C=1C=CC=CC=1)=C(C(F)(F)F)/C1=CC=CC=C1 MHXVDXXARZCVRK-WCWDXBQESA-N 0.000 description 1
- PXJJOGITBQXZEQ-JTHROIFXSA-M 2-[4-[(z)-1,2-diphenylbut-1-enyl]phenoxy]ethyl-trimethylazanium;iodide Chemical compound [I-].C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCC[N+](C)(C)C)=CC=1)/C1=CC=CC=C1 PXJJOGITBQXZEQ-JTHROIFXSA-M 0.000 description 1
- OTLLEIBWKHEHGU-UHFFFAOYSA-N 2-[5-[[5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy]-3,4-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3,5-dihydroxy-4-phosphonooxyhexanedioic acid Chemical compound C1=NC=2C(N)=NC=NC=2N1C(C(C1O)O)OC1COC1C(CO)OC(OC(C(O)C(OP(O)(O)=O)C(O)C(O)=O)C(O)=O)C(O)C1O OTLLEIBWKHEHGU-UHFFFAOYSA-N 0.000 description 1
- HYHJFNXFVPGMBI-UHFFFAOYSA-N 2-[[2-chloroethyl(nitroso)carbamoyl]-methylamino]acetamide Chemical compound NC(=O)CN(C)C(=O)N(CCCl)N=O HYHJFNXFVPGMBI-UHFFFAOYSA-N 0.000 description 1
- QCXJFISCRQIYID-IAEPZHFASA-N 2-amino-1-n-[(3s,6s,7r,10s,16s)-3-[(2s)-butan-2-yl]-7,11,14-trimethyl-2,5,9,12,15-pentaoxo-10-propan-2-yl-8-oxa-1,4,11,14-tetrazabicyclo[14.3.0]nonadecan-6-yl]-4,6-dimethyl-3-oxo-9-n-[(3s,6s,7r,10s,16s)-7,11,14-trimethyl-2,5,9,12,15-pentaoxo-3,10-di(propa Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N=C2C(C(=O)N[C@@H]3C(=O)N[C@H](C(N4CCC[C@H]4C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]3C)=O)[C@@H](C)CC)=C(N)C(=O)C(C)=C2O2)C2=C(C)C=C1 QCXJFISCRQIYID-IAEPZHFASA-N 0.000 description 1
- VDCRFBBZFHHYGT-IOSLPCCCSA-N 2-amino-9-[(2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-7-prop-2-enyl-3h-purine-6,8-dione Chemical compound O=C1N(CC=C)C=2C(=O)NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O VDCRFBBZFHHYGT-IOSLPCCCSA-N 0.000 description 1
- NIXVOFULDIFBLB-QVRNUERCSA-N 2-amino-9-[(2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]purine-6-sulfinamide Chemical compound C12=NC(N)=NC(S(N)=O)=C2N=CN1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O NIXVOFULDIFBLB-QVRNUERCSA-N 0.000 description 1
- DSWLRNLRVBAVFC-UHFFFAOYSA-N 2-methylsulfinyl-1-pyridin-2-ylethanone Chemical compound CS(=O)CC(=O)C1=CC=CC=N1 DSWLRNLRVBAVFC-UHFFFAOYSA-N 0.000 description 1
- CTRPRMNBTVRDFH-UHFFFAOYSA-N 2-n-methyl-1,3,5-triazine-2,4,6-triamine Chemical class CNC1=NC(N)=NC(N)=N1 CTRPRMNBTVRDFH-UHFFFAOYSA-N 0.000 description 1
- 102100040973 26S proteasome non-ATPase regulatory subunit 1 Human genes 0.000 description 1
- 102100036734 26S proteasome non-ATPase regulatory subunit 10 Human genes 0.000 description 1
- 102100040964 26S proteasome non-ATPase regulatory subunit 11 Human genes 0.000 description 1
- 102100040961 26S proteasome non-ATPase regulatory subunit 12 Human genes 0.000 description 1
- 102100040962 26S proteasome non-ATPase regulatory subunit 13 Human genes 0.000 description 1
- 102100032282 26S proteasome non-ATPase regulatory subunit 14 Human genes 0.000 description 1
- 102100032303 26S proteasome non-ATPase regulatory subunit 2 Human genes 0.000 description 1
- 102100032301 26S proteasome non-ATPase regulatory subunit 3 Human genes 0.000 description 1
- 102100033458 26S proteasome non-ATPase regulatory subunit 4 Human genes 0.000 description 1
- 102100033453 26S proteasome non-ATPase regulatory subunit 5 Human genes 0.000 description 1
- 102100033097 26S proteasome non-ATPase regulatory subunit 6 Human genes 0.000 description 1
- 102100036657 26S proteasome non-ATPase regulatory subunit 7 Human genes 0.000 description 1
- 102100033828 26S proteasome regulatory subunit 10B Human genes 0.000 description 1
- 102100022644 26S proteasome regulatory subunit 4 Human genes 0.000 description 1
- 102100029510 26S proteasome regulatory subunit 6A Human genes 0.000 description 1
- 102100029511 26S proteasome regulatory subunit 6B Human genes 0.000 description 1
- 102100034682 26S proteasome regulatory subunit 7 Human genes 0.000 description 1
- 102100036563 26S proteasome regulatory subunit 8 Human genes 0.000 description 1
- SIVJKYRAPQKLIM-UHFFFAOYSA-N 3-(3,4-difluorophenyl)-n-(3-fluoro-5-morpholin-4-ylphenyl)propanamide Chemical compound C=1C(N2CCOCC2)=CC(F)=CC=1NC(=O)CCC1=CC=C(F)C(F)=C1 SIVJKYRAPQKLIM-UHFFFAOYSA-N 0.000 description 1
- GRLUHXSUZYFZCW-UHFFFAOYSA-N 3-(8,8-diethyl-2-aza-8-germaspiro[4.5]decan-2-yl)-n,n-dimethylpropan-1-amine;dihydrochloride Chemical compound Cl.Cl.C1C[Ge](CC)(CC)CCC11CN(CCCN(C)C)CC1 GRLUHXSUZYFZCW-UHFFFAOYSA-N 0.000 description 1
- QGJZLNKBHJESQX-UHFFFAOYSA-N 3-Epi-Betulin-Saeure Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C(=C)C)C5C4CCC3C21C QGJZLNKBHJESQX-UHFFFAOYSA-N 0.000 description 1
- RCLQNICOARASSR-SECBINFHSA-N 3-[(2r)-2,3-dihydroxypropyl]-6-fluoro-5-(2-fluoro-4-iodoanilino)-8-methylpyrido[2,3-d]pyrimidine-4,7-dione Chemical compound FC=1C(=O)N(C)C=2N=CN(C[C@@H](O)CO)C(=O)C=2C=1NC1=CC=C(I)C=C1F RCLQNICOARASSR-SECBINFHSA-N 0.000 description 1
- GTJXPMSTODOYNP-BTKVJIOYSA-N 3-[(e)-1-[4-[2-(dimethylamino)ethoxy]phenyl]-2-phenylbut-1-enyl]phenol;2-hydroxypropane-1,2,3-tricarboxylic acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O.C=1C=CC=CC=1C(/CC)=C(C=1C=C(O)C=CC=1)\C1=CC=C(OCCN(C)C)C=C1 GTJXPMSTODOYNP-BTKVJIOYSA-N 0.000 description 1
- WUIABRMSWOKTOF-OYALTWQYSA-O 3-[[2-[2-[2-[[(2s,3r)-2-[[(2s,3s,4r)-4-[[(2s,3r)-2-[[6-amino-2-[(1s)-3-amino-1-[[(2s)-2,3-diamino-3-oxopropyl]amino]-3-oxopropyl]-5-methylpyrimidine-4-carbonyl]amino]-3-[(2r,3s,4s,5s,6s)-3-[(2r,3s,4s,5r,6r)-4-carbamoyloxy-3,5-dihydroxy-6-(hydroxymethyl)ox Chemical compound OS(O)(=O)=O.N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C WUIABRMSWOKTOF-OYALTWQYSA-O 0.000 description 1
- WELIVEBWRWAGOM-UHFFFAOYSA-N 3-amino-n-[2-[2-(3-aminopropanoylamino)ethyldisulfanyl]ethyl]propanamide Chemical compound NCCC(=O)NCCSSCCNC(=O)CCN WELIVEBWRWAGOM-UHFFFAOYSA-N 0.000 description 1
- 102100037263 3-phosphoinositide-dependent protein kinase 1 Human genes 0.000 description 1
- CLOUCVRNYSHRCF-UHFFFAOYSA-N 3beta-Hydroxy-20(29)-Lupen-3,27-oic acid Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C(O)=O)CCC5(C)CCC(C(=C)C)C5C4CCC3C21C CLOUCVRNYSHRCF-UHFFFAOYSA-N 0.000 description 1
- PDQGEKGUTOTUNV-TZSSRYMLSA-N 4'-deoxy-4'-iododoxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](I)[C@H](C)O1 PDQGEKGUTOTUNV-TZSSRYMLSA-N 0.000 description 1
- LIETVYHJBSLSSW-UHFFFAOYSA-N 4,6,9-trihydroxy-8-methyl-3,4-dihydro-2h-anthracen-1-one Chemical compound OC1CCC(=O)C2=C1C=C1C=C(O)C=C(C)C1=C2O LIETVYHJBSLSSW-UHFFFAOYSA-N 0.000 description 1
- JARCFMKMOFFIGZ-UHFFFAOYSA-N 4,6-dioxo-n-phenyl-2-sulfanylidene-1,3-diazinane-5-carboxamide Chemical compound O=C1NC(=S)NC(=O)C1C(=O)NC1=CC=CC=C1 JARCFMKMOFFIGZ-UHFFFAOYSA-N 0.000 description 1
- HQFSNUYUXXPVKL-UHFFFAOYSA-N 4-[(4-fluorophenyl)methyl]-2-[1-(2-phenylethyl)azepan-4-yl]phthalazin-1-one Chemical compound C1=CC(F)=CC=C1CC(C1=CC=CC=C1C1=O)=NN1C1CCN(CCC=2C=CC=CC=2)CCC1 HQFSNUYUXXPVKL-UHFFFAOYSA-N 0.000 description 1
- OUQPTBCOEKUHBH-LSDHQDQOSA-N 4-[2-[4-[(e)-2-(5,5,8,8-tetramethyl-6,7-dihydronaphthalen-2-yl)prop-1-enyl]phenoxy]ethyl]morpholine Chemical compound C=1C=C(C(CCC2(C)C)(C)C)C2=CC=1C(/C)=C/C(C=C1)=CC=C1OCCN1CCOCC1 OUQPTBCOEKUHBH-LSDHQDQOSA-N 0.000 description 1
- CTSNHMQGVWXIEG-UHFFFAOYSA-N 4-amino-n-(5-chloroquinoxalin-2-yl)benzenesulfonamide Chemical compound C1=CC(N)=CC=C1S(=O)(=O)NC1=CN=C(C(Cl)=CC=C2)C2=N1 CTSNHMQGVWXIEG-UHFFFAOYSA-N 0.000 description 1
- SGOOQMRIPALTEL-UHFFFAOYSA-N 4-hydroxy-N,1-dimethyl-2-oxo-N-phenyl-3-quinolinecarboxamide Chemical compound OC=1C2=CC=CC=C2N(C)C(=O)C=1C(=O)N(C)C1=CC=CC=C1 SGOOQMRIPALTEL-UHFFFAOYSA-N 0.000 description 1
- UZFMOKQJFYMBGY-UHFFFAOYSA-N 4-hydroxy-TEMPO Chemical compound CC1(C)CC(O)CC(C)(C)N1[O] UZFMOKQJFYMBGY-UHFFFAOYSA-N 0.000 description 1
- AKJHMTWEGVYYSE-FXILSDISSA-N 4-hydroxyphenyl retinamide Chemical compound C=1C=C(O)C=CC=1NC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C AKJHMTWEGVYYSE-FXILSDISSA-N 0.000 description 1
- UWXSAYUXVSFDBQ-CYBMUJFWSA-N 4-n-[3-chloro-4-(1,3-thiazol-2-ylmethoxy)phenyl]-6-n-[(4r)-4-methyl-4,5-dihydro-1,3-oxazol-2-yl]quinazoline-4,6-diamine Chemical compound C[C@@H]1COC(NC=2C=C3C(NC=4C=C(Cl)C(OCC=5SC=CN=5)=CC=4)=NC=NC3=CC=2)=N1 UWXSAYUXVSFDBQ-CYBMUJFWSA-N 0.000 description 1
- NSUDGNLOXMLAEB-UHFFFAOYSA-N 5-(2-formyl-3-hydroxyphenoxy)pentanoic acid Chemical compound OC(=O)CCCCOC1=CC=CC(O)=C1C=O NSUDGNLOXMLAEB-UHFFFAOYSA-N 0.000 description 1
- PXLPCZJACKUXGP-UHFFFAOYSA-N 5-(3,4-dichlorophenyl)-6-ethylpyrimidine-2,4-diamine Chemical compound CCC1=NC(N)=NC(N)=C1C1=CC=C(Cl)C(Cl)=C1 PXLPCZJACKUXGP-UHFFFAOYSA-N 0.000 description 1
- APNRZHLOPQFNMR-WEIUTZTHSA-N 5-[(e)-5-[(1s)-2,2-dimethyl-6-methylidenecyclohexyl]-3-methylpent-2-enyl]phenazin-1-one Chemical compound C12=CC=CC=C2N=C(C(C=CC=2)=O)C=2N1C\C=C(/C)CC[C@@H]1C(=C)CCCC1(C)C APNRZHLOPQFNMR-WEIUTZTHSA-N 0.000 description 1
- NMUSYJAQQFHJEW-KVTDHHQDSA-N 5-azacytidine Chemical compound O=C1N=C(N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 NMUSYJAQQFHJEW-KVTDHHQDSA-N 0.000 description 1
- VGULLEUAAMBZTQ-UHFFFAOYSA-N 5-desacetylaltohyrtin A Natural products OC1C(O2)(O)CC(O)C(C)C2CCCC=CC(O2)CC(O)CC2(O2)CC(OC)CC2CC(=O)C(C)C(OC(C)=O)C(C)C(=C)CC(O2)CC(C)(O)CC2(O2)CC(O)CC2CC(=O)OC2C(O)C(CC(=C)CC(O)C=CC(Cl)=C)OC1C2C VGULLEUAAMBZTQ-UHFFFAOYSA-N 0.000 description 1
- DQOGWKZQQBYYMW-LQGIGNHCSA-N 5-methyl-6-[(3,4,5-trimethoxyanilino)methyl]quinazoline-2,4-diamine;(2s,3s,4s,5r,6s)-3,4,5,6-tetrahydroxyoxane-2-carboxylic acid Chemical compound O[C@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O.COC1=C(OC)C(OC)=CC(NCC=2C(=C3C(N)=NC(N)=NC3=CC=2)C)=C1 DQOGWKZQQBYYMW-LQGIGNHCSA-N 0.000 description 1
- PXBZKHOQHTVCSQ-QZTJIDSGSA-N 5-nitro-2-[(2r)-1-[2-[[(2r)-2-(5-nitro-1,3-dioxobenzo[de]isoquinolin-2-yl)propyl]amino]ethylamino]propan-2-yl]benzo[de]isoquinoline-1,3-dione Chemical compound [O-][N+](=O)C1=CC(C(N([C@@H](CNCCNC[C@@H](C)N2C(C=3C=C(C=C4C=CC=C(C=34)C2=O)[N+]([O-])=O)=O)C)C2=O)=O)=C3C2=CC=CC3=C1 PXBZKHOQHTVCSQ-QZTJIDSGSA-N 0.000 description 1
- YHSMSRREJYOGQJ-UHFFFAOYSA-N 5-nonyloxytryptamine Chemical compound CCCCCCCCCOC1=CC=C2NC=C(CCN)C2=C1 YHSMSRREJYOGQJ-UHFFFAOYSA-N 0.000 description 1
- ATCGGEJZONJOCL-UHFFFAOYSA-N 6-(2,5-dichlorophenyl)-1,3,5-triazine-2,4-diamine Chemical compound NC1=NC(N)=NC(C=2C(=CC=C(Cl)C=2)Cl)=N1 ATCGGEJZONJOCL-UHFFFAOYSA-N 0.000 description 1
- VJXSSYDSOJBUAV-UHFFFAOYSA-N 6-(2,5-dimethoxy-benzyl)-5-methyl-pyrido[2,3-d]pyrimidine-2,4-diamine Chemical compound COC1=CC=C(OC)C(CC=2C(=C3C(N)=NC(N)=NC3=NC=2)C)=C1 VJXSSYDSOJBUAV-UHFFFAOYSA-N 0.000 description 1
- OTSZCHORPMQCBZ-UHFFFAOYSA-N 6-[(3-chlorophenyl)-imidazol-1-ylmethyl]-1h-benzimidazole;hydron;chloride Chemical compound Cl.ClC1=CC=CC(C(C=2C=C3NC=NC3=CC=2)N2C=NC=C2)=C1 OTSZCHORPMQCBZ-UHFFFAOYSA-N 0.000 description 1
- LRHPCRBOMKRVOA-UHFFFAOYSA-N 6-[2-(2-hydroxyethylamino)ethyl]indeno[1,2-c]isoquinoline-5,11-dione Chemical compound C12=CC=CC=C2C(=O)N(CCNCCO)C2=C1C(=O)C1=CC=CC=C12 LRHPCRBOMKRVOA-UHFFFAOYSA-N 0.000 description 1
- KXBCLNRMQPRVTP-UHFFFAOYSA-N 6-amino-1,5-dihydroimidazo[4,5-c]pyridin-4-one Chemical compound O=C1NC(N)=CC2=C1N=CN2 KXBCLNRMQPRVTP-UHFFFAOYSA-N 0.000 description 1
- ZNTIXVYOBQDFFV-UHFFFAOYSA-N 6-amino-1,5-dihydroimidazo[4,5-c]pyridin-4-one;methanesulfonic acid Chemical compound CS(O)(=O)=O.O=C1NC(N)=CC2=C1N=CN2 ZNTIXVYOBQDFFV-UHFFFAOYSA-N 0.000 description 1
- LJIRBXZDQGQUOO-KVTDHHQDSA-N 6-amino-3-[(2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-1,4-dihydro-1,3,5-triazin-2-one Chemical compound C1NC(N)=NC(=O)N1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 LJIRBXZDQGQUOO-KVTDHHQDSA-N 0.000 description 1
- SDEAXTCZPQIFQM-UHFFFAOYSA-N 6-n-(4,4-dimethyl-5h-1,3-oxazol-2-yl)-4-n-[3-methyl-4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)phenyl]quinazoline-4,6-diamine Chemical compound C=1C=C(OC2=CC3=NC=NN3C=C2)C(C)=CC=1NC(C1=C2)=NC=NC1=CC=C2NC1=NC(C)(C)CO1 SDEAXTCZPQIFQM-UHFFFAOYSA-N 0.000 description 1
- PLIVFNIUGLLCEK-UHFFFAOYSA-N 7-[4-(3-ethynylanilino)-7-methoxyquinazolin-6-yl]oxy-n-hydroxyheptanamide Chemical compound C=12C=C(OCCCCCCC(=O)NO)C(OC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 PLIVFNIUGLLCEK-UHFFFAOYSA-N 0.000 description 1
- GOYNNCPGHOBFCK-UHFFFAOYSA-N 7-[4-(dimethylamino)-5-[(2,9-dimethyl-3-oxo-4,4a,5a,6,7,9,9a,10a-octahydrodipyrano[4,2-a:4',3'-e][1,4]dioxin-7-yl)oxy]-6-methyloxan-2-yl]oxy-9-ethyl-4,6,9,10,11-pentahydroxy-8,10-dihydro-7h-tetracene-5,12-dione Chemical compound O=C1C2=C(O)C=CC=C2C(=O)C2=C1C(O)=C1C(OC3OC(C)C(OC4OC(C)C5OC6OC(C)C(=O)CC6OC5C4)C(C3)N(C)C)CC(CC)(O)C(O)C1=C2O GOYNNCPGHOBFCK-UHFFFAOYSA-N 0.000 description 1
- KABRXLINDSPGDF-UHFFFAOYSA-N 7-bromoisoquinoline Chemical compound C1=CN=CC2=CC(Br)=CC=C21 KABRXLINDSPGDF-UHFFFAOYSA-N 0.000 description 1
- GOJJWDOZNKBUSR-UHFFFAOYSA-N 7-sulfamoyloxyheptyl sulfamate Chemical compound NS(=O)(=O)OCCCCCCCOS(N)(=O)=O GOJJWDOZNKBUSR-UHFFFAOYSA-N 0.000 description 1
- LPDLEICKXUVJHW-QJILNLRNSA-N 78nz2pmp25 Chemical compound OS(O)(=O)=O.O([C@]12[C@H](OC(C)=O)[C@]3(CC)C=CCN4CC[C@@]5([C@H]34)[C@H]1N(C)C1=C5C=C(C(=C1)OC)[C@]1(C(=O)OC)C3=C(C4=CC=CC=C4N3)CCN3C[C@H](C1)C[C@@](C3)(O)CC)C(=O)N(CCCl)C2=O LPDLEICKXUVJHW-QJILNLRNSA-N 0.000 description 1
- JPASRFGVACYSJG-UHFFFAOYSA-N 8,10-dihydroimidazo[4,5-a]acridin-9-one Chemical class N1=C2C=CC3=NC=NC3=C2C=C2C1=CCC(=O)C2 JPASRFGVACYSJG-UHFFFAOYSA-N 0.000 description 1
- ZGXJTSGNIOSYLO-UHFFFAOYSA-N 88755TAZ87 Chemical compound NCC(=O)CCC(O)=O ZGXJTSGNIOSYLO-UHFFFAOYSA-N 0.000 description 1
- ZUZXYJOSNSTJMU-UHFFFAOYSA-N 9-cyclohexyl-2-n,6-n-bis[(4-methoxyphenyl)methyl]purine-2,6-diamine Chemical compound C1=CC(OC)=CC=C1CNC1=NC(NCC=2C=CC(OC)=CC=2)=C(N=CN2C3CCCCC3)C2=N1 ZUZXYJOSNSTJMU-UHFFFAOYSA-N 0.000 description 1
- 102100024049 A-kinase anchor protein 13 Human genes 0.000 description 1
- 101150092476 ABCA1 gene Proteins 0.000 description 1
- 108091007505 ADAM17 Proteins 0.000 description 1
- 102000017919 ADRB2 Human genes 0.000 description 1
- OONFNUWBHFSNBT-HXUWFJFHSA-N AEE788 Chemical compound C1CN(CC)CCN1CC1=CC=C(C=2NC3=NC=NC(N[C@H](C)C=4C=CC=CC=4)=C3C=2)C=C1 OONFNUWBHFSNBT-HXUWFJFHSA-N 0.000 description 1
- 102000010553 ALAD Human genes 0.000 description 1
- 101150082527 ALAD gene Proteins 0.000 description 1
- 102100036610 AN1-type zinc finger protein 5 Human genes 0.000 description 1
- 102100036605 AN1-type zinc finger protein 6 Human genes 0.000 description 1
- 101150046097 ANAPC11 gene Proteins 0.000 description 1
- 101150060590 ANAPC5 gene Proteins 0.000 description 1
- 101150075418 ARHGAP15 gene Proteins 0.000 description 1
- 108700005241 ATP Binding Cassette Transporter 1 Proteins 0.000 description 1
- 102100032792 ATPase family AAA domain-containing protein 2B Human genes 0.000 description 1
- 102100022936 ATPase inhibitor, mitochondrial Human genes 0.000 description 1
- 102100040431 Activator of basal transcription 1 Human genes 0.000 description 1
- 101710106492 Acyl-CoA-binding protein Proteins 0.000 description 1
- 101710169323 Acyl-CoA-binding protein homolog Proteins 0.000 description 1
- 102100029374 Adapter molecule crk Human genes 0.000 description 1
- 208000010507 Adenocarcinoma of Lung Diseases 0.000 description 1
- 206010052747 Adenocarcinoma pancreas Diseases 0.000 description 1
- 102100032873 Adenosine 3'-phospho 5'-phosphosulfate transporter 2 Human genes 0.000 description 1
- 102100031830 Afadin- and alpha-actinin-binding protein Human genes 0.000 description 1
- 102100036457 Akirin-1 Human genes 0.000 description 1
- 108010080691 Alcohol O-acetyltransferase Proteins 0.000 description 1
- 101150115961 Anapc10 gene Proteins 0.000 description 1
- 102000052567 Anaphase-Promoting Complex-Cyclosome Apc1 Subunit Human genes 0.000 description 1
- 108700004581 Anaphase-Promoting Complex-Cyclosome Apc1 Subunit Proteins 0.000 description 1
- 102000052593 Anaphase-Promoting Complex-Cyclosome Apc11 Subunit Human genes 0.000 description 1
- 102000052594 Anaphase-Promoting Complex-Cyclosome Apc2 Subunit Human genes 0.000 description 1
- 102000052587 Anaphase-Promoting Complex-Cyclosome Apc3 Subunit Human genes 0.000 description 1
- 108700004606 Anaphase-Promoting Complex-Cyclosome Apc3 Subunit Proteins 0.000 description 1
- 108700004605 Anaphase-Promoting Complex-Cyclosome Apc4 Subunit Proteins 0.000 description 1
- 102000052589 Anaphase-Promoting Complex-Cyclosome Apc4 Subunit Human genes 0.000 description 1
- 102000052588 Anaphase-Promoting Complex-Cyclosome Apc5 Subunit Human genes 0.000 description 1
- 108700004604 Anaphase-Promoting Complex-Cyclosome Apc5 Subunit Proteins 0.000 description 1
- 102000052591 Anaphase-Promoting Complex-Cyclosome Apc6 Subunit Human genes 0.000 description 1
- 108700004603 Anaphase-Promoting Complex-Cyclosome Apc6 Subunit Proteins 0.000 description 1
- 102000052584 Anaphase-Promoting Complex-Cyclosome Apc7 Subunit Human genes 0.000 description 1
- 108700004602 Anaphase-Promoting Complex-Cyclosome Apc7 Subunit Proteins 0.000 description 1
- 102000052583 Anaphase-Promoting Complex-Cyclosome Apc8 Subunit Human genes 0.000 description 1
- 102100033973 Anaphase-promoting complex subunit 10 Human genes 0.000 description 1
- 102100033695 Anaphase-promoting complex subunit 13 Human genes 0.000 description 1
- BOJKULTULYSRAS-OTESTREVSA-N Andrographolide Chemical compound C([C@H]1[C@]2(C)CC[C@@H](O)[C@]([C@H]2CCC1=C)(CO)C)\C=C1/[C@H](O)COC1=O BOJKULTULYSRAS-OTESTREVSA-N 0.000 description 1
- 102100033897 Ankyrin repeat and SOCS box protein 1 Human genes 0.000 description 1
- 102100021618 Ankyrin repeat and SOCS box protein 6 Human genes 0.000 description 1
- 102100021623 Ankyrin repeat and SOCS box protein 7 Human genes 0.000 description 1
- 102100030716 Ankyrin repeat and SOCS box protein 8 Human genes 0.000 description 1
- 102100031325 Anthrax toxin receptor 2 Human genes 0.000 description 1
- NQGMIPUYCWIEAW-UHFFFAOYSA-N Antibiotic SF 2738 Natural products COc1cc(nc(C=NO)c1SC)-c1ccccn1 NQGMIPUYCWIEAW-UHFFFAOYSA-N 0.000 description 1
- 108020000948 Antisense Oligonucleotides Proteins 0.000 description 1
- 102100034150 Apoptosis-enhancing nuclease Human genes 0.000 description 1
- 101100005736 Arabidopsis thaliana APC6 gene Proteins 0.000 description 1
- 102100033653 Arf-GAP with Rho-GAP domain, ANK repeat and PH domain-containing protein 2 Human genes 0.000 description 1
- MJINRRBEMOLJAK-DCAQKATOSA-N Arg-Lys-Asp Chemical compound OC(=O)C[C@@H](C(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](N)CCCN=C(N)N MJINRRBEMOLJAK-DCAQKATOSA-N 0.000 description 1
- DRCNRVYVCHHIJP-AQBORDMYSA-N Arg-Lys-Glu-Val-Tyr Chemical compound NC(N)=NCCC[C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 DRCNRVYVCHHIJP-AQBORDMYSA-N 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- BFYIZQONLCFLEV-DAELLWKTSA-N Aromasine Chemical compound O=C1C=C[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC(=C)C2=C1 BFYIZQONLCFLEV-DAELLWKTSA-N 0.000 description 1
- 108700032558 Aspergillus restrictus MITF Proteins 0.000 description 1
- 241001263178 Auriparus Species 0.000 description 1
- 108010092778 Autophagy-Related Protein 7 Proteins 0.000 description 1
- 102100023898 Autophagy-related protein 101 Human genes 0.000 description 1
- YOZSEGPJAXTSFZ-ZETCQYMHSA-N Azatyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=N1 YOZSEGPJAXTSFZ-ZETCQYMHSA-N 0.000 description 1
- NOWKCMXCCJGMRR-UHFFFAOYSA-N Aziridine Chemical compound C1CN1 NOWKCMXCCJGMRR-UHFFFAOYSA-N 0.000 description 1
- 108700024832 B-Cell CLL-Lymphoma 10 Proteins 0.000 description 1
- 108700009171 B-Cell Lymphoma 3 Proteins 0.000 description 1
- 102100027203 B-cell antigen receptor complex-associated protein beta chain Human genes 0.000 description 1
- 102100021570 B-cell lymphoma 3 protein Human genes 0.000 description 1
- 102100037598 B-cell lymphoma/leukemia 10 Human genes 0.000 description 1
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 description 1
- 102100027954 BAG family molecular chaperone regulator 3 Human genes 0.000 description 1
- 101700002522 BARD1 Proteins 0.000 description 1
- 101150074953 BCL10 gene Proteins 0.000 description 1
- 108091007065 BIRCs Proteins 0.000 description 1
- 102100028048 BRCA1-associated RING domain protein 1 Human genes 0.000 description 1
- 102100022045 BTB/POZ domain-containing protein 10 Human genes 0.000 description 1
- 102100024273 BTB/POZ domain-containing protein 3 Human genes 0.000 description 1
- 102100021677 Baculoviral IAP repeat-containing protein 2 Human genes 0.000 description 1
- 102100022970 Basic leucine zipper transcriptional factor ATF-like Human genes 0.000 description 1
- 102100023013 Basic leucine zipper transcriptional factor ATF-like 3 Human genes 0.000 description 1
- 102100026596 Bcl-2-like protein 1 Human genes 0.000 description 1
- 101150008012 Bcl2l1 gene Proteins 0.000 description 1
- 101150072667 Bcl3 gene Proteins 0.000 description 1
- VGGGPCQERPFHOB-MCIONIFRSA-N Bestatin Chemical compound CC(C)C[C@H](C(O)=O)NC(=O)[C@@H](O)[C@H](N)CC1=CC=CC=C1 VGGGPCQERPFHOB-MCIONIFRSA-N 0.000 description 1
- DIZWSDNSTNAYHK-XGWVBXMLSA-N Betulinic acid Natural products CC(=C)[C@@H]1C[C@H]([C@H]2CC[C@]3(C)[C@H](CC[C@@H]4[C@@]5(C)CC[C@H](O)C(C)(C)[C@@H]5CC[C@@]34C)[C@@H]12)C(=O)O DIZWSDNSTNAYHK-XGWVBXMLSA-N 0.000 description 1
- 102100027058 Bleomycin hydrolase Human genes 0.000 description 1
- 241000219198 Brassica Species 0.000 description 1
- 235000003351 Brassica cretica Nutrition 0.000 description 1
- 235000003343 Brassica rupestris Nutrition 0.000 description 1
- 102100027157 Butyrophilin subfamily 2 member A1 Human genes 0.000 description 1
- 102100028667 C-type lectin domain family 4 member A Human genes 0.000 description 1
- 102100025752 CASP8 and FADD-like apoptosis regulator Human genes 0.000 description 1
- 102100031025 CCR4-NOT transcription complex subunit 2 Human genes 0.000 description 1
- 102100031042 CCR4-NOT transcription complex subunit 6-like Human genes 0.000 description 1
- 229940124292 CD20 monoclonal antibody Drugs 0.000 description 1
- 102100027207 CD27 antigen Human genes 0.000 description 1
- 102100035793 CD83 antigen Human genes 0.000 description 1
- 102100037904 CD9 antigen Human genes 0.000 description 1
- 101150017278 CDC16 gene Proteins 0.000 description 1
- 102000014578 CDC26 Human genes 0.000 description 1
- 101150108242 CDC27 gene Proteins 0.000 description 1
- 102100031974 CMP-N-acetylneuraminate-beta-galactosamide-alpha-2,3-sialyltransferase 4 Human genes 0.000 description 1
- LLVZBTWPGQVVLW-SNAWJCMRSA-N CP-724714 Chemical compound C12=CC(/C=C/CNC(=O)COC)=CC=C2N=CN=C1NC(C=C1C)=CC=C1OC1=CC=C(C)N=C1 LLVZBTWPGQVVLW-SNAWJCMRSA-N 0.000 description 1
- 102100033210 CUGBP Elav-like family member 2 Human genes 0.000 description 1
- 102100037885 Calcium-independent phospholipase A2-gamma Human genes 0.000 description 1
- 102100025228 Calcium/calmodulin-dependent protein kinase type II subunit delta Human genes 0.000 description 1
- 102100021868 Calnexin Human genes 0.000 description 1
- 102100029968 Calreticulin Human genes 0.000 description 1
- 239000005461 Canertinib Substances 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 208000017897 Carcinoma of esophagus Diseases 0.000 description 1
- 102100029391 Cardiotrophin-like cytokine factor 1 Human genes 0.000 description 1
- 108010031425 Casein Kinases Proteins 0.000 description 1
- 102000005403 Casein Kinases Human genes 0.000 description 1
- 102100037402 Casein kinase I isoform delta Human genes 0.000 description 1
- 102100037398 Casein kinase I isoform epsilon Human genes 0.000 description 1
- 102100026550 Caspase-9 Human genes 0.000 description 1
- JDVVGAQPNNXQDW-WCMLQCRESA-N Castanospermine Natural products O[C@H]1[C@@H](O)[C@H]2[C@@H](O)CCN2C[C@H]1O JDVVGAQPNNXQDW-WCMLQCRESA-N 0.000 description 1
- JDVVGAQPNNXQDW-TVNFTVLESA-N Castinospermine Chemical compound C1[C@H](O)[C@@H](O)[C@H](O)[C@H]2[C@@H](O)CCN21 JDVVGAQPNNXQDW-TVNFTVLESA-N 0.000 description 1
- 108090000994 Catalytic RNA Proteins 0.000 description 1
- 102000053642 Catalytic RNA Human genes 0.000 description 1
- 102100032219 Cathepsin D Human genes 0.000 description 1
- 102100035654 Cathepsin S Human genes 0.000 description 1
- 102100026657 Cathepsin Z Human genes 0.000 description 1
- 102100033471 Cbp/p300-interacting transactivator 2 Human genes 0.000 description 1
- 102100033487 Cbp/p300-interacting transactivator 4 Human genes 0.000 description 1
- 101150008735 Cdc26 gene Proteins 0.000 description 1
- 102100024492 Cdc42 effector protein 2 Human genes 0.000 description 1
- 102100024502 Ceramide glucosyltransferase Human genes 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 241000282994 Cervidae Species 0.000 description 1
- 206010008342 Cervix carcinoma Diseases 0.000 description 1
- 108010012236 Chemokines Proteins 0.000 description 1
- 102000019034 Chemokines Human genes 0.000 description 1
- 102100038164 Chromodomain-helicase-DNA-binding protein 9 Human genes 0.000 description 1
- PPASFTRHCXASPY-UHFFFAOYSA-N Cl.Cl.NCCCNc1ccc2c3c(nn2CCNCCO)c4c(O)ccc(O)c4C(=O)c13 Chemical compound Cl.Cl.NCCCNc1ccc2c3c(nn2CCNCCO)c4c(O)ccc(O)c4C(=O)c13 PPASFTRHCXASPY-UHFFFAOYSA-N 0.000 description 1
- 102100031552 Coactosin-like protein Human genes 0.000 description 1
- HVXBOLULGPECHP-WAYWQWQTSA-N Combretastatin A4 Chemical compound C1=C(O)C(OC)=CC=C1\C=C/C1=CC(OC)=C(OC)C(OC)=C1 HVXBOLULGPECHP-WAYWQWQTSA-N 0.000 description 1
- 102100025680 Complement decay-accelerating factor Human genes 0.000 description 1
- DFDTZECTHJFPHE-UHFFFAOYSA-N Crambescidin 816 Natural products C1CC=CC(CC)OC11NC(N23)=NC4(OC(C)CCC4)C(C(=O)OCCCCCCCCCCCCCCCC(=O)N(CCCN)CC(O)CCN)C3(O)CCC2C1 DFDTZECTHJFPHE-UHFFFAOYSA-N 0.000 description 1
- 102100029375 Crk-like protein Human genes 0.000 description 1
- 102100039195 Cullin-1 Human genes 0.000 description 1
- 102100039193 Cullin-2 Human genes 0.000 description 1
- 102100028908 Cullin-3 Human genes 0.000 description 1
- 102100025525 Cullin-5 Human genes 0.000 description 1
- LUEYTMPPCOCKBX-UHFFFAOYSA-N Curacin A Natural products C=CCC(OC)CCC(C)=CC=CCCC=CC1CSC(C2C(C2)C)=N1 LUEYTMPPCOCKBX-UHFFFAOYSA-N 0.000 description 1
- LUEYTMPPCOCKBX-KWYHTCOPSA-N Curacin A Chemical compound C=CC[C@H](OC)CC\C(C)=C\C=C\CC\C=C/[C@@H]1CSC([C@H]2[C@H](C2)C)=N1 LUEYTMPPCOCKBX-KWYHTCOPSA-N 0.000 description 1
- 102100026359 Cyclic AMP-responsive element-binding protein 1 Human genes 0.000 description 1
- 108050006400 Cyclin Proteins 0.000 description 1
- 108010009392 Cyclin-Dependent Kinase Inhibitor p16 Proteins 0.000 description 1
- 102000009503 Cyclin-Dependent Kinase Inhibitor p18 Human genes 0.000 description 1
- 108010009367 Cyclin-Dependent Kinase Inhibitor p18 Proteins 0.000 description 1
- 108010016788 Cyclin-Dependent Kinase Inhibitor p21 Proteins 0.000 description 1
- 102000000577 Cyclin-Dependent Kinase Inhibitor p27 Human genes 0.000 description 1
- 108010016777 Cyclin-Dependent Kinase Inhibitor p27 Proteins 0.000 description 1
- 102000004480 Cyclin-Dependent Kinase Inhibitor p57 Human genes 0.000 description 1
- 108010017222 Cyclin-Dependent Kinase Inhibitor p57 Proteins 0.000 description 1
- 102100038250 Cyclin-G2 Human genes 0.000 description 1
- 102100033234 Cyclin-dependent kinase 17 Human genes 0.000 description 1
- 102100033145 Cyclin-dependent kinase 19 Human genes 0.000 description 1
- 102100033270 Cyclin-dependent kinase inhibitor 1 Human genes 0.000 description 1
- 102100024458 Cyclin-dependent kinase inhibitor 2A Human genes 0.000 description 1
- 102100026897 Cystatin-C Human genes 0.000 description 1
- 102100028188 Cystatin-F Human genes 0.000 description 1
- 102100027417 Cytochrome P450 1B1 Human genes 0.000 description 1
- 102100025620 Cytochrome b-245 light chain Human genes 0.000 description 1
- 102100026234 Cytokine receptor common subunit gamma Human genes 0.000 description 1
- 101710132484 Cytokine-inducible SH2-containing protein Proteins 0.000 description 1
- 102100036952 Cytoplasmic protein NCK2 Human genes 0.000 description 1
- 102100028629 Cytoskeleton-associated protein 4 Human genes 0.000 description 1
- PQNNIEWMPIULRS-UHFFFAOYSA-N Cytostatin Natural products CC=CC=CC=CC(O)C(C)C(OP(O)(O)=O)CCC(C)C1OC(=O)C=CC1C PQNNIEWMPIULRS-UHFFFAOYSA-N 0.000 description 1
- SPKNARKFCOPTSY-UHFFFAOYSA-N D-asperlin Natural products CC1OC1C1C(OC(C)=O)C=CC(=O)O1 SPKNARKFCOPTSY-UHFFFAOYSA-N 0.000 description 1
- 102100029582 DDB1- and CUL4-associated factor 1 Human genes 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 102100024607 DNA topoisomerase 1 Human genes 0.000 description 1
- 102100033589 DNA topoisomerase 2-beta Human genes 0.000 description 1
- 102100037799 DNA-binding protein Ikaros Human genes 0.000 description 1
- 102100032881 DNA-binding protein SATB1 Human genes 0.000 description 1
- 102100039436 DNA-binding protein inhibitor ID-3 Human genes 0.000 description 1
- 101100107081 Danio rerio zbtb16a gene Proteins 0.000 description 1
- ZBNZXTGUTAYRHI-UHFFFAOYSA-N Dasatinib Chemical compound C=1C(N2CCN(CCO)CC2)=NC(C)=NC=1NC(S1)=NC=C1C(=O)NC1=C(C)C=CC=C1Cl ZBNZXTGUTAYRHI-UHFFFAOYSA-N 0.000 description 1
- 102100031602 Dedicator of cytokinesis protein 10 Human genes 0.000 description 1
- GJKXGJCSJWBJEZ-XRSSZCMZSA-N Deslorelin Chemical compound CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CNC2=CC=CC=C12 GJKXGJCSJWBJEZ-XRSSZCMZSA-N 0.000 description 1
- OALVLUFFPXEHFO-UHFFFAOYSA-N Diazonamide A Natural products O1C=2C34C(O)OC5=C3C=CC=C5C(C3=5)=CC=CC=5NC(Cl)=C3C(=C(N=3)Cl)OC=3C=2N=C1C(C(C)C)NC(=O)C(NC(=O)C(N)C(C)C)CC1=CC=C(O)C4=C1 OALVLUFFPXEHFO-UHFFFAOYSA-N 0.000 description 1
- 101100216227 Dictyostelium discoideum anapc3 gene Proteins 0.000 description 1
- 101100327311 Dictyostelium discoideum anapc6 gene Proteins 0.000 description 1
- KYHUYMLIVQFXRI-SJPGYWQQSA-N Didemnin B Chemical compound CN([C@H](CC(C)C)C(=O)N[C@@H]1C(=O)N[C@@H]([C@H](CC(=O)O[C@H](C(=O)[C@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N2CCC[C@H]2C(=O)N(C)[C@@H](CC=2C=CC(OC)=CC=2)C(=O)O[C@@H]1C)C(C)C)O)[C@@H](C)CC)C(=O)[C@@H]1CCCN1C(=O)[C@H](C)O KYHUYMLIVQFXRI-SJPGYWQQSA-N 0.000 description 1
- AADVCYNFEREWOS-OBRABYBLSA-N Discodermolide Chemical compound C=C\C=C/[C@H](C)[C@H](OC(N)=O)[C@@H](C)[C@H](O)[C@@H](C)C\C(C)=C/[C@H](C)[C@@H](O)[C@@H](C)\C=C/[C@@H](O)C[C@@H]1OC(=O)[C@H](C)[C@@H](O)[C@H]1C AADVCYNFEREWOS-OBRABYBLSA-N 0.000 description 1
- 102100031111 Disintegrin and metalloproteinase domain-containing protein 17 Human genes 0.000 description 1
- 102100024364 Disintegrin and metalloproteinase domain-containing protein 8 Human genes 0.000 description 1
- 102100020977 DnaJ homolog subfamily A member 1 Human genes 0.000 description 1
- 102100029721 DnaJ homolog subfamily B member 1 Human genes 0.000 description 1
- 102100029707 DnaJ homolog subfamily B member 4 Human genes 0.000 description 1
- 102100037830 Docking protein 2 Human genes 0.000 description 1
- OFDNQWIFNXBECV-UHFFFAOYSA-N Dolastatin 10 Natural products CC(C)C(N(C)C)C(=O)NC(C(C)C)C(=O)N(C)C(C(C)CC)C(OC)CC(=O)N1CCCC1C(OC)C(C)C(=O)NC(C=1SC=CN=1)CC1=CC=CC=C1 OFDNQWIFNXBECV-UHFFFAOYSA-N 0.000 description 1
- MWWSFMDVAYGXBV-RUELKSSGSA-N Doxorubicin hydrochloride Chemical compound Cl.O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 MWWSFMDVAYGXBV-RUELKSSGSA-N 0.000 description 1
- CYQFCXCEBYINGO-DLBZAZTESA-N Dronabinol Natural products C1=C(C)CC[C@H]2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3[C@H]21 CYQFCXCEBYINGO-DLBZAZTESA-N 0.000 description 1
- 101001092183 Drosophila melanogaster Regulator of gene activity Proteins 0.000 description 1
- 102100023274 Dual specificity mitogen-activated protein kinase kinase 4 Human genes 0.000 description 1
- 102100037569 Dual specificity protein phosphatase 10 Human genes 0.000 description 1
- 102100028987 Dual specificity protein phosphatase 2 Human genes 0.000 description 1
- 102100027275 Dual specificity protein phosphatase 7 Human genes 0.000 description 1
- VQNATVDKACXKTF-UHFFFAOYSA-N Duocarmycin SA Natural products COC1=C(OC)C(OC)=C2NC(C(=O)N3C4=CC(=O)C5=C(C64CC6C3)C=C(N5)C(=O)OC)=CC2=C1 VQNATVDKACXKTF-UHFFFAOYSA-N 0.000 description 1
- 102100035834 Dynactin subunit 6 Human genes 0.000 description 1
- 102100024821 Dynamin-binding protein Human genes 0.000 description 1
- 102100032249 Dystonin Human genes 0.000 description 1
- 102100028836 E3 SUMO-protein ligase NSE2 Human genes 0.000 description 1
- 102100035989 E3 SUMO-protein ligase PIAS1 Human genes 0.000 description 1
- 102100030837 E3 SUMO-protein ligase PIAS3 Human genes 0.000 description 1
- 102100038912 E3 SUMO-protein ligase RanBP2 Human genes 0.000 description 1
- 102100038509 E3 ubiquitin-protein ligase ARIH1 Human genes 0.000 description 1
- 102100038513 E3 ubiquitin-protein ligase ARIH2 Human genes 0.000 description 1
- 102100037334 E3 ubiquitin-protein ligase CHIP Human genes 0.000 description 1
- 102100033360 E3 ubiquitin-protein ligase DZIP3 Human genes 0.000 description 1
- 102100034678 E3 ubiquitin-protein ligase HECTD3 Human genes 0.000 description 1
- 102100034745 E3 ubiquitin-protein ligase HERC2 Human genes 0.000 description 1
- 102100032049 E3 ubiquitin-protein ligase LRSAM1 Human genes 0.000 description 1
- 102100026246 E3 ubiquitin-protein ligase NRDP1 Human genes 0.000 description 1
- 102100036326 E3 ubiquitin-protein ligase Praja-1 Human genes 0.000 description 1
- 102100036333 E3 ubiquitin-protein ligase Praja-2 Human genes 0.000 description 1
- 102100025189 E3 ubiquitin-protein ligase RBBP6 Human genes 0.000 description 1
- 102100023877 E3 ubiquitin-protein ligase RBX1 Human genes 0.000 description 1
- 101710095156 E3 ubiquitin-protein ligase RBX1 Proteins 0.000 description 1
- 102100034121 E3 ubiquitin-protein ligase RNF125 Human genes 0.000 description 1
- 102100027414 E3 ubiquitin-protein ligase RNF19B Human genes 0.000 description 1
- 102100039495 E3 ubiquitin-protein ligase RNF25 Human genes 0.000 description 1
- 102100039502 E3 ubiquitin-protein ligase RNF34 Human genes 0.000 description 1
- 102100021820 E3 ubiquitin-protein ligase RNF4 Human genes 0.000 description 1
- 102100021810 E3 ubiquitin-protein ligase RNF6 Human genes 0.000 description 1
- 102100031748 E3 ubiquitin-protein ligase SIAH2 Human genes 0.000 description 1
- 102100038662 E3 ubiquitin-protein ligase SMURF2 Human genes 0.000 description 1
- 102100038797 E3 ubiquitin-protein ligase TRIM11 Human genes 0.000 description 1
- 102100029503 E3 ubiquitin-protein ligase TRIM32 Human genes 0.000 description 1
- 102100040068 E3 ubiquitin-protein ligase TRIM37 Human genes 0.000 description 1
- 102100028093 E3 ubiquitin-protein ligase TRIP12 Human genes 0.000 description 1
- 102100037240 E3 ubiquitin-protein ligase UBR2 Human genes 0.000 description 1
- 102100033594 E3 ubiquitin-protein ligase makorin-1 Human genes 0.000 description 1
- 102100039639 E3 ubiquitin-protein ligase pellino homolog 1 Human genes 0.000 description 1
- 102100032037 EH domain-containing protein 4 Human genes 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 101150097734 EPHB2 gene Proteins 0.000 description 1
- DYEFUKCXAQOFHX-UHFFFAOYSA-N Ebselen Chemical compound [se]1C2=CC=CC=C2C(=O)N1C1=CC=CC=C1 DYEFUKCXAQOFHX-UHFFFAOYSA-N 0.000 description 1
- 102100027261 Ecotropic viral integration site 5 protein homolog Human genes 0.000 description 1
- 102100030209 Elongin-B Human genes 0.000 description 1
- 102100037114 Elongin-C Human genes 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 206010014733 Endometrial cancer Diseases 0.000 description 1
- 206010014759 Endometrial neoplasm Diseases 0.000 description 1
- 108700041152 Endoplasmic Reticulum Chaperone BiP Proteins 0.000 description 1
- 102100021598 Endoplasmic reticulum aminopeptidase 1 Human genes 0.000 description 1
- 102100021451 Endoplasmic reticulum chaperone BiP Human genes 0.000 description 1
- 102100021579 Enhancer of filamentation 1 Human genes 0.000 description 1
- NBEALWAVEGMZQY-UHFFFAOYSA-N Enpromate Chemical compound C=1C=CC=CC=1C(C#C)(C=1C=CC=CC=1)OC(=O)NC1CCCCC1 NBEALWAVEGMZQY-UHFFFAOYSA-N 0.000 description 1
- 102100031968 Ephrin type-B receptor 2 Human genes 0.000 description 1
- BEFZAMRWPCMWFJ-JRBBLYSQSA-N Epothilone C Natural products O=C1[C@H](C)[C@@H](O)[C@@H](C)CCC/C=C\C[C@@H](/C(=C\c2nc(C)sc2)/C)OC(=O)C[C@H](O)C1(C)C BEFZAMRWPCMWFJ-JRBBLYSQSA-N 0.000 description 1
- XOZIUKBZLSUILX-SDMHVBBESA-N Epothilone D Natural products O=C1[C@H](C)[C@@H](O)[C@@H](C)CCC/C(/C)=C/C[C@@H](/C(=C\c2nc(C)sc2)/C)OC(=O)C[C@H](O)C1(C)C XOZIUKBZLSUILX-SDMHVBBESA-N 0.000 description 1
- UKIMCRYGLFQEOE-UHFFFAOYSA-N Epothilone F Natural products O1C(=O)CC(O)C(C)(C)C(=O)C(C)C(O)C(C)CCCC2(C)OC2CC1C(C)=CC1=CSC(CO)=N1 UKIMCRYGLFQEOE-UHFFFAOYSA-N 0.000 description 1
- VAPSMQAHNAZRKC-PQWRYPMOSA-N Epristeride Chemical compound C1C=C2C=C(C(O)=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)NC(C)(C)C)[C@@]1(C)CC2 VAPSMQAHNAZRKC-PQWRYPMOSA-N 0.000 description 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 description 1
- 208000032027 Essential Thrombocythemia Diseases 0.000 description 1
- 102100033175 Ethanolamine kinase 1 Human genes 0.000 description 1
- BFPYWIDHMRZLRN-SLHNCBLASA-N Ethinyl estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 BFPYWIDHMRZLRN-SLHNCBLASA-N 0.000 description 1
- ITIONVBQFUNVJV-UHFFFAOYSA-N Etomidoline Chemical compound C12=CC=CC=C2C(=O)N(CC)C1NC(C=C1)=CC=C1OCCN1CCCCC1 ITIONVBQFUNVJV-UHFFFAOYSA-N 0.000 description 1
- 102000005233 Eukaryotic Initiation Factor-4E Human genes 0.000 description 1
- 108060002636 Eukaryotic Initiation Factor-4E Proteins 0.000 description 1
- 102100039950 Eukaryotic initiation factor 4A-I Human genes 0.000 description 1
- 102100022462 Eukaryotic initiation factor 4A-II Human genes 0.000 description 1
- 102100022461 Eukaryotic initiation factor 4A-III Human genes 0.000 description 1
- 102100039735 Eukaryotic translation initiation factor 4 gamma 1 Human genes 0.000 description 1
- 102100039737 Eukaryotic translation initiation factor 4 gamma 2 Human genes 0.000 description 1
- 102100040022 Eukaryotic translation initiation factor 4 gamma 3 Human genes 0.000 description 1
- 102100029922 Eukaryotic translation initiation factor 4E type 2 Human genes 0.000 description 1
- 102100029907 Exocyst complex component 6B Human genes 0.000 description 1
- 102100029055 Exostosin-1 Human genes 0.000 description 1
- 102100020903 Ezrin Human genes 0.000 description 1
- 102100026078 F-box only protein 3 Human genes 0.000 description 1
- 102100024524 F-box only protein 4 Human genes 0.000 description 1
- 102100026080 F-box only protein 44 Human genes 0.000 description 1
- 102100038577 F-box/WD repeat-containing protein 11 Human genes 0.000 description 1
- 101710105178 F-box/WD repeat-containing protein 7 Proteins 0.000 description 1
- 102100028138 F-box/WD repeat-containing protein 7 Human genes 0.000 description 1
- 102000012031 FAM76B Human genes 0.000 description 1
- 108050002540 FAM76B Proteins 0.000 description 1
- 101150111119 Fem1c gene Proteins 0.000 description 1
- 102100020760 Ferritin heavy chain Human genes 0.000 description 1
- 102100024785 Fibroblast growth factor 2 Human genes 0.000 description 1
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 description 1
- 102100021066 Fibroblast growth factor receptor substrate 2 Human genes 0.000 description 1
- 102100038647 Fibroleukin Human genes 0.000 description 1
- 102100026559 Filamin-B Human genes 0.000 description 1
- 108010029961 Filgrastim Proteins 0.000 description 1
- 102100028122 Forkhead box protein P1 Human genes 0.000 description 1
- 102100039827 G protein-regulated inducer of neurite outgrowth 3 Human genes 0.000 description 1
- 102100021245 G-protein coupled receptor 183 Human genes 0.000 description 1
- 102100024185 G1/S-specific cyclin-D2 Human genes 0.000 description 1
- 102100037740 GRB2-associated-binding protein 1 Human genes 0.000 description 1
- 102100037759 GRB2-associated-binding protein 2 Human genes 0.000 description 1
- 102100032170 GTP-binding protein SAR1b Human genes 0.000 description 1
- 102100033512 GTP:AMP phosphotransferase AK3, mitochondrial Human genes 0.000 description 1
- 102100030708 GTPase KRas Human genes 0.000 description 1
- 102100039788 GTPase NRas Human genes 0.000 description 1
- 102100028496 Galactocerebrosidase Human genes 0.000 description 1
- 108010001498 Galectin 1 Proteins 0.000 description 1
- 102100034004 Gamma-adducin Human genes 0.000 description 1
- 102100033296 Gamma-aminobutyric acid receptor-associated protein-like 1 Human genes 0.000 description 1
- JRZJKWGQFNTSRN-UHFFFAOYSA-N Geldanamycin Natural products C1C(C)CC(OC)C(O)C(C)C=C(C)C(OC(N)=O)C(OC)CCC=C(C)C(=O)NC2=CC(=O)C(OC)=C1C2=O JRZJKWGQFNTSRN-UHFFFAOYSA-N 0.000 description 1
- 102100037410 Gigaxonin Human genes 0.000 description 1
- 102100033295 Glial cell line-derived neurotrophic factor Human genes 0.000 description 1
- 201000010915 Glioblastoma multiforme Diseases 0.000 description 1
- 102100028689 Glucocorticoid-induced transcript 1 protein Human genes 0.000 description 1
- 102100029003 Glucose-fructose oxidoreductase domain-containing protein 1 Human genes 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- 229920002683 Glycosaminoglycan Polymers 0.000 description 1
- 239000000579 Gonadotropin-Releasing Hormone Substances 0.000 description 1
- 108010069236 Goserelin Proteins 0.000 description 1
- BLCLNMBMMGCOAS-URPVMXJPSA-N Goserelin Chemical compound C([C@@H](C(=O)N[C@H](COC(C)(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1[C@@H](CCC1)C(=O)NNC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 BLCLNMBMMGCOAS-URPVMXJPSA-N 0.000 description 1
- 102100031150 Growth arrest and DNA damage-inducible protein GADD45 alpha Human genes 0.000 description 1
- 102100033321 Guanine nucleotide-binding protein G(I)/G(S)/G(O) subunit gamma-11 Human genes 0.000 description 1
- 102100035910 Guanine nucleotide-binding protein G(I)/G(S)/G(O) subunit gamma-2 Human genes 0.000 description 1
- 102100040739 Guanylate cyclase soluble subunit beta-1 Human genes 0.000 description 1
- 102100027377 HBS1-like protein Human genes 0.000 description 1
- 102100028490 HEAT repeat-containing protein 5A Human genes 0.000 description 1
- 108010010378 HLA-DP Antigens Proteins 0.000 description 1
- 102000015789 HLA-DP Antigens Human genes 0.000 description 1
- 108010041384 HLA-DPA antigen Proteins 0.000 description 1
- 108010062347 HLA-DQ Antigens Proteins 0.000 description 1
- 108010058597 HLA-DR Antigens Proteins 0.000 description 1
- 102000006354 HLA-DR Antigens Human genes 0.000 description 1
- 101150112743 HSPA5 gene Proteins 0.000 description 1
- 108010072471 HTI-286 Proteins 0.000 description 1
- ZBLLGPUWGCOJNG-UHFFFAOYSA-N Halichondrin B Natural products CC1CC2(CC(C)C3OC4(CC5OC6C(CC5O4)OC7CC8OC9CCC%10OC(CC(C(C9)C8=C)C%11%12CC%13OC%14C(OC%15CCC(CC(=O)OC7C6C)OC%15C%14O%11)C%13O%12)CC%10=C)CC3O2)OC%16OC(CC1%16)C(O)CC(O)CO ZBLLGPUWGCOJNG-UHFFFAOYSA-N 0.000 description 1
- 102100038006 High affinity immunoglobulin epsilon receptor subunit alpha Human genes 0.000 description 1
- 102100030673 Histone H2A.V Human genes 0.000 description 1
- 102100033070 Histone acetyltransferase KAT6B Human genes 0.000 description 1
- 102100027770 Histone-lysine N-methyltransferase KMT5B Human genes 0.000 description 1
- 208000017604 Hodgkin disease Diseases 0.000 description 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 description 1
- 102100035081 Homeobox protein TGIF1 Human genes 0.000 description 1
- 102100023607 Homer protein homolog 1 Human genes 0.000 description 1
- 101000659105 Homo sapiens (E3-independent) E2 ubiquitin-conjugating enzyme Proteins 0.000 description 1
- 101000691599 Homo sapiens 1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase gamma-1 Proteins 0.000 description 1
- 101000691589 Homo sapiens 1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase gamma-2 Proteins 0.000 description 1
- 101000818893 Homo sapiens 14-3-3 protein beta/alpha Proteins 0.000 description 1
- 101000964898 Homo sapiens 14-3-3 protein zeta/delta Proteins 0.000 description 1
- 101001080057 Homo sapiens 2-5A-dependent ribonuclease Proteins 0.000 description 1
- 101000612655 Homo sapiens 26S proteasome non-ATPase regulatory subunit 1 Proteins 0.000 description 1
- 101001136581 Homo sapiens 26S proteasome non-ATPase regulatory subunit 10 Proteins 0.000 description 1
- 101000612519 Homo sapiens 26S proteasome non-ATPase regulatory subunit 11 Proteins 0.000 description 1
- 101000612528 Homo sapiens 26S proteasome non-ATPase regulatory subunit 12 Proteins 0.000 description 1
- 101000612536 Homo sapiens 26S proteasome non-ATPase regulatory subunit 13 Proteins 0.000 description 1
- 101000590281 Homo sapiens 26S proteasome non-ATPase regulatory subunit 14 Proteins 0.000 description 1
- 101000590272 Homo sapiens 26S proteasome non-ATPase regulatory subunit 2 Proteins 0.000 description 1
- 101000590224 Homo sapiens 26S proteasome non-ATPase regulatory subunit 3 Proteins 0.000 description 1
- 101001135231 Homo sapiens 26S proteasome non-ATPase regulatory subunit 4 Proteins 0.000 description 1
- 101001135226 Homo sapiens 26S proteasome non-ATPase regulatory subunit 5 Proteins 0.000 description 1
- 101001135306 Homo sapiens 26S proteasome non-ATPase regulatory subunit 6 Proteins 0.000 description 1
- 101001136696 Homo sapiens 26S proteasome non-ATPase regulatory subunit 7 Proteins 0.000 description 1
- 101001069718 Homo sapiens 26S proteasome regulatory subunit 10B Proteins 0.000 description 1
- 101000619137 Homo sapiens 26S proteasome regulatory subunit 4 Proteins 0.000 description 1
- 101001125540 Homo sapiens 26S proteasome regulatory subunit 6A Proteins 0.000 description 1
- 101001125524 Homo sapiens 26S proteasome regulatory subunit 6B Proteins 0.000 description 1
- 101001090865 Homo sapiens 26S proteasome regulatory subunit 7 Proteins 0.000 description 1
- 101001136753 Homo sapiens 26S proteasome regulatory subunit 8 Proteins 0.000 description 1
- 101000600756 Homo sapiens 3-phosphoinositide-dependent protein kinase 1 Proteins 0.000 description 1
- 101000833679 Homo sapiens A-kinase anchor protein 13 Proteins 0.000 description 1
- 101000782077 Homo sapiens AN1-type zinc finger protein 5 Proteins 0.000 description 1
- 101000782083 Homo sapiens AN1-type zinc finger protein 6 Proteins 0.000 description 1
- 101000923353 Homo sapiens ATPase family AAA domain-containing protein 2B Proteins 0.000 description 1
- 101000902767 Homo sapiens ATPase inhibitor, mitochondrial Proteins 0.000 description 1
- 101000964349 Homo sapiens Activator of basal transcription 1 Proteins 0.000 description 1
- 101000919320 Homo sapiens Adapter molecule crk Proteins 0.000 description 1
- 101000614487 Homo sapiens Adenylate kinase 4, mitochondrial Proteins 0.000 description 1
- 101000775477 Homo sapiens Afadin- and alpha-actinin-binding protein Proteins 0.000 description 1
- 101000928511 Homo sapiens Akirin-1 Proteins 0.000 description 1
- 101000733832 Homo sapiens Anaphase-promoting complex subunit 13 Proteins 0.000 description 1
- 101000961191 Homo sapiens Anaphase-promoting complex subunit 2 Proteins 0.000 description 1
- 101000925496 Homo sapiens Ankyrin repeat and SOCS box protein 1 Proteins 0.000 description 1
- 101000754305 Homo sapiens Ankyrin repeat and SOCS box protein 6 Proteins 0.000 description 1
- 101000754271 Homo sapiens Ankyrin repeat and SOCS box protein 7 Proteins 0.000 description 1
- 101000703115 Homo sapiens Ankyrin repeat and SOCS box protein 8 Proteins 0.000 description 1
- 101000796085 Homo sapiens Anthrax toxin receptor 2 Proteins 0.000 description 1
- 101000780559 Homo sapiens Apoptosis-enhancing nuclease Proteins 0.000 description 1
- 101000733557 Homo sapiens Arf-GAP with Rho-GAP domain, ANK repeat and PH domain-containing protein 2 Proteins 0.000 description 1
- 101000905423 Homo sapiens Autophagy-related protein 101 Proteins 0.000 description 1
- 101000914491 Homo sapiens B-cell antigen receptor complex-associated protein beta chain Proteins 0.000 description 1
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 description 1
- 101000697871 Homo sapiens BAG family molecular chaperone regulator 3 Proteins 0.000 description 1
- 101000896834 Homo sapiens BTB/POZ domain-containing protein 10 Proteins 0.000 description 1
- 101000761886 Homo sapiens BTB/POZ domain-containing protein 3 Proteins 0.000 description 1
- 101000903742 Homo sapiens Basic leucine zipper transcriptional factor ATF-like Proteins 0.000 description 1
- 101000903609 Homo sapiens Basic leucine zipper transcriptional factor ATF-like 3 Proteins 0.000 description 1
- 101000959437 Homo sapiens Beta-2 adrenergic receptor Proteins 0.000 description 1
- 101000984541 Homo sapiens Bleomycin hydrolase Proteins 0.000 description 1
- 101000984926 Homo sapiens Butyrophilin subfamily 2 member A1 Proteins 0.000 description 1
- 101000766908 Homo sapiens C-type lectin domain family 4 member A Proteins 0.000 description 1
- 101000914211 Homo sapiens CASP8 and FADD-like apoptosis regulator Proteins 0.000 description 1
- 101000919667 Homo sapiens CCR4-NOT transcription complex subunit 2 Proteins 0.000 description 1
- 101000919666 Homo sapiens CCR4-NOT transcription complex subunit 6-like Proteins 0.000 description 1
- 101000914511 Homo sapiens CD27 antigen Proteins 0.000 description 1
- 101000946856 Homo sapiens CD83 antigen Proteins 0.000 description 1
- 101000738354 Homo sapiens CD9 antigen Proteins 0.000 description 1
- 101000703754 Homo sapiens CMP-N-acetylneuraminate-beta-galactosamide-alpha-2,3-sialyltransferase 4 Proteins 0.000 description 1
- 101000944442 Homo sapiens CUGBP Elav-like family member 2 Proteins 0.000 description 1
- 101001095970 Homo sapiens Calcium-independent phospholipase A2-gamma Proteins 0.000 description 1
- 101001077338 Homo sapiens Calcium/calmodulin-dependent protein kinase type II subunit delta Proteins 0.000 description 1
- 101000898052 Homo sapiens Calnexin Proteins 0.000 description 1
- 101000793651 Homo sapiens Calreticulin Proteins 0.000 description 1
- 101000989964 Homo sapiens Cardiotrophin-like cytokine factor 1 Proteins 0.000 description 1
- 101001026336 Homo sapiens Casein kinase I isoform delta Proteins 0.000 description 1
- 101001026376 Homo sapiens Casein kinase I isoform epsilon Proteins 0.000 description 1
- 101000983523 Homo sapiens Caspase-9 Proteins 0.000 description 1
- 101000869010 Homo sapiens Cathepsin D Proteins 0.000 description 1
- 101000947086 Homo sapiens Cathepsin S Proteins 0.000 description 1
- 101000910979 Homo sapiens Cathepsin Z Proteins 0.000 description 1
- 101000944098 Homo sapiens Cbp/p300-interacting transactivator 2 Proteins 0.000 description 1
- 101000944074 Homo sapiens Cbp/p300-interacting transactivator 4 Proteins 0.000 description 1
- 101000762417 Homo sapiens Cdc42 effector protein 2 Proteins 0.000 description 1
- 101000912124 Homo sapiens Cell division cycle protein 23 homolog Proteins 0.000 description 1
- 101000981050 Homo sapiens Ceramide glucosyltransferase Proteins 0.000 description 1
- 101000883548 Homo sapiens Chromodomain-helicase-DNA-binding protein 9 Proteins 0.000 description 1
- 101000940352 Homo sapiens Coactosin-like protein Proteins 0.000 description 1
- 101000856022 Homo sapiens Complement decay-accelerating factor Proteins 0.000 description 1
- 101000919315 Homo sapiens Crk-like protein Proteins 0.000 description 1
- 101000746063 Homo sapiens Cullin-1 Proteins 0.000 description 1
- 101000746072 Homo sapiens Cullin-2 Proteins 0.000 description 1
- 101000916238 Homo sapiens Cullin-3 Proteins 0.000 description 1
- 101000856414 Homo sapiens Cullin-5 Proteins 0.000 description 1
- 101000855516 Homo sapiens Cyclic AMP-responsive element-binding protein 1 Proteins 0.000 description 1
- 101000884216 Homo sapiens Cyclin-G2 Proteins 0.000 description 1
- 101000944358 Homo sapiens Cyclin-dependent kinase 17 Proteins 0.000 description 1
- 101000944345 Homo sapiens Cyclin-dependent kinase 19 Proteins 0.000 description 1
- 101000912205 Homo sapiens Cystatin-C Proteins 0.000 description 1
- 101000916688 Homo sapiens Cystatin-F Proteins 0.000 description 1
- 101000725164 Homo sapiens Cytochrome P450 1B1 Proteins 0.000 description 1
- 101000856723 Homo sapiens Cytochrome b-245 light chain Proteins 0.000 description 1
- 101001055227 Homo sapiens Cytokine receptor common subunit gamma Proteins 0.000 description 1
- 101001024712 Homo sapiens Cytoplasmic protein NCK2 Proteins 0.000 description 1
- 101000766853 Homo sapiens Cytoskeleton-associated protein 4 Proteins 0.000 description 1
- 101000917426 Homo sapiens DDB1- and CUL4-associated factor 1 Proteins 0.000 description 1
- 101000830681 Homo sapiens DNA topoisomerase 1 Proteins 0.000 description 1
- 101000599038 Homo sapiens DNA-binding protein Ikaros Proteins 0.000 description 1
- 101000655234 Homo sapiens DNA-binding protein SATB1 Proteins 0.000 description 1
- 101001036287 Homo sapiens DNA-binding protein inhibitor ID-3 Proteins 0.000 description 1
- 101000866268 Homo sapiens Dedicator of cytokinesis protein 10 Proteins 0.000 description 1
- 101000832767 Homo sapiens Disintegrin and metalloproteinase domain-containing protein 8 Proteins 0.000 description 1
- 101000931227 Homo sapiens DnaJ homolog subfamily A member 1 Proteins 0.000 description 1
- 101000866018 Homo sapiens DnaJ homolog subfamily B member 1 Proteins 0.000 description 1
- 101000866008 Homo sapiens DnaJ homolog subfamily B member 4 Proteins 0.000 description 1
- 101000805166 Homo sapiens Docking protein 2 Proteins 0.000 description 1
- 101001115395 Homo sapiens Dual specificity mitogen-activated protein kinase kinase 4 Proteins 0.000 description 1
- 101000881127 Homo sapiens Dual specificity protein phosphatase 10 Proteins 0.000 description 1
- 101000838335 Homo sapiens Dual specificity protein phosphatase 2 Proteins 0.000 description 1
- 101001057603 Homo sapiens Dual specificity protein phosphatase 7 Proteins 0.000 description 1
- 101000873769 Homo sapiens Dynactin subunit 6 Proteins 0.000 description 1
- 101000909230 Homo sapiens Dynamin-binding protein Proteins 0.000 description 1
- 101001016186 Homo sapiens Dystonin Proteins 0.000 description 1
- 101000577736 Homo sapiens E3 SUMO-protein ligase NSE2 Proteins 0.000 description 1
- 101000583444 Homo sapiens E3 SUMO-protein ligase PIAS3 Proteins 0.000 description 1
- 101000808922 Homo sapiens E3 ubiquitin-protein ligase ARIH1 Proteins 0.000 description 1
- 101000808888 Homo sapiens E3 ubiquitin-protein ligase ARIH2 Proteins 0.000 description 1
- 101000879619 Homo sapiens E3 ubiquitin-protein ligase CHIP Proteins 0.000 description 1
- 101000926716 Homo sapiens E3 ubiquitin-protein ligase DZIP3 Proteins 0.000 description 1
- 101000872865 Homo sapiens E3 ubiquitin-protein ligase HECTD3 Proteins 0.000 description 1
- 101000872516 Homo sapiens E3 ubiquitin-protein ligase HERC2 Proteins 0.000 description 1
- 101001065747 Homo sapiens E3 ubiquitin-protein ligase LRSAM1 Proteins 0.000 description 1
- 101000692706 Homo sapiens E3 ubiquitin-protein ligase NRDP1 Proteins 0.000 description 1
- 101001001813 Homo sapiens E3 ubiquitin-protein ligase Praja-1 Proteins 0.000 description 1
- 101001001821 Homo sapiens E3 ubiquitin-protein ligase Praja-2 Proteins 0.000 description 1
- 101001077300 Homo sapiens E3 ubiquitin-protein ligase RBBP6 Proteins 0.000 description 1
- 101000711567 Homo sapiens E3 ubiquitin-protein ligase RNF125 Proteins 0.000 description 1
- 101000734280 Homo sapiens E3 ubiquitin-protein ligase RNF217 Proteins 0.000 description 1
- 101001103592 Homo sapiens E3 ubiquitin-protein ligase RNF25 Proteins 0.000 description 1
- 101001103581 Homo sapiens E3 ubiquitin-protein ligase RNF34 Proteins 0.000 description 1
- 101001107086 Homo sapiens E3 ubiquitin-protein ligase RNF4 Proteins 0.000 description 1
- 101001107079 Homo sapiens E3 ubiquitin-protein ligase RNF6 Proteins 0.000 description 1
- 101000707245 Homo sapiens E3 ubiquitin-protein ligase SIAH2 Proteins 0.000 description 1
- 101000664952 Homo sapiens E3 ubiquitin-protein ligase SMURF2 Proteins 0.000 description 1
- 101000664584 Homo sapiens E3 ubiquitin-protein ligase TRIM11 Proteins 0.000 description 1
- 101000634982 Homo sapiens E3 ubiquitin-protein ligase TRIM32 Proteins 0.000 description 1
- 101000610400 Homo sapiens E3 ubiquitin-protein ligase TRIM37 Proteins 0.000 description 1
- 101000807547 Homo sapiens E3 ubiquitin-protein ligase UBR4 Proteins 0.000 description 1
- 101001018965 Homo sapiens E3 ubiquitin-protein ligase makorin-1 Proteins 0.000 description 1
- 101000606708 Homo sapiens E3 ubiquitin-protein ligase pellino homolog 1 Proteins 0.000 description 1
- 101000921218 Homo sapiens EH domain-containing protein 4 Proteins 0.000 description 1
- 101001057141 Homo sapiens Ecotropic viral integration site 5 protein homolog Proteins 0.000 description 1
- 101001011846 Homo sapiens Elongin-B Proteins 0.000 description 1
- 101000881731 Homo sapiens Elongin-C Proteins 0.000 description 1
- 101000898750 Homo sapiens Endoplasmic reticulum aminopeptidase 1 Proteins 0.000 description 1
- 101000898310 Homo sapiens Enhancer of filamentation 1 Proteins 0.000 description 1
- 101000851032 Homo sapiens Ethanolamine kinase 1 Proteins 0.000 description 1
- 101000959666 Homo sapiens Eukaryotic initiation factor 4A-I Proteins 0.000 description 1
- 101001044475 Homo sapiens Eukaryotic initiation factor 4A-II Proteins 0.000 description 1
- 101001044466 Homo sapiens Eukaryotic initiation factor 4A-III Proteins 0.000 description 1
- 101001034825 Homo sapiens Eukaryotic translation initiation factor 4 gamma 1 Proteins 0.000 description 1
- 101001034811 Homo sapiens Eukaryotic translation initiation factor 4 gamma 2 Proteins 0.000 description 1
- 101001034840 Homo sapiens Eukaryotic translation initiation factor 4 gamma 3 Proteins 0.000 description 1
- 101001011096 Homo sapiens Eukaryotic translation initiation factor 4E type 2 Proteins 0.000 description 1
- 101001011230 Homo sapiens Exocyst complex component 6B Proteins 0.000 description 1
- 101000918311 Homo sapiens Exostosin-1 Proteins 0.000 description 1
- 101000854648 Homo sapiens Ezrin Proteins 0.000 description 1
- 101000913305 Homo sapiens F-box only protein 3 Proteins 0.000 description 1
- 101001052775 Homo sapiens F-box only protein 4 Proteins 0.000 description 1
- 101000913298 Homo sapiens F-box only protein 44 Proteins 0.000 description 1
- 101001030696 Homo sapiens F-box/WD repeat-containing protein 11 Proteins 0.000 description 1
- 101000848171 Homo sapiens Fanconi anemia group J protein Proteins 0.000 description 1
- 101001002987 Homo sapiens Ferritin heavy chain Proteins 0.000 description 1
- 101000818410 Homo sapiens Fibroblast growth factor receptor substrate 2 Proteins 0.000 description 1
- 101001031613 Homo sapiens Fibroleukin Proteins 0.000 description 1
- 101000913551 Homo sapiens Filamin-B Proteins 0.000 description 1
- 101001059893 Homo sapiens Forkhead box protein P1 Proteins 0.000 description 1
- 101001034044 Homo sapiens G protein-regulated inducer of neurite outgrowth 3 Proteins 0.000 description 1
- 101001040801 Homo sapiens G-protein coupled receptor 183 Proteins 0.000 description 1
- 101000980741 Homo sapiens G1/S-specific cyclin-D2 Proteins 0.000 description 1
- 101001024897 Homo sapiens GRB2-associated-binding protein 1 Proteins 0.000 description 1
- 101001024902 Homo sapiens GRB2-associated-binding protein 2 Proteins 0.000 description 1
- 101000637633 Homo sapiens GTP-binding protein SAR1b Proteins 0.000 description 1
- 101000998053 Homo sapiens GTP:AMP phosphotransferase AK3, mitochondrial Proteins 0.000 description 1
- 101000584612 Homo sapiens GTPase KRas Proteins 0.000 description 1
- 101000744505 Homo sapiens GTPase NRas Proteins 0.000 description 1
- 101000860395 Homo sapiens Galactocerebrosidase Proteins 0.000 description 1
- 101000799011 Homo sapiens Gamma-adducin Proteins 0.000 description 1
- 101000926844 Homo sapiens Gamma-aminobutyric acid receptor-associated protein-like 1 Proteins 0.000 description 1
- 101001025761 Homo sapiens Gigaxonin Proteins 0.000 description 1
- 101001058426 Homo sapiens Glucocorticoid-induced transcript 1 protein Proteins 0.000 description 1
- 101001059225 Homo sapiens Glucose-fructose oxidoreductase domain-containing protein 1 Proteins 0.000 description 1
- 101001066158 Homo sapiens Growth arrest and DNA damage-inducible protein GADD45 alpha Proteins 0.000 description 1
- 101000926795 Homo sapiens Guanine nucleotide-binding protein G(I)/G(S)/G(O) subunit gamma-11 Proteins 0.000 description 1
- 101001073272 Homo sapiens Guanine nucleotide-binding protein G(I)/G(S)/G(O) subunit gamma-2 Proteins 0.000 description 1
- 101001038731 Homo sapiens Guanylate cyclase soluble subunit beta-1 Proteins 0.000 description 1
- 101001009070 Homo sapiens HBS1-like protein Proteins 0.000 description 1
- 101000839976 Homo sapiens HEAT repeat-containing protein 5A Proteins 0.000 description 1
- 101000898034 Homo sapiens Hepatocyte growth factor Proteins 0.000 description 1
- 101000878611 Homo sapiens High affinity immunoglobulin epsilon receptor subunit alpha Proteins 0.000 description 1
- 101001084711 Homo sapiens Histone H2A.V Proteins 0.000 description 1
- 101000944174 Homo sapiens Histone acetyltransferase KAT6B Proteins 0.000 description 1
- 101001008821 Homo sapiens Histone-lysine N-methyltransferase KMT5B Proteins 0.000 description 1
- 101000596925 Homo sapiens Homeobox protein TGIF1 Proteins 0.000 description 1
- 101001048469 Homo sapiens Homer protein homolog 1 Proteins 0.000 description 1
- 101001035135 Homo sapiens Homocysteine-responsive endoplasmic reticulum-resident ubiquitin-like domain member 2 protein Proteins 0.000 description 1
- 101100286226 Homo sapiens IBTK gene Proteins 0.000 description 1
- 101001001478 Homo sapiens Importin subunit alpha-3 Proteins 0.000 description 1
- 101001001473 Homo sapiens Importin subunit alpha-4 Proteins 0.000 description 1
- 101001001462 Homo sapiens Importin subunit alpha-5 Proteins 0.000 description 1
- 101001054807 Homo sapiens Importin subunit alpha-6 Proteins 0.000 description 1
- 101000998629 Homo sapiens Importin subunit beta-1 Proteins 0.000 description 1
- 101001043764 Homo sapiens Inhibitor of nuclear factor kappa-B kinase subunit alpha Proteins 0.000 description 1
- 101000993959 Homo sapiens Inositol 1,4,5-trisphosphate receptor-interacting protein Proteins 0.000 description 1
- 101001011989 Homo sapiens Inositol hexakisphosphate kinase 2 Proteins 0.000 description 1
- 101001054823 Homo sapiens Inositol polyphosphate 1-phosphatase Proteins 0.000 description 1
- 101001050468 Homo sapiens Integral membrane protein 2B Proteins 0.000 description 1
- 101000935043 Homo sapiens Integrin beta-1 Proteins 0.000 description 1
- 101000852870 Homo sapiens Interferon alpha/beta receptor 1 Proteins 0.000 description 1
- 101001032345 Homo sapiens Interferon regulatory factor 8 Proteins 0.000 description 1
- 101001033249 Homo sapiens Interleukin-1 beta Proteins 0.000 description 1
- 101001003142 Homo sapiens Interleukin-12 receptor subunit beta-1 Proteins 0.000 description 1
- 101001003135 Homo sapiens Interleukin-13 receptor subunit alpha-1 Proteins 0.000 description 1
- 101001019591 Homo sapiens Interleukin-18-binding protein Proteins 0.000 description 1
- 101000998120 Homo sapiens Interleukin-3 receptor subunit alpha Proteins 0.000 description 1
- 101001076408 Homo sapiens Interleukin-6 Proteins 0.000 description 1
- 101000599056 Homo sapiens Interleukin-6 receptor subunit beta Proteins 0.000 description 1
- 101001026236 Homo sapiens Intermediate conductance calcium-activated potassium channel protein 4 Proteins 0.000 description 1
- 101000994432 Homo sapiens Josephin-1 Proteins 0.000 description 1
- 101000997318 Homo sapiens Kelch repeat and BTB domain-containing protein 2 Proteins 0.000 description 1
- 101001049204 Homo sapiens Kelch-like protein 20 Proteins 0.000 description 1
- 101001008917 Homo sapiens Kelch-like protein 9 Proteins 0.000 description 1
- 101000971538 Homo sapiens Killer cell lectin-like receptor subfamily F member 1 Proteins 0.000 description 1
- 101000605734 Homo sapiens Kinesin-like protein KIF22 Proteins 0.000 description 1
- 101001046564 Homo sapiens Krueppel-like factor 13 Proteins 0.000 description 1
- 101001139146 Homo sapiens Krueppel-like factor 2 Proteins 0.000 description 1
- 101001139136 Homo sapiens Krueppel-like factor 3 Proteins 0.000 description 1
- 101001139134 Homo sapiens Krueppel-like factor 4 Proteins 0.000 description 1
- 101001018097 Homo sapiens L-selectin Proteins 0.000 description 1
- 101000874532 Homo sapiens Lactosylceramide 1,3-N-acetyl-beta-D-glucosaminyltransferase Proteins 0.000 description 1
- 101000966275 Homo sapiens Lethal(3)malignant brain tumor-like protein 3 Proteins 0.000 description 1
- 101000941886 Homo sapiens Leucine-rich repeat and calponin homology domain-containing protein 1 Proteins 0.000 description 1
- 101001017828 Homo sapiens Leucine-rich repeat flightless-interacting protein 1 Proteins 0.000 description 1
- 101001038321 Homo sapiens Leucine-rich repeat protein 1 Proteins 0.000 description 1
- 101000984848 Homo sapiens Leucine-rich repeat-containing protein 41 Proteins 0.000 description 1
- 101001137975 Homo sapiens Leucyl-cystinyl aminopeptidase Proteins 0.000 description 1
- 101000619898 Homo sapiens Leukotriene A-4 hydrolase Proteins 0.000 description 1
- 101000619643 Homo sapiens Ligand-dependent nuclear receptor-interacting factor 1 Proteins 0.000 description 1
- 101000878605 Homo sapiens Low affinity immunoglobulin epsilon Fc receptor Proteins 0.000 description 1
- 101000917858 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-A Proteins 0.000 description 1
- 101000917839 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-B Proteins 0.000 description 1
- 101000764294 Homo sapiens Lymphotoxin-beta Proteins 0.000 description 1
- 101000614017 Homo sapiens Lysine-specific demethylase 3A Proteins 0.000 description 1
- 101001025971 Homo sapiens Lysine-specific demethylase 6B Proteins 0.000 description 1
- 101001122938 Homo sapiens Lysosomal protective protein Proteins 0.000 description 1
- 101001014572 Homo sapiens MARCKS-related protein Proteins 0.000 description 1
- 101000576160 Homo sapiens MOB kinase activator 3B Proteins 0.000 description 1
- 101000760817 Homo sapiens Macrophage-capping protein Proteins 0.000 description 1
- 101000958390 Homo sapiens Mannosyl-oligosaccharide 1,2-alpha-mannosidase IA Proteins 0.000 description 1
- 101000615932 Homo sapiens Mannosyl-oligosaccharide 1,2-alpha-mannosidase IB Proteins 0.000 description 1
- 101000962483 Homo sapiens Max dimerization protein 1 Proteins 0.000 description 1
- 101000950687 Homo sapiens Mitogen-activated protein kinase 7 Proteins 0.000 description 1
- 101000950669 Homo sapiens Mitogen-activated protein kinase 9 Proteins 0.000 description 1
- 101001018196 Homo sapiens Mitogen-activated protein kinase kinase kinase 5 Proteins 0.000 description 1
- 101001055092 Homo sapiens Mitogen-activated protein kinase kinase kinase 7 Proteins 0.000 description 1
- 101001059991 Homo sapiens Mitogen-activated protein kinase kinase kinase kinase 1 Proteins 0.000 description 1
- 101001059984 Homo sapiens Mitogen-activated protein kinase kinase kinase kinase 4 Proteins 0.000 description 1
- 101001074975 Homo sapiens Molybdopterin molybdenumtransferase Proteins 0.000 description 1
- 101001012646 Homo sapiens Monoglyceride lipase Proteins 0.000 description 1
- 101000583839 Homo sapiens Muscleblind-like protein 1 Proteins 0.000 description 1
- 101000583841 Homo sapiens Muscleblind-like protein 2 Proteins 0.000 description 1
- 101000969770 Homo sapiens Myelin protein zero-like protein 2 Proteins 0.000 description 1
- 101001018552 Homo sapiens MyoD family inhibitor domain-containing protein Proteins 0.000 description 1
- 101001132874 Homo sapiens Myotubularin Proteins 0.000 description 1
- 101000886220 Homo sapiens N-acetylgalactosaminyltransferase 7 Proteins 0.000 description 1
- 101001072470 Homo sapiens N-acetylglucosamine-1-phosphotransferase subunits alpha/beta Proteins 0.000 description 1
- 101000874526 Homo sapiens N-acetyllactosaminide beta-1,3-N-acetylglucosaminyltransferase 2 Proteins 0.000 description 1
- 101001059802 Homo sapiens N-formyl peptide receptor 3 Proteins 0.000 description 1
- 101000650158 Homo sapiens NEDD4-like E3 ubiquitin-protein ligase WWP1 Proteins 0.000 description 1
- 101000644718 Homo sapiens NEDD8-conjugating enzyme UBE2F Proteins 0.000 description 1
- 101000644669 Homo sapiens NEDD8-conjugating enzyme Ubc12 Proteins 0.000 description 1
- 101000973618 Homo sapiens NF-kappa-B essential modulator Proteins 0.000 description 1
- 101000583057 Homo sapiens NGFI-A-binding protein 2 Proteins 0.000 description 1
- 101001109501 Homo sapiens NKG2-D type II integral membrane protein Proteins 0.000 description 1
- 101000970025 Homo sapiens NUAK family SNF1-like kinase 2 Proteins 0.000 description 1
- 101000581981 Homo sapiens Neural cell adhesion molecule 1 Proteins 0.000 description 1
- 101000775053 Homo sapiens Neuroblast differentiation-associated protein AHNAK Proteins 0.000 description 1
- 101001121613 Homo sapiens Nuclear envelope pore membrane protein POM 121 Proteins 0.000 description 1
- 101001107586 Homo sapiens Nuclear pore complex protein Nup107 Proteins 0.000 description 1
- 101000970315 Homo sapiens Nuclear pore complex protein Nup133 Proteins 0.000 description 1
- 101001108932 Homo sapiens Nuclear pore complex protein Nup155 Proteins 0.000 description 1
- 101000589749 Homo sapiens Nuclear pore complex protein Nup205 Proteins 0.000 description 1
- 101000996563 Homo sapiens Nuclear pore complex protein Nup214 Proteins 0.000 description 1
- 101001121654 Homo sapiens Nuclear pore complex protein Nup50 Proteins 0.000 description 1
- 101001007862 Homo sapiens Nuclear pore complex protein Nup85 Proteins 0.000 description 1
- 101001007901 Homo sapiens Nuclear pore complex protein Nup88 Proteins 0.000 description 1
- 101001118493 Homo sapiens Nuclear pore glycoprotein p62 Proteins 0.000 description 1
- 101001109700 Homo sapiens Nuclear receptor subfamily 4 group A member 1 Proteins 0.000 description 1
- 101000577335 Homo sapiens Nuclear receptor-binding factor 2 Proteins 0.000 description 1
- 101001108862 Homo sapiens Nucleoporin NUP188 Proteins 0.000 description 1
- 101001139122 Homo sapiens Nucleoporin NUP35 Proteins 0.000 description 1
- 101000598403 Homo sapiens Nucleoporin NUP42 Proteins 0.000 description 1
- 101000598495 Homo sapiens Nucleoporin Nup37 Proteins 0.000 description 1
- 101000598421 Homo sapiens Nucleoporin Nup43 Proteins 0.000 description 1
- 101000683898 Homo sapiens Nucleoporin SEH1 Proteins 0.000 description 1
- 101001121642 Homo sapiens Nucleoporin p54 Proteins 0.000 description 1
- 101001121636 Homo sapiens Nucleoporin p58/p45 Proteins 0.000 description 1
- 101000801664 Homo sapiens Nucleoprotein TPR Proteins 0.000 description 1
- 101001125032 Homo sapiens Nucleotide-binding oligomerization domain-containing protein 1 Proteins 0.000 description 1
- 101001109269 Homo sapiens NudC domain-containing protein 3 Proteins 0.000 description 1
- 101001098179 Homo sapiens P2X purinoceptor 4 Proteins 0.000 description 1
- 101000988394 Homo sapiens PDZ and LIM domain protein 5 Proteins 0.000 description 1
- 101001095329 Homo sapiens POM121 and ZP3 fusion protein Proteins 0.000 description 1
- 101001000780 Homo sapiens POU domain, class 2, transcription factor 1 Proteins 0.000 description 1
- 101000735213 Homo sapiens Palladin Proteins 0.000 description 1
- 101000612657 Homo sapiens Paraspeckle component 1 Proteins 0.000 description 1
- 101001098517 Homo sapiens Paxillin Proteins 0.000 description 1
- 101000579484 Homo sapiens Period circadian protein homolog 1 Proteins 0.000 description 1
- 101001073216 Homo sapiens Period circadian protein homolog 2 Proteins 0.000 description 1
- 101001131990 Homo sapiens Peroxidasin homolog Proteins 0.000 description 1
- 101001098116 Homo sapiens Phosphatidylinositol 3-kinase regulatory subunit gamma Proteins 0.000 description 1
- 101000595741 Homo sapiens Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform Proteins 0.000 description 1
- 101000595751 Homo sapiens Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform Proteins 0.000 description 1
- 101001001531 Homo sapiens Phosphatidylinositol 5-phosphate 4-kinase type-2 alpha Proteins 0.000 description 1
- 101000604565 Homo sapiens Phosphatidylinositol glycan anchor biosynthesis class U protein Proteins 0.000 description 1
- 101000609532 Homo sapiens Phosphoinositide-3-kinase-interacting protein 1 Proteins 0.000 description 1
- 101000728095 Homo sapiens Plasma membrane calcium-transporting ATPase 1 Proteins 0.000 description 1
- 101000947178 Homo sapiens Platelet basic protein Proteins 0.000 description 1
- 101000611888 Homo sapiens Platelet-derived growth factor C Proteins 0.000 description 1
- 101000582936 Homo sapiens Pleckstrin Proteins 0.000 description 1
- 101000730610 Homo sapiens Pleckstrin homology domain-containing family G member 3 Proteins 0.000 description 1
- 101001001799 Homo sapiens Pleckstrin homology domain-containing family O member 2 Proteins 0.000 description 1
- 101000586618 Homo sapiens Poliovirus receptor Proteins 0.000 description 1
- 101000829538 Homo sapiens Polypeptide N-acetylgalactosaminyltransferase 15 Proteins 0.000 description 1
- 101000886179 Homo sapiens Polypeptide N-acetylgalactosaminyltransferase 3 Proteins 0.000 description 1
- 101001126582 Homo sapiens Post-GPI attachment to proteins factor 3 Proteins 0.000 description 1
- 101001028703 Homo sapiens Probable JmjC domain-containing histone demethylation protein 2C Proteins 0.000 description 1
- 101000705770 Homo sapiens Proteasome activator complex subunit 4 Proteins 0.000 description 1
- 101001080429 Homo sapiens Proteasome inhibitor PI31 subunit Proteins 0.000 description 1
- 101000577424 Homo sapiens Proteasome subunit alpha type-4 Proteins 0.000 description 1
- 101001124667 Homo sapiens Proteasome subunit alpha type-5 Proteins 0.000 description 1
- 101001090813 Homo sapiens Proteasome subunit alpha type-6 Proteins 0.000 description 1
- 101000706678 Homo sapiens Proteasome subunit beta type-1 Proteins 0.000 description 1
- 101000611053 Homo sapiens Proteasome subunit beta type-2 Proteins 0.000 description 1
- 101001089120 Homo sapiens Proteasome subunit beta type-3 Proteins 0.000 description 1
- 101000592466 Homo sapiens Proteasome subunit beta type-4 Proteins 0.000 description 1
- 101000735881 Homo sapiens Proteasome subunit beta type-5 Proteins 0.000 description 1
- 101000735893 Homo sapiens Proteasome subunit beta type-6 Proteins 0.000 description 1
- 101001136954 Homo sapiens Proteasome subunit beta type-7 Proteins 0.000 description 1
- 101000933607 Homo sapiens Protein BTG3 Proteins 0.000 description 1
- 101000881943 Homo sapiens Protein EURL homolog Proteins 0.000 description 1
- 101000813325 Homo sapiens Protein FAM126B Proteins 0.000 description 1
- 101000891845 Homo sapiens Protein FAM3C Proteins 0.000 description 1
- 101000911553 Homo sapiens Protein FAM91A1 Proteins 0.000 description 1
- 101001056567 Homo sapiens Protein Jumonji Proteins 0.000 description 1
- 101001023422 Homo sapiens Protein LBH Proteins 0.000 description 1
- 101000617296 Homo sapiens Protein SEC13 homolog Proteins 0.000 description 1
- 101000764357 Homo sapiens Protein Tob1 Proteins 0.000 description 1
- 101001098802 Homo sapiens Protein disulfide-isomerase A3 Proteins 0.000 description 1
- 101001051777 Homo sapiens Protein kinase C alpha type Proteins 0.000 description 1
- 101001051767 Homo sapiens Protein kinase C beta type Proteins 0.000 description 1
- 101001026854 Homo sapiens Protein kinase C delta type Proteins 0.000 description 1
- 101000735473 Homo sapiens Protein mono-ADP-ribosyltransferase TIPARP Proteins 0.000 description 1
- 101000742051 Homo sapiens Protein phosphatase 1B Proteins 0.000 description 1
- 101000685918 Homo sapiens Protein transport protein Sec23A Proteins 0.000 description 1
- 101000684926 Homo sapiens Protein transport protein Sec24B Proteins 0.000 description 1
- 101000822312 Homo sapiens Protein transport protein Sec24C Proteins 0.000 description 1
- 101000822339 Homo sapiens Protein transport protein Sec24D Proteins 0.000 description 1
- 101000822459 Homo sapiens Protein transport protein Sec31A Proteins 0.000 description 1
- 101000641111 Homo sapiens Protein transport protein Sec61 subunit alpha isoform 1 Proteins 0.000 description 1
- 101001093116 Homo sapiens Protein transport protein Sec61 subunit beta Proteins 0.000 description 1
- 101001093143 Homo sapiens Protein transport protein Sec61 subunit gamma Proteins 0.000 description 1
- 101000775749 Homo sapiens Proto-oncogene vav Proteins 0.000 description 1
- 101000738506 Homo sapiens Psychosine receptor Proteins 0.000 description 1
- 101000728107 Homo sapiens Putative Polycomb group protein ASXL2 Proteins 0.000 description 1
- 101000878920 Homo sapiens Putative uncharacterized protein encoded by MIR22HG Proteins 0.000 description 1
- 101000798015 Homo sapiens RAC-beta serine/threonine-protein kinase Proteins 0.000 description 1
- 101000788755 Homo sapiens RING finger and CHY zinc finger domain-containing protein 1 Proteins 0.000 description 1
- 101000692686 Homo sapiens RING finger protein 37 Proteins 0.000 description 1
- 101000668165 Homo sapiens RNA-binding motif, single-stranded-interacting protein 1 Proteins 0.000 description 1
- 101000926083 Homo sapiens Rab GDP dissociation inhibitor beta Proteins 0.000 description 1
- 101001077015 Homo sapiens Rab GTPase-activating protein 1-like Proteins 0.000 description 1
- 101001077011 Homo sapiens Rab GTPase-activating protein 1-like, isoform 10 Proteins 0.000 description 1
- 101000848700 Homo sapiens Rap guanine nucleotide exchange factor 1 Proteins 0.000 description 1
- 101000848745 Homo sapiens Rap guanine nucleotide exchange factor 6 Proteins 0.000 description 1
- 101001130509 Homo sapiens Ras GTPase-activating protein 1 Proteins 0.000 description 1
- 101001132575 Homo sapiens Ras-related protein Rab-8B Proteins 0.000 description 1
- 101000584600 Homo sapiens Ras-related protein Rap-1b Proteins 0.000 description 1
- 101000665846 Homo sapiens Receptor expression-enhancing protein 3 Proteins 0.000 description 1
- 101000742859 Homo sapiens Retinoblastoma-associated protein Proteins 0.000 description 1
- 101001091991 Homo sapiens Rho GTPase-activating protein 25 Proteins 0.000 description 1
- 101001106395 Homo sapiens Rho GTPase-activating protein 5 Proteins 0.000 description 1
- 101001106325 Homo sapiens Rho GTPase-activating protein 6 Proteins 0.000 description 1
- 101000752249 Homo sapiens Rho guanine nucleotide exchange factor 3 Proteins 0.000 description 1
- 101001104307 Homo sapiens Ribonuclease 7 Proteins 0.000 description 1
- 101000944909 Homo sapiens Ribosomal protein S6 kinase alpha-1 Proteins 0.000 description 1
- 101001051706 Homo sapiens Ribosomal protein S6 kinase beta-1 Proteins 0.000 description 1
- 101001092917 Homo sapiens SAM domain-containing protein SAMSN-1 Proteins 0.000 description 1
- 101000688579 Homo sapiens SH3 domain-binding glutamic acid-rich-like protein Proteins 0.000 description 1
- 101000633784 Homo sapiens SLAM family member 7 Proteins 0.000 description 1
- 101000825291 Homo sapiens SPRY domain-containing SOCS box protein 2 Proteins 0.000 description 1
- 101000652133 Homo sapiens STE20-like serine/threonine-protein kinase Proteins 0.000 description 1
- 101000693367 Homo sapiens SUMO-activating enzyme subunit 1 Proteins 0.000 description 1
- 101001094146 Homo sapiens SUMO-activating enzyme subunit 2 Proteins 0.000 description 1
- 101000632266 Homo sapiens Semaphorin-3C Proteins 0.000 description 1
- 101000644537 Homo sapiens Sequestosome-1 Proteins 0.000 description 1
- 101000707471 Homo sapiens Serine incorporator 3 Proteins 0.000 description 1
- 101001047637 Homo sapiens Serine/threonine-protein kinase LATS2 Proteins 0.000 description 1
- 101000588545 Homo sapiens Serine/threonine-protein kinase Nek7 Proteins 0.000 description 1
- 101001098464 Homo sapiens Serine/threonine-protein kinase OSR1 Proteins 0.000 description 1
- 101000709238 Homo sapiens Serine/threonine-protein kinase SIK1 Proteins 0.000 description 1
- 101000654491 Homo sapiens Serine/threonine-protein kinase SIK3 Proteins 0.000 description 1
- 101000864800 Homo sapiens Serine/threonine-protein kinase Sgk1 Proteins 0.000 description 1
- 101000785904 Homo sapiens Serine/threonine-protein phosphatase 2A 56 kDa regulatory subunit delta isoform Proteins 0.000 description 1
- 101000783373 Homo sapiens Serine/threonine-protein phosphatase 2A 56 kDa regulatory subunit gamma isoform Proteins 0.000 description 1
- 101001068027 Homo sapiens Serine/threonine-protein phosphatase 2A catalytic subunit alpha isoform Proteins 0.000 description 1
- 101000611251 Homo sapiens Serine/threonine-protein phosphatase 2B catalytic subunit gamma isoform Proteins 0.000 description 1
- 101000836079 Homo sapiens Serpin B8 Proteins 0.000 description 1
- 101000836394 Homo sapiens Sestrin-1 Proteins 0.000 description 1
- 101000616767 Homo sapiens Small integral membrane protein 29 Proteins 0.000 description 1
- 101000628899 Homo sapiens Small ubiquitin-related modifier 1 Proteins 0.000 description 1
- 101001125170 Homo sapiens Sodium-dependent lysophosphatidylcholine symporter 1 Proteins 0.000 description 1
- 101000974834 Homo sapiens Sodium/potassium-transporting ATPase subunit beta-3 Proteins 0.000 description 1
- 101000868152 Homo sapiens Son of sevenless homolog 1 Proteins 0.000 description 1
- 101000831940 Homo sapiens Stathmin Proteins 0.000 description 1
- 101000617830 Homo sapiens Sterol O-acyltransferase 1 Proteins 0.000 description 1
- 101000585019 Homo sapiens Striatin-3 Proteins 0.000 description 1
- 101000687808 Homo sapiens Suppressor of cytokine signaling 2 Proteins 0.000 description 1
- 101000946863 Homo sapiens T-cell surface glycoprotein CD3 delta chain Proteins 0.000 description 1
- 101000653585 Homo sapiens TBC1 domain family member 15 Proteins 0.000 description 1
- 101000891623 Homo sapiens TBC1 domain family member 5 Proteins 0.000 description 1
- 101000674728 Homo sapiens TGF-beta-activated kinase 1 and MAP3K7-binding protein 2 Proteins 0.000 description 1
- 101000663000 Homo sapiens TNFAIP3-interacting protein 1 Proteins 0.000 description 1
- 101000596335 Homo sapiens TSC22 domain family protein 2 Proteins 0.000 description 1
- 101000809875 Homo sapiens TYRO protein tyrosine kinase-binding protein Proteins 0.000 description 1
- 101000659173 Homo sapiens Tetratricopeptide repeat protein 39B Proteins 0.000 description 1
- 101000845194 Homo sapiens Tetratricopeptide repeat protein 9A Proteins 0.000 description 1
- 101000674603 Homo sapiens Threonine aspartase 1 Proteins 0.000 description 1
- 101000763314 Homo sapiens Thrombomodulin Proteins 0.000 description 1
- 101000785523 Homo sapiens Tight junction protein ZO-2 Proteins 0.000 description 1
- 101000831567 Homo sapiens Toll-like receptor 2 Proteins 0.000 description 1
- 101000669402 Homo sapiens Toll-like receptor 7 Proteins 0.000 description 1
- 101001041525 Homo sapiens Transcription factor 12 Proteins 0.000 description 1
- 101000723923 Homo sapiens Transcription factor HIVEP2 Proteins 0.000 description 1
- 101000756787 Homo sapiens Transcription factor RFX3 Proteins 0.000 description 1
- 101000894871 Homo sapiens Transcription regulator protein BACH1 Proteins 0.000 description 1
- 101000802109 Homo sapiens Transducin-like enhancer protein 3 Proteins 0.000 description 1
- 101000835093 Homo sapiens Transferrin receptor protein 1 Proteins 0.000 description 1
- 101000679343 Homo sapiens Transformer-2 protein homolog beta Proteins 0.000 description 1
- 101000714762 Homo sapiens Transmembrane protein 176A Proteins 0.000 description 1
- 101000714756 Homo sapiens Transmembrane protein 176B Proteins 0.000 description 1
- 101000851550 Homo sapiens Transmembrane protein 64 Proteins 0.000 description 1
- 101000801742 Homo sapiens Triosephosphate isomerase Proteins 0.000 description 1
- 101000680652 Homo sapiens Tripartite motif-containing protein 14 Proteins 0.000 description 1
- 101000801701 Homo sapiens Tropomyosin alpha-1 chain Proteins 0.000 description 1
- 101000788548 Homo sapiens Tubulin alpha-4A chain Proteins 0.000 description 1
- 101000610604 Homo sapiens Tumor necrosis factor receptor superfamily member 10B Proteins 0.000 description 1
- 101000836174 Homo sapiens Tumor protein p53-inducible nuclear protein 1 Proteins 0.000 description 1
- 101001009087 Homo sapiens Tyrosine-protein kinase HCK Proteins 0.000 description 1
- 101000934996 Homo sapiens Tyrosine-protein kinase JAK3 Proteins 0.000 description 1
- 101001047681 Homo sapiens Tyrosine-protein kinase Lck Proteins 0.000 description 1
- 101000604583 Homo sapiens Tyrosine-protein kinase SYK Proteins 0.000 description 1
- 101000820294 Homo sapiens Tyrosine-protein kinase Yes Proteins 0.000 description 1
- 101000760210 Homo sapiens Ubiquitin carboxyl-terminal hydrolase 12 Proteins 0.000 description 1
- 101000808654 Homo sapiens Ubiquitin conjugation factor E4 A Proteins 0.000 description 1
- 101000662031 Homo sapiens Ubiquitin-associated domain-containing protein 2 Proteins 0.000 description 1
- 101000807344 Homo sapiens Ubiquitin-conjugating enzyme E2 A Proteins 0.000 description 1
- 101000807337 Homo sapiens Ubiquitin-conjugating enzyme E2 B Proteins 0.000 description 1
- 101000772904 Homo sapiens Ubiquitin-conjugating enzyme E2 D1 Proteins 0.000 description 1
- 101000772901 Homo sapiens Ubiquitin-conjugating enzyme E2 D2 Proteins 0.000 description 1
- 101000772913 Homo sapiens Ubiquitin-conjugating enzyme E2 D3 Proteins 0.000 description 1
- 101000644675 Homo sapiens Ubiquitin-conjugating enzyme E2 D4 Proteins 0.000 description 1
- 101000644661 Homo sapiens Ubiquitin-conjugating enzyme E2 E3 Proteins 0.000 description 1
- 101000644657 Homo sapiens Ubiquitin-conjugating enzyme E2 G1 Proteins 0.000 description 1
- 101000761646 Homo sapiens Ubiquitin-conjugating enzyme E2 G2 Proteins 0.000 description 1
- 101000761725 Homo sapiens Ubiquitin-conjugating enzyme E2 J1 Proteins 0.000 description 1
- 101000761723 Homo sapiens Ubiquitin-conjugating enzyme E2 J2 Proteins 0.000 description 1
- 101000644689 Homo sapiens Ubiquitin-conjugating enzyme E2 K Proteins 0.000 description 1
- 101000761737 Homo sapiens Ubiquitin-conjugating enzyme E2 L3 Proteins 0.000 description 1
- 101000761741 Homo sapiens Ubiquitin-conjugating enzyme E2 Q1 Proteins 0.000 description 1
- 101000808785 Homo sapiens Ubiquitin-conjugating enzyme E2 Q2 Proteins 0.000 description 1
- 101000808784 Homo sapiens Ubiquitin-conjugating enzyme E2 R1 Proteins 0.000 description 1
- 101000808789 Homo sapiens Ubiquitin-conjugating enzyme E2 R2 Proteins 0.000 description 1
- 101000837565 Homo sapiens Ubiquitin-conjugating enzyme E2 S Proteins 0.000 description 1
- 101000837574 Homo sapiens Ubiquitin-conjugating enzyme E2 W Proteins 0.000 description 1
- 101000772891 Homo sapiens Ubiquitin-conjugating enzyme E2 Z Proteins 0.000 description 1
- 101000940063 Homo sapiens Ubiquitin-conjugating enzyme E2 variant 2 Proteins 0.000 description 1
- 101000807306 Homo sapiens Ubiquitin-like modifier-activating enzyme 1 Proteins 0.000 description 1
- 101000608584 Homo sapiens Ubiquitin-like modifier-activating enzyme 5 Proteins 0.000 description 1
- 101000662020 Homo sapiens Ubiquitin-like modifier-activating enzyme 6 Proteins 0.000 description 1
- 101000772888 Homo sapiens Ubiquitin-protein ligase E3A Proteins 0.000 description 1
- 101000772955 Homo sapiens Ubiquitin-protein ligase E3B Proteins 0.000 description 1
- 101000772964 Homo sapiens Ubiquitin-protein ligase E3C Proteins 0.000 description 1
- 101000944530 Homo sapiens Uncharacterized protein C6orf62 Proteins 0.000 description 1
- 101001027867 Homo sapiens Uncharacterized protein FAM241A Proteins 0.000 description 1
- 101000644174 Homo sapiens Uridine phosphorylase 1 Proteins 0.000 description 1
- 101000804736 Homo sapiens Vacuolar protein sorting-associated protein 54 Proteins 0.000 description 1
- 101000953818 Homo sapiens Vesicular, overexpressed in cancer, prosurvival protein 1 Proteins 0.000 description 1
- 101000621991 Homo sapiens Vinculin Proteins 0.000 description 1
- 101000804811 Homo sapiens WD repeat and SOCS box-containing protein 1 Proteins 0.000 description 1
- 101000954820 Homo sapiens WD repeat domain phosphoinositide-interacting protein 4 Proteins 0.000 description 1
- 101000955107 Homo sapiens WD repeat-containing protein 37 Proteins 0.000 description 1
- 101000666295 Homo sapiens X-box-binding protein 1 Proteins 0.000 description 1
- 101000916084 Homo sapiens YrdC domain-containing protein, mitochondrial Proteins 0.000 description 1
- 101100377226 Homo sapiens ZBTB16 gene Proteins 0.000 description 1
- 101000916514 Homo sapiens Zinc finger CCCH-type antiviral protein 1 Proteins 0.000 description 1
- 101000818532 Homo sapiens Zinc finger and BTB domain-containing protein 20 Proteins 0.000 description 1
- 101000818563 Homo sapiens Zinc finger and BTB domain-containing protein 25 Proteins 0.000 description 1
- 101000784546 Homo sapiens Zinc finger and SCAN domain-containing protein 16 Proteins 0.000 description 1
- 101000976595 Homo sapiens Zinc finger protein 107 Proteins 0.000 description 1
- 101000782132 Homo sapiens Zinc finger protein 217 Proteins 0.000 description 1
- 101000944219 Homo sapiens cAMP-dependent protein kinase catalytic subunit beta Proteins 0.000 description 1
- 101000919269 Homo sapiens cAMP-responsive element modulator Proteins 0.000 description 1
- 101000988424 Homo sapiens cAMP-specific 3',5'-cyclic phosphodiesterase 4B Proteins 0.000 description 1
- 101000871498 Homo sapiens m7GpppX diphosphatase Proteins 0.000 description 1
- 101000620751 Homo sapiens mRNA export factor RAE1 Proteins 0.000 description 1
- 102100039926 Homocysteine-responsive endoplasmic reticulum-resident ubiquitin-like domain member 2 protein Human genes 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical class ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 description 1
- DOMWKUIIPQCAJU-LJHIYBGHSA-N Hydroxyprogesterone caproate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(C)=O)(OC(=O)CCCCC)[C@@]1(C)CC2 DOMWKUIIPQCAJU-LJHIYBGHSA-N 0.000 description 1
- 208000037147 Hypercalcaemia Diseases 0.000 description 1
- 101150103227 IFN gene Proteins 0.000 description 1
- 102000043138 IRF family Human genes 0.000 description 1
- 108091054729 IRF family Proteins 0.000 description 1
- MPBVHIBUJCELCL-UHFFFAOYSA-N Ibandronate Chemical compound CCCCCN(C)CCC(O)(P(O)(O)=O)P(O)(O)=O MPBVHIBUJCELCL-UHFFFAOYSA-N 0.000 description 1
- XDXDZDZNSLXDNA-UHFFFAOYSA-N Idarubicin Natural products C1C(N)C(O)C(C)OC1OC1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2CC(O)(C(C)=O)C1 XDXDZDZNSLXDNA-UHFFFAOYSA-N 0.000 description 1
- JJKOTMDDZAJTGQ-DQSJHHFOSA-N Idoxifene Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN2CCCC2)=CC=1)/C1=CC=C(I)C=C1 JJKOTMDDZAJTGQ-DQSJHHFOSA-N 0.000 description 1
- 102100035692 Importin subunit alpha-1 Human genes 0.000 description 1
- 102100036188 Importin subunit alpha-3 Human genes 0.000 description 1
- 102100036187 Importin subunit alpha-4 Human genes 0.000 description 1
- 102100036186 Importin subunit alpha-5 Human genes 0.000 description 1
- 102100027007 Importin subunit alpha-6 Human genes 0.000 description 1
- 102100033258 Importin subunit beta-1 Human genes 0.000 description 1
- 101000668058 Infectious salmon anemia virus (isolate Atlantic salmon/Norway/810/9/99) RNA-directed RNA polymerase catalytic subunit Proteins 0.000 description 1
- 102100027638 Inhibitor of Bruton tyrosine kinase Human genes 0.000 description 1
- 102100021892 Inhibitor of nuclear factor kappa-B kinase subunit alpha Human genes 0.000 description 1
- 102100031533 Inositol 1,4,5-trisphosphate receptor-interacting protein Human genes 0.000 description 1
- 102100030212 Inositol hexakisphosphate kinase 2 Human genes 0.000 description 1
- 102100026819 Inositol polyphosphate 1-phosphatase Human genes 0.000 description 1
- 108700022013 Insecta cecropin B Proteins 0.000 description 1
- 102100023350 Integral membrane protein 2B Human genes 0.000 description 1
- 102100025304 Integrin beta-1 Human genes 0.000 description 1
- 108010054698 Interferon Alfa-n3 Proteins 0.000 description 1
- 102100036714 Interferon alpha/beta receptor 1 Human genes 0.000 description 1
- 108010005716 Interferon beta-1a Proteins 0.000 description 1
- 102100038069 Interferon regulatory factor 8 Human genes 0.000 description 1
- 102100039065 Interleukin-1 beta Human genes 0.000 description 1
- 102100020790 Interleukin-12 receptor subunit beta-1 Human genes 0.000 description 1
- 102100020791 Interleukin-13 receptor subunit alpha-1 Human genes 0.000 description 1
- 102100035017 Interleukin-18-binding protein Human genes 0.000 description 1
- 102100033493 Interleukin-3 receptor subunit alpha Human genes 0.000 description 1
- 102100037795 Interleukin-6 receptor subunit beta Human genes 0.000 description 1
- 102100037441 Intermediate conductance calcium-activated potassium channel protein 4 Human genes 0.000 description 1
- 102100032732 Josephin-1 Human genes 0.000 description 1
- 102100034075 Kelch repeat and BTB domain-containing protein 2 Human genes 0.000 description 1
- 108090000484 Kelch-Like ECH-Associated Protein 1 Proteins 0.000 description 1
- 102000004034 Kelch-Like ECH-Associated Protein 1 Human genes 0.000 description 1
- 102100023681 Kelch-like protein 20 Human genes 0.000 description 1
- 102100027614 Kelch-like protein 9 Human genes 0.000 description 1
- 102100021458 Killer cell lectin-like receptor subfamily F member 1 Human genes 0.000 description 1
- 102100038408 Kinesin-like protein KIF22 Human genes 0.000 description 1
- 102100022254 Krueppel-like factor 13 Human genes 0.000 description 1
- 102100020675 Krueppel-like factor 2 Human genes 0.000 description 1
- 102100020678 Krueppel-like factor 3 Human genes 0.000 description 1
- 102100020677 Krueppel-like factor 4 Human genes 0.000 description 1
- KJQFBVYMGADDTQ-CVSPRKDYSA-N L-buthionine-(S,R)-sulfoximine Chemical compound CCCCS(=N)(=O)CC[C@H](N)C(O)=O KJQFBVYMGADDTQ-CVSPRKDYSA-N 0.000 description 1
- GSDBGCKBBJVPNC-BYPYZUCNSA-N L-lombricine Chemical compound NC(=[NH2+])NCCOP([O-])(=O)OC[C@H]([NH3+])C([O-])=O GSDBGCKBBJVPNC-BYPYZUCNSA-N 0.000 description 1
- 108010043135 L-methionine gamma-lyase Proteins 0.000 description 1
- 102100033467 L-selectin Human genes 0.000 description 1
- 239000002147 L01XE04 - Sunitinib Substances 0.000 description 1
- 239000005511 L01XE05 - Sorafenib Substances 0.000 description 1
- 239000002067 L01XE06 - Dasatinib Substances 0.000 description 1
- 239000002136 L01XE07 - Lapatinib Substances 0.000 description 1
- 239000002118 L01XE12 - Vandetanib Substances 0.000 description 1
- 102100035655 Lactosylceramide 1,3-N-acetyl-beta-D-glucosaminyltransferase Human genes 0.000 description 1
- ZHTRILQJTPJGNK-FYBAATNNSA-N Leinamycin Chemical compound N([C@@H](C=1SC=C(N=1)\C=C/C=C/C(=O)[C@H](O)/C=C(C)/CC1)C)C(=O)C[C@@]21S(=O)SC(=O)[C@]2(C)O ZHTRILQJTPJGNK-FYBAATNNSA-N 0.000 description 1
- ZHTRILQJTPJGNK-UHFFFAOYSA-N Leinamycin Natural products C1CC(C)=CC(O)C(=O)C=CC=CC(N=2)=CSC=2C(C)NC(=O)CC21S(=O)SC(=O)C2(C)O ZHTRILQJTPJGNK-UHFFFAOYSA-N 0.000 description 1
- 108010062867 Lenograstim Proteins 0.000 description 1
- 229920001491 Lentinan Polymers 0.000 description 1
- LMVRPBWWHMVLPC-KBPJCXPTSA-N Leptolstatin Natural products CC(CC=CC(=CC(C)C(=O)C(C)C(O)C(C)CC(=CCO)C)C)C=C(C)/C=C/C1CC=CC(=O)O1 LMVRPBWWHMVLPC-KBPJCXPTSA-N 0.000 description 1
- 102100040548 Lethal(3)malignant brain tumor-like protein 3 Human genes 0.000 description 1
- 102100032696 Leucine-rich repeat and calponin homology domain-containing protein 1 Human genes 0.000 description 1
- 102100033303 Leucine-rich repeat flightless-interacting protein 1 Human genes 0.000 description 1
- 102100040249 Leucine-rich repeat protein 1 Human genes 0.000 description 1
- 102100027168 Leucine-rich repeat-containing protein 41 Human genes 0.000 description 1
- 102100020872 Leucyl-cystinyl aminopeptidase Human genes 0.000 description 1
- 102100022118 Leukotriene A-4 hydrolase Human genes 0.000 description 1
- 102100022172 Ligand-dependent nuclear receptor-interacting factor 1 Human genes 0.000 description 1
- GQYIWUVLTXOXAJ-UHFFFAOYSA-N Lomustine Chemical compound ClCCN(N=O)C(=O)NC1CCCCC1 GQYIWUVLTXOXAJ-UHFFFAOYSA-N 0.000 description 1
- 102100038007 Low affinity immunoglobulin epsilon Fc receptor Human genes 0.000 description 1
- 102100029193 Low affinity immunoglobulin gamma Fc region receptor III-A Human genes 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 102100026894 Lymphotoxin-beta Human genes 0.000 description 1
- 102100040581 Lysine-specific demethylase 3A Human genes 0.000 description 1
- 102100037461 Lysine-specific demethylase 6B Human genes 0.000 description 1
- 102100028524 Lysosomal protective protein Human genes 0.000 description 1
- 101150113681 MALT1 gene Proteins 0.000 description 1
- 108010068353 MAP Kinase Kinase 2 Proteins 0.000 description 1
- 108010075654 MAP Kinase Kinase Kinase 1 Proteins 0.000 description 1
- 102000043136 MAP kinase family Human genes 0.000 description 1
- 108091054455 MAP kinase family Proteins 0.000 description 1
- 102100032514 MARCKS-related protein Human genes 0.000 description 1
- 108060004872 MIF Proteins 0.000 description 1
- 102100025931 MOB kinase activator 3B Human genes 0.000 description 1
- 102100024573 Macrophage-capping protein Human genes 0.000 description 1
- BLOFGONIVNXZME-UHFFFAOYSA-N Mannostatin A Natural products CSC1C(N)C(O)C(O)C1O BLOFGONIVNXZME-UHFFFAOYSA-N 0.000 description 1
- 102100038245 Mannosyl-oligosaccharide 1,2-alpha-mannosidase IA Human genes 0.000 description 1
- 102100021767 Mannosyl-oligosaccharide 1,2-alpha-mannosidase IB Human genes 0.000 description 1
- 102000004318 Matrilysin Human genes 0.000 description 1
- 108090000855 Matrilysin Proteins 0.000 description 1
- 102000000422 Matrix Metalloproteinase 3 Human genes 0.000 description 1
- 102100039185 Max dimerization protein 1 Human genes 0.000 description 1
- 208000009018 Medullary thyroid cancer Diseases 0.000 description 1
- 208000037196 Medullary thyroid carcinoma Diseases 0.000 description 1
- 208000000172 Medulloblastoma Diseases 0.000 description 1
- 102000047724 Member 2 Solute Carrier Family 12 Human genes 0.000 description 1
- 206010027406 Mesothelioma Diseases 0.000 description 1
- 108700021154 Metallothionein 3 Proteins 0.000 description 1
- 102100028708 Metallothionein-3 Human genes 0.000 description 1
- 108091022875 Microtubule Proteins 0.000 description 1
- 102000029749 Microtubule Human genes 0.000 description 1
- 108090000744 Mitogen-Activated Protein Kinase Kinases Proteins 0.000 description 1
- 102000004232 Mitogen-Activated Protein Kinase Kinases Human genes 0.000 description 1
- 102100037805 Mitogen-activated protein kinase 7 Human genes 0.000 description 1
- 102100037809 Mitogen-activated protein kinase 9 Human genes 0.000 description 1
- 102100033115 Mitogen-activated protein kinase kinase kinase 1 Human genes 0.000 description 1
- 102100033127 Mitogen-activated protein kinase kinase kinase 5 Human genes 0.000 description 1
- 102100026888 Mitogen-activated protein kinase kinase kinase 7 Human genes 0.000 description 1
- 102100028199 Mitogen-activated protein kinase kinase kinase kinase 1 Human genes 0.000 description 1
- 102100028194 Mitogen-activated protein kinase kinase kinase kinase 4 Human genes 0.000 description 1
- 102100035971 Molybdopterin molybdenumtransferase Human genes 0.000 description 1
- PCZOHLXUXFIOCF-UHFFFAOYSA-N Monacolin X Natural products C12C(OC(=O)C(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 PCZOHLXUXFIOCF-UHFFFAOYSA-N 0.000 description 1
- 102100029814 Monoglyceride lipase Human genes 0.000 description 1
- 102100025744 Mothers against decapentaplegic homolog 1 Human genes 0.000 description 1
- 102100030608 Mothers against decapentaplegic homolog 7 Human genes 0.000 description 1
- 108700026676 Mucosa-Associated Lymphoid Tissue Lymphoma Translocation 1 Proteins 0.000 description 1
- 102100038732 Mucosa-associated lymphoid tissue lymphoma translocation protein 1 Human genes 0.000 description 1
- 208000034578 Multiple myelomas Diseases 0.000 description 1
- 206010048723 Multiple-drug resistance Diseases 0.000 description 1
- 101100533558 Mus musculus Sipa1 gene Proteins 0.000 description 1
- 102100030965 Muscleblind-like protein 1 Human genes 0.000 description 1
- 102100030964 Muscleblind-like protein 2 Human genes 0.000 description 1
- HFPXYDFQVINJBV-UHFFFAOYSA-N Mycaperoxide B Natural products O1OC(C(C)C(O)=O)CCC1(C)CCC1(O)C2(C)CCCC(C)(C)C2CCC1C HFPXYDFQVINJBV-UHFFFAOYSA-N 0.000 description 1
- 102100021272 Myelin protein zero-like protein 2 Human genes 0.000 description 1
- 102100033699 MyoD family inhibitor domain-containing protein Human genes 0.000 description 1
- 102100033817 Myotubularin Human genes 0.000 description 1
- USVMJSALORZVDV-SDBHATRESA-N N(6)-(Delta(2)-isopentenyl)adenosine Chemical compound C1=NC=2C(NCC=C(C)C)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O USVMJSALORZVDV-SDBHATRESA-N 0.000 description 1
- WUKZPHOXUVCQOR-UHFFFAOYSA-N N-(1-azabicyclo[2.2.2]octan-3-yl)-6-chloro-4-methyl-3-oxo-1,4-benzoxazine-8-carboxamide Chemical compound C1N(CC2)CCC2C1NC(=O)C1=CC(Cl)=CC2=C1OCC(=O)N2C WUKZPHOXUVCQOR-UHFFFAOYSA-N 0.000 description 1
- CZSLEMCYYGEGKP-UHFFFAOYSA-N N-(2-chlorobenzyl)-1-(2,5-dimethylphenyl)benzimidazole-5-carboxamide Chemical compound CC1=CC=C(C)C(N2C3=CC=C(C=C3N=C2)C(=O)NCC=2C(=CC=CC=2)Cl)=C1 CZSLEMCYYGEGKP-UHFFFAOYSA-N 0.000 description 1
- BNQSTAOJRULKNX-UHFFFAOYSA-N N-(6-acetamidohexyl)acetamide Chemical compound CC(=O)NCCCCCCNC(C)=O BNQSTAOJRULKNX-UHFFFAOYSA-N 0.000 description 1
- QJMCKEPOKRERLN-UHFFFAOYSA-N N-3,4-tridhydroxybenzamide Chemical compound ONC(=O)C1=CC=C(O)C(O)=C1 QJMCKEPOKRERLN-UHFFFAOYSA-N 0.000 description 1
- MVZGYPSXNDCANY-UHFFFAOYSA-N N-[4-[3-chloro-4-[(3-fluorophenyl)methoxy]anilino]-6-quinazolinyl]-2-propenamide Chemical compound FC1=CC=CC(COC=2C(=CC(NC=3C4=CC(NC(=O)C=C)=CC=C4N=CN=3)=CC=2)Cl)=C1 MVZGYPSXNDCANY-UHFFFAOYSA-N 0.000 description 1
- 102100036710 N-acetylglucosamine-1-phosphotransferase subunits alpha/beta Human genes 0.000 description 1
- 102100035628 N-acetyllactosaminide beta-1,3-N-acetylglucosaminyltransferase 2 Human genes 0.000 description 1
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 description 1
- 102100028130 N-formyl peptide receptor 3 Human genes 0.000 description 1
- 102100027550 NEDD4-like E3 ubiquitin-protein ligase WWP1 Human genes 0.000 description 1
- 102100020694 NEDD8-conjugating enzyme UBE2F Human genes 0.000 description 1
- 102100020710 NEDD8-conjugating enzyme Ubc12 Human genes 0.000 description 1
- 102100022219 NF-kappa-B essential modulator Human genes 0.000 description 1
- 102100030391 NGFI-A-binding protein 2 Human genes 0.000 description 1
- 108010059419 NIMA-Interacting Peptidylprolyl Isomerase Proteins 0.000 description 1
- 102000005591 NIMA-Interacting Peptidylprolyl Isomerase Human genes 0.000 description 1
- 102100022680 NKG2-D type II integral membrane protein Human genes 0.000 description 1
- 102100021733 NUAK family SNF1-like kinase 2 Human genes 0.000 description 1
- 101710104492 NUP210 Proteins 0.000 description 1
- 108010021717 Nafarelin Proteins 0.000 description 1
- GTEXXGIEZVKSLH-UHFFFAOYSA-N Naphterpin Natural products O=C1C2=CC(O)=C(C)C(O)=C2C(=O)C2=C1C1C=C(C)CCC1C(C)(C)O2 GTEXXGIEZVKSLH-UHFFFAOYSA-N 0.000 description 1
- 102000003729 Neprilysin Human genes 0.000 description 1
- 108090000028 Neprilysin Proteins 0.000 description 1
- 102100027347 Neural cell adhesion molecule 1 Human genes 0.000 description 1
- 102400000058 Neuregulin-1 Human genes 0.000 description 1
- 108090000556 Neuregulin-1 Proteins 0.000 description 1
- 102100031837 Neuroblast differentiation-associated protein AHNAK Human genes 0.000 description 1
- 102100023617 Neutrophil cytosol factor 4 Human genes 0.000 description 1
- BUSGWUFLNHIBPT-UHFFFAOYSA-N Nisamycin Natural products O=C1C2OC2C(C=CC=CC=CC(=O)O)(O)C=C1NC(=O)C=CC=CC1CCCCC1 BUSGWUFLNHIBPT-UHFFFAOYSA-N 0.000 description 1
- KGTDRFCXGRULNK-UHFFFAOYSA-N Nogalamycin Natural products COC1C(OC)(C)C(OC)C(C)OC1OC1C2=C(O)C(C(=O)C3=C(O)C=C4C5(C)OC(C(C(C5O)N(C)C)O)OC4=C3C3=O)=C3C=C2C(C(=O)OC)C(C)(O)C1 KGTDRFCXGRULNK-UHFFFAOYSA-N 0.000 description 1
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 1
- 102100025812 Nuclear envelope pore membrane protein POM 121 Human genes 0.000 description 1
- 102100021976 Nuclear pore complex protein Nup107 Human genes 0.000 description 1
- 102100021726 Nuclear pore complex protein Nup133 Human genes 0.000 description 1
- 102100021512 Nuclear pore complex protein Nup155 Human genes 0.000 description 1
- 102100032226 Nuclear pore complex protein Nup205 Human genes 0.000 description 1
- 102100033819 Nuclear pore complex protein Nup214 Human genes 0.000 description 1
- 102100025447 Nuclear pore complex protein Nup50 Human genes 0.000 description 1
- 102100027582 Nuclear pore complex protein Nup85 Human genes 0.000 description 1
- 102100027586 Nuclear pore complex protein Nup88 Human genes 0.000 description 1
- 102100024057 Nuclear pore glycoprotein p62 Human genes 0.000 description 1
- 102100035570 Nuclear pore membrane glycoprotein 210 Human genes 0.000 description 1
- 102100022679 Nuclear receptor subfamily 4 group A member 1 Human genes 0.000 description 1
- 102100028791 Nuclear receptor-binding factor 2 Human genes 0.000 description 1
- 102100021530 Nucleoporin NUP188 Human genes 0.000 description 1
- 102100020682 Nucleoporin NUP35 Human genes 0.000 description 1
- 102100037821 Nucleoporin NUP42 Human genes 0.000 description 1
- 102100037837 Nucleoporin Nup37 Human genes 0.000 description 1
- 102100037823 Nucleoporin Nup43 Human genes 0.000 description 1
- 102100023782 Nucleoporin SEH1 Human genes 0.000 description 1
- 102100025453 Nucleoporin p54 Human genes 0.000 description 1
- 102100025794 Nucleoporin p58/p45 Human genes 0.000 description 1
- 102100033615 Nucleoprotein TPR Human genes 0.000 description 1
- 102100029424 Nucleotide-binding oligomerization domain-containing protein 1 Human genes 0.000 description 1
- 102100022471 NudC domain-containing protein 3 Human genes 0.000 description 1
- WQLDJUQUFZDTSD-XXODBJNXSA-N O([C@@H]1[C@]2(O)C[C@@H](C(=C([C@@H](OC(C)=O)C(=O)[C@]3(C)[C@@H](O)C[C@H]4OC[C@]4([C@H]31)OC(C)=O)C2(C)C)C)OC(=O)[C@H](O)[C@@H](NC(=O)C(C)C)C=1C=CC=CC=1)C(=O)C1=CC=CC=C1 Chemical compound O([C@@H]1[C@]2(O)C[C@@H](C(=C([C@@H](OC(C)=O)C(=O)[C@]3(C)[C@@H](O)C[C@H]4OC[C@]4([C@H]31)OC(C)=O)C2(C)C)C)OC(=O)[C@H](O)[C@@H](NC(=O)C(C)C)C=1C=CC=CC=1)C(=O)C1=CC=CC=C1 WQLDJUQUFZDTSD-XXODBJNXSA-N 0.000 description 1
- 229960005524 O6-benzylguanine Drugs 0.000 description 1
- KRWMERLEINMZFT-UHFFFAOYSA-N O6-benzylguanine Chemical compound C=12NC=NC2=NC(N)=NC=1OCC1=CC=CC=C1 KRWMERLEINMZFT-UHFFFAOYSA-N 0.000 description 1
- HBPQPBSTHOHSFP-UHFFFAOYSA-N OC(=O)C([Pt])=O Chemical compound OC(=O)C([Pt])=O HBPQPBSTHOHSFP-UHFFFAOYSA-N 0.000 description 1
- 108010016076 Octreotide Proteins 0.000 description 1
- VTAZRSXSBIHBMH-UHFFFAOYSA-N Ophiocordin Natural products OC1=CC(C(=O)O)=CC(O)=C1C(=O)C1=C(O)C=CC=C1C(=O)NC1C(OC(=O)C=2C=CC(O)=CC=2)CCCNC1 VTAZRSXSBIHBMH-UHFFFAOYSA-N 0.000 description 1
- LKBBOPGQDRPCDS-UHFFFAOYSA-N Oxaunomycin Natural products C12=C(O)C=3C(=O)C4=C(O)C=CC=C4C(=O)C=3C(O)=C2C(O)C(CC)(O)CC1OC1CC(N)C(O)C(C)O1 LKBBOPGQDRPCDS-UHFFFAOYSA-N 0.000 description 1
- 102100037601 P2X purinoceptor 4 Human genes 0.000 description 1
- 102100029181 PDZ and LIM domain protein 5 Human genes 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 102100035593 POU domain, class 2, transcription factor 1 Human genes 0.000 description 1
- MIQYPPGTNIFAPO-CABCVRRESA-N PS(6:0/6:0) Chemical compound CCCCCC(=O)OC[C@@H](OC(=O)CCCCC)COP(O)(=O)OC[C@H](N)C(O)=O MIQYPPGTNIFAPO-CABCVRRESA-N 0.000 description 1
- 108010011536 PTEN Phosphohydrolase Proteins 0.000 description 1
- VYOQBYCIIJYKJA-UHFFFAOYSA-N Palauamine Natural products C1N2C(=O)C3=CC=CN3C3N=C(N)NC32C2C1C(CN)C(Cl)C12NC(N)=NC1O VYOQBYCIIJYKJA-UHFFFAOYSA-N 0.000 description 1
- 102100035031 Palladin Human genes 0.000 description 1
- 206010033701 Papillary thyroid cancer Diseases 0.000 description 1
- FRCJDPPXHQGEKS-UHFFFAOYSA-N Parabactin Natural products CC1OC(=NC1C(=O)N(CCCCNC(=O)c1cccc(O)c1O)CCCNC(=O)c1cccc(O)c1O)c1ccccc1O FRCJDPPXHQGEKS-UHFFFAOYSA-N 0.000 description 1
- 102100040974 Paraspeckle component 1 Human genes 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 108010057150 Peplomycin Proteins 0.000 description 1
- 229940083963 Peptide antagonist Drugs 0.000 description 1
- 108010067163 Perilipin-2 Proteins 0.000 description 1
- 102000017794 Perilipin-2 Human genes 0.000 description 1
- 102100028293 Period circadian protein homolog 1 Human genes 0.000 description 1
- 102100035787 Period circadian protein homolog 2 Human genes 0.000 description 1
- 241000577979 Peromyscus spicilegus Species 0.000 description 1
- 102100034601 Peroxidasin homolog Human genes 0.000 description 1
- APNRZHLOPQFNMR-UHFFFAOYSA-N Phenazinomycin Natural products C12=CC=CC=C2N=C(C(C=CC=2)=O)C=2N1CC=C(C)CCC1C(=C)CCCC1(C)C APNRZHLOPQFNMR-UHFFFAOYSA-N 0.000 description 1
- 102100032543 Phosphatidylinositol 3,4,5-trisphosphate 3-phosphatase and dual-specificity protein phosphatase PTEN Human genes 0.000 description 1
- 102100037553 Phosphatidylinositol 3-kinase regulatory subunit gamma Human genes 0.000 description 1
- 102100036061 Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform Human genes 0.000 description 1
- 102100036052 Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform Human genes 0.000 description 1
- 102100036146 Phosphatidylinositol 5-phosphate 4-kinase type-2 alpha Human genes 0.000 description 1
- 102100039472 Phosphoinositide-3-kinase-interacting protein 1 Human genes 0.000 description 1
- 102100033616 Phospholipid-transporting ATPase ABCA1 Human genes 0.000 description 1
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 1
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 1
- KMSKQZKKOZQFFG-HSUXVGOQSA-N Pirarubicin Chemical compound O([C@H]1[C@@H](N)C[C@@H](O[C@H]1C)O[C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1CCCCO1 KMSKQZKKOZQFFG-HSUXVGOQSA-N 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 102100029751 Plasma membrane calcium-transporting ATPase 1 Human genes 0.000 description 1
- 102000010752 Plasminogen Inactivators Human genes 0.000 description 1
- 108010077971 Plasminogen Inactivators Proteins 0.000 description 1
- 102100036154 Platelet basic protein Human genes 0.000 description 1
- 102100040681 Platelet-derived growth factor C Human genes 0.000 description 1
- 102100030264 Pleckstrin Human genes 0.000 description 1
- 102100032588 Pleckstrin homology domain-containing family G member 3 Human genes 0.000 description 1
- 102100036245 Pleckstrin homology domain-containing family O member 2 Human genes 0.000 description 1
- 102100029740 Poliovirus receptor Human genes 0.000 description 1
- 102100023229 Polypeptide N-acetylgalactosaminyltransferase 15 Human genes 0.000 description 1
- 102100039685 Polypeptide N-acetylgalactosaminyltransferase 3 Human genes 0.000 description 1
- 101710163348 Potassium voltage-gated channel subfamily H member 8 Proteins 0.000 description 1
- 102100025073 Potassium voltage-gated channel subfamily H member 8 Human genes 0.000 description 1
- HFVNWDWLWUCIHC-GUPDPFMOSA-N Prednimustine Chemical compound O=C([C@@]1(O)CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)[C@@H](O)C[C@@]21C)COC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 HFVNWDWLWUCIHC-GUPDPFMOSA-N 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 102100037169 Probable JmjC domain-containing histone demethylation protein 2C Human genes 0.000 description 1
- 102100036691 Proliferating cell nuclear antigen Human genes 0.000 description 1
- 108700003766 Promyelocytic Leukemia Zinc Finger Proteins 0.000 description 1
- 102100031297 Proteasome activator complex subunit 4 Human genes 0.000 description 1
- 229940079156 Proteasome inhibitor Drugs 0.000 description 1
- 102100027565 Proteasome inhibitor PI31 subunit Human genes 0.000 description 1
- 102100028813 Proteasome subunit alpha type-4 Human genes 0.000 description 1
- 102100029270 Proteasome subunit alpha type-5 Human genes 0.000 description 1
- 102100034664 Proteasome subunit alpha type-6 Human genes 0.000 description 1
- 102100031566 Proteasome subunit beta type-1 Human genes 0.000 description 1
- 102100040400 Proteasome subunit beta type-2 Human genes 0.000 description 1
- 102100033755 Proteasome subunit beta type-3 Human genes 0.000 description 1
- 102100033190 Proteasome subunit beta type-4 Human genes 0.000 description 1
- 102100036127 Proteasome subunit beta type-5 Human genes 0.000 description 1
- 102100036128 Proteasome subunit beta type-6 Human genes 0.000 description 1
- 102100035763 Proteasome subunit beta type-7 Human genes 0.000 description 1
- 102100026035 Protein BTG3 Human genes 0.000 description 1
- 102100037083 Protein EURL homolog Human genes 0.000 description 1
- 102100039199 Protein FAM126B Human genes 0.000 description 1
- 102100040823 Protein FAM3C Human genes 0.000 description 1
- 102100026955 Protein FAM91A1 Human genes 0.000 description 1
- 108010038241 Protein Inhibitors of Activated STAT Proteins 0.000 description 1
- 102100025733 Protein Jumonji Human genes 0.000 description 1
- 102100023075 Protein Niban 2 Human genes 0.000 description 1
- 102100032420 Protein S100-A9 Human genes 0.000 description 1
- 102100021725 Protein SEC13 homolog Human genes 0.000 description 1
- 102100037097 Protein disulfide-isomerase A3 Human genes 0.000 description 1
- 102100037277 Protein fem-1 homolog C Human genes 0.000 description 1
- 102100024924 Protein kinase C alpha type Human genes 0.000 description 1
- 102100024923 Protein kinase C beta type Human genes 0.000 description 1
- 102100037340 Protein kinase C delta type Human genes 0.000 description 1
- 102100034905 Protein mono-ADP-ribosyltransferase TIPARP Human genes 0.000 description 1
- 102100038702 Protein phosphatase 1B Human genes 0.000 description 1
- 102100023365 Protein transport protein Sec23A Human genes 0.000 description 1
- 102100023146 Protein transport protein Sec24B Human genes 0.000 description 1
- 102100022538 Protein transport protein Sec24C Human genes 0.000 description 1
- 102100022542 Protein transport protein Sec24D Human genes 0.000 description 1
- 102100022484 Protein transport protein Sec31A Human genes 0.000 description 1
- 102100034271 Protein transport protein Sec61 subunit alpha isoform 1 Human genes 0.000 description 1
- 102100036308 Protein transport protein Sec61 subunit beta Human genes 0.000 description 1
- 102100036306 Protein transport protein Sec61 subunit gamma Human genes 0.000 description 1
- 102100032190 Proto-oncogene vav Human genes 0.000 description 1
- PICZCWCKOLHDOJ-UHFFFAOYSA-N Pseudoaxinellin Natural products N1C(=O)C2CCCN2C(=O)C(CC(N)=O)NC(=O)C(C(C)C)NC(=O)C2CCCN2C(=O)C(C(C)C)NC(=O)C(C(C)C)NC(=O)C1CC1=CC=CC=C1 PICZCWCKOLHDOJ-UHFFFAOYSA-N 0.000 description 1
- 102100037860 Psychosine receptor Human genes 0.000 description 1
- 102100029750 Putative Polycomb group protein ASXL2 Human genes 0.000 description 1
- 102100031269 Putative peripheral benzodiazepine receptor-related protein Human genes 0.000 description 1
- 102100037987 Putative uncharacterized protein encoded by MIR22HG Human genes 0.000 description 1
- XESARGFCSKSFID-UHFFFAOYSA-N Pyrazofurin Natural products OC1=C(C(=O)N)NN=C1C1C(O)C(O)C(CO)O1 XESARGFCSKSFID-UHFFFAOYSA-N 0.000 description 1
- 102100032315 RAC-beta serine/threonine-protein kinase Human genes 0.000 description 1
- 101150111584 RHOA gene Proteins 0.000 description 1
- 102100025427 RING finger and CHY zinc finger domain-containing protein 1 Human genes 0.000 description 1
- 102100026249 RING finger protein 37 Human genes 0.000 description 1
- 101710178916 RING-box protein 1 Proteins 0.000 description 1
- 102100039692 RNA-binding motif, single-stranded-interacting protein 1 Human genes 0.000 description 1
- 108091007336 RNF19B Proteins 0.000 description 1
- 102000001154 RNF217 Human genes 0.000 description 1
- 102100034328 Rab GDP dissociation inhibitor beta Human genes 0.000 description 1
- 102100025165 Rab GTPase-activating protein 1-like, isoform 10 Human genes 0.000 description 1
- 102100034589 Rap guanine nucleotide exchange factor 1 Human genes 0.000 description 1
- 102100034587 Rap guanine nucleotide exchange factor 6 Human genes 0.000 description 1
- 102100031426 Ras GTPase-activating protein 1 Human genes 0.000 description 1
- 108090000231 Ras GTPase-activating proteins Proteins 0.000 description 1
- 102000003901 Ras GTPase-activating proteins Human genes 0.000 description 1
- 229940078123 Ras inhibitor Drugs 0.000 description 1
- 102100033959 Ras-related protein Rab-8B Human genes 0.000 description 1
- 102100030706 Ras-related protein Rap-1A Human genes 0.000 description 1
- 102100030705 Ras-related protein Rap-1b Human genes 0.000 description 1
- 101000832669 Rattus norvegicus Probable alcohol sulfotransferase Proteins 0.000 description 1
- 102100038273 Receptor expression-enhancing protein 3 Human genes 0.000 description 1
- 102000005622 Receptor for Advanced Glycation End Products Human genes 0.000 description 1
- 108010045108 Receptor for Advanced Glycation End Products Proteins 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 108010003494 Retinoblastoma-Like Protein p130 Proteins 0.000 description 1
- 102000004642 Retinoblastoma-Like Protein p130 Human genes 0.000 description 1
- 102100038042 Retinoblastoma-associated protein Human genes 0.000 description 1
- OWPCHSCAPHNHAV-UHFFFAOYSA-N Rhizoxin Natural products C1C(O)C2(C)OC2C=CC(C)C(OC(=O)C2)CC2CC2OC2C(=O)OC1C(C)C(OC)C(C)=CC=CC(C)=CC1=COC(C)=N1 OWPCHSCAPHNHAV-UHFFFAOYSA-N 0.000 description 1
- 102100027660 Rho GTPase-activating protein 15 Human genes 0.000 description 1
- 102100035759 Rho GTPase-activating protein 25 Human genes 0.000 description 1
- 102100021428 Rho GTPase-activating protein 5 Human genes 0.000 description 1
- 102100021426 Rho GTPase-activating protein 6 Human genes 0.000 description 1
- 102100021689 Rho guanine nucleotide exchange factor 3 Human genes 0.000 description 1
- 102100040312 Ribonuclease 7 Human genes 0.000 description 1
- 102100033536 Ribosomal protein S6 kinase alpha-1 Human genes 0.000 description 1
- 102100024908 Ribosomal protein S6 kinase beta-1 Human genes 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- GCPUVEMWOWMALU-UHFFFAOYSA-N Rubiginone B1 Natural products C1C(C)CC(O)C2=C1C=CC1=C2C(=O)C(C=CC=C2OC)=C2C1=O GCPUVEMWOWMALU-UHFFFAOYSA-N 0.000 description 1
- 102100034374 S-phase kinase-associated protein 2 Human genes 0.000 description 1
- 102100036195 SAM domain-containing protein SAMSN-1 Human genes 0.000 description 1
- ZQUSFAUAYSEREK-WKILWMFISA-N SB-239063 Chemical compound COC1=NC=CC(C=2N(C=NC=2C=2C=CC(F)=CC=2)[C@@H]2CC[C@@H](O)CC2)=N1 ZQUSFAUAYSEREK-WKILWMFISA-N 0.000 description 1
- 108010005173 SERPIN-B5 Proteins 0.000 description 1
- 102100024243 SH3 domain-binding glutamic acid-rich-like protein Human genes 0.000 description 1
- 102100029198 SLAM family member 7 Human genes 0.000 description 1
- 108091006620 SLC12A2 Proteins 0.000 description 1
- 108091006788 SLC20A1 Proteins 0.000 description 1
- 108091006302 SLC2A14 Proteins 0.000 description 1
- 108091006298 SLC2A3 Proteins 0.000 description 1
- 108091006949 SLC35B3 Proteins 0.000 description 1
- 101700032040 SMAD1 Proteins 0.000 description 1
- 101700026522 SMAD7 Proteins 0.000 description 1
- 102100022330 SPRY domain-containing SOCS box protein 2 Human genes 0.000 description 1
- 102000001332 SRC Human genes 0.000 description 1
- 108060006706 SRC Proteins 0.000 description 1
- 102100030571 STE20-like serine/threonine-protein kinase Human genes 0.000 description 1
- 102100025809 SUMO-activating enzyme subunit 1 Human genes 0.000 description 1
- 102100035250 SUMO-activating enzyme subunit 2 Human genes 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- YADVRLOQIWILGX-MIWLTHJTSA-N Sarcophytol A Chemical compound CC(C)C/1=C/C=C(C)/CC\C=C(C)\CC\C=C(C)\C[C@@H]\1O YADVRLOQIWILGX-MIWLTHJTSA-N 0.000 description 1
- 102100027980 Semaphorin-3C Human genes 0.000 description 1
- 102100020814 Sequestosome-1 Human genes 0.000 description 1
- 102100031727 Serine incorporator 3 Human genes 0.000 description 1
- 102100024043 Serine/threonine-protein kinase LATS2 Human genes 0.000 description 1
- 102100031400 Serine/threonine-protein kinase Nek7 Human genes 0.000 description 1
- 102100037143 Serine/threonine-protein kinase OSR1 Human genes 0.000 description 1
- 102100032771 Serine/threonine-protein kinase SIK1 Human genes 0.000 description 1
- 102100031445 Serine/threonine-protein kinase SIK3 Human genes 0.000 description 1
- 102100030070 Serine/threonine-protein kinase Sgk1 Human genes 0.000 description 1
- 102100026281 Serine/threonine-protein phosphatase 2A 56 kDa regulatory subunit delta isoform Human genes 0.000 description 1
- 102100036140 Serine/threonine-protein phosphatase 2A 56 kDa regulatory subunit gamma isoform Human genes 0.000 description 1
- 102100034464 Serine/threonine-protein phosphatase 2A catalytic subunit alpha isoform Human genes 0.000 description 1
- 102100040320 Serine/threonine-protein phosphatase 2B catalytic subunit gamma isoform Human genes 0.000 description 1
- 102100030333 Serpin B5 Human genes 0.000 description 1
- 102100025520 Serpin B8 Human genes 0.000 description 1
- 108010042291 Serum Response Factor Proteins 0.000 description 1
- 102100022056 Serum response factor Human genes 0.000 description 1
- 102100027288 Sestrin-1 Human genes 0.000 description 1
- 206010041067 Small cell lung cancer Diseases 0.000 description 1
- 102100021829 Small integral membrane protein 29 Human genes 0.000 description 1
- 102100026940 Small ubiquitin-related modifier 1 Human genes 0.000 description 1
- OCOKWVBYZHBHLU-UHFFFAOYSA-N Sobuzoxane Chemical compound C1C(=O)N(COC(=O)OCC(C)C)C(=O)CN1CCN1CC(=O)N(COC(=O)OCC(C)C)C(=O)C1 OCOKWVBYZHBHLU-UHFFFAOYSA-N 0.000 description 1
- 101150107526 Socs2 gene Proteins 0.000 description 1
- 102100029462 Sodium-dependent lysophosphatidylcholine symporter 1 Human genes 0.000 description 1
- 102100029797 Sodium-dependent phosphate transporter 1 Human genes 0.000 description 1
- 102100022792 Sodium/potassium-transporting ATPase subunit beta-3 Human genes 0.000 description 1
- 102100039672 Solute carrier family 2, facilitated glucose transporter member 14 Human genes 0.000 description 1
- 102100022722 Solute carrier family 2, facilitated glucose transporter member 3 Human genes 0.000 description 1
- GCEUCUGYUPYUEC-UHFFFAOYSA-N Spongistatin 3 Natural products COC1CC2CC(=O)C(C)C(OC(=O)C)C(C)C(=C)CC3CC(C)(O)CC4(CCCC(CC(=O)OC5C(C)C(OC(CC(=C)CC(O)C=CC(=C)Cl)C5O)C(O)C6(O)CC(O)C(C)C(CCCC=C/C7CC(O)CC(C1)(O2)O7)O6)O4)O3 GCEUCUGYUPYUEC-UHFFFAOYSA-N 0.000 description 1
- JOEPUFOWFXWEDN-UHFFFAOYSA-N Spongistatin 5 Natural products C1C(=O)C(C)C(C2C)OCC2=CC(O2)CC(C)(O)CC2(O2)CC(O)CC2CC(=O)OC(C(C(CC(=C)CC(O)C=CC(Cl)=C)O2)O)C(C)C2C(O)C(O2)(O)CC(O)C(C)C2CCCC=CC(O2)CC(O)CC22CC(OC)CC1O2 JOEPUFOWFXWEDN-UHFFFAOYSA-N 0.000 description 1
- BTCJGYMVVGSTDN-UHFFFAOYSA-N Spongistatin 7 Natural products C1C(=O)C(C)C(C2C)OCC2=CC(O2)CC(C)(O)CC2(O2)CC(O)CC2CC(=O)OC(C(C(CC(=C)CC(O)C=CC=C)O2)O)C(C)C2C(O)C(O2)(O)CC(O)C(C)C2CCCC=CC(O2)CC(O)CC22CC(OC)CC1O2 BTCJGYMVVGSTDN-UHFFFAOYSA-N 0.000 description 1
- GLMCWICCTJHQKE-UHFFFAOYSA-N Spongistatin 9 Natural products C1C(=O)C(C)C(C2C)OCC2=CC(O2)CC(C)(O)CC2(O2)CC(OC(C)=O)CC2CC(=O)OC(C(C(CC(=C)CC(O)C=CC(Cl)=C)O2)O)C(C)C2C(O)C(O2)(O)CC(O)C(C)C2CCCC=CC(O2)CC(O)CC22CC(OC)CC1O2 GLMCWICCTJHQKE-UHFFFAOYSA-N 0.000 description 1
- UIRKNQLZZXALBI-MSVGPLKSSA-N Squalamine Chemical compound C([C@@H]1C[C@H]2O)[C@@H](NCCCNCCCCN)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@H](C)CC[C@H](C(C)C)OS(O)(=O)=O)[C@@]2(C)CC1 UIRKNQLZZXALBI-MSVGPLKSSA-N 0.000 description 1
- UIRKNQLZZXALBI-UHFFFAOYSA-N Squalamine Natural products OC1CC2CC(NCCCNCCCCN)CCC2(C)C2C1C1CCC(C(C)CCC(C(C)C)OS(O)(=O)=O)C1(C)CC2 UIRKNQLZZXALBI-UHFFFAOYSA-N 0.000 description 1
- 208000000102 Squamous Cell Carcinoma of Head and Neck Diseases 0.000 description 1
- 102100024237 Stathmin Human genes 0.000 description 1
- 102100021993 Sterol O-acyltransferase 1 Human genes 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 101000697584 Streptomyces lavendulae Streptothricin acetyltransferase Proteins 0.000 description 1
- 102100029955 Striatin-3 Human genes 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 102100032891 Superoxide dismutase [Mn], mitochondrial Human genes 0.000 description 1
- 102100024784 Suppressor of cytokine signaling 2 Human genes 0.000 description 1
- 108010001288 T-Lymphoma Invasion and Metastasis-inducing Protein 1 Proteins 0.000 description 1
- 102000002154 T-Lymphoma Invasion and Metastasis-inducing Protein 1 Human genes 0.000 description 1
- 102100035891 T-cell surface glycoprotein CD3 delta chain Human genes 0.000 description 1
- 102100029870 TBC1 domain family member 15 Human genes 0.000 description 1
- 102100040256 TBC1 domain family member 5 Human genes 0.000 description 1
- 102100033456 TGF-beta receptor type-1 Human genes 0.000 description 1
- 102100021227 TGF-beta-activated kinase 1 and MAP3K7-binding protein 2 Human genes 0.000 description 1
- CYQFCXCEBYINGO-UHFFFAOYSA-N THC Natural products C1=C(C)CCC2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3C21 CYQFCXCEBYINGO-UHFFFAOYSA-N 0.000 description 1
- 102000003714 TNF receptor-associated factor 6 Human genes 0.000 description 1
- 108090000009 TNF receptor-associated factor 6 Proteins 0.000 description 1
- 102100037667 TNFAIP3-interacting protein 1 Human genes 0.000 description 1
- 108091007076 TRIP12 Proteins 0.000 description 1
- 102100035052 TSC22 domain family protein 2 Human genes 0.000 description 1
- 102100038717 TYRO protein tyrosine kinase-binding protein Human genes 0.000 description 1
- PTTJLTMUKRRHAT-VJAKQJMOSA-N Taccalonolide A Chemical compound C([C@@H]1C(=O)[C@@H]2O)[C@@H]3O[C@@H]3[C@H](OC(C)=O)[C@]1(C)[C@@H]1[C@@H]2[C@@H]2[C@@H](OC(C)=O)[C@H]3[C@@]4(C)[C@](C)(O)C(=O)OC4=C[C@@H](C)[C@@H]3[C@@]2(C)[C@@H](OC(C)=O)[C@H]1OC(C)=O PTTJLTMUKRRHAT-VJAKQJMOSA-N 0.000 description 1
- 229940123237 Taxane Drugs 0.000 description 1
- BPEGJWRSRHCHSN-UHFFFAOYSA-N Temozolomide Chemical compound O=C1N(C)N=NC2=C(C(N)=O)N=CN21 BPEGJWRSRHCHSN-UHFFFAOYSA-N 0.000 description 1
- 208000024313 Testicular Neoplasms Diseases 0.000 description 1
- 206010057644 Testis cancer Diseases 0.000 description 1
- PDMMFKSKQVNJMI-BLQWBTBKSA-N Testosterone propionate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](OC(=O)CC)[C@@]1(C)CC2 PDMMFKSKQVNJMI-BLQWBTBKSA-N 0.000 description 1
- 102100036125 Tetratricopeptide repeat protein 39B Human genes 0.000 description 1
- 102100031286 Tetratricopeptide repeat protein 9A Human genes 0.000 description 1
- WXZSUBHBYQYTNM-UHFFFAOYSA-N Tetrazomine Natural products C1=CC=2CC(N34)C(N5C)C(CO)CC5C4OCC3C=2C(OC)=C1NC(=O)C1NCCCC1O WXZSUBHBYQYTNM-UHFFFAOYSA-N 0.000 description 1
- UPGGKUQISSWRJJ-XLTUSUNSSA-N Thiocoraline Chemical compound O=C([C@H]1CSSC[C@@H](N(C(=O)CNC2=O)C)C(=O)N(C)[C@@H](C(SC[C@@H](C(=O)NCC(=O)N1C)NC(=O)C=1C(=CC3=CC=CC=C3N=1)O)=O)CSC)N(C)[C@H](CSC)C(=O)SC[C@@H]2NC(=O)C1=NC2=CC=CC=C2C=C1O UPGGKUQISSWRJJ-XLTUSUNSSA-N 0.000 description 1
- 102100040483 Threonine aspartase 1 Human genes 0.000 description 1
- 102100026966 Thrombomodulin Human genes 0.000 description 1
- 108010078233 Thymalfasin Proteins 0.000 description 1
- 208000033781 Thyroid carcinoma Diseases 0.000 description 1
- 102000011923 Thyrotropin Human genes 0.000 description 1
- 108010061174 Thyrotropin Proteins 0.000 description 1
- 102100026637 Tight junction protein ZO-2 Human genes 0.000 description 1
- ATJFFYVFTNAWJD-UHFFFAOYSA-N Tin Chemical compound [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 description 1
- 102000019347 Tob1 Human genes 0.000 description 1
- 102100024333 Toll-like receptor 2 Human genes 0.000 description 1
- 102100039390 Toll-like receptor 7 Human genes 0.000 description 1
- IWEQQRMGNVVKQW-OQKDUQJOSA-N Toremifene citrate Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O.C1=CC(OCCN(C)C)=CC=C1C(\C=1C=CC=CC=1)=C(\CCCl)C1=CC=CC=C1 IWEQQRMGNVVKQW-OQKDUQJOSA-N 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 102100021123 Transcription factor 12 Human genes 0.000 description 1
- 102100028438 Transcription factor HIVEP2 Human genes 0.000 description 1
- 102100022821 Transcription factor RFX3 Human genes 0.000 description 1
- 102100021268 Transcription regulator protein BACH1 Human genes 0.000 description 1
- 102100034698 Transducin-like enhancer protein 3 Human genes 0.000 description 1
- 102100026144 Transferrin receptor protein 1 Human genes 0.000 description 1
- 102100022572 Transformer-2 protein homolog beta Human genes 0.000 description 1
- 108010011702 Transforming Growth Factor-beta Type I Receptor Proteins 0.000 description 1
- 102100022387 Transforming protein RhoA Human genes 0.000 description 1
- 102100036380 Transmembrane protein 176A Human genes 0.000 description 1
- 102100036387 Transmembrane protein 176B Human genes 0.000 description 1
- 102100036756 Transmembrane protein 64 Human genes 0.000 description 1
- 102100033598 Triosephosphate isomerase Human genes 0.000 description 1
- 102100022350 Tripartite motif-containing protein 14 Human genes 0.000 description 1
- DFBIRQPKNDILPW-CIVMWXNOSA-N Triptolide Chemical compound O=C1OCC([C@@H]2C3)=C1CC[C@]2(C)[C@]12O[C@H]1[C@@H]1O[C@]1(C(C)C)[C@@H](O)[C@]21[C@H]3O1 DFBIRQPKNDILPW-CIVMWXNOSA-N 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 102100033632 Tropomyosin alpha-1 chain Human genes 0.000 description 1
- 102100025239 Tubulin alpha-4A chain Human genes 0.000 description 1
- IBEDDHUHZBDXGB-UHFFFAOYSA-N Tubulysin A Natural products N=1C(C(=O)NC(CC(C)C(O)=O)CC=2C=CC(O)=CC=2)=CSC=1C(OC(C)=O)CC(C(C)C)N(COC(=O)CC(C)C)C(=O)C(C(C)CC)NC(=O)C1CCCCN1C IBEDDHUHZBDXGB-UHFFFAOYSA-N 0.000 description 1
- IBEDDHUHZBDXGB-OEJISELMSA-N Tubulysin A Chemical compound N([C@@H]([C@@H](C)CC)C(=O)N(COC(=O)CC(C)C)[C@H](C[C@@H](OC(C)=O)C=1SC=C(N=1)C(=O)N[C@H](C[C@H](C)C(O)=O)CC=1C=CC(O)=CC=1)C(C)C)C(=O)[C@H]1CCCCN1C IBEDDHUHZBDXGB-OEJISELMSA-N 0.000 description 1
- 238000010162 Tukey test Methods 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102100040112 Tumor necrosis factor receptor superfamily member 10B Human genes 0.000 description 1
- 102100027224 Tumor protein p53-inducible nuclear protein 1 Human genes 0.000 description 1
- 108010046308 Type II DNA Topoisomerases Proteins 0.000 description 1
- 102100035221 Tyrosine-protein kinase Fyn Human genes 0.000 description 1
- 102100027389 Tyrosine-protein kinase HCK Human genes 0.000 description 1
- 102100025387 Tyrosine-protein kinase JAK3 Human genes 0.000 description 1
- 102100024036 Tyrosine-protein kinase Lck Human genes 0.000 description 1
- 102100038183 Tyrosine-protein kinase SYK Human genes 0.000 description 1
- 102100021788 Tyrosine-protein kinase Yes Human genes 0.000 description 1
- 102000003436 UBA3 Human genes 0.000 description 1
- 108060008744 UBA3 Proteins 0.000 description 1
- 102000056723 UBE3C Human genes 0.000 description 1
- 102000003441 UBR1 Human genes 0.000 description 1
- 101150118716 UBR1 gene Proteins 0.000 description 1
- 101150056689 UBR2 gene Proteins 0.000 description 1
- 102000003442 UBR4 Human genes 0.000 description 1
- VGQOVCHZGQWAOI-UHFFFAOYSA-N UNPD55612 Natural products N1C(O)C2CC(C=CC(N)=O)=CN2C(=O)C2=CC=C(C)C(O)=C12 VGQOVCHZGQWAOI-UHFFFAOYSA-N 0.000 description 1
- 108090000848 Ubiquitin Proteins 0.000 description 1
- 102000044159 Ubiquitin Human genes 0.000 description 1
- 102100024662 Ubiquitin carboxyl-terminal hydrolase 12 Human genes 0.000 description 1
- 102100038532 Ubiquitin conjugation factor E4 A Human genes 0.000 description 1
- 102100037933 Ubiquitin-associated domain-containing protein 2 Human genes 0.000 description 1
- 102100037261 Ubiquitin-conjugating enzyme E2 A Human genes 0.000 description 1
- 102100037262 Ubiquitin-conjugating enzyme E2 B Human genes 0.000 description 1
- 102100030433 Ubiquitin-conjugating enzyme E2 D1 Human genes 0.000 description 1
- 102100030439 Ubiquitin-conjugating enzyme E2 D2 Human genes 0.000 description 1
- 102100030425 Ubiquitin-conjugating enzyme E2 D3 Human genes 0.000 description 1
- 102100020699 Ubiquitin-conjugating enzyme E2 D4 Human genes 0.000 description 1
- 102100020709 Ubiquitin-conjugating enzyme E2 E3 Human genes 0.000 description 1
- 102100020712 Ubiquitin-conjugating enzyme E2 G1 Human genes 0.000 description 1
- 102100024870 Ubiquitin-conjugating enzyme E2 G2 Human genes 0.000 description 1
- 102100024860 Ubiquitin-conjugating enzyme E2 J1 Human genes 0.000 description 1
- 102100024863 Ubiquitin-conjugating enzyme E2 J2 Human genes 0.000 description 1
- 102100020696 Ubiquitin-conjugating enzyme E2 K Human genes 0.000 description 1
- 102100024861 Ubiquitin-conjugating enzyme E2 L3 Human genes 0.000 description 1
- 102100024846 Ubiquitin-conjugating enzyme E2 Q1 Human genes 0.000 description 1
- 102100038500 Ubiquitin-conjugating enzyme E2 Q2 Human genes 0.000 description 1
- 102100038466 Ubiquitin-conjugating enzyme E2 R1 Human genes 0.000 description 1
- 102100038499 Ubiquitin-conjugating enzyme E2 R2 Human genes 0.000 description 1
- 102100028718 Ubiquitin-conjugating enzyme E2 S Human genes 0.000 description 1
- 102100028700 Ubiquitin-conjugating enzyme E2 W Human genes 0.000 description 1
- 102100030441 Ubiquitin-conjugating enzyme E2 Z Human genes 0.000 description 1
- 102100031122 Ubiquitin-conjugating enzyme E2 variant 2 Human genes 0.000 description 1
- 102100037160 Ubiquitin-like modifier-activating enzyme 1 Human genes 0.000 description 1
- 102100039197 Ubiquitin-like modifier-activating enzyme 5 Human genes 0.000 description 1
- 102100037939 Ubiquitin-like modifier-activating enzyme 6 Human genes 0.000 description 1
- 102100022979 Ubiquitin-like modifier-activating enzyme ATG7 Human genes 0.000 description 1
- 102100030434 Ubiquitin-protein ligase E3A Human genes 0.000 description 1
- 102100030429 Ubiquitin-protein ligase E3B Human genes 0.000 description 1
- 102100033655 Uncharacterized protein C6orf62 Human genes 0.000 description 1
- 102100037535 Uncharacterized protein FAM241A Human genes 0.000 description 1
- 102100020892 Uridine phosphorylase 1 Human genes 0.000 description 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
- 102000003990 Urokinase-type plasminogen activator Human genes 0.000 description 1
- 108090000435 Urokinase-type plasminogen activator Proteins 0.000 description 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
- 102100035288 Vacuolar protein sorting-associated protein 54 Human genes 0.000 description 1
- 108010003205 Vasoactive Intestinal Peptide Proteins 0.000 description 1
- 102400000015 Vasoactive intestinal peptide Human genes 0.000 description 1
- 102100037582 Vesicular, overexpressed in cancer, prosurvival protein 1 Human genes 0.000 description 1
- 102100023486 Vinculin Human genes 0.000 description 1
- 102100035334 WD repeat and SOCS box-containing protein 1 Human genes 0.000 description 1
- 102100037048 WD repeat domain phosphoinositide-interacting protein 4 Human genes 0.000 description 1
- 102100038947 WD repeat-containing protein 37 Human genes 0.000 description 1
- 208000033559 Waldenström macroglobulinemia Diseases 0.000 description 1
- 102100038151 X-box-binding protein 1 Human genes 0.000 description 1
- 102100028994 YrdC domain-containing protein, mitochondrial Human genes 0.000 description 1
- MHDDZDPNIDVLNK-ZGIWMXSJSA-N Zanoterone Chemical compound C1C2=NN(S(C)(=O)=O)C=C2C[C@]2(C)[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CC[C@H]21 MHDDZDPNIDVLNK-ZGIWMXSJSA-N 0.000 description 1
- 101100022813 Zea mays MEG3 gene Proteins 0.000 description 1
- 102100028882 Zinc finger CCCH-type antiviral protein 1 Human genes 0.000 description 1
- 102100040314 Zinc finger and BTB domain-containing protein 16 Human genes 0.000 description 1
- 102100021146 Zinc finger and BTB domain-containing protein 20 Human genes 0.000 description 1
- 102100021127 Zinc finger and BTB domain-containing protein 25 Human genes 0.000 description 1
- 102100020912 Zinc finger and SCAN domain-containing protein 16 Human genes 0.000 description 1
- 102100023559 Zinc finger protein 107 Human genes 0.000 description 1
- 102100036595 Zinc finger protein 217 Human genes 0.000 description 1
- OGQICQVSFDPSEI-UHFFFAOYSA-N Zorac Chemical compound N1=CC(C(=O)OCC)=CC=C1C#CC1=CC=C(SCCC2(C)C)C2=C1 OGQICQVSFDPSEI-UHFFFAOYSA-N 0.000 description 1
- ZZWKZQDOSJAGGF-VRSYWUPDSA-N [(1s,2e,7s,10e,12r,13r,15s)-12-hydroxy-7-methyl-9-oxo-8-oxabicyclo[11.3.0]hexadeca-2,10-dien-15-yl] 2-(dimethylamino)acetate Chemical compound O[C@@H]1\C=C\C(=O)O[C@@H](C)CCC\C=C\[C@@H]2C[C@H](OC(=O)CN(C)C)C[C@H]21 ZZWKZQDOSJAGGF-VRSYWUPDSA-N 0.000 description 1
- VUPBDWQPEOWRQP-RTUCOMKBSA-N [(2R,3S,4S,5R,6R)-2-[(2R,3S,4S,5S,6S)-2-[(1S,2S)-3-[[(2R,3S)-5-[[(2S,3R)-1-[[2-[4-[4-[[4-amino-6-[3-(4-aminobutylamino)propylamino]-6-oxohexyl]carbamoyl]-1,3-thiazol-2-yl]-1,3-thiazol-2-yl]-1-[(2S,3R,4R,5S,6S)-5-amino-3,4-dihydroxy-6-methyloxan-2-yl]oxy-2-hydroxyethyl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-3-hydroxy-5-oxopentan-2-yl]amino]-2-[[6-amino-2-[(1S)-3-amino-1-[[(2S)-2,3-diamino-3-oxopropyl]amino]-3-oxopropyl]-5-methylpyrimidine-4-carbonyl]amino]-1-(1H-imidazol-5-yl)-3-oxopropoxy]-4,5-dihydroxy-6-(hydroxymethyl)oxan-3-yl]oxy-3,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl] carbamate Chemical compound C[C@@H](O)[C@H](NC(=O)C[C@H](O)[C@@H](C)NC(=O)[C@@H](NC(=O)c1nc(nc(N)c1C)[C@H](CC(N)=O)NC[C@H](N)C(N)=O)[C@H](O[C@@H]1O[C@@H](CO)[C@@H](O)[C@H](O)[C@@H]1O[C@H]1O[C@H](CO)[C@@H](O)[C@H](OC(N)=O)[C@@H]1O)c1cnc[nH]1)C(=O)NC(O[C@@H]1O[C@@H](C)[C@@H](N)[C@@H](O)[C@H]1O)C(O)c1nc(cs1)-c1nc(cs1)C(=O)NCCCC(N)CC(=O)NCCCNCCCCN VUPBDWQPEOWRQP-RTUCOMKBSA-N 0.000 description 1
- SPKNARKFCOPTSY-XWPZMVOTSA-N [(2r,3s)-2-[(2s,3r)-3-methyloxiran-2-yl]-6-oxo-2,3-dihydropyran-3-yl] acetate Chemical compound C[C@H]1O[C@@H]1[C@H]1[C@@H](OC(C)=O)C=CC(=O)O1 SPKNARKFCOPTSY-XWPZMVOTSA-N 0.000 description 1
- LUJZZYWHBDHDQX-QFIPXVFZSA-N [(3s)-morpholin-3-yl]methyl n-[4-[[1-[(3-fluorophenyl)methyl]indazol-5-yl]amino]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl]carbamate Chemical compound C=1N2N=CN=C(NC=3C=C4C=NN(CC=5C=C(F)C=CC=5)C4=CC=3)C2=C(C)C=1NC(=O)OC[C@@H]1COCCN1 LUJZZYWHBDHDQX-QFIPXVFZSA-N 0.000 description 1
- VQSGYKUTGGRSPK-SIOACEIBSA-N [(3s,4s,7s)-2-[3-[(2s,5s,8s,11s,14r,17r,20s,23r,26r)-11,14-bis(2-amino-2-oxoethyl)-5,20-bis[(1r)-1-hydroxyethyl]-8-methyl-17,23-bis(2-methylpropyl)-26-octyl-3,6,9,12,15,18,21,24,27-nonaoxo-1,4,7,10,13,16,19,22,25-nonazacycloheptacos-2-yl]propyl]-5-chloro- Chemical compound N1C(=O)[C@@H](CCCCCCCC)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@@H](CC(C)C)NC(=O)[C@@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@@H]1CCCN1[C@@]2(OCCC2)[C@@H](O)C2=C(Cl)C(=O)[C@@](C)(OC(=O)CCC)C(=O)C2=C1 VQSGYKUTGGRSPK-SIOACEIBSA-N 0.000 description 1
- IVCRCPJOLWECJU-XQVQQVTHSA-N [(7r,8r,9s,10r,13s,14s,17s)-7,13-dimethyl-3-oxo-2,6,7,8,9,10,11,12,14,15,16,17-dodecahydro-1h-cyclopenta[a]phenanthren-17-yl] acetate Chemical compound C1C[C@]2(C)[C@@H](OC(C)=O)CC[C@H]2[C@@H]2[C@H](C)CC3=CC(=O)CC[C@@H]3[C@H]21 IVCRCPJOLWECJU-XQVQQVTHSA-N 0.000 description 1
- PQNNIEWMPIULRS-SUTYWZMXSA-N [(8e,10e,12e)-7-hydroxy-6-methyl-2-(3-methyl-6-oxo-2,3-dihydropyran-2-yl)tetradeca-8,10,12-trien-5-yl] dihydrogen phosphate Chemical compound C\C=C\C=C\C=C\C(O)C(C)C(OP(O)(O)=O)CCC(C)C1OC(=O)C=CC1C PQNNIEWMPIULRS-SUTYWZMXSA-N 0.000 description 1
- IFJUINDAXYAPTO-UUBSBJJBSA-N [(8r,9s,13s,14s,17s)-17-[2-[4-[4-[bis(2-chloroethyl)amino]phenyl]butanoyloxy]acetyl]oxy-13-methyl-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthren-3-yl] benzoate Chemical compound C([C@@H]1[C@@H](C2=CC=3)CC[C@]4([C@H]1CC[C@@H]4OC(=O)COC(=O)CCCC=1C=CC(=CC=1)N(CCCl)CCCl)C)CC2=CC=3OC(=O)C1=CC=CC=C1 IFJUINDAXYAPTO-UUBSBJJBSA-N 0.000 description 1
- KMLCRELJHYKIIL-UHFFFAOYSA-N [1-(azanidylmethyl)cyclohexyl]methylazanide;platinum(2+);sulfuric acid Chemical compound [Pt+2].OS(O)(=O)=O.[NH-]CC1(C[NH-])CCCCC1 KMLCRELJHYKIIL-UHFFFAOYSA-N 0.000 description 1
- JJULHOZRTCDZOH-JGJFOBQESA-N [1-[[[(2r,3s,4s,5r)-5-(4-amino-2-oxopyrimidin-1-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-hydroxyphosphoryl]oxy-3-octadecylsulfanylpropan-2-yl] hexadecanoate Chemical compound O[C@H]1[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(CSCCCCCCCCCCCCCCCCCC)OC(=O)CCCCCCCCCCCCCCC)O[C@H]1N1C(=O)N=C(N)C=C1 JJULHOZRTCDZOH-JGJFOBQESA-N 0.000 description 1
- XSMVECZRZBFTIZ-UHFFFAOYSA-M [2-(aminomethyl)cyclobutyl]methanamine;2-oxidopropanoate;platinum(4+) Chemical compound [Pt+4].CC([O-])C([O-])=O.NCC1CCC1CN XSMVECZRZBFTIZ-UHFFFAOYSA-M 0.000 description 1
- ODEDPKNSRBCSDO-UHFFFAOYSA-N [2-(hexadecylsulfanylmethyl)-3-methoxypropyl] 2-(trimethylazaniumyl)ethyl phosphate Chemical compound CCCCCCCCCCCCCCCCSCC(COC)COP([O-])(=O)OCC[N+](C)(C)C ODEDPKNSRBCSDO-UHFFFAOYSA-N 0.000 description 1
- NAFFDQVVNWTDJD-UHFFFAOYSA-L [4-(azanidylmethyl)oxan-4-yl]methylazanide;cyclobutane-1,1-dicarboxylate;platinum(4+) Chemical compound [Pt+4].[NH-]CC1(C[NH-])CCOCC1.[O-]C(=O)C1(C([O-])=O)CCC1 NAFFDQVVNWTDJD-UHFFFAOYSA-L 0.000 description 1
- JURAJLFHWXNPHG-UHFFFAOYSA-N [acetyl(methylcarbamoyl)amino] n-methylcarbamate Chemical compound CNC(=O)ON(C(C)=O)C(=O)NC JURAJLFHWXNPHG-UHFFFAOYSA-N 0.000 description 1
- GZOSMCIZMLWJML-VJLLXTKPSA-N abiraterone Chemical compound C([C@H]1[C@H]2[C@@H]([C@]3(CC[C@H](O)CC3=CC2)C)CC[C@@]11C)C=C1C1=CC=CN=C1 GZOSMCIZMLWJML-VJLLXTKPSA-N 0.000 description 1
- 229960000853 abiraterone Drugs 0.000 description 1
- IPBVNPXQWQGGJP-UHFFFAOYSA-N acetic acid phenyl ester Natural products CC(=O)OC1=CC=CC=C1 IPBVNPXQWQGGJP-UHFFFAOYSA-N 0.000 description 1
- RUGAHXUZHWYHNG-NLGNTGLNSA-N acetic acid;(4r,7s,10s,13r,16s,19r)-10-(4-aminobutyl)-n-[(2s,3r)-1-amino-3-hydroxy-1-oxobutan-2-yl]-19-[[(2r)-2-amino-3-naphthalen-2-ylpropanoyl]amino]-16-[(4-hydroxyphenyl)methyl]-13-(1h-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-7-propan-2-yl-1,2-dithia-5, Chemical compound CC(O)=O.CC(O)=O.CC(O)=O.CC(O)=O.CC(O)=O.C([C@H]1C(=O)N[C@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(N[C@@H](CSSC[C@@H](C(=O)N1)NC(=O)[C@H](N)CC=1C=C2C=CC=CC2=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(N)=O)=O)C(C)C)C1=CC=C(O)C=C1.C([C@H]1C(=O)N[C@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(N[C@@H](CSSC[C@@H](C(=O)N1)NC(=O)[C@H](N)CC=1C=C2C=CC=CC2=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(N)=O)=O)C(C)C)C1=CC=C(O)C=C1 RUGAHXUZHWYHNG-NLGNTGLNSA-N 0.000 description 1
- IGCAUIJHGNYDKE-UHFFFAOYSA-N acetic acid;1,4-bis[2-(2-hydroxyethylamino)ethylamino]anthracene-9,10-dione Chemical compound CC([O-])=O.CC([O-])=O.O=C1C2=CC=CC=C2C(=O)C2=C1C(NCC[NH2+]CCO)=CC=C2NCC[NH2+]CCO IGCAUIJHGNYDKE-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 229950008427 acivicin Drugs 0.000 description 1
- QAWIHIJWNYOLBE-OKKQSCSOSA-N acivicin Chemical compound OC(=O)[C@@H](N)[C@@H]1CC(Cl)=NO1 QAWIHIJWNYOLBE-OKKQSCSOSA-N 0.000 description 1
- 229950000616 acronine Drugs 0.000 description 1
- 229930183665 actinomycin Natural products 0.000 description 1
- HLAKJNQXUARACO-UHFFFAOYSA-N acylfulvene Natural products CC1(O)C(=O)C2=CC(C)=CC2=C(C)C21CC2 HLAKJNQXUARACO-UHFFFAOYSA-N 0.000 description 1
- 230000003044 adaptive effect Effects 0.000 description 1
- 210000005006 adaptive immune system Anatomy 0.000 description 1
- 238000011374 additional therapy Methods 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- DPGOLRILOKERAV-AAWJQDODSA-N adecypenol Chemical compound OC1C(CO)=CCC1(O)N1C(N=CNC[C@H]2O)C2N=C1 DPGOLRILOKERAV-AAWJQDODSA-N 0.000 description 1
- WJSAFKJWCOMTLH-UHFFFAOYSA-N adecypenol Natural products OC1C(O)C(CO)=CC1N1C(NC=NCC2O)=C2N=C1 WJSAFKJWCOMTLH-UHFFFAOYSA-N 0.000 description 1
- 230000001919 adrenal effect Effects 0.000 description 1
- 230000001780 adrenocortical effect Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 229940045714 alkyl sulfonate alkylating agent Drugs 0.000 description 1
- 150000008052 alkyl sulfonates Chemical class 0.000 description 1
- 229940100198 alkylating agent Drugs 0.000 description 1
- 239000002168 alkylating agent Substances 0.000 description 1
- 229950010949 ambamustine Drugs 0.000 description 1
- 229950004821 ambomycin Drugs 0.000 description 1
- 229960001097 amifostine Drugs 0.000 description 1
- JKOQGQFVAUAYPM-UHFFFAOYSA-N amifostine Chemical compound NCCCNCCSP(O)(O)=O JKOQGQFVAUAYPM-UHFFFAOYSA-N 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 229960002749 aminolevulinic acid Drugs 0.000 description 1
- 229960002550 amrubicin Drugs 0.000 description 1
- VJZITPJGSQKZMX-XDPRQOKASA-N amrubicin Chemical compound O([C@H]1C[C@](CC2=C(O)C=3C(=O)C4=CC=CC=C4C(=O)C=3C(O)=C21)(N)C(=O)C)[C@H]1C[C@H](O)[C@H](O)CO1 VJZITPJGSQKZMX-XDPRQOKASA-N 0.000 description 1
- 229960001694 anagrelide Drugs 0.000 description 1
- OTBXOEAOVRKTNQ-UHFFFAOYSA-N anagrelide Chemical compound N1=C2NC(=O)CN2CC2=C(Cl)C(Cl)=CC=C21 OTBXOEAOVRKTNQ-UHFFFAOYSA-N 0.000 description 1
- 101150072346 anapc1 gene Proteins 0.000 description 1
- 101150001938 anapc4 gene Proteins 0.000 description 1
- 101150085085 anapc7 gene Proteins 0.000 description 1
- 239000003098 androgen Substances 0.000 description 1
- 229940030486 androgens Drugs 0.000 description 1
- ASLUCFFROXVMFL-UHFFFAOYSA-N andrographolide Natural products CC1(CO)C(O)CCC2(C)C(CC=C3/C(O)OCC3=O)C(=C)CCC12 ASLUCFFROXVMFL-UHFFFAOYSA-N 0.000 description 1
- 239000004037 angiogenesis inhibitor Substances 0.000 description 1
- 229940121369 angiogenesis inhibitor Drugs 0.000 description 1
- 108010070670 antarelix Proteins 0.000 description 1
- ACPOUJIDANTYHO-UHFFFAOYSA-N anthra[1,9-cd]pyrazol-6(2H)-one Chemical compound C1=CC(C(=O)C=2C3=CC=CC=2)=C2C3=NNC2=C1 ACPOUJIDANTYHO-UHFFFAOYSA-N 0.000 description 1
- RGHILYZRVFRRNK-UHFFFAOYSA-N anthracene-1,2-dione Chemical compound C1=CC=C2C=C(C(C(=O)C=C3)=O)C3=CC2=C1 RGHILYZRVFRRNK-UHFFFAOYSA-N 0.000 description 1
- VGQOVCHZGQWAOI-HYUHUPJXSA-N anthramycin Chemical compound N1[C@@H](O)[C@@H]2CC(\C=C\C(N)=O)=CN2C(=O)C2=CC=C(C)C(O)=C12 VGQOVCHZGQWAOI-HYUHUPJXSA-N 0.000 description 1
- 230000000340 anti-metabolite Effects 0.000 description 1
- 230000000118 anti-neoplastic effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 102000025171 antigen binding proteins Human genes 0.000 description 1
- 108091000831 antigen binding proteins Proteins 0.000 description 1
- 229940100197 antimetabolite Drugs 0.000 description 1
- 239000002256 antimetabolite Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 239000000074 antisense oligonucleotide Substances 0.000 description 1
- 238000012230 antisense oligonucleotides Methods 0.000 description 1
- IOASYARYEYRREA-LQAJYKIKSA-N aphidicolin glycinate Chemical compound C1[C@]23[C@]4(C)CC[C@H](O)[C@](C)(CO)[C@H]4CC[C@@H]3C[C@@H]1[C@@](COC(=O)CN)(O)CC2 IOASYARYEYRREA-LQAJYKIKSA-N 0.000 description 1
- 239000012062 aqueous buffer Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 108010055530 arginyl-tryptophyl-N-methylphenylalanyl-tryptophyl-leucyl-methioninamide Proteins 0.000 description 1
- 239000003886 aromatase inhibitor Substances 0.000 description 1
- 229940046844 aromatase inhibitors Drugs 0.000 description 1
- 229960003272 asparaginase Drugs 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-M asparaginate Chemical compound [O-]C(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-M 0.000 description 1
- TWHSQQYCDVSBRK-UHFFFAOYSA-N asulacrine Chemical compound C12=CC=CC(C)=C2N=C2C(C(=O)NC)=CC=CC2=C1NC1=CC=C(NS(C)(=O)=O)C=C1OC TWHSQQYCDVSBRK-UHFFFAOYSA-N 0.000 description 1
- 229950011088 asulacrine Drugs 0.000 description 1
- PEPMWUSGRKINHX-TXTPUJOMSA-N atamestane Chemical compound C1C[C@@H]2[C@@]3(C)C(C)=CC(=O)C=C3CC[C@H]2[C@@H]2CCC(=O)[C@]21C PEPMWUSGRKINHX-TXTPUJOMSA-N 0.000 description 1
- 229950004810 atamestane Drugs 0.000 description 1
- 229950006933 atrimustine Drugs 0.000 description 1
- 108010093161 axinastatin 1 Proteins 0.000 description 1
- PICZCWCKOLHDOJ-GHTSNYPWSA-N axinastatin 1 Chemical compound C([C@H]1C(=O)N[C@H](C(=O)N[C@H](C(=O)N2CCC[C@H]2C(=O)N[C@H](C(N[C@@H](CC(N)=O)C(=O)N2CCC[C@H]2C(=O)N1)=O)C(C)C)C(C)C)C(C)C)C1=CC=CC=C1 PICZCWCKOLHDOJ-GHTSNYPWSA-N 0.000 description 1
- 108010093000 axinastatin 2 Proteins 0.000 description 1
- OXNAATCTZCSVKR-AVGVIDKOSA-N axinastatin 2 Chemical compound C([C@H]1C(=O)N[C@H](C(=O)N[C@H](C(N2CCC[C@H]2C(=O)N[C@@H](C(=O)N[C@@H](CC(N)=O)C(=O)N2CCC[C@H]2C(=O)N1)C(C)C)=O)CC(C)C)C(C)C)C1=CC=CC=C1 OXNAATCTZCSVKR-AVGVIDKOSA-N 0.000 description 1
- UZCPCRPHNVHKKP-UHFFFAOYSA-N axinastatin 2 Natural products CC(C)CC1NC(=O)C2CCCN2C(=O)C(NC(=O)C(CC(=O)N)NC(=O)C3CCCN3C(=O)C(Cc4ccccc4)NC(=O)C(NC1=O)C(C)C)C(C)C UZCPCRPHNVHKKP-UHFFFAOYSA-N 0.000 description 1
- 108010092978 axinastatin 3 Proteins 0.000 description 1
- ANLDPEXRVVIABH-WUUSPZRJSA-N axinastatin 3 Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CC(C)C)C(=O)N2CCC[C@H]2C(=O)N[C@@H](C(=O)N[C@@H](CC(N)=O)C(=O)N2CCC[C@H]2C(=O)N1)C(C)C)=O)[C@@H](C)CC)C1=CC=CC=C1 ANLDPEXRVVIABH-WUUSPZRJSA-N 0.000 description 1
- RTGMQVUKARGBNM-UHFFFAOYSA-N axinastatin 3 Natural products CCC(C)C1NC(=O)C(CC(C)C)NC(=O)C2CCCN2C(=O)C(NC(=O)C(CC(=O)N)NC(=O)C3CCCN3C(=O)C(Cc4ccccc4)NC1=O)C(C)C RTGMQVUKARGBNM-UHFFFAOYSA-N 0.000 description 1
- 229960002756 azacitidine Drugs 0.000 description 1
- OPWOOOGFNULJAQ-UHFFFAOYSA-L azane;cyclopentanamine;2-hydroxybutanedioate;platinum(2+) Chemical compound N.[Pt+2].NC1CCCC1.[O-]C(=O)C(O)CC([O-])=O OPWOOOGFNULJAQ-UHFFFAOYSA-L 0.000 description 1
- GRHLMSBCOPRFNA-UHFFFAOYSA-M azanide 2-oxidoacetate platinum(4+) Chemical compound N[Pt]1(N)OCC(=O)O1 GRHLMSBCOPRFNA-UHFFFAOYSA-M 0.000 description 1
- 229950005951 azasetron Drugs 0.000 description 1
- HRXVDDOKERXBEY-UHFFFAOYSA-N azatepa Chemical compound C1CN1P(=O)(N1CC1)N(CC)C1=NN=CS1 HRXVDDOKERXBEY-UHFFFAOYSA-N 0.000 description 1
- 229960002170 azathioprine Drugs 0.000 description 1
- MIXLRUYCYZPSOQ-HXPMCKFVSA-N azatoxin Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=C(C4=CC=CC=C4N3)C[C@@H]3N2C(OC3)=O)=C1 MIXLRUYCYZPSOQ-HXPMCKFVSA-N 0.000 description 1
- 229950004295 azotomycin Drugs 0.000 description 1
- 150000004200 baccatin III derivatives Chemical class 0.000 description 1
- XYUFCXJZFZPEJD-PGRDOPGGSA-N balanol Chemical compound OC(=O)C1=CC=CC(O)=C1C(=O)C1=C(O)C=C(C(=O)O[C@H]2[C@H](CNCCC2)NC(=O)C=2C=CC(O)=CC=2)C=C1O XYUFCXJZFZPEJD-PGRDOPGGSA-N 0.000 description 1
- 108700000711 bcl-X Proteins 0.000 description 1
- 229950005567 benzodepa Drugs 0.000 description 1
- KMGARVOVYXNAOF-UHFFFAOYSA-N benzpiperylone Chemical compound C1CN(C)CCC1N1C(=O)C(CC=2C=CC=CC=2)=C(C=2C=CC=CC=2)N1 KMGARVOVYXNAOF-UHFFFAOYSA-N 0.000 description 1
- MMIMIFULGMZVPO-UHFFFAOYSA-N benzyl 3-bromo-2,6-dinitro-5-phenylmethoxybenzoate Chemical compound [O-][N+](=O)C1=C(C(=O)OCC=2C=CC=CC=2)C([N+](=O)[O-])=C(Br)C=C1OCC1=CC=CC=C1 MMIMIFULGMZVPO-UHFFFAOYSA-N 0.000 description 1
- VFIUCBTYGKMLCM-UHFFFAOYSA-N benzyl n-[bis(aziridin-1-yl)phosphoryl]carbamate Chemical compound C=1C=CC=CC=1COC(=O)NP(=O)(N1CC1)N1CC1 VFIUCBTYGKMLCM-UHFFFAOYSA-N 0.000 description 1
- QGJZLNKBHJESQX-FZFNOLFKSA-N betulinic acid Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CC[C@@H](C(=C)C)[C@@H]5[C@H]4CC[C@@H]3[C@]21C QGJZLNKBHJESQX-FZFNOLFKSA-N 0.000 description 1
- 201000009036 biliary tract cancer Diseases 0.000 description 1
- 208000020790 biliary tract neoplasm Diseases 0.000 description 1
- ACWZRVQXLIRSDF-UHFFFAOYSA-N binimetinib Chemical compound OCCONC(=O)C=1C=C2N(C)C=NC2=C(F)C=1NC1=CC=C(Br)C=C1F ACWZRVQXLIRSDF-UHFFFAOYSA-N 0.000 description 1
- 239000013060 biological fluid Substances 0.000 description 1
- 235000010290 biphenyl Nutrition 0.000 description 1
- 239000004305 biphenyl Substances 0.000 description 1
- QKSKPIVNLNLAAV-UHFFFAOYSA-N bis(2-chloroethyl) sulfide Chemical compound ClCCSCCCl QKSKPIVNLNLAAV-UHFFFAOYSA-N 0.000 description 1
- 229950002370 bisnafide Drugs 0.000 description 1
- NPSOIFAWYAHWOH-UHFFFAOYSA-N bistratene A Natural products O1C(CC(=O)C=CC)CCC(O2)(O)CC(C)C2CCCNC(=O)C(C)C2OC(CCC(C)C=C(C)C(C)O)CCCCC(C)C1CC(=O)NC2 NPSOIFAWYAHWOH-UHFFFAOYSA-N 0.000 description 1
- 229960004395 bleomycin sulfate Drugs 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 229960001467 bortezomib Drugs 0.000 description 1
- GXJABQQUPOEUTA-RDJZCZTQSA-N bortezomib Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)B(O)O)NC(=O)C=1N=CC=NC=1)C1=CC=CC=C1 GXJABQQUPOEUTA-RDJZCZTQSA-N 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- PZOHOALJQOFNTB-UHFFFAOYSA-M brequinar sodium Chemical compound [Na+].N1=C2C=CC(F)=CC2=C(C([O-])=O)C(C)=C1C(C=C1)=CC=C1C1=CC=CC=C1F PZOHOALJQOFNTB-UHFFFAOYSA-M 0.000 description 1
- 229960005520 bryostatin Drugs 0.000 description 1
- MJQUEDHRCUIRLF-TVIXENOKSA-N bryostatin 1 Chemical compound C([C@@H]1CC(/[C@@H]([C@@](C(C)(C)/C=C/2)(O)O1)OC(=O)/C=C/C=C/CCC)=C\C(=O)OC)[C@H]([C@@H](C)O)OC(=O)C[C@H](O)C[C@@H](O1)C[C@H](OC(C)=O)C(C)(C)[C@]1(O)C[C@@H]1C\C(=C\C(=O)OC)C[C@H]\2O1 MJQUEDHRCUIRLF-TVIXENOKSA-N 0.000 description 1
- MUIWQCKLQMOUAT-AKUNNTHJSA-N bryostatin 20 Natural products COC(=O)C=C1C[C@@]2(C)C[C@]3(O)O[C@](C)(C[C@@H](O)CC(=O)O[C@](C)(C[C@@]4(C)O[C@](O)(CC5=CC(=O)O[C@]45C)C(C)(C)C=C[C@@](C)(C1)O2)[C@@H](C)O)C[C@H](OC(=O)C(C)(C)C)C3(C)C MUIWQCKLQMOUAT-AKUNNTHJSA-N 0.000 description 1
- 229950002361 budotitane Drugs 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 102100033065 cAMP-dependent protein kinase catalytic subunit beta Human genes 0.000 description 1
- 102100029387 cAMP-responsive element modulator Human genes 0.000 description 1
- 102100029168 cAMP-specific 3',5'-cyclic phosphodiesterase 4B Human genes 0.000 description 1
- 108700002839 cactinomycin Proteins 0.000 description 1
- 229950009908 cactinomycin Drugs 0.000 description 1
- 229960002882 calcipotriol Drugs 0.000 description 1
- LWQQLNNNIPYSNX-UROSTWAQSA-N calcipotriol Chemical compound C1([C@H](O)/C=C/[C@@H](C)[C@@H]2[C@]3(CCCC(/[C@@H]3CC2)=C\C=C\2C([C@@H](O)C[C@H](O)C/2)=C)C)CC1 LWQQLNNNIPYSNX-UROSTWAQSA-N 0.000 description 1
- 229960005084 calcitriol Drugs 0.000 description 1
- LSUTUUOITDQYNO-UHFFFAOYSA-N calphostin C Chemical compound C=12C3=C4C(CC(C)OC(=O)C=5C=CC=CC=5)=C(OC)C(O)=C(C(C=C5OC)=O)C4=C5C=1C(OC)=CC(=O)C2=C(O)C(OC)=C3CC(C)OC(=O)OC1=CC=C(O)C=C1 LSUTUUOITDQYNO-UHFFFAOYSA-N 0.000 description 1
- IVFYLRMMHVYGJH-PVPPCFLZSA-N calusterone Chemical compound C1C[C@]2(C)[C@](O)(C)CC[C@H]2[C@@H]2[C@@H](C)CC3=CC(=O)CC[C@]3(C)[C@H]21 IVFYLRMMHVYGJH-PVPPCFLZSA-N 0.000 description 1
- 229950009823 calusterone Drugs 0.000 description 1
- VSJKWCGYPAHWDS-FQEVSTJZSA-N camptothecin Chemical class C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-FQEVSTJZSA-N 0.000 description 1
- 230000004611 cancer cell death Effects 0.000 description 1
- 208000035269 cancer or benign tumor Diseases 0.000 description 1
- 229950009338 caracemide Drugs 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 229950005155 carbetimer Drugs 0.000 description 1
- WNRZHQBJSXRYJK-UHFFFAOYSA-N carboxyamidotriazole Chemical compound NC1=C(C(=O)N)N=NN1CC(C=C1Cl)=CC(Cl)=C1C(=O)C1=CC=C(Cl)C=C1 WNRZHQBJSXRYJK-UHFFFAOYSA-N 0.000 description 1
- 208000002458 carcinoid tumor Diseases 0.000 description 1
- WIUSFZNUZWLLDZ-UHFFFAOYSA-N caribaeolin Natural products C1=CC(OC)(C(=CC2C(C(C=CC2C(C)C)(C)O)C2)COC(C)=O)OC1(C)C2OC(=O)C=CC1=CN(C)C=N1 WIUSFZNUZWLLDZ-UHFFFAOYSA-N 0.000 description 1
- KGOMYXIKIJGWKS-UHFFFAOYSA-N caribaeoside Natural products C1=CC2(OC)OC1(C)C(OC(=O)C=CC=1N=CN(C)C=1)CC(C(C=CC1C(C)C)(C)O)C1C=C2COC1OCC(O)C(O)C1OC(C)=O KGOMYXIKIJGWKS-UHFFFAOYSA-N 0.000 description 1
- XREUEWVEMYWFFA-CSKJXFQVSA-N carminomycin Chemical compound C1[C@H](N)[C@H](O)[C@H](C)O[C@H]1O[C@@H]1C2=C(O)C(C(=O)C3=C(O)C=CC=C3C3=O)=C3C(O)=C2C[C@@](O)(C(C)=O)C1 XREUEWVEMYWFFA-CSKJXFQVSA-N 0.000 description 1
- 210000000845 cartilage Anatomy 0.000 description 1
- 229950001725 carubicin Drugs 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 229950010667 cedefingol Drugs 0.000 description 1
- WYUSVOMTXWRGEK-HBWVYFAYSA-N cefpodoxime Chemical compound N([C@H]1[C@@H]2N(C1=O)C(=C(CS2)COC)C(O)=O)C(=O)C(=N/OC)\C1=CSC(N)=N1 WYUSVOMTXWRGEK-HBWVYFAYSA-N 0.000 description 1
- 230000020411 cell activation Effects 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000008614 cellular interaction Effects 0.000 description 1
- CCWSQXBMKLEALQ-WMZOPIPTSA-N centaureidin Natural products CO[C@@H]1[C@@H](Oc2cc(O)c(OC)c(O)c2C1=O)c3ccc(OC)c(O)c3 CCWSQXBMKLEALQ-WMZOPIPTSA-N 0.000 description 1
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 1
- SEERZIQQUAZTOL-ANMDKAQQSA-N cerivastatin Chemical compound COCC1=C(C(C)C)N=C(C(C)C)C(\C=C\[C@@H](O)C[C@@H](O)CC(O)=O)=C1C1=CC=C(F)C=C1 SEERZIQQUAZTOL-ANMDKAQQSA-N 0.000 description 1
- 229960005110 cerivastatin Drugs 0.000 description 1
- 201000010881 cervical cancer Diseases 0.000 description 1
- 210000003679 cervix uteri Anatomy 0.000 description 1
- 108700008462 cetrorelix Proteins 0.000 description 1
- SBNPWPIBESPSIF-MHWMIDJBSA-N cetrorelix Chemical compound C([C@@H](C(=O)N[C@H](CCCNC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@H](C)C(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](CC=1C=NC=CC=1)NC(=O)[C@@H](CC=1C=CC(Cl)=CC=1)NC(=O)[C@@H](CC=1C=C2C=CC=CC2=CC=1)NC(C)=O)C1=CC=C(O)C=C1 SBNPWPIBESPSIF-MHWMIDJBSA-N 0.000 description 1
- 229960003230 cetrorelix Drugs 0.000 description 1
- 229960005395 cetuximab Drugs 0.000 description 1
- HZCWPKGYTCJSEB-UHFFFAOYSA-N chembl118841 Chemical compound C12=CC(OC)=CC=C2NC2=C([N+]([O-])=O)C=CC3=C2C1=NN3CCCN(C)C HZCWPKGYTCJSEB-UHFFFAOYSA-N 0.000 description 1
- JOAASNKBYBFGDN-UHFFFAOYSA-N chembl1214554 Chemical compound ON=C(N)C1=CC=C(O)C(O)=C1 JOAASNKBYBFGDN-UHFFFAOYSA-N 0.000 description 1
- KGOMYXIKIJGWKS-DKNGGRFKSA-N chembl1916173 Chemical compound C(/[C@H]1[C@H]([C@](C=C[C@@H]1C(C)C)(C)O)C[C@@H]([C@@]1(C)O[C@@]2(C=C1)OC)OC(=O)\C=C\C=1N=CN(C)C=1)=C2\CO[C@@H]1OC[C@@H](O)[C@@H](O)[C@@H]1OC(C)=O KGOMYXIKIJGWKS-DKNGGRFKSA-N 0.000 description 1
- OWSKEUBOCMEJMI-KPXOXKRLSA-N chembl2105946 Chemical compound [N-]=[N+]=CC(=O)CC[C@H](NC(=O)[C@@H](N)C)C(=O)N[C@H](CCC(=O)C=[N+]=[N-])C(O)=O OWSKEUBOCMEJMI-KPXOXKRLSA-N 0.000 description 1
- UKTAZPQNNNJVKR-KJGYPYNMSA-N chembl2368925 Chemical compound C1=CC=C2C(C(O[C@@H]3C[C@@H]4C[C@H]5C[C@@H](N4CC5=O)C3)=O)=CNC2=C1 UKTAZPQNNNJVKR-KJGYPYNMSA-N 0.000 description 1
- ZWVZORIKUNOTCS-OAQYLSRUSA-N chembl401930 Chemical compound C1([C@H](O)CNC2=C(C(NC=C2)=O)C=2NC=3C=C(C=C(C=3N=2)C)N2CCOCC2)=CC=CC(Cl)=C1 ZWVZORIKUNOTCS-OAQYLSRUSA-N 0.000 description 1
- DCKFXSZUWVWFEU-JECTWPLRSA-N chembl499423 Chemical compound O1[C@@H](CC)CCCC[C@]11NC(N23)=N[C@]4(O[C@H](C)CCC4)[C@@H](C(=O)OCCCCCCCCCCCCCCCC(=O)N(CCCN)C[C@@H](O)CCN)[C@@]3(O)CC[C@H]2C1 DCKFXSZUWVWFEU-JECTWPLRSA-N 0.000 description 1
- 230000000973 chemotherapeutic effect Effects 0.000 description 1
- 150000004035 chlorins Chemical class 0.000 description 1
- 108010076060 chlorofusin Proteins 0.000 description 1
- VQSGYKUTGGRSPK-UHFFFAOYSA-N chlorofusin Natural products N1C(=O)C(CCCCCCCC)NC(=O)C(CC(C)C)NC(=O)C(C(C)O)NC(=O)C(CC(C)C)NC(=O)C(CC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(C)NC(=O)C(C(C)O)NC(=O)C1CCCN1C2(OCCC2)C(O)C2=C(Cl)C(=O)C(C)(OC(=O)CCC)C(=O)C2=C1 VQSGYKUTGGRSPK-UHFFFAOYSA-N 0.000 description 1
- 208000006990 cholangiocarcinoma Diseases 0.000 description 1
- 229960004407 chorionic gonadotrophin Drugs 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- ARUGKOZUKWAXDS-SEWALLKFSA-N cicaprost Chemical compound C1\C(=C/COCC(O)=O)C[C@@H]2[C@@H](C#C[C@@H](O)[C@@H](C)CC#CCC)[C@H](O)C[C@@H]21 ARUGKOZUKWAXDS-SEWALLKFSA-N 0.000 description 1
- 229950000634 cicaprost Drugs 0.000 description 1
- 229950011359 cirolemycin Drugs 0.000 description 1
- JKNIRLKHOOMGOJ-UHFFFAOYSA-N cladochrome D Natural products COC1=C(CC(C)OC(=O)Oc2ccc(O)cc2)c3c4C(=C(OC)C(=O)c5c(O)cc(OC)c(c45)c6c(OC)cc(O)c(C1=O)c36)CC(C)OC(=O)c7ccc(O)cc7 JKNIRLKHOOMGOJ-UHFFFAOYSA-N 0.000 description 1
- SRJYZPCBWDVSGO-UHFFFAOYSA-N cladochrome E Natural products COC1=CC(O)=C(C(C(OC)=C(CC(C)OC(=O)OC=2C=CC(O)=CC=2)C2=3)=O)C2=C1C1=C(OC)C=C(O)C(C(C=2OC)=O)=C1C=3C=2CC(C)OC(=O)C1=CC=CC=C1 SRJYZPCBWDVSGO-UHFFFAOYSA-N 0.000 description 1
- WDQPAMHFFCXSNU-BGABXYSRSA-N clofazimine Chemical compound C12=CC=CC=C2N=C2C=C(NC=3C=CC(Cl)=CC=3)C(=N/C(C)C)/C=C2N1C1=CC=C(Cl)C=C1 WDQPAMHFFCXSNU-BGABXYSRSA-N 0.000 description 1
- 229960004287 clofazimine Drugs 0.000 description 1
- GKIRPKYJQBWNGO-OCEACIFDSA-N clomifene Chemical class C1=CC(OCCN(CC)CC)=CC=C1C(\C=1C=CC=CC=1)=C(\Cl)C1=CC=CC=C1 GKIRPKYJQBWNGO-OCEACIFDSA-N 0.000 description 1
- VNFPBHJOKIVQEB-UHFFFAOYSA-N clotrimazole Chemical compound ClC1=CC=CC=C1C(N1C=NC=C1)(C=1C=CC=CC=1)C1=CC=CC=C1 VNFPBHJOKIVQEB-UHFFFAOYSA-N 0.000 description 1
- 229960004022 clotrimazole Drugs 0.000 description 1
- 238000011260 co-administration Methods 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 201000010897 colon adenocarcinoma Diseases 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 201000010989 colorectal carcinoma Diseases 0.000 description 1
- 238000009096 combination chemotherapy Methods 0.000 description 1
- 238000011220 combination immunotherapy Methods 0.000 description 1
- 229960005537 combretastatin A-4 Drugs 0.000 description 1
- HVXBOLULGPECHP-UHFFFAOYSA-N combretastatin A4 Natural products C1=C(O)C(OC)=CC=C1C=CC1=CC(OC)=C(OC)C(OC)=C1 HVXBOLULGPECHP-UHFFFAOYSA-N 0.000 description 1
- 150000004814 combretastatins Chemical class 0.000 description 1
- GLESHRYLRAOJPS-DHCFDGJBSA-N conagenin Chemical compound C[C@@H](O)[C@H](C)[C@@H](O)C(=O)N[C@@](C)(CO)C(O)=O GLESHRYLRAOJPS-DHCFDGJBSA-N 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 230000001054 cortical effect Effects 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- SBRXTSOCZITGQG-UHFFFAOYSA-N crisnatol Chemical compound C1=CC=C2C(CNC(CO)(CO)C)=CC3=C(C=CC=C4)C4=CC=C3C2=C1 SBRXTSOCZITGQG-UHFFFAOYSA-N 0.000 description 1
- 229950007258 crisnatol Drugs 0.000 description 1
- PSNOPSMXOBPNNV-VVCTWANISA-N cryptophycin 1 Chemical class C1=C(Cl)C(OC)=CC=C1C[C@@H]1C(=O)NC[C@@H](C)C(=O)O[C@@H](CC(C)C)C(=O)O[C@H]([C@H](C)[C@@H]2[C@H](O2)C=2C=CC=CC=2)C/C=C/C(=O)N1 PSNOPSMXOBPNNV-VVCTWANISA-N 0.000 description 1
- YFGZFQNBPSCWPN-UHFFFAOYSA-N cryptophycin 52 Natural products C1=CC(OC)=CC=C1CC1C(=O)NCC(C)C(=O)OC(CC(C)C)C(=O)OC(C(C)C2C(O2)C=2C=CC=CC=2)CC=CC(=O)N1 YFGZFQNBPSCWPN-UHFFFAOYSA-N 0.000 description 1
- 108010090203 cryptophycin 8 Proteins 0.000 description 1
- 238000011461 current therapy Methods 0.000 description 1
- 208000030381 cutaneous melanoma Diseases 0.000 description 1
- KOMDZQSPRDYARS-UHFFFAOYSA-N cyclopenta-1,3-diene titanium Chemical compound [Ti].C1C=CC=C1.C1C=CC=C1 KOMDZQSPRDYARS-UHFFFAOYSA-N 0.000 description 1
- YXQWGVLNDXNSJJ-UHFFFAOYSA-N cyclopenta-1,3-diene;vanadium(2+) Chemical compound [V+2].C=1C=C[CH-]C=1.C=1C=C[CH-]C=1 YXQWGVLNDXNSJJ-UHFFFAOYSA-N 0.000 description 1
- 108010041566 cypemycin Proteins 0.000 description 1
- YJTVZHOYBAOUTO-URBBEOKESA-N cytarabine ocfosfate Chemical compound O[C@H]1[C@H](O)[C@@H](COP(O)(=O)OCCCCCCCCCCCCCCCCCC)O[C@H]1N1C(=O)N=C(N)C=C1 YJTVZHOYBAOUTO-URBBEOKESA-N 0.000 description 1
- 229950006614 cytarabine ocfosfate Drugs 0.000 description 1
- 230000001461 cytolytic effect Effects 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- YCWXIQRLONXJLF-PFFGJIDWSA-N d06307 Chemical compound OS(O)(=O)=O.C([C@]1([C@@H]2O1)CC)N(CCC=1C3=CC=CC=C3NC=11)C[C@H]2C[C@]1(C(=O)OC)C1=CC([C@]23[C@H]([C@@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC.C([C@]1([C@@H]2O1)CC)N(CCC=1C3=CC=CC=C3NC=11)C[C@H]2C[C@]1(C(=O)OC)C1=CC([C@]23[C@H]([C@@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC YCWXIQRLONXJLF-PFFGJIDWSA-N 0.000 description 1
- BFSMGDJOXZAERB-UHFFFAOYSA-N dabrafenib Chemical compound S1C(C(C)(C)C)=NC(C=2C(=C(NS(=O)(=O)C=3C(=CC=CC=3F)F)C=CC=2)F)=C1C1=CC=NC(N)=N1 BFSMGDJOXZAERB-UHFFFAOYSA-N 0.000 description 1
- 229960002465 dabrafenib Drugs 0.000 description 1
- 229960003901 dacarbazine Drugs 0.000 description 1
- 229950002205 dacomitinib Drugs 0.000 description 1
- 229960002448 dasatinib Drugs 0.000 description 1
- 229960003109 daunorubicin hydrochloride Drugs 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- CYQFCXCEBYINGO-IAGOWNOFSA-N delta1-THC Chemical compound C1=C(C)CC[C@H]2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3[C@@H]21 CYQFCXCEBYINGO-IAGOWNOFSA-N 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 108700025485 deslorelin Proteins 0.000 description 1
- 229960005408 deslorelin Drugs 0.000 description 1
- WRPLJTYNAMMOEE-TXILBGFKSA-N desmethyleleutherobin Chemical compound O([C@H]1C[C@H]2C(C)=CC[C@@H]([C@H]2\C=C(CO[C@H]2[C@H]([C@H](O)[C@H](O)CO2)OC(C)=O)/[C@]2(O)O[C@@]1(C)C=C2)C(C)C)C(=O)\C=C\C1=CN(C)C=N1 WRPLJTYNAMMOEE-TXILBGFKSA-N 0.000 description 1
- WRPLJTYNAMMOEE-UHFFFAOYSA-N desmethyleleutherobin Natural products C1=CC2(C)OC1(O)C(COC1C(C(O)C(O)CO1)OC(C)=O)=CC1C(C(C)C)CC=C(C)C1CC2OC(=O)C=CC1=CN(C)C=N1 WRPLJTYNAMMOEE-UHFFFAOYSA-N 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- VPOCYEOOFRNHNL-RQDPQJJXSA-J dexormaplatin Chemical compound Cl[Pt](Cl)(Cl)Cl.N[C@@H]1CCCC[C@H]1N VPOCYEOOFRNHNL-RQDPQJJXSA-J 0.000 description 1
- 229950001640 dexormaplatin Drugs 0.000 description 1
- 229960000605 dexrazoxane Drugs 0.000 description 1
- SGTNSNPWRIOYBX-HHHXNRCGSA-N dexverapamil Chemical compound C1=C(OC)C(OC)=CC=C1CCN(C)CCC[C@@](C#N)(C(C)C)C1=CC=C(OC)C(OC)=C1 SGTNSNPWRIOYBX-HHHXNRCGSA-N 0.000 description 1
- 229950005878 dexverapamil Drugs 0.000 description 1
- 229950010621 dezaguanine Drugs 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- YKBUODYYSZSEIY-PLSHLZFXSA-N diazonamide a Chemical compound N([C@H]([C@]12C=3O4)O5)C6=C2C=CC=C6C(C2=6)=CC=CC=6NC(Cl)=C2C(=C(N=2)Cl)OC=2C=3N=C4[C@H](C(C)C)NC(=O)[C@@H](NC(=O)[C@@H](O)C(C)C)CC2=CC=C5C1=C2 YKBUODYYSZSEIY-PLSHLZFXSA-N 0.000 description 1
- KYHUYMLIVQFXRI-UHFFFAOYSA-N didemnin B Natural products CC1OC(=O)C(CC=2C=CC(OC)=CC=2)N(C)C(=O)C2CCCN2C(=O)C(CC(C)C)NC(=O)C(C)C(=O)C(C(C)C)OC(=O)CC(O)C(C(C)CC)NC(=O)C1NC(=O)C(CC(C)C)N(C)C(=O)C1CCCN1C(=O)C(C)O KYHUYMLIVQFXRI-UHFFFAOYSA-N 0.000 description 1
- 108010061297 didemnins Proteins 0.000 description 1
- PZXJOHSZQAEJFE-UHFFFAOYSA-N dihydrobetulinic acid Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C(C)C)C5C4CCC3C21C PZXJOHSZQAEJFE-UHFFFAOYSA-N 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 230000003467 diminishing effect Effects 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 231100000676 disease causative agent Toxicity 0.000 description 1
- CZLKTMHQYXYHOO-QTNFYWBSSA-L disodium;(2s)-2-[(2-phosphonatoacetyl)amino]butanedioic acid Chemical compound [Na+].[Na+].OC(=O)C[C@@H](C(O)=O)NC(=O)CP([O-])([O-])=O CZLKTMHQYXYHOO-QTNFYWBSSA-L 0.000 description 1
- SVJSWELRJWVPQD-KJWOGLQMSA-L disodium;(2s)-2-[[4-[2-[(6r)-2-amino-4-oxo-5,6,7,8-tetrahydro-1h-pyrido[2,3-d]pyrimidin-6-yl]ethyl]benzoyl]amino]pentanedioate Chemical compound [Na+].[Na+].C([C@@H]1CC=2C(=O)N=C(NC=2NC1)N)CC1=CC=C(C(=O)N[C@@H](CCC([O-])=O)C([O-])=O)C=C1 SVJSWELRJWVPQD-KJWOGLQMSA-L 0.000 description 1
- 239000003534 dna topoisomerase inhibitor Substances 0.000 description 1
- 229960003668 docetaxel Drugs 0.000 description 1
- 229960000735 docosanol Drugs 0.000 description 1
- 229960003413 dolasetron Drugs 0.000 description 1
- 230000002222 downregulating effect Effects 0.000 description 1
- 230000007783 downstream signaling Effects 0.000 description 1
- ZWAOHEXOSAUJHY-ZIYNGMLESA-N doxifluridine Chemical compound O[C@@H]1[C@H](O)[C@@H](C)O[C@H]1N1C(=O)NC(=O)C(F)=C1 ZWAOHEXOSAUJHY-ZIYNGMLESA-N 0.000 description 1
- 229950005454 doxifluridine Drugs 0.000 description 1
- 229960002918 doxorubicin hydrochloride Drugs 0.000 description 1
- NOTIQUSPUUHHEH-UXOVVSIBSA-N dromostanolone propionate Chemical compound C([C@@H]1CC2)C(=O)[C@H](C)C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H](OC(=O)CC)[C@@]2(C)CC1 NOTIQUSPUUHHEH-UXOVVSIBSA-N 0.000 description 1
- 229960004242 dronabinol Drugs 0.000 description 1
- 229950004683 drostanolone propionate Drugs 0.000 description 1
- 229950005133 duazomycin Drugs 0.000 description 1
- 229930192837 duazomycin Natural products 0.000 description 1
- VQNATVDKACXKTF-XELLLNAOSA-N duocarmycin Chemical compound COC1=C(OC)C(OC)=C2NC(C(=O)N3C4=CC(=O)C5=C([C@@]64C[C@@H]6C3)C=C(N5)C(=O)OC)=CC2=C1 VQNATVDKACXKTF-XELLLNAOSA-N 0.000 description 1
- 229960005510 duocarmycin SA Drugs 0.000 description 1
- 229950010033 ebselen Drugs 0.000 description 1
- 229950005678 ecomustine Drugs 0.000 description 1
- FSIRXIHZBIXHKT-MHTVFEQDSA-N edatrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CC(CC)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FSIRXIHZBIXHKT-MHTVFEQDSA-N 0.000 description 1
- 229950006700 edatrexate Drugs 0.000 description 1
- 229950011461 edelfosine Drugs 0.000 description 1
- 229960001776 edrecolomab Drugs 0.000 description 1
- 229960002759 eflornithine Drugs 0.000 description 1
- VLCYCQAOQCDTCN-UHFFFAOYSA-N eflornithine Chemical compound NCCCC(N)(C(F)F)C(O)=O VLCYCQAOQCDTCN-UHFFFAOYSA-N 0.000 description 1
- 229960002046 eflornithine hydrochloride Drugs 0.000 description 1
- 229940121647 egfr inhibitor Drugs 0.000 description 1
- XOPYFXBZMVTEJF-UHFFFAOYSA-N eleutherobin Natural products C1=CC2(OC)OC1(C)C(OC(=O)C=CC=1N=CN(C)C=1)CC(C(=CCC1C(C)C)C)C1C=C2COC1OCC(O)C(O)C1OC(C)=O XOPYFXBZMVTEJF-UHFFFAOYSA-N 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 229940120655 eloxatin Drugs 0.000 description 1
- MGQRRMONVLMKJL-KWJIQSIXSA-N elsamitrucin Chemical compound O1[C@H](C)[C@H](O)[C@H](OC)[C@@H](N)[C@H]1O[C@@H]1[C@](O)(C)[C@@H](O)[C@@H](C)O[C@H]1OC1=CC=CC2=C(O)C(C(O3)=O)=C4C5=C3C=CC(C)=C5C(=O)OC4=C12 MGQRRMONVLMKJL-KWJIQSIXSA-N 0.000 description 1
- 229950002339 elsamitrucin Drugs 0.000 description 1
- 229950005450 emitefur Drugs 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 210000000750 endocrine system Anatomy 0.000 description 1
- JOZGNYDSEBIJDH-UHFFFAOYSA-N eniluracil Chemical compound O=C1NC=C(C#C)C(=O)N1 JOZGNYDSEBIJDH-UHFFFAOYSA-N 0.000 description 1
- 229950010625 enloplatin Drugs 0.000 description 1
- 229950001022 enpromate Drugs 0.000 description 1
- YJGVMLPVUAXIQN-UHFFFAOYSA-N epipodophyllotoxin Natural products COC1=C(OC)C(OC)=CC(C2C3=CC=4OCOC=4C=C3C(O)C3C2C(OC3)=O)=C1 YJGVMLPVUAXIQN-UHFFFAOYSA-N 0.000 description 1
- 229950004926 epipropidine Drugs 0.000 description 1
- 229960003265 epirubicin hydrochloride Drugs 0.000 description 1
- 229930013356 epothilone Natural products 0.000 description 1
- QXRSDHAAWVKZLJ-PVYNADRNSA-N epothilone B Chemical compound C/C([C@@H]1C[C@@H]2O[C@]2(C)CCC[C@@H]([C@@H]([C@@H](C)C(=O)C(C)(C)[C@@H](O)CC(=O)O1)O)C)=C\C1=CSC(C)=N1 QXRSDHAAWVKZLJ-PVYNADRNSA-N 0.000 description 1
- FCCNKYGSMOSYPV-UHFFFAOYSA-N epothilone E Natural products O1C(=O)CC(O)C(C)(C)C(=O)C(C)C(O)C(C)CCCC2OC2CC1C(C)=CC1=CSC(CO)=N1 FCCNKYGSMOSYPV-UHFFFAOYSA-N 0.000 description 1
- FCCNKYGSMOSYPV-OKOHHBBGSA-N epothilone e Chemical compound C/C([C@@H]1C[C@@H]2O[C@@H]2CCC[C@@H]([C@@H]([C@@H](C)C(=O)C(C)(C)[C@@H](O)CC(=O)O1)O)C)=C\C1=CSC(CO)=N1 FCCNKYGSMOSYPV-OKOHHBBGSA-N 0.000 description 1
- UKIMCRYGLFQEOE-RGJAOAFDSA-N epothilone f Chemical compound C/C([C@@H]1C[C@@H]2O[C@]2(C)CCC[C@@H]([C@@H]([C@@H](C)C(=O)C(C)(C)[C@@H](O)CC(=O)O1)O)C)=C\C1=CSC(CO)=N1 UKIMCRYGLFQEOE-RGJAOAFDSA-N 0.000 description 1
- 229950009537 epristeride Drugs 0.000 description 1
- 201000004101 esophageal cancer Diseases 0.000 description 1
- 201000005619 esophageal carcinoma Diseases 0.000 description 1
- 229960001842 estramustine Drugs 0.000 description 1
- 229960001766 estramustine phosphate sodium Drugs 0.000 description 1
- IIUMCNJTGSMNRO-VVSKJQCTSA-L estramustine sodium phosphate Chemical compound [Na+].[Na+].ClCCN(CCCl)C(=O)OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)OP([O-])([O-])=O)[C@@H]4[C@@H]3CCC2=C1 IIUMCNJTGSMNRO-VVSKJQCTSA-L 0.000 description 1
- HYSIJEPDMLSIQJ-UHFFFAOYSA-N ethanolate;1-phenylbutane-1,3-dione;titanium(4+) Chemical compound [Ti+4].CC[O-].CC[O-].CC(=O)[CH-]C(=O)C1=CC=CC=C1.CC(=O)[CH-]C(=O)C1=CC=CC=C1 HYSIJEPDMLSIQJ-UHFFFAOYSA-N 0.000 description 1
- 229960002568 ethinylestradiol Drugs 0.000 description 1
- XPGDODOEEWLHOI-GSDHBNRESA-N ethyl (2s)-2-[[(2s)-2-[[(2s)-2-amino-3-(4-fluorophenyl)propanoyl]amino]-3-[3-[bis(2-chloroethyl)amino]phenyl]propanoyl]amino]-4-methylsulfanylbutanoate Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(=O)OCC)NC(=O)[C@@H](N)CC=1C=CC(F)=CC=1)C1=CC=CC(N(CCCl)CCCl)=C1 XPGDODOEEWLHOI-GSDHBNRESA-N 0.000 description 1
- VFRSADQPWYCXDG-LEUCUCNGSA-N ethyl (2s,5s)-5-methylpyrrolidine-2-carboxylate;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.CCOC(=O)[C@@H]1CC[C@H](C)N1 VFRSADQPWYCXDG-LEUCUCNGSA-N 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- HZQPPNNARUQMJA-IMIWJGOWSA-N ethyl n-[4-[[(2r,4r)-2-(2,4-dichlorophenyl)-2-(imidazol-1-ylmethyl)-1,3-dioxolan-4-yl]methylsulfanyl]phenyl]carbamate;hydrochloride Chemical compound Cl.C1=CC(NC(=O)OCC)=CC=C1SC[C@@H]1O[C@@](CN2C=NC=C2)(C=2C(=CC(Cl)=CC=2)Cl)OC1 HZQPPNNARUQMJA-IMIWJGOWSA-N 0.000 description 1
- ISVXIZFUEUVXPG-UHFFFAOYSA-N etiopurpurin Chemical compound CC1C2(CC)C(C(=O)OCC)=CC(C3=NC(C(=C3C)CC)=C3)=C2N=C1C=C(N1)C(CC)=C(C)C1=CC1=C(CC)C(C)=C3N1 ISVXIZFUEUVXPG-UHFFFAOYSA-N 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000017188 evasion or tolerance of host immune response Effects 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 229960000255 exemestane Drugs 0.000 description 1
- 210000003020 exocrine pancreas Anatomy 0.000 description 1
- 208000021045 exocrine pancreatic carcinoma Diseases 0.000 description 1
- 239000002095 exotoxin Substances 0.000 description 1
- 231100000776 exotoxin Toxicity 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 229960004177 filgrastim Drugs 0.000 description 1
- 229950006000 flezelastine Drugs 0.000 description 1
- 229960000961 floxuridine Drugs 0.000 description 1
- ODKNJVUHOIMIIZ-RRKCRQDMSA-N floxuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(F)=C1 ODKNJVUHOIMIIZ-RRKCRQDMSA-N 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 229960001751 fluoxymesterone Drugs 0.000 description 1
- YLRFCQOZQXIBAB-RBZZARIASA-N fluoxymesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1CC[C@](C)(O)[C@@]1(C)C[C@@H]2O YLRFCQOZQXIBAB-RBZZARIASA-N 0.000 description 1
- 229960002074 flutamide Drugs 0.000 description 1
- MKXKFYHWDHIYRV-UHFFFAOYSA-N flutamide Chemical compound CC(C)C(=O)NC1=CC=C([N+]([O-])=O)C(C(F)(F)F)=C1 MKXKFYHWDHIYRV-UHFFFAOYSA-N 0.000 description 1
- 150000002224 folic acids Chemical class 0.000 description 1
- 229950004217 forfenimex Drugs 0.000 description 1
- 229960004421 formestane Drugs 0.000 description 1
- OSVMTWJCGUFAOD-KZQROQTASA-N formestane Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1O OSVMTWJCGUFAOD-KZQROQTASA-N 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- UXTSQCOOUJTIAC-UHFFFAOYSA-N fosquidone Chemical compound C=1N2CC3=CC=CC=C3C(C)C2=C(C(C2=CC=C3)=O)C=1C(=O)C2=C3OP(O)(=O)OCC1=CC=CC=C1 UXTSQCOOUJTIAC-UHFFFAOYSA-N 0.000 description 1
- 229950005611 fosquidone Drugs 0.000 description 1
- 229950010404 fostriecin Drugs 0.000 description 1
- 229960004783 fotemustine Drugs 0.000 description 1
- YAKWPXVTIGTRJH-UHFFFAOYSA-N fotemustine Chemical compound CCOP(=O)(OCC)C(C)NC(=O)N(CCCl)N=O YAKWPXVTIGTRJH-UHFFFAOYSA-N 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 229940044658 gallium nitrate Drugs 0.000 description 1
- 229950004410 galocitabine Drugs 0.000 description 1
- 108700032141 ganirelix Proteins 0.000 description 1
- 229960003794 ganirelix Drugs 0.000 description 1
- GJNXBNATEDXMAK-PFLSVRRQSA-N ganirelix Chemical compound C([C@@H](C(=O)N[C@H](CCCCN=C(NCC)NCC)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN=C(NCC)NCC)C(=O)N1[C@@H](CCC1)C(=O)N[C@H](C)C(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](CC=1C=NC=CC=1)NC(=O)[C@@H](CC=1C=CC(Cl)=CC=1)NC(=O)[C@@H](CC=1C=C2C=CC=CC2=CC=1)NC(C)=O)C1=CC=C(O)C=C1 GJNXBNATEDXMAK-PFLSVRRQSA-N 0.000 description 1
- 201000006585 gastric adenocarcinoma Diseases 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000002406 gelatinase inhibitor Substances 0.000 description 1
- QTQAWLPCGQOSGP-GBTDJJJQSA-N geldanamycin Chemical compound N1C(=O)\C(C)=C/C=C\[C@@H](OC)[C@H](OC(N)=O)\C(C)=C/[C@@H](C)[C@@H](O)[C@H](OC)C[C@@H](C)CC2=C(OC)C(=O)C=C1C2=O QTQAWLPCGQOSGP-GBTDJJJQSA-N 0.000 description 1
- 229960005144 gemcitabine hydrochloride Drugs 0.000 description 1
- 230000004547 gene signature Effects 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- 229940080856 gleevec Drugs 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- XLXSAKCOAKORKW-AQJXLSMYSA-N gonadorelin Chemical compound C([C@@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 XLXSAKCOAKORKW-AQJXLSMYSA-N 0.000 description 1
- 229940035638 gonadotropin-releasing hormone Drugs 0.000 description 1
- 229960002913 goserelin Drugs 0.000 description 1
- FXNFULJVOQMBCW-VZBLNRDYSA-N halichondrin b Chemical compound O([C@@H]1[C@@H](C)[C@@H]2O[C@@H]3C[C@@]4(O[C@H]5[C@@H](C)C[C@@]6(C[C@@H]([C@@H]7O[C@@H](C[C@@H]7O6)[C@@H](O)C[C@@H](O)CO)C)O[C@H]5C4)O[C@@H]3C[C@@H]2O[C@H]1C[C@@H]1C(=C)[C@H](C)C[C@@H](O1)CC[C@H]1C(=C)C[C@@H](O1)CC1)C(=O)C[C@H](O2)CC[C@H]3[C@H]2[C@H](O2)[C@@H]4O[C@@H]5C[C@@]21O[C@@H]5[C@@H]4O3 FXNFULJVOQMBCW-VZBLNRDYSA-N 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 208000014829 head and neck neoplasm Diseases 0.000 description 1
- 201000000459 head and neck squamous cell carcinoma Diseases 0.000 description 1
- 230000003862 health status Effects 0.000 description 1
- 101150055960 hemB gene Proteins 0.000 description 1
- 108010057806 hemiasterlin Proteins 0.000 description 1
- 229930187626 hemiasterlin Natural products 0.000 description 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 1
- HYFHYPWGAURHIV-UHFFFAOYSA-N homoharringtonine Natural products C1=C2CCN3CCCC43C=C(OC)C(OC(=O)C(O)(CCCC(C)(C)O)CC(=O)OC)C4C2=CC2=C1OCO2 HYFHYPWGAURHIV-UHFFFAOYSA-N 0.000 description 1
- SOCGJDYHNGLZEC-UHFFFAOYSA-N hydron;n-methyl-n-[4-[(7-methyl-3h-imidazo[4,5-f]quinolin-9-yl)amino]phenyl]acetamide;chloride Chemical compound Cl.C1=CC(N(C(C)=O)C)=CC=C1NC1=CC(C)=NC2=CC=C(NC=N3)C3=C12 SOCGJDYHNGLZEC-UHFFFAOYSA-N 0.000 description 1
- 229950000801 hydroxyprogesterone caproate Drugs 0.000 description 1
- 230000000148 hypercalcaemia Effects 0.000 description 1
- 208000030915 hypercalcemia disease Diseases 0.000 description 1
- BTXNYTINYBABQR-UHFFFAOYSA-N hypericin Chemical compound C12=C(O)C=C(O)C(C(C=3C(O)=CC(C)=C4C=33)=O)=C2C3=C2C3=C4C(C)=CC(O)=C3C(=O)C3=C(O)C=C(O)C1=C32 BTXNYTINYBABQR-UHFFFAOYSA-N 0.000 description 1
- 229940005608 hypericin Drugs 0.000 description 1
- PHOKTTKFQUYZPI-UHFFFAOYSA-N hypericin Natural products Cc1cc(O)c2c3C(=O)C(=Cc4c(O)c5c(O)cc(O)c6c7C(=O)C(=Cc8c(C)c1c2c(c78)c(c34)c56)O)O PHOKTTKFQUYZPI-UHFFFAOYSA-N 0.000 description 1
- 229960005236 ibandronic acid Drugs 0.000 description 1
- 229960000908 idarubicin Drugs 0.000 description 1
- 229960001176 idarubicin hydrochloride Drugs 0.000 description 1
- 229950002248 idoxifene Drugs 0.000 description 1
- TZBDEVBNMSLVKT-UHFFFAOYSA-N idramantone Chemical compound C1C(C2)CC3CC1(O)CC2C3=O TZBDEVBNMSLVKT-UHFFFAOYSA-N 0.000 description 1
- 229950009926 idramantone Drugs 0.000 description 1
- 229950006905 ilmofosine Drugs 0.000 description 1
- NITYDPDXAAFEIT-DYVFJYSZSA-N ilomastat Chemical compound C1=CC=C2C(C[C@@H](C(=O)NC)NC(=O)[C@H](CC(C)C)CC(=O)NO)=CNC2=C1 NITYDPDXAAFEIT-DYVFJYSZSA-N 0.000 description 1
- 229960003696 ilomastat Drugs 0.000 description 1
- 229960002751 imiquimod Drugs 0.000 description 1
- DOUYETYNHWVLEO-UHFFFAOYSA-N imiquimod Chemical compound C1=CC=CC2=C3N(CC(C)C)C=NC3=C(N)N=C21 DOUYETYNHWVLEO-UHFFFAOYSA-N 0.000 description 1
- 230000005965 immune activity Effects 0.000 description 1
- 230000005931 immune cell recruitment Effects 0.000 description 1
- 230000008629 immune suppression Effects 0.000 description 1
- 238000010166 immunofluorescence Methods 0.000 description 1
- 238000003364 immunohistochemistry Methods 0.000 description 1
- 230000002637 immunotoxin Effects 0.000 description 1
- 229940051026 immunotoxin Drugs 0.000 description 1
- 239000002596 immunotoxin Substances 0.000 description 1
- 231100000608 immunotoxin Toxicity 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000000415 inactivating effect Effects 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 108091022911 insulin-like growth factor binding Proteins 0.000 description 1
- 102000028416 insulin-like growth factor binding Human genes 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 229960003521 interferon alfa-2a Drugs 0.000 description 1
- 229960003507 interferon alfa-2b Drugs 0.000 description 1
- 229960004061 interferon alfa-n1 Drugs 0.000 description 1
- 108010006088 interferon alfa-n1 Proteins 0.000 description 1
- 229940109242 interferon alfa-n3 Drugs 0.000 description 1
- 229960004461 interferon beta-1a Drugs 0.000 description 1
- 108010042414 interferon gamma-1b Proteins 0.000 description 1
- 229940028862 interferon gamma-1b Drugs 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000007917 intracranial administration Methods 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 230000002601 intratumoral effect Effects 0.000 description 1
- 238000007914 intraventricular administration Methods 0.000 description 1
- 208000024312 invasive carcinoma Diseases 0.000 description 1
- VBUWHHLIZKOSMS-RIWXPGAOSA-N invicorp Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)C(C)C)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=C(O)C=C1 VBUWHHLIZKOSMS-RIWXPGAOSA-N 0.000 description 1
- 229960003795 iobenguane (123i) Drugs 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 229950010897 iproplatin Drugs 0.000 description 1
- 229960000779 irinotecan hydrochloride Drugs 0.000 description 1
- 229950000855 iroplact Drugs 0.000 description 1
- 229950010984 irsogladine Drugs 0.000 description 1
- 210000004153 islets of langerhan Anatomy 0.000 description 1
- RWXRJSRJIITQAK-ZSBIGDGJSA-N itasetron Chemical compound C12=CC=CC=C2NC(=O)N1C(=O)N[C@H](C1)C[C@H]2CC[C@@H]1N2C RWXRJSRJIITQAK-ZSBIGDGJSA-N 0.000 description 1
- 229950007654 itasetron Drugs 0.000 description 1
- 229960004130 itraconazole Drugs 0.000 description 1
- FABUFPQFXZVHFB-PVYNADRNSA-N ixabepilone Chemical compound C/C([C@@H]1C[C@@H]2O[C@]2(C)CCC[C@@H]([C@@H]([C@@H](C)C(=O)C(C)(C)[C@@H](O)CC(=O)N1)O)C)=C\C1=CSC(C)=N1 FABUFPQFXZVHFB-PVYNADRNSA-N 0.000 description 1
- GQWYWHOHRVVHAP-DHKPLNAMSA-N jaspamide Chemical compound C1([C@@H]2NC(=O)[C@@H](CC=3C4=CC=CC=C4NC=3Br)N(C)C(=O)[C@H](C)NC(=O)[C@@H](C)C/C(C)=C/[C@H](C)C[C@@H](OC(=O)C2)C)=CC=C(O)C=C1 GQWYWHOHRVVHAP-DHKPLNAMSA-N 0.000 description 1
- 108010052440 jasplakinolide Proteins 0.000 description 1
- GQWYWHOHRVVHAP-UHFFFAOYSA-N jasplakinolide Natural products C1C(=O)OC(C)CC(C)C=C(C)CC(C)C(=O)NC(C)C(=O)N(C)C(CC=2C3=CC=CC=C3NC=2Br)C(=O)NC1C1=CC=C(O)C=C1 GQWYWHOHRVVHAP-UHFFFAOYSA-N 0.000 description 1
- 235000015110 jellies Nutrition 0.000 description 1
- 108010091711 kahalalide F Proteins 0.000 description 1
- 108010011989 karyopherin alpha 2 Proteins 0.000 description 1
- 101150044508 key gene Proteins 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 229940043355 kinase inhibitor Drugs 0.000 description 1
- 229960002437 lanreotide Drugs 0.000 description 1
- 229960001739 lanreotide acetate Drugs 0.000 description 1
- 229960004891 lapatinib Drugs 0.000 description 1
- BCFGMOOMADDAQU-UHFFFAOYSA-N lapatinib Chemical compound O1C(CNCCS(=O)(=O)C)=CC=C1C1=CC=C(N=CN=C2NC=3C=C(Cl)C(OCC=4C=C(F)C=CC=4)=CC=3)C2=C1 BCFGMOOMADDAQU-UHFFFAOYSA-N 0.000 description 1
- 229960002618 lenograstim Drugs 0.000 description 1
- 229940115286 lentinan Drugs 0.000 description 1
- KDQAABAKXDWYSZ-SDCRJXSCSA-N leurosidine sulfate Chemical compound OS(O)(=O)=O.C([C@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 KDQAABAKXDWYSZ-SDCRJXSCSA-N 0.000 description 1
- UGFHIPBXIWJXNA-UHFFFAOYSA-N liarozole Chemical compound ClC1=CC=CC(C(C=2C=C3NC=NC3=CC=2)N2C=NC=C2)=C1 UGFHIPBXIWJXNA-UHFFFAOYSA-N 0.000 description 1
- 229950007056 liarozole Drugs 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 108010020270 lissoclinamide 7 Proteins 0.000 description 1
- RBBBWKUBQVARPL-SWQMWMPHSA-N lissoclinamide 7 Chemical compound C([C@H]1C(=O)N2CCC[C@H]2C2=N[C@@H]([C@H](O2)C)C(=O)N[C@@H](C=2SC[C@H](N=2)C(=O)N[C@H](CC=2C=CC=CC=2)C=2SC[C@H](N=2)C(=O)N1)C(C)C)C1=CC=CC=C1 RBBBWKUBQVARPL-SWQMWMPHSA-N 0.000 description 1
- RBBBWKUBQVARPL-UHFFFAOYSA-N lissoclinamide 7 Natural products N1C(=O)C(N=2)CSC=2C(CC=2C=CC=CC=2)NC(=O)C(N=2)CSC=2C(C(C)C)NC(=O)C(C(O2)C)N=C2C2CCCN2C(=O)C1CC1=CC=CC=C1 RBBBWKUBQVARPL-UHFFFAOYSA-N 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 229950008991 lobaplatin Drugs 0.000 description 1
- 238000007477 logistic regression Methods 0.000 description 1
- 229950000909 lometrexol Drugs 0.000 description 1
- 229960002247 lomustine Drugs 0.000 description 1
- 229960003538 lonidamine Drugs 0.000 description 1
- WDRYRZXSPDWGEB-UHFFFAOYSA-N lonidamine Chemical compound C12=CC=CC=C2C(C(=O)O)=NN1CC1=CC=C(Cl)C=C1Cl WDRYRZXSPDWGEB-UHFFFAOYSA-N 0.000 description 1
- YROQEQPFUCPDCP-UHFFFAOYSA-N losoxantrone Chemical compound OCCNCCN1N=C2C3=CC=CC(O)=C3C(=O)C3=C2C1=CC=C3NCCNCCO YROQEQPFUCPDCP-UHFFFAOYSA-N 0.000 description 1
- 229950008745 losoxantrone Drugs 0.000 description 1
- XDMHALQMTPSGEA-UHFFFAOYSA-N losoxantrone hydrochloride Chemical compound Cl.Cl.OCCNCCN1N=C2C3=CC=CC(O)=C3C(=O)C3=C2C1=CC=C3NCCNCCO XDMHALQMTPSGEA-UHFFFAOYSA-N 0.000 description 1
- 229960004844 lovastatin Drugs 0.000 description 1
- PCZOHLXUXFIOCF-BXMDZJJMSA-N lovastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 PCZOHLXUXFIOCF-BXMDZJJMSA-N 0.000 description 1
- QLJODMDSTUBWDW-UHFFFAOYSA-N lovastatin hydroxy acid Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(C)C=C21 QLJODMDSTUBWDW-UHFFFAOYSA-N 0.000 description 1
- 229950005634 loxoribine Drugs 0.000 description 1
- 238000009593 lumbar puncture Methods 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 201000005249 lung adenocarcinoma Diseases 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 201000005243 lung squamous cell carcinoma Diseases 0.000 description 1
- RVFGKBWWUQOIOU-NDEPHWFRSA-N lurtotecan Chemical compound O=C([C@]1(O)CC)OCC(C(N2CC3=4)=O)=C1C=C2C3=NC1=CC=2OCCOC=2C=C1C=4CN1CCN(C)CC1 RVFGKBWWUQOIOU-NDEPHWFRSA-N 0.000 description 1
- 229950002654 lurtotecan Drugs 0.000 description 1
- 230000002101 lytic effect Effects 0.000 description 1
- 102100033718 m7GpppX diphosphatase Human genes 0.000 description 1
- 229940124302 mTOR inhibitor Drugs 0.000 description 1
- 201000000564 macroglobulinemia Diseases 0.000 description 1
- 229950001474 maitansine Drugs 0.000 description 1
- 239000003628 mammalian target of rapamycin inhibitor Substances 0.000 description 1
- BLOFGONIVNXZME-YDMGZANHSA-N mannostatin A Chemical compound CS[C@@H]1[C@@H](N)[C@@H](O)[C@@H](O)[C@H]1O BLOFGONIVNXZME-YDMGZANHSA-N 0.000 description 1
- 229950008959 marimastat Drugs 0.000 description 1
- OCSMOTCMPXTDND-OUAUKWLOSA-N marimastat Chemical compound CNC(=O)[C@H](C(C)(C)C)NC(=O)[C@H](CC(C)C)[C@H](O)C(=O)NO OCSMOTCMPXTDND-OUAUKWLOSA-N 0.000 description 1
- 238000013178 mathematical model Methods 0.000 description 1
- 239000003771 matrix metalloproteinase inhibitor Substances 0.000 description 1
- 229940121386 matrix metalloproteinase inhibitor Drugs 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 229960004961 mechlorethamine Drugs 0.000 description 1
- 229960002868 mechlorethamine hydrochloride Drugs 0.000 description 1
- QZIQJVCYUQZDIR-UHFFFAOYSA-N mechlorethamine hydrochloride Chemical compound Cl.ClCCN(C)CCCl QZIQJVCYUQZDIR-UHFFFAOYSA-N 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 230000005541 medical transmission Effects 0.000 description 1
- 229960002985 medroxyprogesterone acetate Drugs 0.000 description 1
- PSGAAPLEWMOORI-PEINSRQWSA-N medroxyprogesterone acetate Chemical compound C([C@@]12C)CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2CC[C@]2(C)[C@@](OC(C)=O)(C(C)=O)CC[C@H]21 PSGAAPLEWMOORI-PEINSRQWSA-N 0.000 description 1
- 229960003846 melengestrol acetate Drugs 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 108700025096 meterelin Proteins 0.000 description 1
- KPQJSSLKKBKWEW-RKDOVGOJSA-N methanesulfonic acid;5-nitro-2-[(2r)-1-[2-[[(2r)-2-(5-nitro-1,3-dioxobenzo[de]isoquinolin-2-yl)propyl]amino]ethylamino]propan-2-yl]benzo[de]isoquinoline-1,3-dione Chemical compound CS(O)(=O)=O.CS(O)(=O)=O.[O-][N+](=O)C1=CC(C(N([C@@H](CNCCNC[C@@H](C)N2C(C=3C=C(C=C4C=CC=C(C=34)C2=O)[N+]([O-])=O)=O)C)C2=O)=O)=C3C2=CC=CC3=C1 KPQJSSLKKBKWEW-RKDOVGOJSA-N 0.000 description 1
- 125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 description 1
- BKBBTCORRZMASO-ZOWNYOTGSA-M methotrexate monosodium Chemical compound [Na+].C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C([O-])=O)C=C1 BKBBTCORRZMASO-ZOWNYOTGSA-M 0.000 description 1
- 229960003058 methotrexate sodium Drugs 0.000 description 1
- 229960004503 metoclopramide Drugs 0.000 description 1
- TTWJBBZEZQICBI-UHFFFAOYSA-N metoclopramide Chemical compound CCN(CC)CCNC(=O)C1=CC(Cl)=C(N)C=C1OC TTWJBBZEZQICBI-UHFFFAOYSA-N 0.000 description 1
- VQJHOPSWBGJHQS-UHFFFAOYSA-N metoprine, methodichlorophen Chemical compound CC1=NC(N)=NC(N)=C1C1=CC=C(Cl)C(Cl)=C1 VQJHOPSWBGJHQS-UHFFFAOYSA-N 0.000 description 1
- QTFKTBRIGWJQQL-UHFFFAOYSA-N meturedepa Chemical compound C1C(C)(C)N1P(=O)(NC(=O)OCC)N1CC1(C)C QTFKTBRIGWJQQL-UHFFFAOYSA-N 0.000 description 1
- 229950009847 meturedepa Drugs 0.000 description 1
- HPNSFSBZBAHARI-UHFFFAOYSA-N micophenolic acid Natural products OC1=C(CC=C(C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-UHFFFAOYSA-N 0.000 description 1
- 210000004688 microtubule Anatomy 0.000 description 1
- 229950010895 midostaurin Drugs 0.000 description 1
- 229960003248 mifepristone Drugs 0.000 description 1
- VKHAHZOOUSRJNA-GCNJZUOMSA-N mifepristone Chemical compound C1([C@@H]2C3=C4CCC(=O)C=C4CC[C@H]3[C@@H]3CC[C@@]([C@]3(C2)C)(O)C#CC)=CC=C(N(C)C)C=C1 VKHAHZOOUSRJNA-GCNJZUOMSA-N 0.000 description 1
- 229960003775 miltefosine Drugs 0.000 description 1
- PQLXHQMOHUQAKB-UHFFFAOYSA-N miltefosine Chemical compound CCCCCCCCCCCCCCCCOP([O-])(=O)OCC[N+](C)(C)C PQLXHQMOHUQAKB-UHFFFAOYSA-N 0.000 description 1
- 229950008541 mirimostim Drugs 0.000 description 1
- DRCJGCOYHLTVNR-ZUIZSQJWSA-N mitindomide Chemical compound C1=C[C@@H]2[C@@H]3[C@H]4C(=O)NC(=O)[C@H]4[C@@H]3[C@H]1[C@@H]1C(=O)NC(=O)[C@H]21 DRCJGCOYHLTVNR-ZUIZSQJWSA-N 0.000 description 1
- 229950001314 mitindomide Drugs 0.000 description 1
- 229950002137 mitocarcin Drugs 0.000 description 1
- 229950000911 mitogillin Drugs 0.000 description 1
- 229960003539 mitoguazone Drugs 0.000 description 1
- MXWHMTNPTTVWDM-NXOFHUPFSA-N mitoguazone Chemical compound NC(N)=N\N=C(/C)\C=N\N=C(N)N MXWHMTNPTTVWDM-NXOFHUPFSA-N 0.000 description 1
- VFKZTMPDYBFSTM-GUCUJZIJSA-N mitolactol Chemical compound BrC[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)CBr VFKZTMPDYBFSTM-GUCUJZIJSA-N 0.000 description 1
- 229950010913 mitolactol Drugs 0.000 description 1
- 108010026677 mitomalcin Proteins 0.000 description 1
- 229950007612 mitomalcin Drugs 0.000 description 1
- 229950001745 mitonafide Drugs 0.000 description 1
- 229950005715 mitosper Drugs 0.000 description 1
- ZAHQPTJLOCWVPG-UHFFFAOYSA-N mitoxantrone dihydrochloride Chemical compound Cl.Cl.O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO ZAHQPTJLOCWVPG-UHFFFAOYSA-N 0.000 description 1
- 229960004169 mitoxantrone hydrochloride Drugs 0.000 description 1
- 108091005601 modified peptides Proteins 0.000 description 1
- 229950008012 mofarotene Drugs 0.000 description 1
- VOWOEBADKMXUBU-UHFFFAOYSA-J molecular oxygen;tetrachlorite;hydrate Chemical compound O.O=O.[O-]Cl=O.[O-]Cl=O.[O-]Cl=O.[O-]Cl=O VOWOEBADKMXUBU-UHFFFAOYSA-J 0.000 description 1
- 230000003990 molecular pathway Effects 0.000 description 1
- 108010032806 molgramostim Proteins 0.000 description 1
- 229960003063 molgramostim Drugs 0.000 description 1
- HDZGCSFEDULWCS-UHFFFAOYSA-N monomethylhydrazine Chemical class CNN HDZGCSFEDULWCS-UHFFFAOYSA-N 0.000 description 1
- 229940035032 monophosphoryl lipid a Drugs 0.000 description 1
- FOYWNSCCNCUEPU-UHFFFAOYSA-N mopidamol Chemical compound C12=NC(N(CCO)CCO)=NC=C2N=C(N(CCO)CCO)N=C1N1CCCCC1 FOYWNSCCNCUEPU-UHFFFAOYSA-N 0.000 description 1
- 229950010718 mopidamol Drugs 0.000 description 1
- 230000001002 morphogenetic effect Effects 0.000 description 1
- AARXZCZYLAFQQU-UHFFFAOYSA-N motexafin gadolinium Chemical compound [Gd].CC(O)=O.CC(O)=O.C1=C([N-]2)C(CC)=C(CC)C2=CC(C(=C2C)CCCO)=NC2=CN=C2C=C(OCCOCCOCCOC)C(OCCOCCOCCOC)=CC2=NC=C2C(C)=C(CCCO)C1=N2 AARXZCZYLAFQQU-UHFFFAOYSA-N 0.000 description 1
- WIQKYZYFTAEWBF-UHFFFAOYSA-L motexafin lutetium hydrate Chemical compound O.[Lu+3].CC([O-])=O.CC([O-])=O.C1=C([N-]2)C(CC)=C(CC)C2=CC(C(=C2C)CCCO)=NC2=CN=C2C=C(OCCOCCOCCOC)C(OCCOCCOCCOC)=CC2=NC=C2C(C)=C(CCCO)C1=N2 WIQKYZYFTAEWBF-UHFFFAOYSA-L 0.000 description 1
- 235000010460 mustard Nutrition 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 230000000869 mutational effect Effects 0.000 description 1
- 229960000951 mycophenolic acid Drugs 0.000 description 1
- HPNSFSBZBAHARI-RUDMXATFSA-N mycophenolic acid Chemical compound OC1=C(C\C=C(/C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-RUDMXATFSA-N 0.000 description 1
- PAVKBQLPQCDVNI-UHFFFAOYSA-N n',n'-diethyl-n-(9-methoxy-5,11-dimethyl-6h-pyrido[4,3-b]carbazol-1-yl)propane-1,3-diamine Chemical compound N1C2=CC=C(OC)C=C2C2=C1C(C)=C1C=CN=C(NCCCN(CC)CC)C1=C2C PAVKBQLPQCDVNI-UHFFFAOYSA-N 0.000 description 1
- CRJGESKKUOMBCT-PMACEKPBSA-N n-[(2s,3s)-1,3-dihydroxyoctadecan-2-yl]acetamide Chemical compound CCCCCCCCCCCCCCC[C@H](O)[C@H](CO)NC(C)=O CRJGESKKUOMBCT-PMACEKPBSA-N 0.000 description 1
- NKFHKYQGZDAKMX-PPRKPIOESA-N n-[(e)-1-[(2s,4s)-4-[(2r,4s,5s,6s)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-2,5,12-trihydroxy-7-methoxy-6,11-dioxo-3,4-dihydro-1h-tetracen-2-yl]ethylideneamino]benzamide;hydrochloride Chemical compound Cl.O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(\C)=N\NC(=O)C=1C=CC=CC=1)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 NKFHKYQGZDAKMX-PPRKPIOESA-N 0.000 description 1
- TVYPSLDUBVTDIS-FUOMVGGVSA-N n-[1-[(2r,3r,4s,5r)-3,4-dihydroxy-5-methyloxolan-2-yl]-5-fluoro-2-oxopyrimidin-4-yl]-3,4,5-trimethoxybenzamide Chemical compound COC1=C(OC)C(OC)=CC(C(=O)NC=2C(=CN(C(=O)N=2)[C@H]2[C@@H]([C@H](O)[C@@H](C)O2)O)F)=C1 TVYPSLDUBVTDIS-FUOMVGGVSA-N 0.000 description 1
- ZYQXEVJIFYIBHZ-UHFFFAOYSA-N n-[2-[4-[3-chloro-4-[3-(trifluoromethyl)phenoxy]anilino]pyrrolo[3,2-d]pyrimidin-5-yl]ethyl]-3-hydroxy-3-methylbutanamide Chemical compound C=12N(CCNC(=O)CC(C)(O)C)C=CC2=NC=NC=1NC(C=C1Cl)=CC=C1OC1=CC=CC(C(F)(F)F)=C1 ZYQXEVJIFYIBHZ-UHFFFAOYSA-N 0.000 description 1
- RDSACQWTXKSHJT-NSHDSACASA-N n-[3,4-difluoro-2-(2-fluoro-4-iodoanilino)-6-methoxyphenyl]-1-[(2s)-2,3-dihydroxypropyl]cyclopropane-1-sulfonamide Chemical compound C1CC1(C[C@H](O)CO)S(=O)(=O)NC=1C(OC)=CC(F)=C(F)C=1NC1=CC=C(I)C=C1F RDSACQWTXKSHJT-NSHDSACASA-N 0.000 description 1
- ARKYUICTMUZVEW-UHFFFAOYSA-N n-[5-[[5-[(3-amino-3-iminopropyl)carbamoyl]-1-methylpyrrol-3-yl]carbamoyl]-1-methylpyrrol-3-yl]-4-[[4-[bis(2-chloroethyl)amino]benzoyl]amino]-1-methylpyrrole-2-carboxamide Chemical compound C1=C(C(=O)NCCC(N)=N)N(C)C=C1NC(=O)C1=CC(NC(=O)C=2N(C=C(NC(=O)C=3C=CC(=CC=3)N(CCCl)CCCl)C=2)C)=CN1C ARKYUICTMUZVEW-UHFFFAOYSA-N 0.000 description 1
- JNGQUJZDVFZPEN-UHFFFAOYSA-N n-[[4-(5-bromopyrimidin-2-yl)oxy-3-methylphenyl]carbamoyl]-2-(dimethylamino)benzamide Chemical compound CN(C)C1=CC=CC=C1C(=O)NC(=O)NC(C=C1C)=CC=C1OC1=NC=C(Br)C=N1 JNGQUJZDVFZPEN-UHFFFAOYSA-N 0.000 description 1
- UMJJGDUYVQCBMC-UHFFFAOYSA-N n-ethyl-n'-[3-[3-(ethylamino)propylamino]propyl]propane-1,3-diamine Chemical compound CCNCCCNCCCNCCCNCC UMJJGDUYVQCBMC-UHFFFAOYSA-N 0.000 description 1
- WRINSSLBPNLASA-FOCLMDBBSA-N n-methyl-n-[(e)-(n-methylanilino)diazenyl]aniline Chemical compound C=1C=CC=CC=1N(C)\N=N\N(C)C1=CC=CC=C1 WRINSSLBPNLASA-FOCLMDBBSA-N 0.000 description 1
- RWHUEXWOYVBUCI-ITQXDASVSA-N nafarelin Chemical compound C([C@@H](C(=O)N[C@H](CC=1C=C2C=CC=CC2=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 RWHUEXWOYVBUCI-ITQXDASVSA-N 0.000 description 1
- 229960002333 nafarelin Drugs 0.000 description 1
- 229960004127 naloxone Drugs 0.000 description 1
- UZHSEJADLWPNLE-GRGSLBFTSA-N naloxone Chemical compound O=C([C@@H]1O2)CC[C@@]3(O)[C@H]4CC5=CC=C(O)C2=C5[C@@]13CCN4CC=C UZHSEJADLWPNLE-GRGSLBFTSA-N 0.000 description 1
- JZGDNMXSOCDEFQ-UHFFFAOYSA-N napavin Chemical compound C1C(CC)(O)CC(C2)CN1CCC(C1=CC=CC=C1N1)=C1C2(C(=O)OC)C(C(=C1)OC)=CC2=C1N(C)C1C2(C23)CCN3CC=CC2(CC)C(O)C1(O)C(=O)NCCNC1=CC=C(N=[N+]=[N-])C=C1[N+]([O-])=O JZGDNMXSOCDEFQ-UHFFFAOYSA-N 0.000 description 1
- 108010032539 nartograstim Proteins 0.000 description 1
- 229950010676 nartograstim Drugs 0.000 description 1
- 102000034288 naturally occurring fusion proteins Human genes 0.000 description 1
- 108091006048 naturally occurring fusion proteins Proteins 0.000 description 1
- 210000003739 neck Anatomy 0.000 description 1
- 229950007221 nedaplatin Drugs 0.000 description 1
- CTMCWCONSULRHO-UHQPFXKFSA-N nemorubicin Chemical compound C1CO[C@H](OC)CN1[C@@H]1[C@H](O)[C@H](C)O[C@@H](O[C@@H]2C3=C(O)C=4C(=O)C5=C(OC)C=CC=C5C(=O)C=4C(O)=C3C[C@](O)(C2)C(=O)CO)C1 CTMCWCONSULRHO-UHQPFXKFSA-N 0.000 description 1
- 229950010159 nemorubicin Drugs 0.000 description 1
- QZGIWPZCWHMVQL-UIYAJPBUSA-N neocarzinostatin chromophore Chemical compound O1[C@H](C)[C@H](O)[C@H](O)[C@@H](NC)[C@H]1O[C@@H]1C/2=C/C#C[C@H]3O[C@@]3([C@@H]3OC(=O)OC3)C#CC\2=C[C@H]1OC(=O)C1=C(O)C=CC2=C(C)C=C(OC)C=C12 QZGIWPZCWHMVQL-UIYAJPBUSA-N 0.000 description 1
- MQYXUWHLBZFQQO-UHFFFAOYSA-N nepehinol Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C)CCC(C(=C)C)C5C4CCC3C21C MQYXUWHLBZFQQO-UHFFFAOYSA-N 0.000 description 1
- PUUSSSIBPPTKTP-UHFFFAOYSA-N neridronic acid Chemical compound NCCCCCC(O)(P(O)(O)=O)P(O)(O)=O PUUSSSIBPPTKTP-UHFFFAOYSA-N 0.000 description 1
- 229950010733 neridronic acid Drugs 0.000 description 1
- 108010086154 neutrophil cytosol factor 40K Proteins 0.000 description 1
- 229960002653 nilutamide Drugs 0.000 description 1
- XWXYUMMDTVBTOU-UHFFFAOYSA-N nilutamide Chemical compound O=C1C(C)(C)NC(=O)N1C1=CC=C([N+]([O-])=O)C(C(F)(F)F)=C1 XWXYUMMDTVBTOU-UHFFFAOYSA-N 0.000 description 1
- 229940125745 nitric oxide modulator Drugs 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 229960005419 nitrogen Drugs 0.000 description 1
- KGTDRFCXGRULNK-JYOBTZKQSA-N nogalamycin Chemical compound CO[C@@H]1[C@@](OC)(C)[C@@H](OC)[C@H](C)O[C@H]1O[C@@H]1C2=C(O)C(C(=O)C3=C(O)C=C4[C@@]5(C)O[C@H]([C@H]([C@@H]([C@H]5O)N(C)C)O)OC4=C3C3=O)=C3C=C2[C@@H](C(=O)OC)[C@@](C)(O)C1 KGTDRFCXGRULNK-JYOBTZKQSA-N 0.000 description 1
- 229950009266 nogalamycin Drugs 0.000 description 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 1
- 229960004708 noscapine Drugs 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 229960000435 oblimersen Drugs 0.000 description 1
- MIMNFCVQODTQDP-NDLVEFNKSA-N oblimersen Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COP(S)(=O)O[C@@H]2[C@H](O[C@H](C2)N2C3=NC=NC(N)=C3N=C2)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(N=C(N)C=C2)=O)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(N=C(N)C=C2)=O)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C3=C(C(NC(N)=N3)=O)N=C2)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(N=C(N)C=C2)=O)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C3=C(C(NC(N)=N3)=O)N=C2)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(NC(=O)C(C)=C2)=O)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C3=C(C(NC(N)=N3)=O)N=C2)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(N=C(N)C=C2)=O)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C3=C(C(NC(N)=N3)=O)N=C2)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C3=NC=NC(N)=C3N=C2)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(N=C(N)C=C2)=O)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(N=C(N)C=C2)=O)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(N=C(N)C=C2)=O)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(NC(=O)C(C)=C2)=O)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(N=C(N)C=C2)=O)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(NC(=O)C(C)=C2)=O)CO)[C@@H](O)C1 MIMNFCVQODTQDP-NDLVEFNKSA-N 0.000 description 1
- 229960002700 octreotide Drugs 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 229960002230 omacetaxine mepesuccinate Drugs 0.000 description 1
- HYFHYPWGAURHIV-JFIAXGOJSA-N omacetaxine mepesuccinate Chemical compound C1=C2CCN3CCC[C@]43C=C(OC)[C@@H](OC(=O)[C@@](O)(CCCC(C)(C)O)CC(=O)OC)[C@H]4C2=CC2=C1OCO2 HYFHYPWGAURHIV-JFIAXGOJSA-N 0.000 description 1
- 229950011093 onapristone Drugs 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- ZLLOIFNEEWYATC-XMUHMHRVSA-N osaterone Chemical compound C1=C(Cl)C2=CC(=O)OC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)C)(O)[C@@]1(C)CC2 ZLLOIFNEEWYATC-XMUHMHRVSA-N 0.000 description 1
- 229950006466 osaterone Drugs 0.000 description 1
- ODHHTIYRUDURPW-UHFFFAOYSA-N ottelione A Natural products C1=C(O)C(OC)=CC=C1CC1C(C(=O)C=CC2=C)C2C(C=C)C1 ODHHTIYRUDURPW-UHFFFAOYSA-N 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 229950000370 oxisuran Drugs 0.000 description 1
- 239000003973 paint Substances 0.000 description 1
- VYOQBYCIIJYKJA-VORKOXQSSA-N palau'amine Chemical compound N([C@@]12[C@@H](Cl)[C@@H]([C@@H]3[C@@H]2[C@]24N=C(N)N[C@H]2N2C=CC=C2C(=O)N4C3)CN)C(N)=N[C@H]1O VYOQBYCIIJYKJA-VORKOXQSSA-N 0.000 description 1
- ZFYKZAKRJRNXGF-XRZRNGJYSA-N palmitoyl rhizoxin Chemical compound O1C(=O)C2OC2CC(CC(=O)O2)CC2C(C)\C=C\C2OC2(C)C(OC(=O)CCCCCCCCCCCCCCC)CC1C(C)C(OC)C(\C)=C\C=C\C(\C)=C\C1=COC(C)=N1 ZFYKZAKRJRNXGF-XRZRNGJYSA-N 0.000 description 1
- WRUUGTRCQOWXEG-UHFFFAOYSA-N pamidronate Chemical compound NCCC(O)(P(O)(O)=O)P(O)(O)=O WRUUGTRCQOWXEG-UHFFFAOYSA-N 0.000 description 1
- 229960003978 pamidronic acid Drugs 0.000 description 1
- RDIMTXDFGHNINN-IKGGRYGDSA-N panaxytriol Chemical compound CCCCCCC[C@H](O)[C@@H](O)CC#CC#C[C@H](O)C=C RDIMTXDFGHNINN-IKGGRYGDSA-N 0.000 description 1
- ZCKMUKZQXWHXOF-UHFFFAOYSA-N panaxytriol Natural products CCC(C)C(C)C(C)C(C)C(C)C(O)C(O)CC#CC#CC(O)C=C ZCKMUKZQXWHXOF-UHFFFAOYSA-N 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 201000002094 pancreatic adenocarcinoma Diseases 0.000 description 1
- 229960001972 panitumumab Drugs 0.000 description 1
- 229950003440 panomifene Drugs 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- LPHSYQSMAGVYNT-UHFFFAOYSA-N pazelliptine Chemical compound N1C2=CC=NC=C2C2=C1C(C)=C1C=CN=C(NCCCN(CC)CC)C1=C2 LPHSYQSMAGVYNT-UHFFFAOYSA-N 0.000 description 1
- 229950006361 pazelliptine Drugs 0.000 description 1
- DOHVAKFYAHLCJP-UHFFFAOYSA-N peldesine Chemical compound C1=2NC(N)=NC(=O)C=2NC=C1CC1=CC=CN=C1 DOHVAKFYAHLCJP-UHFFFAOYSA-N 0.000 description 1
- 229950000039 peldesine Drugs 0.000 description 1
- 229950006960 peliomycin Drugs 0.000 description 1
- 229950006299 pelitinib Drugs 0.000 description 1
- 229960005079 pemetrexed Drugs 0.000 description 1
- QOFFJEBXNKRSPX-ZDUSSCGKSA-N pemetrexed Chemical compound C1=N[C]2NC(N)=NC(=O)C2=C1CCC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 QOFFJEBXNKRSPX-ZDUSSCGKSA-N 0.000 description 1
- VOKSWYLNZZRQPF-GDIGMMSISA-N pentazocine Chemical compound C1C2=CC=C(O)C=C2[C@@]2(C)[C@@H](C)[C@@H]1N(CC=C(C)C)CC2 VOKSWYLNZZRQPF-GDIGMMSISA-N 0.000 description 1
- 229960005301 pentazocine Drugs 0.000 description 1
- 229960003820 pentosan polysulfate sodium Drugs 0.000 description 1
- 229950003180 peplomycin Drugs 0.000 description 1
- QIMGFXOHTOXMQP-GFAGFCTOSA-N peplomycin Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCCN[C@@H](C)C=1C=CC=CC=1)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1NC=NC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C QIMGFXOHTOXMQP-GFAGFCTOSA-N 0.000 description 1
- WTWWXOGTJWMJHI-UHFFFAOYSA-N perflubron Chemical compound FC(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)Br WTWWXOGTJWMJHI-UHFFFAOYSA-N 0.000 description 1
- 229960001217 perflubron Drugs 0.000 description 1
- 235000005693 perillyl alcohol Nutrition 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- LCADVYTXPLBAGB-GNCBHIOISA-N phenalamide A1 Natural products CC(CO)NC(=O)C(=CC=CC=C/C=C/C(=C/C(C)C(O)C(=CC(C)CCc1ccccc1)C)/C)C LCADVYTXPLBAGB-GNCBHIOISA-N 0.000 description 1
- 229940049953 phenylacetate Drugs 0.000 description 1
- WLJVXDMOQOGPHL-UHFFFAOYSA-N phenylacetic acid Chemical compound OC(=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-UHFFFAOYSA-N 0.000 description 1
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N phenylbenzene Natural products C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 description 1
- 229960002139 pilocarpine hydrochloride Drugs 0.000 description 1
- RNAICSBVACLLGM-GNAZCLTHSA-N pilocarpine hydrochloride Chemical compound Cl.C1OC(=O)[C@@H](CC)[C@H]1CC1=CN=CN1C RNAICSBVACLLGM-GNAZCLTHSA-N 0.000 description 1
- 229960000952 pipobroman Drugs 0.000 description 1
- NJBFOOCLYDNZJN-UHFFFAOYSA-N pipobroman Chemical compound BrCCC(=O)N1CCN(C(=O)CCBr)CC1 NJBFOOCLYDNZJN-UHFFFAOYSA-N 0.000 description 1
- NUKCGLDCWQXYOQ-UHFFFAOYSA-N piposulfan Chemical compound CS(=O)(=O)OCCC(=O)N1CCN(C(=O)CCOS(C)(=O)=O)CC1 NUKCGLDCWQXYOQ-UHFFFAOYSA-N 0.000 description 1
- 229950001100 piposulfan Drugs 0.000 description 1
- 229960001221 pirarubicin Drugs 0.000 description 1
- XESARGFCSKSFID-FLLFQEBCSA-N pirazofurin Chemical compound OC1=C(C(=O)N)NN=C1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 XESARGFCSKSFID-FLLFQEBCSA-N 0.000 description 1
- 229950001030 piritrexim Drugs 0.000 description 1
- VGYFMXBACGZSIL-MCBHFWOFSA-N pitavastatin Chemical compound OC(=O)C[C@H](O)C[C@H](O)\C=C\C1=C(C2CC2)N=C2C=CC=CC2=C1C1=CC=C(F)C=C1 VGYFMXBACGZSIL-MCBHFWOFSA-N 0.000 description 1
- 229960002797 pitavastatin Drugs 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 239000002797 plasminogen activator inhibitor Substances 0.000 description 1
- 229950008499 plitidepsin Drugs 0.000 description 1
- 108010049948 plitidepsin Proteins 0.000 description 1
- UUSZLLQJYRSZIS-LXNNNBEUSA-N plitidepsin Chemical compound CN([C@H](CC(C)C)C(=O)N[C@@H]1C(=O)N[C@@H]([C@H](CC(=O)O[C@H](C(=O)[C@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N2CCC[C@H]2C(=O)N(C)[C@@H](CC=2C=CC(OC)=CC=2)C(=O)O[C@@H]1C)C(C)C)O)[C@@H](C)CC)C(=O)[C@@H]1CCCN1C(=O)C(C)=O UUSZLLQJYRSZIS-LXNNNBEUSA-N 0.000 description 1
- JKPDEYAOCSQBSZ-OEUJLIAZSA-N plomestane Chemical compound O=C1CC[C@]2(CC#C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1 JKPDEYAOCSQBSZ-OEUJLIAZSA-N 0.000 description 1
- 229950004541 plomestane Drugs 0.000 description 1
- 229960001237 podophyllotoxin Drugs 0.000 description 1
- YJGVMLPVUAXIQN-XVVDYKMHSA-N podophyllotoxin Chemical compound COC1=C(OC)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@H](O)[C@@H]3[C@@H]2C(OC3)=O)=C1 YJGVMLPVUAXIQN-XVVDYKMHSA-N 0.000 description 1
- YVCVYCSAAZQOJI-UHFFFAOYSA-N podophyllotoxin Natural products COC1=C(O)C(OC)=CC(C2C3=CC=4OCOC=4C=C3C(O)C3C2C(OC3)=O)=C1 YVCVYCSAAZQOJI-UHFFFAOYSA-N 0.000 description 1
- 229920000768 polyamine Polymers 0.000 description 1
- 102000040430 polynucleotide Human genes 0.000 description 1
- 108091033319 polynucleotide Proteins 0.000 description 1
- 239000002157 polynucleotide Substances 0.000 description 1
- 150000008442 polyphenolic compounds Chemical class 0.000 description 1
- 235000013824 polyphenols Nutrition 0.000 description 1
- 238000010837 poor prognosis Methods 0.000 description 1
- 230000004481 post-translational protein modification Effects 0.000 description 1
- 230000001124 posttranscriptional effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 229960004694 prednimustine Drugs 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 238000000513 principal component analysis Methods 0.000 description 1
- 230000001686 pro-survival effect Effects 0.000 description 1
- 229960000624 procarbazine Drugs 0.000 description 1
- CPTBDICYNRMXFX-UHFFFAOYSA-N procarbazine Chemical compound CNNCC1=CC=C(C(=O)NC(C)C)C=C1 CPTBDICYNRMXFX-UHFFFAOYSA-N 0.000 description 1
- 229960001586 procarbazine hydrochloride Drugs 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 229960003387 progesterone Drugs 0.000 description 1
- 239000000186 progesterone Substances 0.000 description 1
- 239000000583 progesterone congener Substances 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000000644 propagated effect Effects 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- UQOQENZZLBSFKO-POPPZSFYSA-N prostaglandin J2 Chemical compound CCCCC[C@H](O)\C=C\[C@@H]1[C@@H](C\C=C/CCCC(O)=O)C=CC1=O UQOQENZZLBSFKO-POPPZSFYSA-N 0.000 description 1
- 239000003207 proteasome inhibitor Substances 0.000 description 1
- 230000004952 protein activity Effects 0.000 description 1
- 239000003528 protein farnesyltransferase inhibitor Substances 0.000 description 1
- 239000003806 protein tyrosine phosphatase inhibitor Substances 0.000 description 1
- SSKVDVBQSWQEGJ-UHFFFAOYSA-N pseudohypericin Natural products C12=C(O)C=C(O)C(C(C=3C(O)=CC(O)=C4C=33)=O)=C2C3=C2C3=C4C(C)=CC(O)=C3C(=O)C3=C(O)C=C(O)C1=C32 SSKVDVBQSWQEGJ-UHFFFAOYSA-N 0.000 description 1
- 239000000784 purine nucleoside phosphorylase inhibitor Substances 0.000 description 1
- 150000003212 purines Chemical class 0.000 description 1
- 229950010131 puromycin Drugs 0.000 description 1
- MKSVFGKWZLUTTO-FZFAUISWSA-N puromycin dihydrochloride Chemical compound Cl.Cl.C1=CC(OC)=CC=C1C[C@H](N)C(=O)N[C@H]1[C@@H](O)[C@H](N2C3=NC=NC(=C3N=C2)N(C)C)O[C@@H]1CO MKSVFGKWZLUTTO-FZFAUISWSA-N 0.000 description 1
- 150000003230 pyrimidines Chemical class 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 238000011363 radioimmunotherapy Methods 0.000 description 1
- NTHPAPBPFQJABD-LLVKDONJSA-N ramosetron Chemical compound C12=CC=CC=C2N(C)C=C1C(=O)[C@H]1CC(NC=N2)=C2CC1 NTHPAPBPFQJABD-LLVKDONJSA-N 0.000 description 1
- 229950001588 ramosetron Drugs 0.000 description 1
- 108010062219 ran-binding protein 2 Proteins 0.000 description 1
- 108010036805 rap1 GTP-Binding Proteins Proteins 0.000 description 1
- 102000016914 ras Proteins Human genes 0.000 description 1
- 108010014186 ras Proteins Proteins 0.000 description 1
- 229940044601 receptor agonist Drugs 0.000 description 1
- 239000000018 receptor agonist Substances 0.000 description 1
- 229940044551 receptor antagonist Drugs 0.000 description 1
- 239000002464 receptor antagonist Substances 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 201000001281 rectum adenocarcinoma Diseases 0.000 description 1
- 239000013074 reference sample Substances 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 229950002225 retelliptine Drugs 0.000 description 1
- 201000009410 rhabdomyosarcoma Diseases 0.000 description 1
- OWPCHSCAPHNHAV-LMONGJCWSA-N rhizoxin Chemical compound C/C([C@H](OC)[C@@H](C)[C@@H]1C[C@H](O)[C@]2(C)O[C@@H]2/C=C/[C@@H](C)[C@]2([H])OC(=O)C[C@@](C2)(C[C@@H]2O[C@H]2C(=O)O1)[H])=C\C=C\C(\C)=C\C1=COC(C)=N1 OWPCHSCAPHNHAV-LMONGJCWSA-N 0.000 description 1
- 229960004356 riboprine Drugs 0.000 description 1
- 108091092562 ribozyme Proteins 0.000 description 1
- 229960004641 rituximab Drugs 0.000 description 1
- 229950003733 romurtide Drugs 0.000 description 1
- 108700033545 romurtide Proteins 0.000 description 1
- 229960003522 roquinimex Drugs 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- DFJSJLGUIXFDJP-UHFFFAOYSA-N sapitinib Chemical compound C1CN(CC(=O)NC)CCC1OC(C(=CC1=NC=N2)OC)=CC1=C2NC1=CC=CC(Cl)=C1F DFJSJLGUIXFDJP-UHFFFAOYSA-N 0.000 description 1
- YADVRLOQIWILGX-UHFFFAOYSA-N sarcophytol N Natural products CC(C)C1=CC=C(C)CCC=C(C)CCC=C(C)CC1O YADVRLOQIWILGX-UHFFFAOYSA-N 0.000 description 1
- 108010038379 sargramostim Proteins 0.000 description 1
- 229960002530 sargramostim Drugs 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 229950010746 selumetinib Drugs 0.000 description 1
- 230000009758 senescence Effects 0.000 description 1
- VGKDLMBJGBXTGI-SJCJKPOMSA-N sertraline Chemical compound C1([C@@H]2CC[C@@H](C3=CC=CC=C32)NC)=CC=C(Cl)C(Cl)=C1 VGKDLMBJGBXTGI-SJCJKPOMSA-N 0.000 description 1
- 229960002073 sertraline Drugs 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 229950009089 simtrazene Drugs 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 206010040882 skin lesion Diseases 0.000 description 1
- 231100000444 skin lesion Toxicity 0.000 description 1
- 201000003708 skin melanoma Diseases 0.000 description 1
- 208000000587 small cell lung carcinoma Diseases 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 229950004296 soblidotin Drugs 0.000 description 1
- 229950010372 sobuzoxane Drugs 0.000 description 1
- 229940006198 sodium phenylacetate Drugs 0.000 description 1
- QUCDWLYKDRVKMI-UHFFFAOYSA-M sodium;3,4-dimethylbenzenesulfonate Chemical compound [Na+].CC1=CC=C(S([O-])(=O)=O)C=C1C QUCDWLYKDRVKMI-UHFFFAOYSA-M 0.000 description 1
- MIXCUJKCXRNYFM-UHFFFAOYSA-M sodium;diiodomethanesulfonate;n-propyl-n-[2-(2,4,6-trichlorophenoxy)ethyl]imidazole-1-carboxamide Chemical compound [Na+].[O-]S(=O)(=O)C(I)I.C1=CN=CN1C(=O)N(CCC)CCOC1=C(Cl)C=C(Cl)C=C1Cl MIXCUJKCXRNYFM-UHFFFAOYSA-M 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000005063 solubilization Methods 0.000 description 1
- 230000007928 solubilization Effects 0.000 description 1
- 238000000638 solvent extraction Methods 0.000 description 1
- 229950004225 sonermin Drugs 0.000 description 1
- 229950004796 sparfosic acid Drugs 0.000 description 1
- 229950009641 sparsomycin Drugs 0.000 description 1
- XKLZIVIOZDNKEQ-CLQLPEFOSA-N sparsomycin Chemical compound CSC[S@](=O)C[C@H](CO)NC(=O)\C=C\C1=C(C)NC(=O)NC1=O XKLZIVIOZDNKEQ-CLQLPEFOSA-N 0.000 description 1
- XKLZIVIOZDNKEQ-UHFFFAOYSA-N sparsomycin Natural products CSCS(=O)CC(CO)NC(=O)C=CC1=C(C)NC(=O)NC1=O XKLZIVIOZDNKEQ-UHFFFAOYSA-N 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- YBZRLMLGUBIIDN-NZSGCTDASA-N spicamycin Chemical compound O1[C@@H](C(O)CO)[C@H](NC(=O)CNC(=O)CCCCCCCCCCCCC(C)C)[C@@H](O)[C@@H](O)[C@H]1NC1=NC=NC2=C1N=CN2 YBZRLMLGUBIIDN-NZSGCTDASA-N 0.000 description 1
- YBZRLMLGUBIIDN-UHFFFAOYSA-N spicamycin Natural products O1C(C(O)CO)C(NC(=O)CNC(=O)CCCCCCCCCCCCC(C)C)C(O)C(O)C1NC1=NC=NC2=C1NC=N2 YBZRLMLGUBIIDN-UHFFFAOYSA-N 0.000 description 1
- 229950004330 spiroplatin Drugs 0.000 description 1
- 108010032486 splenopentin Proteins 0.000 description 1
- DTFYGLNONOLGOT-UHFFFAOYSA-N spongistatin 2 Natural products OC1C(O2)(O)CC(O)C(C)C2CCCC=CC(O2)CC(O)CC2(O2)CC(OC)CC2CC(=O)C(C)C(OC(C)=O)C(C)C(=C)CC(O2)CC(C)(O)CC2(O2)CC(OC(C)=O)CC2CC(=O)OC2C(O)C(CC(=C)CC(O)C=CC=C)OC1C2C DTFYGLNONOLGOT-UHFFFAOYSA-N 0.000 description 1
- VGULLEUAAMBZTQ-YGHPZBLNSA-N spongistatin 3 Chemical compound C([C@H](C[C@@]1(O2)C[C@H](O)C[C@H](O1)\C=C/CCC[C@H]1[C@@H](C)[C@H](O)C[C@@](O1)(O)[C@@H]1O)OC)C2CC(=O)[C@@H](C)[C@H](OC(C)=O)[C@@H](C)C(=C)C[C@@H](O2)C[C@@](C)(O)C[C@]2(O2)C[C@H](O)CC2CC(=O)O[C@H]2[C@H](O)[C@@H](CC(=C)C[C@@H](O)\C=C\C(Cl)=C)OC1[C@@H]2C VGULLEUAAMBZTQ-YGHPZBLNSA-N 0.000 description 1
- KRUKGDRIKMPUNX-JWFNSJLHSA-N spongistatin 4 Chemical compound C([C@H](C[C@@]1(O2)C[C@H](O)C[C@H](O1)\C=C/CCC[C@H]1[C@@H](C)[C@H](O)C[C@@](O1)(O)[C@@H]1O)OC)C2CC(=O)[C@@H](C)[C@H](O)[C@@H](C)C(=C)C[C@@H](O2)C[C@@](C)(O)C[C@]2(O2)C[C@H](OC(C)=O)CC2CC(=O)O[C@H]2[C@H](O)[C@@H](CC(=C)C[C@@H](O)\C=C\C(Cl)=C)OC1[C@@H]2C KRUKGDRIKMPUNX-JWFNSJLHSA-N 0.000 description 1
- KRUKGDRIKMPUNX-UHFFFAOYSA-N spongistatin 4 Natural products OC1C(O2)(O)CC(O)C(C)C2CCCC=CC(O2)CC(O)CC2(O2)CC(OC)CC2CC(=O)C(C)C(O)C(C)C(=C)CC(O2)CC(C)(O)CC2(O2)CC(OC(C)=O)CC2CC(=O)OC2C(O)C(CC(=C)CC(O)C=CC(Cl)=C)OC1C2C KRUKGDRIKMPUNX-UHFFFAOYSA-N 0.000 description 1
- GQOOASKKXHUNEJ-PYATXCCJSA-N spongistatin 6 Chemical compound C([C@H](C[C@@]1(O2)C[C@H](O)C[C@H](O1)\C=C/CCC[C@H]1[C@@H](C)[C@H](O)C[C@@](O1)(O)[C@@H]1O)OC)C2CC(=O)[C@@H](C)[C@H](O)[C@@H](C)C(=C)C[C@@H](O2)C[C@@](C)(O)C[C@]2(O2)C[C@H](OC(C)=O)CC2CC(=O)O[C@H]2[C@H](O)[C@@H](CC(=C)C[C@@H](O)\C=C\C=C)OC1[C@@H]2C GQOOASKKXHUNEJ-PYATXCCJSA-N 0.000 description 1
- WYJXOZQMHBISBD-UHFFFAOYSA-N spongistatin 8 Natural products C1C(=O)C(C)C(C2C)OCC2=CC(O2)CC(C)(O)CC2(O2)CC(OC(C)=O)CC2CC(=O)OC(C(C(CC(=C)CC(O)C=CC=C)O2)O)C(C)C2C(O)C(O2)(O)CC(O)C(C)C2CCCC=CC(O2)CC(O)CC22CC(OC)CC1O2 WYJXOZQMHBISBD-UHFFFAOYSA-N 0.000 description 1
- RSHMLTSGIURLKH-SJMMKZBFSA-N spongistatin-2 Chemical compound C([C@@H]1C[C@@H](C[C@@]2(C[C@@H](O)C[C@@H](C2)\C=C/CCC[C@@H]2[C@H](C)[C@@H](O)C[C@](O2)(O)[C@H]2O)O1)OC)C(=O)[C@@H](C)[C@@H](OC(C)=O)[C@H](C)C(=C)C[C@H](O1)C[C@](C)(O)C[C@@]1(O1)C[C@@H](OC(C)=O)C[C@@H]1CC(=O)O[C@H]1[C@H](O)[C@@H](CC(=C)C(C)[C@H](O)\C=C\C=C)O[C@@H]2[C@@H]1C RSHMLTSGIURLKH-SJMMKZBFSA-N 0.000 description 1
- 229950001248 squalamine Drugs 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 230000024642 stem cell division Effects 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 108091007196 stromelysin Proteins 0.000 description 1
- 229950007841 sulofenur Drugs 0.000 description 1
- 229960001796 sunitinib Drugs 0.000 description 1
- WINHZLLDWRZWRT-ATVHPVEESA-N sunitinib Chemical compound CCN(CC)CCNC(=O)C1=C(C)NC(\C=C/2C3=CC(F)=CC=C3NC\2=O)=C1C WINHZLLDWRZWRT-ATVHPVEESA-N 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 108010045815 superoxide dismutase 2 Proteins 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- FIAFUQMPZJWCLV-UHFFFAOYSA-N suramin Chemical compound OS(=O)(=O)C1=CC(S(O)(=O)=O)=C2C(NC(=O)C3=CC=C(C(=C3)NC(=O)C=3C=C(NC(=O)NC=4C=C(C=CC=4)C(=O)NC=4C(=CC=C(C=4)C(=O)NC=4C5=C(C=C(C=C5C(=CC=4)S(O)(=O)=O)S(O)(=O)=O)S(O)(=O)=O)C)C=CC=3)C)=CC=C(S(O)(=O)=O)C2=C1 FIAFUQMPZJWCLV-UHFFFAOYSA-N 0.000 description 1
- 229960005314 suramin Drugs 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 229960005566 swainsonine Drugs 0.000 description 1
- FXUAIOOAOAVCGD-UHFFFAOYSA-N swainsonine Natural products C1CCC(O)C2C(O)C(O)CN21 FXUAIOOAOAVCGD-UHFFFAOYSA-N 0.000 description 1
- FXUAIOOAOAVCGD-FKSUSPILSA-N swainsonine Chemical compound C1CC[C@H](O)[C@H]2[C@H](O)[C@H](O)CN21 FXUAIOOAOAVCGD-FKSUSPILSA-N 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- PTTJLTMUKRRHAT-KYDPQNDISA-N taccalonolide A Natural products O=C(O[C@@H]1[C@H](OC(=O)C)[C@@H]2[C@]3(C)[C@H](OC(=O)C)[C@H]4O[C@H]4C[C@@H]3C(=O)[C@H](O)[C@H]2[C@@H]2[C@@H](OC(=O)C)[C@H]3[C@@]4(C)[C@@](O)(C)C(=O)OC4=C[C@@H](C)[C@@H]3[C@@]12C)C PTTJLTMUKRRHAT-KYDPQNDISA-N 0.000 description 1
- VAZAPHZUAVEOMC-UHFFFAOYSA-N tacedinaline Chemical compound C1=CC(NC(=O)C)=CC=C1C(=O)NC1=CC=CC=C1N VAZAPHZUAVEOMC-UHFFFAOYSA-N 0.000 description 1
- 108700003774 talisomycin Proteins 0.000 description 1
- 229950002687 talisomycin Drugs 0.000 description 1
- 108010021891 tallimustine Proteins 0.000 description 1
- 229950005667 tallimustine Drugs 0.000 description 1
- 229960001603 tamoxifen Drugs 0.000 description 1
- 229950010168 tauromustine Drugs 0.000 description 1
- DKPFODGZWDEEBT-QFIAKTPHSA-N taxane Chemical group C([C@]1(C)CCC[C@@H](C)[C@H]1C1)C[C@H]2[C@H](C)CC[C@@H]1C2(C)C DKPFODGZWDEEBT-QFIAKTPHSA-N 0.000 description 1
- 229960000565 tazarotene Drugs 0.000 description 1
- 239000003277 telomerase inhibitor Substances 0.000 description 1
- RNVNXVVEDMSRJE-UHFFFAOYSA-N teloxantrone hydrochloride Chemical compound Cl.Cl.OCCNCCN1NC2=C3C(=O)C=CC(=O)C3=C(O)C3=C2C1=CC=C3NCCNC RNVNXVVEDMSRJE-UHFFFAOYSA-N 0.000 description 1
- 229960004964 temozolomide Drugs 0.000 description 1
- 230000002123 temporal effect Effects 0.000 description 1
- 229950008703 teroxirone Drugs 0.000 description 1
- 229950003046 tesevatinib Drugs 0.000 description 1
- 201000003120 testicular cancer Diseases 0.000 description 1
- 229960005353 testolactone Drugs 0.000 description 1
- BPEWUONYVDABNZ-DZBHQSCQSA-N testolactone Chemical compound O=C1C=C[C@]2(C)[C@H]3CC[C@](C)(OC(=O)CC4)[C@@H]4[C@@H]3CCC2=C1 BPEWUONYVDABNZ-DZBHQSCQSA-N 0.000 description 1
- 229960001712 testosterone propionate Drugs 0.000 description 1
- WXZSUBHBYQYTNM-WMDJANBXSA-N tetrazomine Chemical compound C=1([C@@H]2CO[C@@H]3[C@H]4C[C@@H](CO)[C@H](N4C)[C@@H](N23)CC=1C=C1)C(OC)=C1NC(=O)C1NCCC[C@H]1O WXZSUBHBYQYTNM-WMDJANBXSA-N 0.000 description 1
- ZCTJIMXXSXQXRI-UHFFFAOYSA-N thaliblastine Natural products CN1CCC2=CC(OC)=C(OC)C3=C2C1CC1=C3C=C(OC)C(OC2=C(CC3C4=CC(OC)=C(OC)C=C4CCN3C)C=C(C(=C2)OC)OC)=C1 ZCTJIMXXSXQXRI-UHFFFAOYSA-N 0.000 description 1
- ZCTJIMXXSXQXRI-KYJUHHDHSA-N thalicarpine Chemical compound CN1CCC2=CC(OC)=C(OC)C3=C2[C@@H]1CC1=C3C=C(OC)C(OC2=C(C[C@H]3C4=CC(OC)=C(OC)C=C4CCN3C)C=C(C(=C2)OC)OC)=C1 ZCTJIMXXSXQXRI-KYJUHHDHSA-N 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 108010062880 thiocoraline Proteins 0.000 description 1
- UPGGKUQISSWRJJ-UHFFFAOYSA-N thiocoraline Natural products CN1C(=O)CNC(=O)C(NC(=O)C=2C(=CC3=CC=CC=C3N=2)O)CSC(=O)C(CSC)N(C)C(=O)C(N(C(=O)CNC2=O)C)CSSCC1C(=O)N(C)C(CSC)C(=O)SCC2NC(=O)C1=NC2=CC=CC=C2C=C1O UPGGKUQISSWRJJ-UHFFFAOYSA-N 0.000 description 1
- NZVYCXVTEHPMHE-ZSUJOUNUSA-N thymalfasin Chemical compound CC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O NZVYCXVTEHPMHE-ZSUJOUNUSA-N 0.000 description 1
- 229960004231 thymalfasin Drugs 0.000 description 1
- 108010013515 thymopoietin receptor Proteins 0.000 description 1
- 229950010183 thymotrinan Drugs 0.000 description 1
- 208000013077 thyroid gland carcinoma Diseases 0.000 description 1
- 208000013818 thyroid gland medullary carcinoma Diseases 0.000 description 1
- 208000030045 thyroid gland papillary carcinoma Diseases 0.000 description 1
- YFTWHEBLORWGNI-UHFFFAOYSA-N tiamiprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC(N)=NC2=C1NC=N2 YFTWHEBLORWGNI-UHFFFAOYSA-N 0.000 description 1
- 229950011457 tiamiprine Drugs 0.000 description 1
- 229960003723 tiazofurine Drugs 0.000 description 1
- FVRDYQYEVDDKCR-DBRKOABJSA-N tiazofurine Chemical compound NC(=O)C1=CSC([C@H]2[C@@H]([C@H](O)[C@@H](CO)O2)O)=N1 FVRDYQYEVDDKCR-DBRKOABJSA-N 0.000 description 1
- 229940044693 topoisomerase inhibitor Drugs 0.000 description 1
- ONYVJPZNVCOAFF-UHFFFAOYSA-N topsentin Natural products Oc1ccc2cc([nH]c2c1)C(=O)c3ncc([nH]3)c4c[nH]c5ccccc45 ONYVJPZNVCOAFF-UHFFFAOYSA-N 0.000 description 1
- 229960005026 toremifene Drugs 0.000 description 1
- XFCLJVABOIYOMF-QPLCGJKRSA-N toremifene Chemical compound C1=CC(OCCN(C)C)=CC=C1C(\C=1C=CC=CC=1)=C(\CCCl)C1=CC=CC=C1 XFCLJVABOIYOMF-QPLCGJKRSA-N 0.000 description 1
- 229960004167 toremifene citrate Drugs 0.000 description 1
- 210000003014 totipotent stem cell Anatomy 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 229960000575 trastuzumab Drugs 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 229960001727 tretinoin Drugs 0.000 description 1
- 150000004654 triazenes Chemical class 0.000 description 1
- 229950003873 triciribine Drugs 0.000 description 1
- 229960000538 trimetrexate glucuronate Drugs 0.000 description 1
- YKUJZZHGTWVWHA-UHFFFAOYSA-N triptolide Natural products COC12CC3OC3(C(C)C)C(O)C14OC4CC5C6=C(CCC25C)C(=O)OC6 YKUJZZHGTWVWHA-UHFFFAOYSA-N 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 229960003688 tropisetron Drugs 0.000 description 1
- UIVFDCIXTSJXBB-ITGUQSILSA-N tropisetron Chemical compound C1=CC=C[C]2C(C(=O)O[C@H]3C[C@H]4CC[C@@H](C3)N4C)=CN=C21 UIVFDCIXTSJXBB-ITGUQSILSA-N 0.000 description 1
- 108010061145 tubulysin A Proteins 0.000 description 1
- WMPQMBUXZHMEFZ-YJPJVVPASA-N turosteride Chemical compound CN([C@@H]1CC2)C(=O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H](C(=O)N(C(C)C)C(=O)NC(C)C)[C@@]2(C)CC1 WMPQMBUXZHMEFZ-YJPJVVPASA-N 0.000 description 1
- 229950007816 turosteride Drugs 0.000 description 1
- 239000005483 tyrosine kinase inhibitor Substances 0.000 description 1
- GFNNBHLJANVSQV-UHFFFAOYSA-N tyrphostin AG 1478 Chemical compound C=12C=C(OC)C(OC)=CC2=NC=NC=1NC1=CC=CC(Cl)=C1 GFNNBHLJANVSQV-UHFFFAOYSA-N 0.000 description 1
- 229950009811 ubenimex Drugs 0.000 description 1
- 150000003672 ureas Chemical class 0.000 description 1
- SPDZFJLQFWSJGA-UHFFFAOYSA-N uredepa Chemical compound C1CN1P(=O)(NC(=O)OCC)N1CC1 SPDZFJLQFWSJGA-UHFFFAOYSA-N 0.000 description 1
- 229950006929 uredepa Drugs 0.000 description 1
- AUFUWRKPQLGTGF-FMKGYKFTSA-N uridine triacetate Chemical compound CC(=O)O[C@@H]1[C@H](OC(C)=O)[C@@H](COC(=O)C)O[C@H]1N1C(=O)NC(=O)C=C1 AUFUWRKPQLGTGF-FMKGYKFTSA-N 0.000 description 1
- 201000005112 urinary bladder cancer Diseases 0.000 description 1
- 229960005356 urokinase Drugs 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 229960000241 vandetanib Drugs 0.000 description 1
- UHTHHESEBZOYNR-UHFFFAOYSA-N vandetanib Chemical compound COC1=CC(C(/N=CN2)=N/C=3C(=CC(Br)=CC=3)F)=C2C=C1OCC1CCN(C)CC1 UHTHHESEBZOYNR-UHFFFAOYSA-N 0.000 description 1
- 229950008261 velaresol Drugs 0.000 description 1
- 229960003862 vemurafenib Drugs 0.000 description 1
- GPXBXXGIAQBQNI-UHFFFAOYSA-N vemurafenib Chemical compound CCCS(=O)(=O)NC1=CC=C(F)C(C(=O)C=2C3=CC(=CN=C3NC=2)C=2C=CC(Cl)=CC=2)=C1F GPXBXXGIAQBQNI-UHFFFAOYSA-N 0.000 description 1
- XLQGICHHYYWYIU-UHFFFAOYSA-N veramine Natural products O1C2CC3C4CC=C5CC(O)CCC5(C)C4CC=C3C2(C)C(C)C21CCC(C)CN2 XLQGICHHYYWYIU-UHFFFAOYSA-N 0.000 description 1
- 230000028973 vesicle-mediated transport Effects 0.000 description 1
- 229960004982 vinblastine sulfate Drugs 0.000 description 1
- KDQAABAKXDWYSZ-PNYVAJAMSA-N vinblastine sulfate Chemical compound OS(O)(=O)=O.C([C@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 KDQAABAKXDWYSZ-PNYVAJAMSA-N 0.000 description 1
- 229960005212 vindesine sulfate Drugs 0.000 description 1
- BCXOZISMDZTYHW-IFQBWSDRSA-N vinepidine sulfate Chemical compound OS(O)(=O)=O.C([C@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C=O)C=2)OC)C[C@@H](C2)CC)N2CCC2=C1NC1=CC=CC=C21 BCXOZISMDZTYHW-IFQBWSDRSA-N 0.000 description 1
- 229960002166 vinorelbine tartrate Drugs 0.000 description 1
- GBABOYUKABKIAF-IWWDSPBFSA-N vinorelbinetartrate Chemical compound C1N(CC=2C3=CC=CC=C3NC=22)CC(CC)=C[C@H]1C[C@]2(C(=O)OC)C1=CC(C23[C@H]([C@@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC GBABOYUKABKIAF-IWWDSPBFSA-N 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 108010079700 vitilevuamide Proteins 0.000 description 1
- UFOVYHGILLJGLP-UHFFFAOYSA-N vitilevuamide Chemical compound N1C(=O)C(NC(=O)CCC(O)=O)CSCC(C(NC(C(=O)NC(=C)C(=O)NC(CC(C)CC)C(=O)NC(C(=O)N(C)C(C(O)COC)C(=O)NC(CO)C(=O)OC2C)C(C)C)C(C)CC)=O)NC(=O)C3CCCN3C(=O)C(CC=3C=CC=CC=3)NC(=O)C2NC(=O)C(CC(C)CC)NC(=O)C(C)NC(=O)C1CC1=CC=CC=C1 UFOVYHGILLJGLP-UHFFFAOYSA-N 0.000 description 1
- 230000036642 wellbeing Effects 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
- QDLHCMPXEPAAMD-QAIWCSMKSA-N wortmannin Chemical compound C1([C@]2(C)C3=C(C4=O)OC=C3C(=O)O[C@@H]2COC)=C4[C@@H]2CCC(=O)[C@@]2(C)C[C@H]1OC(C)=O QDLHCMPXEPAAMD-QAIWCSMKSA-N 0.000 description 1
- QDLHCMPXEPAAMD-UHFFFAOYSA-N wortmannin Natural products COCC1OC(=O)C2=COC(C3=O)=C2C1(C)C1=C3C2CCC(=O)C2(C)CC1OC(C)=O QDLHCMPXEPAAMD-UHFFFAOYSA-N 0.000 description 1
- DVPVGSLIUJPOCJ-XXRQFBABSA-N x1j761618a Chemical compound OS(O)(=O)=O.OS(O)(=O)=O.OS(O)(=O)=O.C([C@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(=O)CN(C)C)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21.C([C@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(=O)CN(C)C)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 DVPVGSLIUJPOCJ-XXRQFBABSA-N 0.000 description 1
- 229950005561 zanoterone Drugs 0.000 description 1
- 229950009268 zinostatin Drugs 0.000 description 1
- FYQZGCBXYVWXSP-STTFAQHVSA-N zinostatin stimalamer Chemical compound O1[C@H](C)[C@H](O)[C@H](O)[C@@H](NC)[C@H]1OC1C/2=C/C#C[C@H]3O[C@@]3([C@H]3OC(=O)OC3)C#CC\2=C[C@H]1OC(=O)C1=C(C)C=CC2=C(C)C=C(OC)C=C12 FYQZGCBXYVWXSP-STTFAQHVSA-N 0.000 description 1
- 229950009233 zinostatin stimalamer Drugs 0.000 description 1
- 150000003952 β-lactams Chemical class 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
- G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
- G01N33/57496—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving intracellular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Health & Medical Sciences (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- Urology & Nephrology (AREA)
- Cell Biology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Oncology (AREA)
- Genetics & Genomics (AREA)
- Microbiology (AREA)
- Hospice & Palliative Care (AREA)
- Physics & Mathematics (AREA)
- Medicinal Chemistry (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biophysics (AREA)
- Food Science & Technology (AREA)
- General Physics & Mathematics (AREA)
- General Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
Provided herein, inter alia, are improved methods and systems of determining immunotherapy response in subjects prior and during treatment. Provided herein are methods of detecting gene expression in T cells and in monocytes as well as measuring relative abundance of particular immune cell populations and determining responsiveness to anticancer immunotherapy.
Description
- This application is a continuation application of U.S. Patent Application No. 17/110,067, filed on Dec. 2, 2020, which claims priority to U.S. Provisional Application No. 62/942,714, filed Dec. 2, 2019, which are hereby incorporated by reference in their entireties and for all purposes.
- This invention was made with government support under U54 CA209978 awarded by the National Institutes of Health. The government has certain rights in the invention.
- Immune checkpoint inhibitors treat a wide range of cancers and work by strengthening the immune system's ability to fight tumor cells. Current therapies may include monoclonal antibodies that target immune inhibitory pathways, which regulate immune activity and are frequently co-opted by cancer cells to prevent tumor recognition. One such pathway is the programmed cell death protein 1 (PD-1) pathway. Increased expression of the programmed death-ligand 1 (PD-L1) by cancer cells or tumor-associated cells allows immune escape by inhibiting proliferation, survival, and effector functions of T lymphocytes. In many cancers, including gastrointestinal (GI), PD-L1 expression has been correlated with poor prognosis. Immunotherapies using PD-1 inhibitors or PD-L1 blockade attempt to antagonize cancer-mediated immune suppression and have shown significant clinical benefits for some patients. Various immunotherapy regimens have been developed to bolster the immune system, including its combined administration with chemotherapy. Chemotherapy-induced cancer cell death releases tumor-specific antigens, promoting antigen presentation to the adaptive immune system, while immunotherapy is expected to increase the number and tumor infiltration of cytotoxic (CD8+) T cells and thereby tumor cell death. A regimen which begins immunotherapy after chemotherapy resulted in substantially improved progression-free survival (PFS) compared with chemotherapy alone or immunotherapy concomitant with chemotherapy in small cell lung cancer.
- Immunotherapy effectiveness depends on multiple factors including neo-antigen creation and tumor mutational load, tumor infiltration by cytotoxic T-cells, effector immune cell signal production, and immune crosstalk. However, the clinical response to immune checkpoint inhibitors varies widely across patients, with approximately 40% of patients showing no beneficial response at treatment end. Many studies have assessed tumor cells and tumor-associated immune cells for biomarkers of response to immunotherapy. PD-L1 expression, tumor mutation burden, gene expression have been suggested as predictive markers of immunotherapy response, but these tests require invasive collection of tumor tissue which can be challenging to obtain on all patients and over time. The frequency of specific monocyte cell types in the peripheral blood has been recently suggested as a non-invasive pre-treatment indicator of melanoma cancer patient response to immunotherapy, with a higher frequency of classical monocytes predicting improved PFS and overall survival. However, it is unclear whether circulating immune cells can serve as a surrogate measurement of tumor response to therapy given that these cells are not collected when physically in the tumor microenvironment. Further, it is unknown whether the numbers and phenotypes of circulating immune cells, as well as their evolution during treatment, can predict treatment success non-invasively prior to or soon after the initiation of therapy.
- In view of the foregoing, there is a need for improved methods of determining immunotherapy response in subjects prior to and during treatment. The present disclosure addresses this need, and provides additional benefits as well.
- In an aspect, provided herein are methods including detecting one or more parameters in a sample of peripheral blood from a subject with cancer, including detecting (i) gene expression in monocytes including (1) increased expression of one or more of NFKB1, MYD88, NFKBIA or NFKBIZ, (2) decreased expression of IKBKB, (3) increased expression of one or more of growth factor genes, and/or (4) increased expression of one or more TNF genes, compared to a control; (ii) a greater number of CD8+ differentiated cells, a greater number of CD4+ naive cells, fewer CD4+ differentiated cells, and/or fewer T follicular helper (TFH) cells compared to a control; or (iii) a lower density of total peripheral blood mononuclear cells, a lower density of CD4+ effector memory (EM) cells, and/or a higher density of classical monocytes compared to a control.
- In an aspect, provided herein are methods of identifying a cancer of a subject as responsive to treatment with a PD-1 inhibitor, the method comprising detecting one or more parameters in a sample of peripheral blood from the subject, including detecting (i) gene expression in monocytes comprising (1) increased expression of one or more of NFKB1, MYD88, NFKBIA or NFKBIZ, (2) decreased expression of IKBKB, (3) increased expression of one or more of growth factor genes, and/or (4) increased expression of one or more TNF genes, compared to a control; (ii) greater number of CD8+ differentiated cells, a greater number of CD4+ naive cells, fewer CD4+ differentiated cells, and/or fewer T follicular helper (TFH) cells compared to a control; or (iii) a lower density of total peripheral blood mononuclear cells, a lower density of CD4+ effector memory (EM) cells, and/or a higher density of classical monocytes compared to a control.
- In an aspect, provided herein is a method for treating cancer in a subject including detecting one or more parameters in a sample of peripheral blood from the subject, including detecting (i) gene expression in monocytes including (1) increased expression of one or more of NFKB1, MYD88, NFKBIA or NFKBIZ, (2) decreased expression of IKBKB, (3) increased expression of one or more of growth factor genes, and/or (4) increased expression of one or more TNF genes, compared to a control; (ii) a greater number of CD8+ differentiated cells, a greater number of CD4+ naive cells, fewer CD4+ differentiated cells, and/or fewer T follicular helper (TFH) cells compared to a control; or (iii) a lower density of total peripheral blood mononuclear cells, a lower density of CD4+ effector memory (EM) cells, and/or a higher density of classical monocytes compared to a control; and identifying the cancer as responsive to treatment with a PD-1 inhibitor if the cancer has one or more of the parameters (i)-(iii).
- In an aspect, provided herein is a method including detecting one or more parameters in a sample of peripheral blood from a subject with cancer previously treated with a PD-1 inhibitor, including detecting (i) in T cells, (1) increased expression of one or more interferon type I or type II signaling genes, (2) increased expression one or more of NFKB1, MYD88, NFKBIA or NFKBIZ, (3) increased expression of one or more major histocompatibility complex (MHC) class I or class II processing genes, (4) increased expression of one or more of CCL3, CCL4, CCL5, and CCR5, (5) decreased expression of one or more of CXCR3 or CCR2 genes, (6) increased expression in CD8+ T cells of one or more cell death genes, (7) a greater number of differentiated CD8+ cells, and/or (8) fewer differentiated CD4+ cells compared to a control; or (ii) in monocytes, (1) increased expression of genes upregulated by IFN stimulation, and/or (2) increased expression of genes upregulated by major histocompatibility complex 2 (MCHII) production.
- In an aspect, provided herein is a method of identifying a cancer of a subject previously treated with a PD-1 inhibitor as responsive to treatment with the PD-1 inhibitor, the method including detecting one or more parameters in a sample of peripheral blood from the subject, including detecting (i) in T cells, (1) increased expression of one or more interferon type I or type II signaling genes, (2) increased expression one or more of NFKB1, MYD88, NFKBIA or NFKBIZ, (3) increased expression of one or more major histocompatibility complex (MHC) class I or class II processing genes, (4) increased expression of one or more of CCL3, CCL4, CCL5, and CCR5, (5) decreased expression of one or more of CXCR3 or CCR2 genes, (6) increased expression in CD8+ T cells of one or more cell death genes, (7) a greater number of differentiated CD8+ cells, and/or (8) fewer differentiated CD4+ cells compared to a control; or (ii) in monocytes, (1) increased expression of genes upregulated by IFN stimulation, and/or (2) increased expression of genes upregulated by major histocompatibility complex 2 (MHCII) production.
- In an aspect, provided herein is a method of monitoring response to PD-1 immunotherapy in a subject previously treated with a PD-1 inhibitor, the method including detecting (i) in T cells, (1) increased expression of one or more interferon (IFN) type I or type II signaling genes, (2) increased expression one or more of NFKB1, MYD88, NFKBIA or NFKBIZ, (3) increased expression of one or more major histocompatibility complex (MHC) class I or class II processing genes, (4) increased expression of one or more of CCL3, CCL4, CCL5, and CCR5, (5) decreased expression of one or more of CXCR3 or CCR2 genes, (6) increased expression in CD8+ T cells of one or more cell death genes, (7) a greater number of differentiated CD8+ cells, and/or (8) fewer differentiated CD4+ cells compared to a control; or (ii) in monocytes, (1) increased expression of genes upregulated by IFN stimulation, and/or (2) increased expression of genes upregulated by major histocompatibility complex 2 (MHCII) production; and identifying the cancer as responsive to continued treatment with the PD-1 inhibitor if one or both of parameters (i) and (ii) are detected.
- In an aspect, provided herein is a method of monitoring response to PD-1 immunotherapy in a subject previously treated with a PD-1 inhibitor, the method including: (a) detecting an increase in peripheral blood mononuclear cells (PBMCs) in a sample of peripheral blood from the subject compared to a control; (b) detecting a reduced rate of tumor growth compared to a control, comprising measuring tumor size and/or a level of one or more tumor antigens; and (c) identifying the cancer as responsive to continued treatment with the PD-1 inhibitor if both of parameters (a) and (b) are detected.
- In an aspect, provided herein is a system including at least one processor; and at least one memory including program code which when executed by the at least one memory provides operations for performing a method as described herein.
-
FIG. 1 illustrates an overview of a clinical trial treatment strategy, classification of patients, and pipeline used to investigate PBMCs. Panel (a) is a schematic of a treatment plan showing advanced gastrointestinal patients received FOLFOX6 chemotherapy at the beginning of the trial for two 14-day cycles. Fromcycles 3 through 12, they received both FOLFOX6 and anti-PD-1 immunotherapy. At baseline (cycle 1=C1), cycle 3 (C3), cycle 5 (C5), cycle 8 (C8) whole blood was collected and PBMCs were isolated and frozen. Panel (b) is a graph showing overall survival of responders and non-responders is plotted as percent survival vs. time in months. Panel (c) is a pictorial of an experimental set up showing PBMC analyses are performed using both flow cytometry and single-cell RNA sequencing. -
FIG. 2 shows data describing the dynamic nature of monocyte and T cell signaling following immunotherapy, but not chemotherapy, treatment in patients. Panel (a) is a Uniform Manifold Approximation and Projection (UMAP) of the scRNA seq data of all patients and all time points analyzed. The major PBMC, RBC (red blood cells), and pDC (plasmacytoid dendritic cells) clusters are labeled. Panel (b) is a chart showing the similarity of cluster annotation between predicted clusters and public datasets. The top portion corresponds to the machine learning prediction for the distribution of immune cells in public datasets, grouped by predicted clusters formed using the Random Forest learner, which was trained using the PD-1 scRNAseq samples (N=69745) data set. The bottom portion (labeled Shared marker genes) shows the number of shared genes between public dataset and the predicted clusters, including NKT (Natural killer T cells) and DC (Dendritic cells). Panel (c) is a graph showing direct comparison of the frequency of major populations of samples of 8 patients analyzed with scRNA-seq and flow cytometry. All time points and patients were pooled in order to compare the overall frequency of populations, the bars indicate s.d., NS (non-significant), and statistical significance is displayed as *P<0.05 and **P<0.01 (two-tailed unpaired t-test). Panel (d) is a plot of immune cell density estimates between scRNA-seq and flow cytometry. The densities of each cell type were obtained by both methods for each patient. The diagonal dashed line shows 1:1 correspondence between the approaches. Panel (e) is a graph showing the relative number of molecular pathways (identified using GSEA, or Gene Set Enrichment Analysis) impacted by chemotherapy (red bars; far left) and PD-1 immunotherapy (grey bars; middle). Also plotted are the number of pathways effected that are specific to PD-1 immunotherapy responders (black bars; right). -
FIGS. 3A-D illustrate that pathway signaling evolution is dynamic in immune cell subtypes upon immunotherapy in responder patients.FIG. 3A are graphs showing differences in interferon (IFN) and inflammatory signaling of CD4+ and CD8+ cells of responders and non-responders, showing overall trends of pathways within each cellular process (solid lines) and variation (shaded regions). Individual GSEA pathways exhibiting differential trends in expression patterns between responders and non-responders are indicated by dashed lines, over C1, C2, and C3 timepoints.FIG. 3B is a heatmap of changes in gene expression of responder and non-responder CD4+ and CD8+ cells over time. Interferon (IFN), cell death, NF-KB, MHC (major histocompatibility complex) I & II and migration signature genes are displayed as the proportion of maximum level of each gene. Genes not detected in a cell type are shaded grey.FIG. 3C are graphs showing the differences in inflammatory signaling, differentiation and growth factor production between the monocytes of responders and non-responders showing overall trends of pathways within each cellular process (solid lines) and variation (shaded regions). The trends of pathways exhibiting differential expression patterns in responders and non-responders are indicated by dashed lines.FIG. 3D is a heatmap displaying the changes in gene expression of responder and non-responder monocytes over time. Interferon, cell death, NF-kB, TNF-α, growth factors production, and migration signature genes are displayed as the proportion of maximum level of each gene, where C stands for cycle, 1 cycle is 14 days, C1 is the baseline, C3 is the chemotherapy mFOLOFX6 regimen, and C5 is chemotherapy including anti PD-1 immunotherapy. -
FIG. 4 presents data illustrating responsiveness to therapy is dependent on circulating memory T cell evolution. Panel (a) is a Uniform Manifold Approximation and Projection (UMAP), representing gradients of CD4+ differentiation state (top: lowest score at right and highest to the left) and CD8+ differentiation state (bottom: lowest score towards the top right and highest at the bottom). Panel (b) is a UMAP identification of CD4+ and CD8+ subclusters, where TFH is Follicular helper. Panel (c) is a plot comparison of CD4+ and CD8+ cell subtype differentiation scores, where all subtypes differ with a Tukey test. The variables EM (Effector memory), EMRA (Effector memory CD45RA+), CM (Central memory) are plotted vs. differentiation score. Panel (d) are graphs showing frequency of CD4+ and CD8+ cells with different states of differentiation of responders and non-responders at each treatment time point (C1, C3, and C5). Panel (e) are graphs showing direct comparison of frequencies of CD4+ (top) T cells and CD8+ (bottom) subpopulations based on CCR7 and CD45RA markers. -
FIG. 5 presents data indicating that the exhaustion of circulating memory T cells is a hallmark of response prior to therapy. Panel (a) are plots showing frequencies of PD-1+ cells in CD8+ (left) CD4+ (right) subpopulations at C1. Panel (b) are plots showing the frequencies of CTLA4+ cells of CD4 EM or EMRA cells (top) and CD8+ EM or EMRA cells (bottom) vs. cycles C1, C3, C5, and C8 (C stands for cycle, 1 cycle is 14 days, C1 is the baseline, C3 is the chemotherapy mFOLOFX6 regimen, C5 and C8 are Chemotherapy including anti-PD-1 immunotherapy). Panel (c) Are plots showing frequencies of PD-1+ cells in CD4+ EM or CD8+ EM cells between responders and non-responders over the course of treatment. Panel (d) are graphs showing the fold change of PD1+ cells of responders and non-responders over the course of treatment. Panel (e) are graphs showing the frequencies (left) and fold change (right) of TFH (Follicular helper) between responders and non-responders across treatment. -
FIG. 6 illustrates that the evolution of classical monocytes in responders from baseline to the start of immunotherapy can represent different activated states. Panel (a) is a Uniform Manifold Approximation and Projection (UMAP) identification of classical and non-classical monocytes and dendritic cells. Panel (b) is a UMAP representing a gradient of interferon activation states (lowest scores situated at the top- and bottom-left and the highest scores at the center right and in dendritic cells). Panel (c) is a graph showing frequency density of monocytes with different interferon (IFN) activation states of responders and non-responders at each treatment time point. Panel (d) are graphs showing a comparison of the frequency of classical monocytes (CD14+/CD16−), CD86+ classical monocytes and HLADR+ classical monocytes of responders and non-responders at different treatment time points as analyzed by flow cytometry is plotted over C1, C3, C5, and C8. The statistical significance is displayed as **P<0.01 (two-tailed unpaired t-test). Box plots represent the interquartile range (IQR), with the horizontal line indicating the median. Whiskers extend to the farthest data point within a maximum of 1.5×IQR. -
FIG. 7 are plots showing that density and signaling states of CD4+ EM cells and monocytes are predictive markers of response to therapy. Panel (a) is a graph showing the relationship between CD4+ EM frequency observed by flow cytometry and the overall survival at 12 months in non-responders and responders. Panel (b) is a graph showing the relationship between classical monocyte frequency observed by flow cytometry and the overall survival at 12 months in non-responders and responders. “No” indicates patients with survival less than 12 months while “Yes” indicates patients with survival greater than 12 months. In Panels (a)-(b), statistical significance is displayed as *P<0.05 and **P<0.01 (two-tailed unpaired t-test), and C stands for cycle, 1 cycle is 14 days, C1 is the baseline, C3 is the chemotherapy mFOLOFX6 regimen, and C5 is the Chemotherapy+anti PD-1 immunotherapy regimen. Panel (c) are graphs showing the response of GI cancer patients to PD-1 inhibitor immunotherapy (point color) depends on PMBC density at the early stages of treatment (C1-C5), as well as CD4+ EM (Effector memory) T cells and classical monocyte density. Patient response boundaries (dashed lines) were predicted using a hierarchical logistic regression model and delineate responsive and non-responsive immune states. Panel (d) is a graph of the pretreatment patient averaged GSEA pathway scores for CD8+ T cell interferon (IFN) activation and monocyte inflammatory response. The figure shows the correlation of monocytes inflammatory signaling and CD8 IFN signaling and responsiveness to therapy. -
FIG. 8 illustrates a model of the dynamics and evolution of PBMCs in responders and non-responders. -
FIGS. 9A-F (includingFIGS. 9A-1, 9A-2, 9B, 9C-1, 9C-2, 9D-1, 9D-2, 9E-1, 9E-2, 9F-1 , and 9F-2) depict a gating strategy used to analyze PBMCs, including a step-wise division of various cell populations, starting from PBMCs, into smaller and smaller subpopulations of interest based on multiple binning methods. In one example, flow cytometry analysis of PBMCs isolated from 3 to 4 time points, C1, C3, C5, and C8 was performed on a set of responder and non-responder patients. The time points refer to cycle 1 (C1), which is baseline without any treatment, cycle 3 (C3), which is treatment with only mFOLFOX6 chemotherapy, and cycle 5 (C5) or cycle 8 (C8), which ar two different time points during treatment with both mFOLFOX6 and PD-1i immunotherapy. A total of 12 patients (responder n=7, non-responder n=5) were analyzed by flow cytometry. In another example, flow cytometry analysis using CD45RA and CCR7 as markers was used to discriminate memory from naïve T cells identified multiple significant differences in the CD4 population. -
FIG. 10 is a plot of UMAP key gene expression markers of major PBMC populations. The gene expression markers include MS4A1, KLRF1, GZMA, CD3D, CD4, CD8A, FCER1A, CD14, and CD16 (UMAP1 vs. UMAP2). Major PBMC types are verified by their characteristic expression of certain combinations of these genes. Unlike other dimension reduction techniques, UMAP representations preserve information about developmental similarity, with nearby cells being developmentally similar to one another. -
FIG. 11 illustrates that UMAP gene expression plots show no batch effects. Panel (a) is a Uniform Manifold Approximation and Projection (UMAP) of the scRNA seq data of all patients and all time points. Major PBMC clusters are labeled in red while subclusters or minor PBMC clusters are labeled in black. Panel (b) is the UMAP gene expression distribution per time point of treatment is plotted for each time point C1, C3, and C5, where C stands for cycle, 1 cycle is 14 days, C1 is the baseline time point, C3 is the chemotherapy FOLFOX regimen, C5 is the chemotherapy+anti PD-1 immunotherapy regimen. Panel (c) is the UMAP gene expression distribution per cancer analyzed. Panel (d) is the UMAP gene expression distribution per patient analyzed. -
FIGS. 12A-B illustrate that UMAP labeled clusters are similar to public datasets. The left panels correspond to the machine learning prediction, where the distribution of immune cells in public datasets is predicted to PD-1 clusters by Random Forest learner using the patient sample cohort as a training set. The right panels are the shared marker genes, corresponding to the number of shared genes between public datasets and the patient sample cohort clusters.FIG. 12A - corresponds to clusters published by Azizi et al. [30].
FIG. 12B corresponds to clusters published by Sade-Feldman et al. [29]. -
FIGS. 13A-E illustrate the connections between PD-1 dataset annotated clusters and public dataset clusters. Cell type annotations determined from anaylsis of transcriptional profiles of cells within the patient cohort applied to single cell data from two recent immune studies. The agreement between cell type annotations predicted for that dataset using our annotation algorithm (x-axis) is compared to the cell type annotations predicted by the authors of the previous studies (y-axis). The heatmaps show the frequency of agreement in cell type annotation.FIGS. 13B-13C (machine learning prediction): Connection of immune cells types identified in public datasets and those predicted for the PD-1 dataset clusters, by applying a Random Forest learning algorithm to the patient cohort as a training set.FIGS. 13D-13E (Shared marker genes): Connections of the number of shared genes between public datasets and our cohort clusters. InFIGS. 13B-13E , the top row corresponds to cluster published by Azizi et al. while the bottom row corresponds to cluster published by Sade-Feldman et al. -
FIG. 14 is a plot providing a comparison of immune cell subtype densities, using scRNA-seq (Y-axis) or flow cytometry (X-axis) estimates. The densities of each cell subtype (colored points) were obtained scaling cell proportions measured by each method by the observed PBMC density in the blood sample. The cell subtype density was calculated for each patient, at each time point. The diagonal dashed line shows the 1:1 correspondence between the approaches. -
FIG. 15 are graphs illustrating that chemotherapy and immunotherapy induce no change in immune cell frequencies in both responders and non-responders except for monocytes and natural killer cells. Comparison of major cell population frequencies over the course of treatment obtained by flow cytometry (top) and scRNA-seq (bottom), where NK are natural killer cells, NKT are natural killer T cells, the statistical significance is displayed as *P<0.05, **P<0.01 (two-tailed unpaired t-test), C stands for cycle, 1 cycle is 14 days, C1 is the baseline, C3 is the chemotherapy FOLFOX regimen, and C5 is the chemotherapy+anti PD-1 immunotherapy regimen. -
FIG. 16 are plots showing the overview of differential temporal trends in monocyte and T cell pathway expression between responders and non-responders. Response (red or blue) related differences in pathway activity was identified relating to: cell death, differentiation, growth factor production, interferon, and inflammatory signaling, migration and stemness. These pathway changes are visualized when present for monocytes, CD4+, and CD8+T cells. Trends of pathways exhibiting differential expression patterns in responders and non-responders are indicated by dashed lines. Overall trends of pathways within each cellular process (solid lines) and variation (shaded red or blue regions) are overlaid. -
FIGS. 17A-C illustrate gene expression data showing that responders' CD4+ and CD8+ T cells show upregulation of IFN gene signature pathways following the addition of anti-PD-1 immunotherapy, as shown in cell density vs. differentiation plots. Heatmaps showing the changes in IFN (interferon) pathway-related gene expression of responders and non-responders CD4+ and CD8+ cells over time are plotted. Gene expression is displayed as the proportion of the maximum level of each gene, compared at time points C1 (baseline, left), C3 (start of chemotherapy FOLFOX regimen, middle) and C5 (two cycles of anti-PD-1 immunotherapy in addition to chemotherapy, right). Results for non-responders are on the left, and responders on the right. -
FIGS. 18A-C illustrate gene expression data showing that non-responder and responder monocytes show a different gene expression pattern of inflammatory, growth factor, and differentiation pathways before and in response to anti-PD-1 immunotherapy. Heatmaps of changes in monocyte differentiation, growth factor production and inflammatory response gene expression over time in responders and non-responders are plotted. Gene expression is displayed as the proportion of the maximum level of each gene. Expression compared at time points C1 (baseline, left), C3 (start of chemotherapy FOLFOX regimen, middle) and C5 (two cycles of anti-PD-1 immunotherapy in addition to chemotherapy, right). Results for non-responders are on the left, and responders on the right. -
FIG. 19 are phenotype axes plots capturing the continuous spectrum of T cell differentiation states. Changes in CD4+ and CD8+ cell gene expression are shown across the T-cell differentiation gradient. For each cell (dot) in each T cell subtype (color), the cell differentiation score is plotted against marker genes of naïve (CCR7) and effector states (LGALS1 and GZMA). Average expression of cells in small regions of the phenotype gradient are calculated, after discretizing the differentiation axis into 100 categories and classifying cells into these groups. A generalized additive model indicates the trend in gene expression across the phenotype gradient. -
FIG. 20 shows graphs illustrating that the abundance of different immune cell subtypes in CD4+/CD8+ T cells and monocytes differs between responders and non-responders and over time. Immune cell densities are shown for each patient (color) for subtypes of: CD4+ T cell as in Panel (a); CD8+ cell as in Panel (b); and monocytes as in Panel (c). Patients are grouped into responders and non-responders in each panel, and C stands for cycle, 1 cycle is 14 days, C1 is the baseline, C3 is the chemotherapy FOLFOX regimen, C5 is the chemotherapy+anti PD-1 immunotherapy regimen. -
FIG. 21 is a graph showing that Major Histocompatibility Complex (MHC) II gene expression of monocytes increases more in responders than non-responders following PD-1i immunotherapy. Frequency of monocytes with different levels of MHC II gene expression compared between responders and non-responders at each treatment time point (C1, C3, and C5, where C stands for cycle, 1 cycle is 14 days, C1 is the baseline, C3 is the chemotherapy FOLFOX regimen, C5 is the chemotherapy+anti PD-1 immunotherapy regimen). The overall MHC II expression score was produced using the first dimension of a principle component analysis applied to the expression of all HLA class II alpha chain genes within each cell. -
FIG. 22 illustrates a mathematical model flowchart of tumor-immune cell interactions. -
FIG. 23 ilustrates a model and estimate of biological parameters for determining tumor response, and example data. - The practice of the technology described herein will employ, unless indicated specifically to the contrary, conventional methods of chemistry, biochemistry, organic chemistry, molecular biology, microbiology, recombinant DNA techniques, genetics, immunology, and cell biology that are within the skill of the art, many of which are described below for the purpose of illustration. Examples of such techniques are available in the literature. [See for example Refs. 61-68]
- All patents, patent applications, articles and publications mentioned herein, both supra and infra, are hereby expressly incorporated herein by reference in their entireties.
- Unless defined otherwise herein, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this disclosure belongs. Various scientific dictionaries that include the terms included herein are well known and available to those in the art. Although any methods and materials similar or equivalent to those described herein find use in the practice or testing of the disclosure, some preferred methods and materials are described. Accordingly, the terms defined immediately below are more fully described by reference to the specification as a whole. It is to be understood that this disclosure is not limited to the particular methodology, protocols, and reagents described, as these may vary, depending upon the context in which they are used by those of skill in the art.
- As used herein, the singular terms “a”, “an”, and “the” include the plural reference unless the context clearly indicates otherwise.
- Reference throughout this specification to, for example, “one embodiment”, “an embodiment”, “another embodiment”, “a particular embodiment”, “a related embodiment”, “a certain embodiment”, “an additional embodiment”, or “a further embodiment” or combinations thereof means that a particular feature, structure or characteristic described in connection with the embodiment is included in at least one embodiment of the present disclosure. Thus, the appearances of the foregoing phrases in various places throughout this specification are not necessarily all referring to the same embodiment. Furthermore, the particular features, structures, or characteristics may be combined in any suitable manner in one or more embodiments.
- As used herein, the term “about” means a range of values including the specified value, which a person of ordinary skill in the art would consider reasonably similar to the specified value. In embodiments, the term “about” means within a standard deviation using measurements generally acceptable in the art. In embodiments, about means a range extending to +/−10% of the specified value. In embodiments, about means the specified value.
- Throughout this specification, unless the context requires otherwise, the words “comprise”, “comprises” and “comprising” will be understood to imply the inclusion of a stated step or element or group of steps or elements but not the exclusion of any other step or element or group of steps or elements. By “consisting of” is meant including, and limited to, whatever follows the phrase “consisting of.” Thus, the phrase “consisting of” indicates that the listed elements are required or mandatory, and that no other elements may be present. By “consisting essentially of” is meant including any elements listed after the phrase, and limited to other elements that do not interfere with or contribute to the activity or action specified in the disclosure for the listed elements. Thus, the phrase “consisting essentially of” indicates that the listed elements are required or mandatory, but that other elements are optional and may or may not be present depending upon whether or not they affect the activity or action of the listed elements.
- The terms “disease” or “condition” refer to a state of being or health status of a patient or subject capable of being diagnosed and/or treated with compounds or methods provided herein. The disease may be a cancer.
- As used herein, the term “cancer” refers to all types of cancer, neoplasm or malignant tumors found in mammals (e.g. humans), including leukemias, lymphomas, carcinomas and sarcomas. Examples of cancers that may be diagnosed and/or treated with a compound or method provided herein include brain cancer, glioma, glioblastoma, neuroblastoma, prostate cancer, colorectal cancer, pancreatic cancer, Medulloblastoma, melanoma, cervical cancer, gastric cancer, ovarian cancer, lung cancer, cancer of the head, Hodgkin's Disease, and Non-Hodgkin's Lymphomas. Example cancers that may be diagnosed and/or treated with a compound or method provided herein include cancer of the thyroid, endocrine system, brain, breast, cervix, colon, head & neck, liver, kidney, lung, ovary, pancreas, rectum, stomach, and uterus. Additional examples include, thyroid carcinoma, cholangiocarcinoma, pancreatic adenocarcinoma, skin cutaneous melanoma, colon adenocarcinoma, rectum adenocarcinoma, stomach adenocarcinoma, esophageal carcinoma, head and neck squamous cell carcinoma, breast invasive carcinoma, lung adenocarcinoma, lung squamous cell carcinoma, non-small cell lung carcinoma, mesothelioma, multiple myeloma, neuroblastoma, glioma, glioblastoma multiforme, ovarian cancer, rhabdomyosarcoma, primary thrombocytosis, primary macroglobulinemia, primary brain tumors, malignant pancreatic insulanoma, malignant carcinoid, urinary bladder cancer, premalignant skin lesions, testicular cancer, thyroid cancer, neuroblastoma, esophageal cancer, genitourinary tract cancer, malignant hypercalcemia, endometrial cancer, adrenal cortical cancer, neoplasms of the endocrine or exocrine pancreas, medullary thyroid cancer, medullary thyroid carcinoma, melanoma, colorectal cancer, papillary thyroid cancer, hepatocellular carcinoma, or prostate cancer. In embodiments, the cancer is gastrointestinal cancer. In embodiments, the cancer is colorectal cancer. In embodiments, the cancer is gastroesophogeal. In embodiments, the cancer is cancer pancreatic cancer. In embodiments, the cancer is biliary cancer.
- As used herein, the term “diagnosis” refers to an identification or likelihood of the presence of a particular type of cancer or outcome in a subject. As also used herein, the term “prognosis” refers to the likelihood or risk of a subject developing a particular outcome or particular event.
- As used herein, a “biological sample” encompasses essentially any sample type obtained from a subject that can be used in a diagnostic or prognostic method described herein. The biological sample may be any bodily fluid, tissue or any other suitable sample. The definition encompasses blood and other liquid samples of biological origin, solid tissue samples such as a biopsy specimen or tissue cultures or cells derived therefrom and the progeny thereof. The definition also includes samples that have been manipulated in any way after their procurement, such as by treatment with reagents, solubilization, or enrichment for certain components, such as cells (e.g., cancer cells), polypeptides, or proteins. The term “biological sample” encompasses a clinical sample, but also, in some instances, includes cells in culture, cell supernatants, cell lysates, blood, serum, plasma, urine, cerebral spinal fluid, biological fluid, and tissue samples. The sample may be pretreated as necessary by dilution in an appropriate buffer solution or concentrated, if desired. Any of a number of standard aqueous buffer solutions, employing one of a variety of buffers, such as phosphate, Tris, or the like, preferably at physiological pH can be used. Biological samples can be derived from patients using well-known techniques such as venipuncture, lumbar puncture, fluid sample such as saliva or urine, or tissue biopsy and the like. In embodiments, the sample is a cancer sample (e.g., containing or suspected of containing cancer cells, such as from a tumor). In embodiments, the sample is a formalin-fixed, paraffin-embedded (FFPE) sample.
- “Treating” or “treatment” as used herein (and as well understood in the art) includes any approach for obtaining beneficial or desired results in a subject's condition, including clinical results. Beneficial or desired clinical results can include, but are not limited to, alleviation or amelioration of one or more symptoms or conditions, diminishment of the extent of a disease, stabilizing (i.e., not worsening) the state of disease, prevention of a disease's transmission or spread, delay or slowing of disease progression, amelioration or palliation of the disease state, diminishment of the reoccurrence of disease, and remission, whether partial or total and whether detectable or undetectable. “Treating” or “treatment” refers to any indicia of success in the therapy or amelioration of an injury, disease, pathology or condition, including any objective or subjective parameter such as abatement; remission; diminishing of symptoms or making the injury, pathology or condition more tolerable to the patient; slowing in the rate of degeneration or decline; making the final point of degeneration less debilitating; improving a patient's physical or mental well-being. The treatment or amelioration of symptoms can be based on objective or subjective parameters; including the results of a physical examination, neuropsychiatric exams, and/or a psychiatric evaluation. In other words, “treatment” as used herein includes any cure, amelioration, or prevention of a disease.
- “Treating” or “treatment” as used herein includes prophylactic treatment. Treatment may prevent the disease from occurring; inhibit the disease's spread; relieve the disease's symptoms, fully or partially remove the disease's underlying cause, shorten a disease's duration, or do a combination of these things. The term “treating” and conjugations thereof may include prevention of an injury, pathology, condition, or disease. In embodiments, treating is preventing. In embodiments, treating does not include preventing. Treatment methods include administering to a subject a therapeutically effective amount of an active agent. The administering step may consist of a single administration or may include a series of administrations. The length of the treatment period depends on a variety of factors, such as the severity of the condition, the age of the patient, the concentration of active agent, the activity of the compositions used in the treatment, or a combination thereof. It will also be appreciated that the effective dosage of an agent used for the treatment or prophylaxis may increase or decrease over the course of a particular treatment or prophylaxis regime. Changes in dosage may result and become apparent by diagnostic assays (e.g., assays described herein or known in the art). In some instances, chronic administration may be required. For example, the compositions are administered to the subject in an amount and for a duration sufficient to treat the patient.
- The term “prevent” refers to a decrease in the occurrence of disease symptoms in a patient. The prevention may be complete (no detectable symptoms) or partial, such that fewer symptoms are observed than would likely occur absent treatment.
- The term “patient” or “subject” refers to a living organism suffering from or prone to a disease or condition that can be treated by administration of a pharmaceutical composition. Non-limiting examples include humans, other mammals, bovines, rats, mice, dogs, monkeys, goat, sheep, cows, deer, and other non-mammalian animals. In some embodiments, a subject is human.
- The term “control” or “control experiment” is used in accordance with its plain and ordinary meaning and refers to an experiment in which the subjects or reagents of the experiment are treated as in a parallel experiment except for omission of a procedure, reagent, or variable of the experiment. In some instances, the control is used as a standard of comparison in evaluating experimental effects. In some embodiments, a control is a measurement of a reference sample. In some instances, the control is a synthetic quantification standard used as a reference for assay measurements. In embodiments, the control is a reference value obtained for a reference individual or population of individuals having a known condition, such as responsiveness or non-responsiveness to PD-1 inhibitor treatment. In embodiments, the reference individual or population is not responsive to PD-1 inhibitor treatment, and detection of of PD-1 inhibitor responsiveness comprises dissimilarity to the control (e.g., an increase or decrease of a particular parameter). In embodiments, the control is a refence value for a sample from the same subject but at a different time, such as at an earlier time (e.g., prior to administering a treatment, such as a PD1 inhibitor).
- As described herein, the terms “marker”, “protein marker”, “polypeptide marker”, and “biomarker” are used interchangeably throughout the disclosure. As used herein, a protein marker refers generally to a protein or polypeptide, the level or concentration of which is associated with a particular biological state. In embodiments, the marker is a gene expression marker, changes in which may be detected at the level of transcribed RNA, or translated polypeptide.
- The terms “polypeptide,” “peptide” and “protein” used interchangeably herein, refer to a polymeric form of amino acids of any length, which can include coded and non-coded amino acids, chemically or biochemically modified or derivatized amino acids, and polypeptides having modified peptide backbones. In various embodiments, detecting the concentrations of naturally occurring protein marker proteins in a biological sample is contemplated for use within diagnostic, prognostic, or monitoring methods disclosed herein. The term also includes fusion proteins, including, but not limited to, naturally occurring fusion proteins with a heterologous amino acid sequence, fusions with heterologous and homologous leader sequences, with or without N-terminal methionine residues; immunologically tagged proteins; and the like. The terms also include polymers that may be conjugated to a moiety that does not consist of amino acids. The terms apply to amino acid polymers in which one or more amino acid residue is an artificial chemical mimetic of a corresponding naturally occurring amino acid, as well as to naturally occurring amino acid polymers and non-naturally occurring amino acid polymers. A “fusion protein” refers to a chimeric protein encoding two or more separate protein sequences that are recombinantly expressed as a single moiety.
- For specific proteins described herein, the named protein includes any of the protein's naturally occurring forms, variants or homologs that maintain the protein's activity (e.g., within at least 50%, 80%, 90%, 95%, 96%, 97%, 98%, 99% or 100% activity compared to the native protein). In some embodiments, variants or homologs have at least 90%, 95%, 96%, 97%, 98%, 99% or 100% amino acid sequence identity across the whole sequence or a portion of the sequence (e.g. a 50, 100, 150 or 200 continuous amino acid portion) compared to a naturally occurring form. Genes and their corresponding proteins are identified by designations commonly used in the art according to their plain and ordinary meaning. Additional information relating to recited gene designations, including sequence information (e.g., DNA, RNA, and amino acid sequences), full names of genes commonly identified by way of acronym, and the like are available in publicly accessible databases known to those skilled in the art, such as databases available from the National Center for Biotechnology Information (www.ncbi.nlm.nih.gov/), including GenBank (www.ncbi.nlm.nih.gov/genbank/) and the NCBI Protein database (www.ncbi.nlm.nih.gov/protein/), and UniProt (www.uniprot.org).
- A “substantially isolated” or “isolated” substance is one that is substantially free of its associated surrounding materials in nature. The term “substantially free” is used herein to mean at least 50%, preferably at least 70%, more preferably at least 80%, and even more preferably at least 90% free of the materials with which it is associated in nature. As used herein, “isolated” can refer to polynucleotides, polypeptides, antibodies, cells, samples, and the like.
- An “effective amount” is an amount sufficient for a compound to accomplish a stated purpose relative to the absence of the compound (e.g. achieve the effect for which it is administered, treat a disease, reduce enzyme activity, increase enzyme activity, reduce a signaling pathway, or reduce one or more symptoms of a disease or condition). An example of an “effective amount” is an amount sufficient to contribute to the treatment, prevention, or reduction of a symptom or symptoms of a disease, which could also be referred to as a “therapeutically effective amount.” A “reduction” of a symptom or symptoms (and grammatical equivalents of this phrase) means decreasing of the severity or frequency of the symptom(s), or elimination of the symptom(s). A “prophylactically effective amount” of a drug is an amount of a drug that, when administered to a subject, will have the intended prophylactic effect, e.g., preventing or delaying the onset (or reoccurrence) of an injury, disease, pathology or condition, or reducing the likelihood of the onset (or reoccurrence) of an injury, disease, pathology, or condition, or their symptoms. The full prophylactic effect does not necessarily occur by administration of one dose, and may occur only after administration of a series of doses. Thus, a prophylactically effective amount may be administered in one or more administrations. An “activity decreasing amount,” as used herein, refers to an amount of antagonist required to decrease the activity of an enzyme relative to the absence of the antagonist. A “function disrupting amount,” as used herein, refers to the amount of antagonist required to disrupt the function of an enzyme or protein relative to the absence of the antagonist. The exact amounts will depend on the purpose of the treatment, and will be ascertainable by one skilled in the art using known techniques.
- The term “administering” as used herein refers to oral administration, administration as a suppository, topical contact, intravenous, parenteral, intraperitoneal, intramuscular, intralesional, intrathecal, intranasal or subcutaneous administration, or the implantation of a slow-release device, e.g., a mini-osmotic pump, to a subject. Administration is by any route, including parenteral and transmucosal (e.g., buccal, sublingual, palatal, gingival, nasal, vaginal, rectal, or transdermal). Parenteral administration includes, e.g., intravenous, intramuscular, intra-arteriole, intradermal, subcutaneous, intraperitoneal, intraventricular, and intracranial. Other modes of delivery include, but are not limited to, the use of liposomal formulations, intravenous infusion, transdermal patches, etc. In embodiments, the administering does not include administration of any active agent other than the recited active agent.
- The term “co-administer” as used herein refers to a composition described herein administered at the same time, just prior to, or just after the administration of one or more additional therapies. The compounds provided herein can be administered alone or can be coadministered to the patient. Co-administration is meant to include simultaneous or sequential administration of the compounds individually or in combination (more than one compound). Thus, the preparations can also be combined, when desired, with other active substances (e.g. to reduce metabolic degradation). The compositions of the present disclosure can be delivered transdermally, by a topical route, or formulated as applicator sticks, solutions, suspensions, emulsions, gels, creams, ointments, pastes, jellies, paints, powders, and aerosols.
- The term “cancer model organism” as used herein refers to an organism exhibiting a phenotype indicative of cancer, or the activity of cancer causing elements, within the organism. A wide variety of organisms may serve as cancer model organisms, and include for example, cancer cells and mammalian organisms such as rodents (e.g. mouse or rat) and primates. Cancer cell lines are widely understood by those skilled in the art as cells exhibiting phenotypes or genotypes similar to in vivo cancers. Cancer cell lines as used herein includes cell lines from animals (e.g. mice) and from humans.
- The term “anticancer agent” is used in accordance with its plain ordinary meaning and refers to a composition (e.g. compound, drug, antagonist, inhibitor, modulator) having antineoplastic properties or the ability to inhibit the growth or proliferation of cells. In some embodiments, an anti-cancer agent is a chemotherapeutic. In some embodiments, an anti-cancer agent is an agent identified herein having utility in methods of treating cancer. In some embodiments, an anti-cancer agent is an agent approved by the FDA or similar regulatory agency of a country other than the USA, for treating cancer. Examples of anti-cancer agents include, but are not limited to, MEK (e.g. MEK1, MEK2, or MEK1 and MEK2) inhibitors (e.g. XL518, CI-1040, PD035901, selumetinib/AZD6244, GSK1120212/trametinib, GDC-0973, ARRY-162, ARRY-300, AZD8330, PD0325901, U0126, PD98059, TAK-733, PD318088, AS703026, BAY 869766), alkylating agents (e.g., cyclophosphamide, ifosfamide, chlorambucil, busulfan, melphalan, mechlorethamine, uramustine, thiotepa, nitrosoureas, nitrogen mustards (e.g., mechloroethamine, cyclophosphamide, chlorambucil, meiphalan), ethylenimine and methylmelamines (e.g., hexamethlymelamine, thiotepa), alkyl sulfonates (e.g., busulfan), nitrosoureas (e.g., carmustine, lomusitne, semustine, streptozocin), triazenes (decarbazine)), anti-metabolites (e.g., 5-azathioprine, leucovorin, capecitabine, fludarabine, gemcitabine, pemetrexed, raltitrexed, folic acid analog (e.g., methotrexate), or pyrimidine analogs (e.g., fluorouracil, floxouridine, Cytarabine), purine analogs (e.g., mercaptopurine, thioguanine, pentostatin), etc.), plant alkaloids (e.g., vincristine, vinblastine, vinorelbine, vindesine, podophyllotoxin, paclitaxel, docetaxel, etc.), topoisomerase inhibitors (e.g., irinotecan, topotecan, amsacrine, etoposide (VP16), etoposide phosphate, teniposide, etc.), antitumor antibiotics (e.g., doxorubicin, adriamycin, daunorubicin, epirubicin, actinomycin, bleomycin, mitomycin, mitoxantrone, plicamycin, etc.), platinum-based compounds (e.g. cisplatin, oxaloplatin, carboplatin), anthracenedione (e.g., mitoxantrone), substituted urea (e.g., hydroxyurea), methyl hydrazine derivative (e.g., procarbazine), adrenocortical suppressant (e.g., mitotane, aminoglutethimide), epipodophyllotoxins (e.g., etoposide), antibiotics (e.g., daunorubicin, doxorubicin, bleomycin), enzymes (e.g., L-asparaginase), inhibitors of mitogen-activated protein kinase signaling (e.g. U0126, PD98059, PD184352, PD0325901, ARRY-142886, SB239063, SP600125, BAY 43-9006, wortmannin, or LY294002, Syk inhibitors, mTOR inhibitors, antibodies (e.g., rituxan), gossyphol, genasense, polyphenol E, Chlorofusin, all trans-retinoic acid (ATRA), bryostatin, tumor necrosis factor-related apoptosis-inducing ligand (TRAIL), 5-aza-2′-deoxycytidine, all trans retinoic acid, doxorubicin, vincristine, etoposide, gemcitabine, imatinib (Gleevec®), geldanamycin, 17-N-Allylamino-17-Demethoxygeldanamycin (17-AAG), flavopiridol, LY294002, bortezomib, trastuzumab, BAY 11-7082, PKC412, PD184352, 20-epi-1, 25 dihydroxyvitamin D3; 5-ethynyluracil; abiraterone; aclarubicin; acylfulvene; adecypenol; adozelesin; aldesleukin; ALL-TK antagonists; altretamine; ambamustine; amidox; amifostine; aminolevulinic acid; amrubicin; amsacrine; anagrelide; anastrozole; andrographolide; angiogenesis inhibitors; antagonist D; antagonist G; antarelix; anti-dorsalizing morphogenetic protein-1; antiandrogen, prostatic carcinoma; antiestrogen; antineoplaston; antisense oligonucleotides; aphidicolin glycinate; apoptosis gene modulators; apoptosis regulators; apurinic acid; ara-CDP-DL-PTBA; arginine deaminase; asulacrine; atamestane; atrimustine; axinastatin 1; axinastatin 2; axinastatin 3; azasetron; azatoxin; azatyrosine; baccatin III derivatives; balanol; batimastat; BCR/ABL antagonists; benzochlorins; benzoylstaurosporine; beta lactam derivatives; beta-alethine; betaclamycin B; betulinic acid; bFGF inhibitor; bicalutamide; bisantrene; bisaziridinylspermine; bisnafide; bistratene A; bizelesin; breflate; bropirimine; budotitane; buthionine sulfoximine; calcipotriol; calphostin C; camptothecin derivatives; canarypox IL-2; capecitabine; carboxamide-amino-triazole; carboxyamidotriazole; CaRest M3; CARN 700; cartilage derived inhibitor; carzelesin; casein kinase inhibitors (ICOS); castanospermine; cecropin B; cetrorelix; chlorins; chloroquinoxaline sulfonamide; cicaprost; cis-porphyrin; cladribine; clomifene analogues; clotrimazole; collismycin A; collismycin B; combretastatin A4; combretastatin analogue; conagenin; crambescidin 816; crisnatol; cryptophycin 8; cryptophycin A derivatives; curacin A; cyclopentanthraquinones; cycloplatam; cypemycin; cytarabine ocfosfate; cytolytic factor; cytostatin; dacliximab; decitabine; dehydrodidemnin B; deslorelin; dexamethasone; dexifosfamide; dexrazoxane; dexverapamil; diaziquone; didemnin B; didox; diethylnorspermine; dihydro-5-azacytidine; 9-dioxamycin; diphenyl spiromustine; docosanol; dolasetron; doxifluridine; droloxifene; dronabinol; duocarmycin SA; ebselen; ecomustine; edelfosine; edrecolomab; eflornithine; elemene; emitefur; epirubicin; epristeride; estramustine analogue; estrogen agonists; estrogen antagonists; etanidazole; etoposide phosphate; exemestane; fadrozole; fazarabine; fenretinide; filgrastim; finasteride; flavopiridol; flezelastine; fluasterone; fludarabine; fluorodaunorunicin hydrochloride; forfenimex; formestane; fostriecin; fotemustine; gadolinium texaphyrin; gallium nitrate; galocitabine; ganirelix; gelatinase inhibitors; gemcitabine; glutathione inhibitors; hepsulfam; heregulin; hexamethylene bisacetamide; hypericin; ibandronic acid; idarubicin; idoxifene; idramantone; ilmofosine; ilomastat; imidazoacridones; imiquimod; immunostimulant peptides; insulin-like growth factor-1 receptor inhibitor; interferon agonists; interferons; interleukins; iobenguane; iododoxorubicin; ipomeanol, 4-; iroplact; irsogladine; isobengazole; isohomohalicondrin B; itasetron; jasplakinolide; kahalalide F; lamellarin-N triacetate; lanreotide; leinamycin; lenograstim; lentinan sulfate; leptolstatin; letrozole; leukemia inhibiting factor; leukocyte alpha interferon; leuprolide+estrogen+progesterone; leuprorelin; levamisole; liarozole; linear polyamine analogue; lipophilic disaccharide peptide; lipophilic platinum compounds; lissoclinamide 7; lobaplatin; lombricine; lometrexol; lonidamine; losoxantrone; lovastatin; loxoribine; lurtotecan; lutetium texaphyrin; lysofylline; lytic peptides; maitansine; mannostatin A; marimastat; masoprocol; maspin; matrilysin inhibitors; matrix metalloproteinase inhibitors; menogaril; merbarone; meterelin; methioninase; metoclopramide; MIF inhibitor; mifepristone; miltefosine; mirimostim; mismatched double stranded RNA; mitoguazone; mitolactol; mitomycin analogues; mitonafide; mitotoxin fibroblast growth factor-saporin; mitoxantrone; mofarotene; molgramostim; monoclonal antibody, human chorionic gonadotrophin; monophosphoryl lipid A+myobacterium cell wall sk; mopidamol; multiple drug resistance gene inhibitor; multiple tumor suppressor 1-based therapy; mustard anticancer agent; mycaperoxide B; mycobacterial cell wall extract; myriaporone; N-acetyldinaline; N-substituted benzamides; nafarelin; nagrestip; naloxone+pentazocine; napavin; naphterpin; nartograstim; nedaplatin; nemorubicin; neridronic acid; neutral endopeptidase; nilutamide; nisamycin; nitric oxide modulators; nitroxide antioxidant; nitrullyn; O6-benzylguanine; octreotide; okicenone; oligonucleotides; onapristone; ondansetron; ondansetron; oracin; oral cytokine inducer; ormaplatin; osaterone; oxaliplatin; oxaunomycin; palauamine; palmitoylrhizoxin; pamidronic acid; panaxytriol; panomifene; parabactin; pazelliptine; pegaspargase; peldesine; pentosan polysulfate sodium; pentostatin; pentrozole; perflubron; perfosfamide; perillyl alcohol; phenazinomycin; phenylacetate; phosphatase inhibitors; picibanil; pilocarpine hydrochloride; pirarubicin; piritrexim; placetin A; placetin B; plasminogen activator inhibitor; platinum complex; platinum compounds; platinum-triamine complex; porfimer sodium; porfiromycin; prednisone; propyl bis-acridone; prostaglandin J2; proteasome inhibitors; protein A-based immune modulator; protein kinase C inhibitor; protein kinase C inhibitors, microalgal; protein tyrosine phosphatase inhibitors; purine nucleoside phosphorylase inhibitors; purpurins; pyrazoloacridine; pyridoxylated hemoglobin polyoxyethylerie conjugate; raf antagonists; raltitrexed; ramosetron; ras farnesyl protein transferase inhibitors; ras inhibitors; ras-GAP inhibitor; retelliptine demethylated; rhenium Re 186 etidronate; rhizoxin; ribozymes; RII retinamide; rogletimide; rohitukine; romurtide; roquinimex; rubiginone B1; ruboxyl; safingol; saintopin; SarCNU; sarcophytol A; sargramostim; Sdi 1 mimetics; semustine; senescence derived inhibitor 1; sense oligonucleotides; signal transduction inhibitors; signal transduction modulators; single chain antigen-binding protein; sizofuran; sobuzoxane; sodium borocaptate; sodium phenylacetate; solverol; somatomedin binding protein; sonermin; sparfosic acid; spicamycin D; spiromustine; splenopentin; spongistatin 1; squalamine; stem cell inhibitor; stem-cell division inhibitors; stipiamide; stromelysin inhibitors; sulfinosine; superactive vasoactive intestinal peptide antagonist; suradista; suramin; swainsonine; synthetic glycosaminoglycans; tallimustine; tamoxifen methiodide; tauromustine; tazarotene; tecogalan sodium; tegafur; tellurapyrylium; telomerase inhibitors; temoporfin; temozolomide; teniposide; tetrachlorodecaoxide; tetrazomine; thaliblastine; thiocoraline; thrombopoietin; thrombopoietin mimetic; thymalfasin; thymopoietin receptor agonist; thymotrinan; thyroid stimulating hormone; tin ethyl etiopurpurin; tirapazamine; titanocene bichloride; topsentin; toremifene; totipotent stem cell factor; translation inhibitors; tretinoin; triacetyluridine; triciribine; trimetrexate; triptorelin; tropisetron; turosteride; tyrosine kinase inhibitors; tyrphostins; UBC inhibitors; ubenimex; urogenital sinus-derived growth inhibitory factor; urokinase receptor antagonists; vapreotide; variolin B; vector system, erythrocyte gene therapy; velaresol; veramine; verdins; verteporfin; vinorelbine; vinxaltine; vitaxin; vorozole; zanoterone; zeniplatin; zilascorb; zinostatin stimalamer, Adriamycin, Dactinomycin, Bleomycin, Vinblastine, Cisplatin, acivicin; aclarubicin; acodazole hydrochloride; acronine; adozelesin; aldesleukin; altretamine; ambomycin; ametantrone acetate; aminoglutethimide; amsacrine; anastrozole; anthramycin; asparaginase; asperlin; azacitidine; azetepa; azotomycin; batimastat; benzodepa; bicalutamide; bisantrene hydrochloride; bisnafide dimesylate; bizelesin; bleomycin sulfate; brequinar sodium; bropirimine; busulfan; cactinomycin; calusterone; caracemide; carbetimer; carboplatin; carmustine; carubicin hydrochloride; carzelesin; cedefingol; chlorambucil; cirolemycin; cladribine; crisnatol mesylate; cyclophosphamide; cytarabine; dacarbazine; daunorubicin hydrochloride; decitabine; dexormaplatin; dezaguanine; dezaguanine mesylate; diaziquone; doxorubicin; doxorubicin hydrochloride; droloxifene; droloxifene citrate; dromostanolone propionate; duazomycin; edatrexate; eflornithine hydrochloride; elsamitrucin; enloplatin; enpromate; epipropidine; epirubicin hydrochloride; erbulozole; esorubicin hydrochloride; estramustine; estramustine phosphate sodium; etanidazole; etoposide; etoposide phosphate; etoprine; fadrozole hydrochloride; fazarabine; fenretinide; floxuridine; fludarabine phosphate; fluorouracil; fluorocitabine; fosquidone; fostriecin sodium; gemcitabine; gemcitabine hydrochloride; hydroxyurea; idarubicin hydrochloride; ifosfamide; iimofosine; interleukin I1 (including recombinant interleukin II, or rlL.sub.2), interferon alfa-2a; interferon alfa-2b; interferon alfa-n1; interferon alfa-n3; interferon beta-1a; interferon gamma-1b; iproplatin; irinotecan hydrochloride; lanreotide acetate; letrozole; leuprolide acetate; liarozole hydrochloride; lometrexol sodium; lomustine; losoxantrone hydrochloride; masoprocol; maytansine; mechlorethamine hydrochloride; megestrol acetate; melengestrol acetate; melphalan; menogaril; mercaptopurine; methotrexate; methotrexate sodium; metoprine; meturedepa; mitindomide; mitocarcin; mitocromin; mitogillin; mitomalcin; mitomycin; mitosper; mitotane; mitoxantrone hydrochloride; mycophenolic acid; nocodazoie; nogalamycin; ormaplatin; oxisuran; pegaspargase; peliomycin; pentamustine; peplomycin sulfate; perfosfamide; pipobroman; piposulfan; piroxantrone hydrochloride; plicamycin; plomestane; porfimer sodium; porfiromycin; prednimustine; procarbazine hydrochloride; puromycin; puromycin hydrochloride; pyrazofurin; riboprine; rogletimide; safingol; safingol hydrochloride; semustine; simtrazene; sparfosate sodium; sparsomycin; spirogermanium hydrochloride; spiromustine; spiroplatin; streptonigrin; streptozocin; sulofenur; talisomycin; tecogalan sodium; tegafur; teloxantrone hydrochloride; temoporfin; teniposide; teroxirone; testolactone; thiamiprine; thioguanine; thiotepa; tiazofurin; tirapazamine; toremifene citrate; trestolone acetate; triciribine phosphate; trimetrexate; trimetrexate glucuronate; triptorelin; tubulozole hydrochloride; uracil mustard; uredepa; vapreotide; verteporfin; vinblastine sulfate; vincristine sulfate; vindesine; vindesine sulfate; vinepidine sulfate; vinglycinate sulfate; vinleurosine sulfate; vinorelbine tartrate; vinrosidine sulfate; vinzolidine sulfate; vorozole; zeniplatin; zinostatin; zorubicin hydrochloride, agents that arrest cells in the G2-M phases and/or modulate the formation or stability of microtubules, (e.g. Taxol™ (i.e. paclitaxel), Taxotere™, compounds comprising the taxane skeleton, Erbulozole (i.e. R-55104), Dolastatin 10 (i.e. DLS-10 and NSC-376128), Mivobulin isethionate (i.e. as CI-980), Vincristine, NSC-639829, Discodermolide (i.e. as NVP-XX-A-296), ABT-751 (Abbott, i.e. E-7010), Altorhyrtins (e.g. Altorhyrtin A and Altorhyrtin C), Spongistatins (e.g. Spongistatin 1,
Spongistatin 2,Spongistatin 3,Spongistatin 4,Spongistatin 5,Spongistatin 6,Spongistatin 7,Spongistatin 8, and Spongistatin 9), Cemadotin hydrochloride (i.e. LU-103793 and NSC-D-669356), Epothilones (e.g. Epothilone A, Epothilone B, Epothilone C (i.e. desoxyepothilone A or dEpoA), Epothilone D (i.e. KOS-862, dEpoB, and desoxyepothilone B), Epothilone E, Epothilone F, Epothilone B N-oxide, Epothilone A N-oxide, 16-aza-epothilone B, 21-aminoepothilone B (i.e. BMS-310705), 21-hydroxyepothilone D (i.e. Desoxyepothilone F and dEpoF), 26-fluoroepothilone, Auristatin PE (i.e. NSC-654663), Soblidotin (i.e. TZT-1027), LS-4559-P (Pharmacia, i.e. LS-4577), LS-4578 (Pharmacia, i.e. LS-477-P), LS-4477 (Pharmacia), LS-4559 (Pharmacia), RPR-112378 (Aventis), Vincristine sulfate, DZ-3358 (Daiichi), FR-182877 (Fujisawa, i.e. WS-9885B), GS-164 (Takeda), GS-198 (Takeda), KAR-2 (Hungarian Academy of Sciences), BSF-223651 (BASF, i.e. ILX-651 and LU-223651), SAH-49960 (Lilly/Novartis), SDZ-268970 (Lilly/Novartis), AM-97 (Armad/Kyowa Hakko), AM-132 (Armad), AM-138 (Armad/Kyowa Hakko), IDN-5005 (Indena), Cryptophycin 52 (i.e. LY-355703), AC-7739 (Ajinomoto, i.e. AVE-8063A and CS-39.HC1), AC-7700 (Ajinomoto, i.e. AVE-8062, AVE-8062A, CS-39-L-Ser.HCl, and RPR-258062A), Vitilevuamide, Tubulysin A, Canadensol, Centaureidin (i.e. NSC-106969), T-138067 (Tularik, i.e. T-67, TL-138067 and TI-138067), COBRA-1 (Parker Hughes Institute, i.e. DDE-261 and WHI-261), H10 (Kansas State University), H16 (Kansas State University), Oncocidin Al (i.e. BTO-956 and DIME), DDE-313 (Parker Hughes Institute), Fijianolide B, Laulimalide, SPA-2 (Parker Hughes Institute), SPA-1 (Parker Hughes Institute, i.e. SPIKET-P), 3-IAABU (Cytoskeleton/Mt. Sinai School of Medicine, i.e. MF-569), Narcosine (also known as NSC-5366), Nascapine, D-24851 (Asta Medica), A-105972 (Abbott), Hemiasterlin, 3-BAABU (Cytoskeleton/Mt. Sinai School of Medicine, i.e. MF-191), TMPN (Arizona State University), Vanadocene acetylacetonate, T-138026 (Tularik), Monsatrol, lnanocine (i.e. NSC-698666), 3-IAABE (Cytoskeleton/Mt. Sinai School of Medicine), A-204197 (Abbott), T-607 (Tuiarik, i.e. T-900607), RPR-115781 (Aventis), Eleutherobins (such as Desmethyleleutherobin, Desaetyleleutherobin, lsoeleutherobin A, and Z-Eleutherobin), Caribaeoside, Caribaeolin, Halichondrin B, D-64131 (Asta Medica), D-68144 (Asta Medica), Diazonamide A, A-293620 (Abbott), NPI-2350 (Nereus), Taccalonolide A, TUB-245 (Aventis), A-259754 (Abbott), Diozostatin, (−)-Phenylahistin (i.e. NSCL-96F037), D-68838 (Asta Medica), D-68836 (Asta Medica), Myoseverin B, D-43411 (Zentaris, i.e. D-81862), A-289099 (Abbott), A-318315 (Abbott), HTI-286 (i.e. SPA-110, trifluoroacetate salt) (Wyeth), D-82317 (Zentaris), D-82318 (Zentaris), SC-12983 (NCI), Resverastatin phosphate sodium, BPR-OY-007 (National Health Research Institutes), and SSR-250411 (Sanofi)), steroids (e.g., dexamethasone), finasteride, aromatase inhibitors, gonadotropin-releasing hormone agonists (GnRH) such as goserelin or leuprolide, adrenocorticosteroids (e.g., prednisone), progestins (e.g., hydroxyprogesterone caproate, megestrol acetate, medroxyprogesterone acetate), estrogens (e.g., diethlystilbestrol, ethinyl estradiol), antiestrogen (e.g., tamoxifen), androgens (e.g., testosterone propionate, fluoxymesterone), antiandrogen (e.g., flutamide), immunostimulants (e.g., Bacillus Calmette-Guérin (BCG), levamisole, interleukin-2, alpha-interferon, etc.), monoclonal antibodies (e.g., anti-CD20, anti-HER2, anti-CD52, anti-HLA-DR, and anti-VEGF monoclonal antibodies), immunotoxins (e.g., anti-CD33 monoclonal antibody-calicheamicin conjugate, anti-CD22 monoclonal antibody-pseudomonas exotoxin conjugate, etc.), radioimmunotherapy (e.g., anti-CD20 monoclonal antibody conjugated to 111In, 90Y, or 131I, etc.), triptolide, homoharringtonine, dactinomycin, doxorubicin, epirubicin, topotecan, itraconazole, vindesine, cerivastatin, vincristine, deoxyadenosine, sertraline, pitavastatin, irinotecan, clofazimine, 5-nonyloxytryptamine, vemurafenib, dabrafenib, erlotinib, gefitinib, EGFR inhibitors, epidermal growth factor receptor (EGFR)-targeted therapy or therapeutic (e.g. gefitinib (Iressa™), erlotinib (Tarceva™), cetuximab (Erbitux™), lapatinib (Tykerb™), panitumumab (Vectibix™), vandetanib (Caprelsa™), afatinib/BIBW2992, CI-1033/canertinib, neratinib/HKI-272, CP-724714, TAK-285, AST-1306, ARRY334543, ARRY-380, AG-1478, dacomitinib/PF299804, OSI-420/desmethyl erlotinib, AZD8931, AEE788, pelitinib/EKB-569, CUDC-101, WZ8040, WZ4002, WZ3146, AG-490, XL647, PD153035, BMS-599626), sorafenib, imatinib, sunitinib, dasatinib, or the like. - As defined herein, the term “activation”, “activate”, “activating”, “activator” and the like in reference to a protein-inhibitor interaction means positively affecting (e.g. increasing) the activity or function of the protein relative to the activity or function of the protein in the absence of the activator. In embodiments activation means positively affecting (e.g. increasing) the concentration or levels of the protein relative to the concentration or level of the protein in the absence of the activator. The terms may reference activation, or activating, sensitizing, or up-regulating signal transduction or enzymatic activity or the amount of a protein decreased in a disease. Thus, activation may include, at least in part, partially or totally increasing stimulation, increasing or enabling activation, or activating, sensitizing, or up-regulating signal transduction or enzymatic activity or the amount of a protein associated with a disease (e.g., a protein which is decreased in a disease relative to a non-diseased control). Activation may include, at least in part, partially or totally increasing stimulation, increasing or enabling activation, or activating, sensitizing, or up-regulating signal transduction or enzymatic activity or the amount of a protein
- The terms “agonist,” “activator,” “upregulator,” etc. refer to a substance capable of detectably increasing the expression or activity of a given gene or protein. The agonist can increase expression or
activity 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90% or more in comparison to a control in the absence of the agonist. In certain instances, expression or activity is 1.5-fold, 2-fold, 3-fold, 4-fold, 5-fold, 10-fold or higher than the expression or activity in the absence of the agonist. - As defined herein, the term “inhibition”, “inhibit”, “inhibiting” and the like in reference to a protein-inhibitor interaction means negatively affecting (e.g. decreasing) the activity or function of the protein relative to the activity or function of the protein in the absence of the inhibitor. In embodiments inhibition means negatively affecting (e.g. decreasing) the concentration or levels of the protein relative to the concentration or level of the protein in the absence of the inhibitor. In embodiments, inhibition refers to reduction of a disease or symptoms of disease. In embodiments, inhibition refers to a reduction in the activity of a particular protein target. Thus, inhibition includes, at least in part, partially or totally blocking stimulation, decreasing, preventing, or delaying activation, or inactivating, desensitizing, or down-regulating signal transduction or enzymatic activity or the amount of a protein. In embodiments, inhibition refers to a reduction of activity of a target protein resulting from a direct interaction (e.g. an inhibitor binds to the target protein). In embodiments, inhibition refers to a reduction of activity of a target protein from an indirect interaction (e.g. an inhibitor binds to a protein that activates the target protein, thereby preventing target protein activation).
- The terms “inhibitor,” “repressor” or “antagonist” or “downregulator” interchangeably refer to a substance capable of detectably decreasing the expression or activity of a given gene or protein. The antagonist can decrease expression or
activity 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90% or more in comparison to a control in the absence of the antagonist. In certain instances, expression or activity is 1.5-fold, 2-fold, 3-fold, 4-fold, 5-fold, 10-fold or lower than the expression or activity in the absence of the antagonist. - The term “expression” includes any step involved in the production of the polypeptide including, but not limited to, transcription, post-transcriptional modification, translation, post-translational modification, and secretion. Expression can be detected using conventional techniques for detecting protein (e.g., ELISA, Western blotting, flow cytometry, immunofluorescence, immunohistochemistry, etc.).
- The term “gene expression” refers to any step in the process by which information from a gene is used in the synthesis of a functional gene product. These products are often proteins, but in non-protein coding genes such as transfer RNA (tRNA) or small nuclear RNA (snRNA) genes, the product is a functional RNA.
- The term “reference value” as used herein refers to a value to which a measured quantity is compared. In embodiments, a reference value is assigned to genes in order to compare measured gene expression levels and make a comparison of whether the measured value is greater, equal, or less than the reference value, which then enables a determination of increased, no change, or decreased expression level of the gene. In embodiments, a reference value is assigned to an activity level representing the collective reference expression levels of several genes (such as genes associated with a particular signature). In embodiments, reference values are pre-determined values, such as from previous measurements for which expression levels were previously measured. In embodiments, a reference value is a control value for a known sample or condition that was previously measured, or is measured in parallel with a test sample. In embodiments, a reference value is a value for a sample from a subject at an earlier time point, to which values a value for a test sample at a later time point may be compared, and which may be measured separately or simultaneously with the test sample. In embodiments, a known sample providing the reference value is a non-cancerous tissue of the same type from which a test cancer cell originated, or a cell line of the same type as a test cancer cell. In embodiments, the reference value represents a difference between two treatment conditions for the known sample (e.g., a measure in the change of an activity level or the expression of one or more genes between a first condition in which a particular signaling pathway was induced, and a second condition in which the particular signaling pathway was not induced). In embodiments, a pathway activity increase or decrease of one standard deviation from the mean is considered significant.
- In embodiments, the reference value is a reference activity score. In embodiments, a reference activity score is the result of a weighted average of normalized expression levels for genes in a pathway signature that may be ranked, linearly combined, and optionally scaled to between zero (0) and one (1). In embodiments, a scaled activity score of more than about 0.05, 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 0.95, or more of the maximum score indicates a significantly increased activity in the corresponding pathway. In embodiments, a significantly increased acitivity is indicated by a scaled activity score of more than about 0.5 of the maximum score. In embodiments, a scaled score of about zero (0), a minimum unscaled score in a set of multiple samples, or a minimum unscaled score from an independent set of reference samples represents the activity score for a population of control cells in which the signaling pathway is not induced.
- The term “associated” or “associated with” in the context of a substance, substance activity, or function associated with a disease (e.g. a protein associated disease, such as a cancer (e.g., cancer, inflammatory disease, autoimmune disease, or infectious disease)) means that the disease (e.g. cancer, inflammatory disease, autoimmune disease, or infectious disease) is caused by (in whole or in part), or a symptom of the disease is caused by (in whole or in part) the substance or substance activity or function. As used herein, what is described as being associated with a disease, if a causative agent, could be a target for treatment of the disease.
- The term “signaling pathway” or “pathway” as used herein refers to a series of interactions between cellular and optionally extra-cellular components (e.g. proteins, nucleic acids, small molecules, ions, lipids) that conveys a change in one component to one or more other components, which in turn may convey a change to additional components, which is optionally propagated to other signaling pathway components. In embodiments, a signaling pathway is identified by a particular gene (e.g., the IFN signaling pathway), which refers to the pathway identified by signaling changes induced by activity of the indicated gene or corresponding protein (e.g., IFN). In embodiments, the signaling pathway includes genes whose expression is statistically significantly increased and/or decreased in response to overexpression of a particular gene that identifies the pathway.
- The term “activity level” as used herein refers to a value representing the level of gene expression of all or a subset of genes in a particular pathway. In embodiments, activity level is determined by measuring gene expression of genes in a particular pathway. In embodiments, an activity level is a value calculated based on the expression levels of a plurality of genes in a particular pathway. A variety of suitable algorithms are available for calculating an activity level based on gene expression data from a plurality of genes. In embodiments, gene expression levels are analyzed using the Adaptive Signature Selection and InteGratioN toolkit (ASSIGN; see, e.g., Shen et al., 2015 Jun. 1; 31(11):1745-53; available from BioConductor) to calculate an activity level. In embodiments, gene expression levels are analyzed using Gene Set Variation Analysis (GSVA; see, e.g., Hänzelmann et al., BMC Bioinformatics. 2013; 14:7) to calculate an activity level. In embodiments, gene expression levels are analyzed using gene set enrichment analysis (GSEA) or single sample GSEA (ssGSEA; see, e.g., Barbie et al., Nature. 2009 Nov. 5; 462(7269): 108-112) to calculate an activity level. In embodiments, expression levels for all genes of a particular signature are collectively expressed as a single activity level value (e.g., a score) for that signature. In embodiments, comparing gene expression values for genes of a signature to a reference is performed by comparing a score for that signature to a reference score or threshold.
- In an aspect, provided herein is a method including detecting one or more parameters in a sample of peripheral blood from a subject with cancer, including detecting (i) gene expression in monocytes including (1) increased expression of one or more of NFKB1, MYD88, NFKBIA or NFKBIZ, (2) decreased expression of IKBKB, (3) increased expression of one or more of growth factor genes, and/or (4) increased expression of one or more TNF genes, compared to a control; (ii) a greater number of CD8+ differentiated cells, a greater number of CD4+ naive cells, fewer CD4+ differentiated cells, and fewer T follicular helper (TFH) cells compared to a control; or (iii) a lower density of total peripheral blood mononuclear cells, a lower density of CD4+ effector memory (EM) cells, and a higher density of classical monocytes compared to a control.
- In an aspect, provided herein is a method of identifying a cancer of a subject as responsive to treatment with a PD-1 inhibitor. The method includes detecting one or more parameters in a sample of peripheral blood from the subject, including detecting (i) gene expression in monocytes including (1) increased expression of one or more of NFKB1, MYD88, NFKBIA or NFKBIZ, (2) decreased expression of IKBKB, (3) increased expression of one or more of growth factor genes, and/or (4) increased expression of one or more TNF genes, compared to a control; (ii) greater number of CD8+ differentiated cells, a greater number of CD4+ naive cells, fewer CD4+ differentiated cells, and fewer T follicular helper (TFH) cells compared to a control; or (iii) a lower density of total peripheral blood mononuclear cells, a lower density of CD4+ effector memory (EM) cells, and a higher density of classical monocytes compared to a control.
- In an aspect, provided herein is a method for treating cancer in a subject. The method includes detecting one or more parameters in a sample of peripheral blood from the subject, including detecting (i) gene expression in monocytes including (1) increased expression of one or more of NFKB1, MYD88, NFKBIA or NFKBIZ, (2) decreased expression of IKBKB, (3) increased expression of one or more of growth factor genes, and/or (4) increased expression of one or more TNF genes, compared to a control; (ii) a greater number of CD8+ differentiated cells, a greater number of CD4+ naive cells, fewer CD4+ differentiated cells, and fewer T follicular helper (TFH) cells compared to a control; or (iii) a lower density of total peripheral blood mononuclear cells, a lower density of CD4+ effector memory (EM) cells, and a higher density of classical monocytes compared to a control; and identifying the cancer as responsive to treatment with a PD-1 inhibitor if the cancer has one or more of the parameters (i)-(iii).
- In embodiments, the cancer is gastrointestinal cancer. In embodiments, the gastrointestinal cancer is selected from colorectal cancer, gastroesophogeal cancer, pancreatic cancer, and biliary cancer. In embodiments, the gastrointestinal cancer is colorectal cancer. In embodiments, the gastrointestinal cancer is gastroesophogeal cancer. In embodiments, the gastrointestinal cancer is pancreatic cancer. In embodiments, the gastrointestinal cancer is biliary cancer.
- In embodiments, the methods described herein further include detecting one or more of the following parameters: (iv) increased expression in T cells of one or more cell death genes compared to a control; (v) greater number of CTLA4+CD4+ EM cells and PD-1+CD8+ cells compared to a control; (vi) greater number of classical, CD86+, and HLADR+ monocytes as measured by florescence-activated cell sorting (FACS) and compared to a control; and (vii) fewer CD4+EM cells and a greater number of CLT4+CD4+ EM cells as measured by FACS and compared to a control.
- In embodiments, the methods described herein include detecting one or more parameters including (i) gene expression in monocytes including (1) increased expression of one or more of NFKB1, MYD88, NFKBIA or NFKBIZ, (2) decreased expression of IKBKB, (3) increased expression of one or more of growth factor genes, and/or (4) increased expression of one or more TNF genes, compared to a control; (ii) a greater number of CD8+ differentiated cells, a greater number of CD4+ naive cells, fewer CD4+ differentiated cells, and fewer T follicular helper (TFH) cells compared to a control; (iii) a lower density of total peripheral blood mononuclear cells, a lower density of CD4+ effector memory (EM) cells, and a higher density of classical monocytes compared to a control; (iv) increased expression in T cells of one or more cell death genes compared to a control; (v) greater number of CTLA4+CD4+ EM cells and PD-1+CD8+ cells compared to a control; (vi) greater number of classical, CD86+, and HLADR+ monocytes as measured by florescence-activated cell sorting (FACS) and compared to a control; and (vii) fewer CD4+EM cells and a greater number of CLT4+CD4+ EM cells as measured by FACS and compared to a control. In embodiments, two, three, four, five, six, or seven of the parameters (i)-(vii) are detected. In embodiments, two of the parameters (i)-(vii) are detected. In embodiments, three of the parameters (i)-(vii) are detected. In embodiments, four of the parameters (i)-(vii) are detected. In embodiments, five of the parameters (i)-(vii) are detected. In embodiments, six of the parameters (i)-(vii) are detected. In embodiments, all of the parameters (i)-(vii) are detected. In embodiments, all of the parameters (i)-(iii) are detected.
- In embodiments, the methods described herein further include selecting a PD-1 inhibitor for administration to the subject, and optionally treating the subject with the PD-1 inhibitor, if one or more of the following parameters is detected: one or more parameters including (i) gene expression in monocytes including (1) increased expression of one or more of NFKB1, MYD88, NFKBIA or NFKBIZ, (2) decreased expression of IKBKB, (3) increased expression of one or more of growth factor genes, and/or (4) increased expression of one or more TNF genes, compared to a control; (ii) a greater number of CD8+ differentiated cells, a greater number of CD4+ naive cells, fewer CD4+ differentiated cells, and fewer T follicular helper (TFH) cells compared to a control; (iii) a lower density of total peripheral blood mononuclear cells, a lower density of CD4+ effector memory (EM) cells, and a higher density of classical monocytes compared to a control; (iv) increased expression in T cells of one or more cell death genes compared to a control; (v) greater number of CTLA4+CD4+ EM cells and PD-1+CD8+ cells compared to a control; (vi) greater number of classical, CD86+, and HLADR+monocytes as measured by florescence-activated cell sorting (FACS) and compared to a control; and (vii) fewer CD4+EM cells and a greater number of CLT4+CD4+ EM cells as measured by FACS and compared to a control. In embodiments, two, three, four, five, six, or seven of the parameters (i)-(vii) are detected. In embodiments, two of the parameters (i)-(vii) are detected. In embodiments, three of the parameters (i)-(vii) are detected. In embodiments, four of the parameters (i)-(vii) are detected. In embodiments, five of the parameters (i)-(vii) are detected. In embodiments, six of the parameters (i)-(vii) are detected. In embodiments, seven of the parameters (i)-(vii) are detected. In embodiments, all of the parameters (i)-(vii) are detected.
- In embodiments, the methods described herein include detecting in monocytes increased expression of one or more of NFKB1, MYD88, NFKBIA or NFKBIZ compared to a control. In embodiments, the methods described herein include detecting in monocytes increased expression of NFKB1 compared to a control. In embodiments, the methods described herein include detecting in monocytes increased expression of MYD88 compared to a control. In embodiments, the methods described herein include detecting in monocytes increased expression of NFKBIA compared to a control. In embodiments, the methods described herein include detecting in monocytes increased expression of NFKBIZ compared to a control. In embodiments, increased expression of two or more of NFKB1, MYD88, NFKBIA or NFKBIZ are detected. In embodiments, increased expression of NFKB1, MYD88, NFKBIA and NFKBIZ are detected.
- In embodiments, the methods described herein include detecting in monocytes increased expression of one or more growth factor genes including one or more of FOS, JUN, or JUNB compared to a control. In embodiments, the methods described herein include detecting in monocytes increased expression of FOS compared to a control. In embodiments, the methods described herein include detecting in monocytes increased expression of JUN compared to a control. In embodiments, the methods described herein include detecting in monocytes increased expression of JUNB compared to a control. In embodiments, increased expression of FOS, JUN, and JUNB is detected.
- In embodiments, the methods described herein include detecting in monocytes increased expression of one or more TNF genes include one or more of TNF, TNFAIP2, or TNFAIP3 compared to a control. In embodiments, the methods described herein include detecting in monocytes increased expression of TNF compared to a control. In embodiments, the methods described herein include detecting in monocytes increased expression of TNFAIP2 compared to a control. In embodiments, the methods described herein include detecting in monocytes increased expression of TNFAIP3 compared to a control. In embodiments, increased expression of TNF, TNFAIP2, and TNFAIP3 is detected.
- In embodiments, the methods described herein include detecting in a sample of peripheral blood a greater number of CD8+ differentiated cells, a greater number of CD4+ naive cells, fewer CD4+ differentiated cells, and fewer T follicular helper (TFH) cells compared to a control.
- In embodiments, the methods described herein include detecting in a sample of peripheral blood a lower density of total peripheral blood mononuclear cells, a lower density of CD4+ effector memory (EM) cells, and a higher density of classical monocytes compared to a control.
- In embodiments, the methods described herein include detecting increased expression in T cells of one or more cell death genes compared to a control, the cell death genes including one or more of CASP1, CASP3, CASP7, or CASP8. In embodiments, the methods described herein include detecting increased expression in T cells of CASP1 compared to a control. In embodiments, the methods described herein include detecting increased expression in T cells of CASP3 compared to a control. In embodiments, the methods described herein include detecting increased expression in T cells of CASP7 compared to a control. In embodiments, the methods described herein include detecting increased expression in T cells of CASP8 compared to a control. In embodiments, incrased expression of CASP1, CASP3, CASP7, and CASP8 is detected.
- In embodiments, the methods described herein include detecting a greater number of CTLA4+CD4+ EM cells and PD-1+CD8+ cells compared to a control.
- In embodiments, the methods described herein include detecting a greater number of classical, CD86+, and HLADR+ monocytes as measured by florescence-activated cell sorting (FACS) and compared to a control.
- In embodiments, the methods described herein include detecting fewer CD4+EM cells and a greater number of CLT4+CD4+ EM cells as measured by FACS and compared to a control.
- In embodiments, detecting gene expression includes one or more of single-cell RNA sequencing, single sample gene set enrichment analysis, Northern blotting, fluorescent in situ hybridization, reverse transcription polymerase chain reaction (RT-PCR), serial analysis of gene expression (SAGE), microarray, or tiling arrays. In embodiments, detecting gene expression includes single-cell RNA sequencing. In embodiments, detecting gene expression includes single sample gene set enrichment analysis. In embodiments, detecting gene expression includes Northern blotting. In embodiments, detecting gene expression includes fluorescent in situ hybridization. In embodiments, detecting gene expression includes reverse transcription polymerase chain reaction (RT-PCR). In embodiments, detecting gene expression includes serial analysis of gene expression (SAGE) microarray. In embodiments, detecting gene expression includes tiling arrays.
- In embodiments, detecting a number of cells as fewer or greater than a control includes one or more of single-cell RNA sequencing, affinity-based pseudotime reconstruction, flow cytometry or immunophenotyping. In embodiments, detecting a number of cells as fewer or greater than a control includes single-cell RNA sequencing. In embodiments, detecting a number of cells as fewer or greater than a control includes affinity-based pseudotime reconstruction. In embodiments, detecting a number of cells as fewer or greater than a control includes flow cytometry. In embodiments, detecting a number of cells as fewer or greater than a control includes immunophenotyping.
- In embodiments, the methods described herein further include selecting a subject for anticancer therapy (other than a PD-1 inhibitor) if the cancer is not identified as responsive to treatment with a PD-1 inhibitor; and optionally administering the anticancer therapy to the subject.
- In embodiments, the methods described herein include selection and/or administration of anticancer therapy where the anticancer therapy includes one or more of radiation therapy, chemotherapy, surgery, or immunotherapy. In embodiments, the anticancer therapy includes radiation therapy. In embodiments, the anticancer therapy includes chemotherapy. In embodiments, the anticancer therapy includes surgery. In embodiments, the anticancer therapy includes immunotherapy.
- In embodiments, the methods described herein include selection and/or administration of a PD-1 inhibitor. In embodiments, the PD-1 inhibitor is a PD-1 antibody. In embodiments, the PD-1 antibody is one or more of pembrolizumab, nivolumab, or cemiplimab. In embodiments, the PD-1 antibody is pembrolizumab. In embodiments, the PD-1 antibody is nivolumab. In embodiments, the PD-1 antibody is cemiplimab.
- In embodiments, the methods described herein further include treating the subject with an anticancer therapy other than a PD-1 inhibitor. In embodiments, anticancer therapy other than a PD-1 inhibitor includes radiation therapy, chemotherapy, surgery, or immunotherapy excluding PD-1 inhibitor. In embodiments, anticancer therapy other than a PD-1 inhibitor is radiation therapy. In embodiments, anticancer therapy other than a PD-1 inhibitor is chemotherapy. In embodiments, anticancer therapy other than a PD-1 inhibitor is surgery. In embodiments, anticancer therapy other than a PD-1 inhibitor is immunotherapy excluding PD-1 inhibitor. Immunotherapy excluding PD-1 inhibitor includes PD-L1inhibitors suchs as atezolizumab, CTLA-4 inhibitors suchs as ipilmumab, adoptive cell transfer, targeted therapy including small-molecule drugs or monoclonal antibodies, cytokines including interferons and interleukins, and Bacillus calmette-guerin (BCG).
- In an aspect, provided herein is a method including detecting one or more parameters in a sample of peripheral blood from a subject with cancer previously treated with a PD-1 inhibitor, including detecting (i) in T cells, (1) increased expression of one or more interferon type I or type II signaling genes, (2) increased expression one or more of NFKB1, MYD88, NFKBIA or NFKBIZ, (3) increased expression of one or more major histocompatibility complex (MHC) class I or class II processing genes, (4) increased expression of one or more of CCL3, CCL4, CCL5, and CCR5, (5) decreased expression of one or more of CXCR3 or CCR2 genes, (6) increased expression in CD8+ T cells of one or more cell death genes, (7) a greater number of differentiated CD8+ cells, and/or (8) fewer differentiated CD4+ cells compared to a control; (ii) or in monocytes, (1) increased expression of genes upregulated by IFN stimulation, and/or (2) increased expression of genes upregulated by major histocompatibility complex 2 (MHCII) production.
- In an aspect, provided herein is a method of identifying a cancer of a subject previously treated with a PD-1 inhibitor as responsive to treatment with the PD-1 inhibitor, the method including detecting one or more parameters in a sample of peripheral blood from the subject, including detecting (i) in T cells, (1) increased expression of one or more interferon type I or type II signaling genes, (2) increased expression one or more of NFKB1, MYD88, NFKBIA or NFKBIZ, (3) increased expression of one or more major histocompatibility complex (MHC) class I or class II processing genes, (4) increased expression of one or more of CCL3, CCL4, CCL5, and CCR5, (5) decreased expression of one or more of CXCR3 or CCR2 genes, (6) increased expression in CD8+ T cells of one or more cell death genes, (7) a greater number of differentiated CD8+ cells, and/or (8) fewer differentiated CD4+ cells compared to a control; or (ii) in monocytes, (1) increased expression of genes upregulated by IFN stimulation, and/or (2) increased expression of genes upregulated by major histocompatibility complex 2 (MHCII) production.
- In an aspect, provided herein is a method of monitoring response to PD-1 immunotherapy in a subject previously treated with a PD-1 inhibitor, the method including detecting (i) in T cells, (1) increased expression of one or more interferon (IFN) type I or type II signaling genes, (2) increased expression one or more of NFKB1, MYD88, NFKBIA or NFKBIZ, (3) increased expression of one or more major histocompatibility complex (MHC) class I or class II processing genes, (4) increased expression of one or more of CCL3, CCL4, CCL5, and CCR5, (5) decreased expression of one or more of CXCR3 or CCR2 genes, (6) increased expression in CD8+ T cells of one or more cell death genes, (7) a greater number of differentiated CD8+ cells, and/or (8) fewer differentiated CD4+ cells compared to a control; or (ii) in monocytes, (1) increased expression of genes upregulated by IFN stimulation, and/or (2) increased expression of genes upregulated by major histocompatibility complex 2 (MCHII) production; and identifying the cancer as responsive to continued treatment with the PD-1 inhibitor if one or both of parameters (i) and (ii) are detected.
- In embodiments, the cancer is gastrointestinal cancer. In embodiments, the gastrointestinal cancer is selected from colorectal cancer, gastroesophogeal cancer, pancreatic cancer, and biliary cancer. In embodiments, the gastrointestinal cancer is colorectal cancer. In embodiments, the gastrointestinal cancer is gastroesophogeal cancer. In embodiments, the gastrointestinal cancer is pancreatic cancer. In embodiments, the gastrointestinal cancer is biliary cancer.
- In embodiments, the methods described herein include detecting in a sample of peripheral blood from a subject with cancer previously treated with a PD-1 inhibitor, in T cells increased expression in one or more interferon (IFN) type I or type II signaling genes compared to a control. In embodiments, the methods described herein include detecting IFN signaling genes including one or more genes of
FIGS. 17A-C . In embodiments, the IFN signaling genes include one or more of IFIT1/3, IFITM3, IFI44L, PSME2, IFI6, ISG15. In embodiments, the IFN singaling genes include two or more of IFIT1/3, IFITM3, IFI44L, PSME2, IFI6, ISG15. In embodiments, the IFN signaling genes include IFIT1/3, IFITM3, IFI44L, PSME2, IFI6, and ISG15. In embodiments, the IFN signaling genes include one or more of IFNG, STAT1, STAT2, IRF1, IRF2, IRF7, SOCS1, SOCS2, SOCS3, IFIT1, IFIT2, IFIT3, IFIT5, IFITM1, IFITM2, IFITM3, ISG15, ISG20, GBP5, IFNGR1, IFNGR2, IFI16, IFI35, IFI44. - In embodiments, the methods described herein include detecting in a sample of peripheral blood from a subject with cancer previously treated with a PD-1 inhibitor, in T cells increased expression of one or more of NFKB1, MYD88, NFKBIA or NFKBIZ. In embodiments, the methods described herein include detecting in T cells increased expression of NFKB1 compared to a control. In embodiments, the methods described herein include detecting in T cells increased expression of MYD88 compared to a control. In embodiments, the methods described herein include detecting in T cells increased expression of NFKBIA compared to a control. In embodiments, the methods described herein include detecting in T cells increased expression of NFKBIZ compared to a control. In embodiments, increased expression of NFKB1, MYD88, NFKBIA and NFKBIZ is detected.
- In embodiments, the methods described herein include detecting in a sample of peripheral blood from a subject with cancer previously treated with a PD-1 inhibitor, in T cells increased expression of one or more of MHC I processing genes including one or more of PIK3CD, PSMA7, PSMB8, PSMD9, HLA-A, HLA-B, or HLA-C compared to a control. In embodiments, the methods described herein include detecting in T cells increased expression of PIK3CD compared to a control. In embodiments, the methods described herein include detecting in T cells increased expression of PSMA7 compared to a control. In embodiments, the methods described herein include detecting in T cells increased expression of PSMB8 compared to a control. In embodiments, the methods described herein include detecting in T cells increased expression of PSMD9 compared to a control. In embodiments, the methods described herein include detecting in T cells increased expression of HLA-A compared to a control. In embodiments, the methods described herein include detecting in T cells increased expression of HLA-B compared to a control. In embodiments, the methods described herein include detecting in T cells increased expression of HLA-C compared to a control. In embodiments, increased expression in two or more of PIK3CD, PSMA7, PSMB8, PSMD9, HLA-A, HLA-B, or HLA-C is detected. In embodiments, increased expression of PIK3CD, PSMA7, PSMB8, PSMD9, HLA-A, HLA-B, and HLA-C is detected.
- In embodiments, the methods described herein include detecting in a sample of peripheral blood from a subject with cancer previously treated with a PD-1 inhibitor, in T cells increased expression of MEW II processing genes including one or more of HLA-DQB1, HLA-DQA1, HLA-DPB1, HLA-DPA1, HLA-DRB1, HLA-DRA, HLA-DMB, or HLA-DMA compared to a control. In embodiments, the methods described herein include detecting in T cells increased expression of HLA-DQB1 compared to a control. In embodiments, the methods described herein include detecting in T cells increased expression of HLA-DQA1 compared to a control. In embodiments, the methods described herein include detecting in T cells increased expression of HLA-DPB1 compared to a control. In embodiments, the methods described herein include detecting in T cells increased expression of HLA-DPA compared to a
control 1. In embodiments, the methods described herein include detecting in T cells increased expression of HLA-DRB1 compared to a control. In embodiments, the methods described herein include detecting in T cells increased expression of HLA-DRA compared to a control. In embodiments, the methods described herein include detecting in T cells increased expression of HLA-DMB compared to a control. In embodiments, the methods described herein include detecting in T cells increased expression of HLA-DMA compared to a control. In embodiments, increased expression of two or more of HLA-DQB1, HLA-DQA1, HLA-DPB1, HLA-DPA1, HLA-DRB1, HLA-DRA, HLA-DMB, or HLA-DMA is detected. In embodiments, increased expression of HLA-DQB1, HLA-DQA1, HLA-DPB1, HLA-DPA1, HLA-DRB1, HLA-DRA, HLA-DMB, and HLA-DMA is detected. - In embodiments, the methods described herein include detecting in a sample of peripheral blood from a subject with cancer previously treated with a PD-1 inhibitor, in T cells increased expression of one or more of CCL3, CCL4, CCL5, and CCR5 compared to a control. In embodiments, the methods described herein include detecting in T cells increased expression of CCL3 compared to a control. In embodiments, the methods described herein include detecting in T cells increased expression of CCL4 compared to a control. In embodiments, the methods described herein include detecting in T cells increased expression of CCL5 compared to a control. In embodiments, the methods described herein include detecting in T cells increased expression of CCR5 compared to a control. In embodiments, increased expression of CCL3, CCL4, CCL5, and CCR5 is detected.
- In embodiments, the methods described herein include detecting in a sample of peripheral blood from a subject with cancer previously treated with a PD-1 inhibitor, in T cells decreased expression of one or more of CXCR3 and/or CCR2 genes compared to a control. In embodiments, the methods described herein include detecting in T cells decreased expression of CXCR3 genes compared to a control. In embodiments, the methods described herein include detecting in T cells decreased expression of CCR2 genes compared to a control.
- In embodiments, the methods described herein include detecting in a sample of peripheral blood from a subject with cancer previously treated with a PD-1 inhibitor, increased expression in CD8+ T cells of one or more cell death genes compared to a control, the cell death genes including one or more of CASP1, CASP3, CASP7, or CASP8. In embodiments, the methods described herein include detecting increased expression in T cells of CASP1 compared to a control. In embodiments, the methods described herein include detecting increased expression in T cells of CASP3 compared to a control. In embodiments, the methods described herein include detecting increased expression in T cells of CASP7 compared to a control. In embodiments, the methods described herein include detecting increased expression in T cells of CASP8 compared to a control. In embodiments, increased expression of CASP1, CASP3, CASP7, and CASP8 is detected.
- In embodiments, the methods described herein include detecting in a sample of peripheral blood from a subject with cancer previously treated with a PD-1 inhibitor a greater number of differentiated CD8+ cells compared to a control.
- In embodiments, the methods described herein include detecting in a sample of peripheral blood from a subject with cancer previously treated with a PD-1 inhibitor, fewer differentiated CD4+ cells compared to a control.
- In embodiments, the methods described herein include detecting in a sample of peripheral blood from a subject with cancer previously treated with a PD-1 inhibitor, in monocytes, increased expression of genes upregulated by IFN stimulation.
- In embodiments, the methods described herein include detecting in a sample of peripheral blood from a subject with cancer previously treated with a PD-1 inhibitor, in monocytes, increased expression of genes upregulated by major histocompatibility complex 2 (MCHII) production.
- In embodiments, the methods described herein identifying a cancer as responsive to continued treatment with the PD-1 inhibitor if one or both of parameters (i) and (ii) are detected. In embodiments, the parameters are (i) in T cells, (1) increased expression of one or more interferon (IFN) type I or type II signaling genes, (2) increased expression one or more of NFKB1, MYD88, NFKBIA or NFKBIZ, (3) increased expression of one or more major histocompatibility complex (MHC) class I or class II processing genes, (4) increased expression of one or more of CCL3, CCL4, CCL5, and CCR5, (5) decreased expression of one or more of CXCR3 or CCR2 genes, (6) increased expression in CD8+ T cells of one or more cell death genes, (7) a greater number of differentiated CD8+ cells, and/or (8) fewer differentiated CD4+ cells compared to a control; and (ii) in monocytes, (1) increased expression of genes upregulated by IFN stimulation, and/or (2) increased expression of genes upregulated by major histocompatibility complex 2 (MCHII) production.
- In embodiments, detecting gene expression includes one or more of single-cell RNA sequencing, single sample gene set enrichment analysis, Northern blotting, fluorescent in situ hybridization, reverse transcription polymerase chain reaction (RT-PCR), serial analysis of gene expression (SAGE), microarray, or tiling arrays. In embodiments, detecting gene expression includes single-cell RNA sequencing. In embodiments, detecting gene expression includes single sample gene set enrichment analysis. In embodiments, detecting gene expression includes Northern blotting. In embodiments, detecting gene expression includes fluorescent in situ hybridization. In embodiments, detecting gene expression includes reverse transcription polymerase chain reaction (RT-PCR). In embodiments, detecting gene expression includes serial analysis of gene expression (SAGE) microarray. In embodiments, detecting gene expression includes tiling arrays.
- In embodiments, detecting a number of cells as fewer or greater than a control includes one or more of single-cell RNA sequencing, affinity-based pseudotime reconstruction, flow cytometry or immunophenotyping. In embodiments, detecting a number of cells as fewer or greater than a control includes single-cell RNA sequencing. In embodiments, detecting a number of cells as fewer or greater than a control includes affinity-based pseudotime reconstruction. In embodiments, detecting a number of cells as fewer or greater than a control includes flow cytometry. In embodiments, detecting a number of cells as fewer or greater than a control includes immunophenotyping.
- In embodiments, the methods described herein further include administering one or more doses of a PD-1 inhibitor after detecting (i) in T cells, (1) increased expression of one or more interferon type I or type II signaling genes, (2) increased expression one or more of NFKB1, MYD88, NFKBIA or NFKBIZ, (3) increased expression of one or more major histocompatibility complex (MHC) class I or class II processing genes, (4) increased expression of one or more of CCL3, CCL4, CCL5, and CCR5, (5) decreased expression of one or more of CXCR3 or CCR2 genes, (6) increased expression in CD8+ T cells of one or more cell death genes, (7) a greater number of differentiated CD8+ cells, and/or (8) fewer differentiated CD4+ cells compared to a control; or (ii) in monocytes, (1) increased expression of genes upregulated by IFN stimulation, and/or (2) increased expression of genes upregulated by major histocompatibility complex 2 (MHCII) production.
- In embodiments, the methods described herein include selection and/or administration of a PD-1 inhibitor. In embodiments, the PD-1 inhibitor is a PD-1 antibody. In embodiments, the PD-1 antibody is one or more of pembrolizumab, nivolumab, or cemiplimab. In embodiments, the PD-1 antibody is pembrolizumab. In embodiments, the PD-1 antibody is nivolumab. In embodiments, the PD-1 antibody is cemiplimab.
- In embodiments, the methods described herein further include selecting the subject for anticancer therapy (other than a PD-1 inhibitor) if the cancer is not identified as responsive to continued treatment with the PD-1 inhibitor, and optionally administering the anticancer therapy to the subject. In embodiments, the methods described herein further include selecting the subject for anticancer therapy if the cancer is not identified as responsive to continued treatment with the PD-1 inhibitor, and administering the anticancer therapy to the subject. In embodiments, the anticancer therapy includes one or more of radiation therapy, chemotherapy, surgery, or immunotherapy. In embodiments, the anticancer therapy includes radiation therapy. In embodiments, the anticancer therapy includes chemotherapy. In embodiments, the anticancer therapy includes surgery. In embodiments, the anticancer therapy includes immunotherapy.
- In embodiments, the methods described herein further include treating the subject with an with an anticancer therapy other than a PD-1 inhibitor. In embodiments, anticancer therapy other than a PD-1 inhibitor includes radiation therapy, chemotherapy, surgery, or immunotherapy excluding PD-1 inhibitor. In embodiments, anticancer therapy other than a PD-1 inhibitor is radiation therapy. In embodiments, anticancer therapy other than a PD-1 inhibitor is chemotherapy. In embodiments, anticancer therapy other than a PD-1 inhibitor is surgery. In embodiments, anticancer therapy other than a PD-1 inhibitor is immunotherapy excluding PD-1 inhibitor. Immunotherapy excluding PD-1 inhibitor includes PD-L1inhibitors suchs as atezolizumab, CTLA-4 inhibitors suchs as ipilmumab, adoptive cell transfer, targeted therapy including small-molecule drugs or monoclonal antibodies, cytokines including interferons and interleukins, and Bacillus calmette-guerin (BCG).
- In an aspect, provided herein is a system including at least one processor; and at least one memory including program code which when executed by the at least one memory provides operations for performing a method as described herein.
- In embodiments, the operations include collecting gene expression data associated with a subject, collecting cell density data associated with a subject; and providing, via a user interface, a prognosis for the subject based at least in part on detected gene expression and/or cell density
- In embodiments, the system includes functional modules, which are defined by computer executable instructions recorded on computer readable media and which cause a computer to perform method steps when executed. The modules are segregated by function for the sake of clarity. However, it should be understood that the modules/systems need not correspond to discreet blocks of code and the described functions can be carried out by the execution of various code portions stored on various media and executed at various times.
- The computer readable storage media can be any available tangible media that can be accessed by a computer. Computer readable storage media includes volatile and nonvolatile, removable and non-removable tangible media implemented in any method or technology for storage of information such as computer readable instructions, data structures, program modules or other data. Computer readable storage media includes, but is not limited to, RAM (random access memory), ROM (read only memory), EPROM (erasable programmable read only memory), EEPROM (electrically erasable programmable read only memory), flash memory or other memory technology, CD-ROM (compact disc read only memory), DVDs (digital versatile disks) or other optical storage media, magnetic cassettes, magnetic tape, magnetic disk storage or other magnetic storage media, other types of volatile and non- volatile memory, and any other tangible medium which can be used to store the desired information and which can accessed by a computer.
- Computer-readable data embodied on one or more computer-readable media may define instructions, for example, as part of one or more programs that, as a result of being executed by a computer, instruct the computer to perform one or more of the functions described herein, and/or various embodiments, variations and combinations thereof. Such instructions may be written in any of a plurality of programming languages, for example, Java, J#, Visual Basic, C, C#, C++, Fortran, Pascal, Eiffel, Basic, COBOL assembly language, and the like, or any of a variety of combinations thereof. The computer-readable media on which such instructions are embodied may reside on one or more of the components of either of a system, or a computer readable storage medium described herein, may be distributed across one or more of such components.
- The computer-readable media may be transportable such that the instructions stored thereon can be loaded onto any computer resource to implement the aspects discussed herein. In addition, it should be appreciated that the instructions stored on the computer- readable medium, described above, are not limited to instructions embodied as part of an application program running on a host computer. Rather, the instructions may be embodied as any type of computer code (e.g., software or microcode) that can be employed to program a computer to implement aspects of the present invention. The computer executable instructions may be written in a suitable computer language or combination of several languages.
- It is understood that the examples and embodiments described herein are for illustrative purposes only and that various modifications or changes in light thereof will be suggested to persons skilled in the art and are to be included within the spirit and purview of this application and scope of the appended claims. All publications, patents, and patent applications cited herein are hereby incorporated by reference in their entirety for all purposes.
- In the experiments described herein, peripheral blood mononuclear cells (PBMCs) were collected from patients with advanced GI cancers throughout treatment with combination chemotherapy and immunotherapy. It was hypothesized that circulating immune cell frequency and signaling reflect intratumoral activity of immune cells, and that subsets of immune cells in patients responsive to immunotherapy are primed to recognize cancer cells but blocked through PD1 directed mechanisms. Immune cell abundance and phenotype evolution during treatment was measured by single cell RNA sequencing (scRNAseq) and flow cytometry. Data showed that patients who respond to immunotherapy can be recognized prior to treatment through increased abundance of naive T cells and monocytes primed for activation and an excess of exhausted T cells. After treatment, these responsive patients show a response both in cell numbers and cell activation as the inhibitory PD-1 pathways are blocked. These findings help identify patients for treatment and optimize the timing of treatment relative to chemotherapy.
- Patients with advanced GI cancers, including colorectal, gastroesophageal, pancreatic, and biliary, were enrolled in a single institution phase I trial (NCT02268825) of modified FOLFOX6 (mFOLOFX6) chemotherapy regimen followed by a combination of chemotherapy and anti-PD-1 immunotherapy (pembrolizumab) (
FIG. 1 panel (a)). Patient response was assessed according to the RECIST1.1 guideline that defined patients as complete responders (CR), partial responders (PR), stable disease (SD) and progressive disease (PD). All patients with a CR, PR, or SD were grouped as responder patients and the remaining as non-responders. Confirming the classification, 89% of responders survived more than 18 months compared to only 26% of non-responders (FIG. 1 panel (b)). PBMCs isolated from 3 to 4 time points were analyzed: cycle 1 (C1) provides the baseline without any treatment, cycle 3 (C3) treatment with only mFOLFOX6 chemotherapy, and cycle 5 (C5) or cycle 8 (C8) during treatment with both mFOLFOX6 and PD-1i. A total of 12 patients (responder n=7, non-responder n=5) were analyzed by flow cytometry and 13 patients (responder n=7, non-responder n=6) by scRNAseq (FIG. 1 panel (c),FIGS. 9A-F and Table 1-2). Eight patients' samples were analyzed using both techniques (responder n=6, non-responder n=2). - As summarized in Table 1, there were a total of 18 patients, with 8 non-responders and 10 responders to the PD-1 immunotherapy treatment. Patient samples were cryopreserved peripheral blood mononuclear cells (PBMC) samples. The patients were treated for advanced (
stage 3/4) gastrointestinal cancers (including colorectal, gastroesophageal, pancreatic and biliary cancers). Patients in this clinical trial (NCT02268825), were treated with modified FOLFOX6 (mFOLOFX6) chemotherapy regimen consisting of 400 mg/m2 intravenous (IV) leucovorin, 400 mg/m2 IV fluorouracil (5-FU) bolus followed by 2400 mg/m2 IV over 46 hrs and 85 mg/m2 IV oxaliplatin (Eloxatin) every 2 weeks (i.e. 1 cycle) until disease progression, death, or completion of the study.Pembrolizumab 200 mg IV every two weeks was added to mFOLFOX6 atcycle 3, after 4 weeks of mFOLFOX. Every two weeks, and before starting treatment, patients' blood was collected and PBMCs were isolated and cryopreserved. Median of previous history of chemotherapy treatment for responders was 101 days and 42 days for non-responders. Clinical trial participants are further identified by gender, race, ECOG performance status, primary cancer type, Pembrolizub dose level, prior systemic treatment, prior 5-FU and Oxaliplatin treatment, number of previous systemic treatment lines for metastatic disease, microsatellite instability (MSI), and whether or not there was correlated testing (FACS, scRNAseq, or FACS and scRNAseq). - Provided in Table 2 are the IQR (interquartile range) and laboratory reference range reported for white blood cells, red blood cells, hemoglobin, platelets, number of granulocytes, number of monocytes, and number of lymphocytes were recorded and grouped by total patients, non-responders, and responders.
-
TABLE 1 The patient and disease characteristics of the patients participating in the clinical trial. Non- All Patients Responders responders (n = 18) (n = 8) (n = 10) Age, median years (IQR) 62 (54-72) 67 (60-73) 60 (48-66) Gender, n (%) F 8 (44) 2 (25) 6 (60) M 10 (56) 6 (75) 4 (40) Race, n (%) White 14 (78) 8 (100) 6 (60) Black or African American 2 (11) 0 (0) 2 (20) Unknown 2 (11) 0 (0) 2 (20) ECOG Performance Status, n (%) 0 Fully active 10 (56) 4 (50) 6 (60) 1 Restricted 8 (44) 4 (50) 4 (40) Primary Cancer Type, n (%) Colorectal Carcinoma 9 (50) 3 (38) 6 (60) Biliary Tract Cancer 4 (22) 1 (13) 3 (30) Gastroesophageal Carcinoma 3 (17) 3 (38) 0 (0) Pancreatic Carcinoma 2 (11) 1 (13) 1 (10) Pembrolizumab Dose level, n (%) 75 mg q 2 weeks 1 (6) 0 (0) 1 (10) 200 mg q 2 weeks 17 (94) 8 (100) 9 (90) Prior Systemic Treatment, n (%) No 6 (33) 6 (75) 0 (0) Yes 12 (67) 2 (25) 10 (100) Days from last dose of 42 (23-293) 101 (34-167) 42 (21-416) treatment, Median (IQR) Prior 5-FU and Oxaliplatin, n (%) No 10 (56) 7 (88) 3 (30) Yes 8 (44) 1 (13) 7 (70) Days from last dose of 606 927 555 5-FU/Ox, Median (IQR) (298-986) (927-927) (249-1005) Number of previous systemic treatment lines for metastatic disease, n (%) 0 7 (39) 6 (75) 1 (10) 1 4 (22) 2 (25) 2 (20) 2 3 (17) 0 (0) 3 (30) 3 4 (22) 0 (0) 4 (40) Microsatellite Instability (MSI) Result, n (%) dMMR (MSI-high) 4 (22) 3 (38) 1 (10) MMR proficient (MSI-stable) 8 (44) 1 (13) 7 (70) Unknown 6 (33) 4 (50) 2 (20) Correlative testing, n (%) FACS 5 (28) 1 (13) 4 (40) Single cell (SC) 5 (28) 1 (13) 4 (40) FACS and SC 8 (44) 6 (75) 2 (20) -
TABLE 2 The total blood count parameters for all clinical trial patients on day 1 ofcycles All Patients (n = 18) Responders (n = 8) Non-responders (n = 10) Blood Count with Differential, Median Median Median laboratory reference range (IQR) Range (IQR) Range (IQR) Range White Blood Cells, 3.20-10.60 k/μL C1 7.0 (4.6) 3.9-17.2 7.3 (5.4) 4.46-11.4 6.4 (4.6) 3.9-17.2 C3 4.2 (2.3) 2.5-19.0 4.5 (1.4) 3.13-6.7 3.6 (3.1) 2.5-19.0 C5 4.5 (1.9) 2.4-11.9 4.7 (1.7) 3.24-10.5 4.1 (4.0) 2.4-11.9 Red Blood Cells, 3.88-5.46 M/μL C1 4.3 (0.8) 3.5-5.4 4.7 (0.6) 3.75-5.4 4.1 (0.8) 3.5-5.0 C3 4.1 (0.9) 2.8-5.4 4.4 (0.9) 3.1-5.4 3.8 (1.0) 2.8-4.8 C5 3.7 (1.2) 2.8-5.3 4.4 (0.9) 2.84-5.3 3.5 (0.8) 3.3-4.6 Hemoglobin, 12.1-15.9 g/dL C1 12.7 (2.6) 9.4-16.1 12.8 (2.5) 9.4-15.2 12.5 (3.4) 9.6-16.1 C3 11.9 (2.9) 8.7-15.2 11.7 (3.3) 9.5-14.7 12.2 (3.3) 8.7-15.2 C5 11.7 (2.6) 8.8-15.9 12.3 (2.4) 8.9-14.7 11.1 (3.5) 8.8-15.9 Platelets, 177-406 k/μL C1 212 (93) 129-353 195 (104.3) 148-339 234 (103) 129-353 C3 154 (50) 93-228 134 (76.0) 93-223 164 (38) 112-228 C5 147 (78) 77-404 114 (118.8) 77-404 166 (59) 120-226 Granulocyte #, 1.3-7.0 k/μL C1 4.6 (3.6) 2.6-15.5 5.4 (4.5) 3-8.6 4.1 (2.9) 2.6-15.5 C3 2.5 (2.1) 1.1-16.7 2.5 (1.1) 2-4.8 2.1 (2.5) 1.1-16.7 C5 3.0 (2.5) 1.1-9.6 2.7 (1.4) 1.37-8.5 3.3 (3.5) 1.1-9.6 Monocyte #, 0.2-0.7 k/μL C1 0.5 (0.3) 0.2-1.1 0.5 (0.5) 0.3-1.1 0.4 (0.4) 0.2-0.9 C3 0.4 (0.3) 0.2-0.9 0.4 (0.5) 0.3-0.9 0.4 (0.3) 0.2-0.7 C5 0.5 (0.4) 0.0-1.1 0.5 (0.6) 0-1.1 0.5 (0.3) 0.3-0.7 Lymphocyte #, 0.8-3.1 k/μL C1 1.4 (0.9) 0.4-2.8 1.1 (0.7) 0.4-1.7 1.7 (1.5) 0.7-2.8 C3 1.3 (0.7) 0.5-2.3 1.1 (0.4) 0.5-1.6 1.7 (0.6) 0.7-2.3 C5 1.3 (0.8) 0.4-3.0 1.2 (0.4) 0.44-2.2 1.6 (1.0) 0.7-3.0
Identifying Immune Cell Populations from scRNA-Seq Profiles - Single cell RNA sequencing was performed using the 10X platform, creating a transcriptional profile from 71,545 cells. Our analysis revealed a diverse set of 35 clusters. To identify cell type for each of these clusters, canonical gene expression was evaluated for each cluster to identify major PBMC lineages. (
FIG. 2 panel (a),FIG. 10 ). Further interrogation of markers identified naïve, central memory and effector memory T cells, classical and non-classical monocytes, active and resting natural kill (NK) cells, naïve and memory B cells, dendritic cells and plasmacytoid dendritic cells (FIG. 11 panel (a), Table 3). No batch effects were found corresponding to time, patient or cancers (FIG. 11 panels (b)-(d)). - Provided in Table 3 are the major clusters and sub clusters annotation for single cell RNA sequencing analysis. Single cell RNA sequencing was performed using the 10X platform, creating a transcriptional profile from 71,545 cells, and the analysis revealed a diverse set of 35 clusters. To identify cell type for each of these clusters, canonical gene expression was evaluated for each cluster to identify major PBMC lineages. Further analysis of markers identified naïve, central memory and effector memory T cells, classical and non-classical monocytes, active and resting natural kill (NK) cells, naïve and memory B cells, dendritic cells and plasmacytoid dendritic cells.
-
TABLE 3 Major clusters and sub clusters annotation Cluster Major clusters Sub clusters 1 NK Cell NK Cell Resting 2 Monocyte Monocyte Classical 3 Monocyte Monocyte Classical 4 Monocyte Monocyte Non-Classical 9 Monocyte Monocyte Classical Platelets 10 Monocyte Monocyte Classical 11 B Cell B Cell Naive 12 NK Cell NK Cell Activated 13 B Cell B Cell Memory 14 Dendritic Cell Dendritic Cell 15 Monocyte Monocyte Classical 17 Cell Cycle Cell Cycle 18 Monocyte Monocyte Classical 19 Plasmacytoid Plasmacytoid Dendritic dendritic cell Cell 20 Plasma Cell Plasma Cell 22 Activated Platelets Activated Platelets 23 T Cell NA 24 RBC RBC 25 Plasma Cell Plasma Cell T0 T Cell CD4 T Cell CD4 EM T1 T Cell CD4 T Cell CD4 Naive T10 T Cell CD8 T Cell CD8 Exhausted T11 T Cell CD8 T Cell CD8 EM T12 T Cell CD8 T Cell CD8 EM T13 T Cell CD8 T Cell CD8 EM T14 T Cell CD8 T Cell CD8 CM T15 T Cell CD4 T Cell TFH T2 T Cell CD8 T Cell CD8 TEMRA T3 T Cell CD8 T Cell CD8 TEMRA T4 T Cell CD4 T Cell CD4 CM T5 T Cell CD8 T Cell CD8 EM T6 NA NA T7 T Cell CD8 T Cell CD8 CM T8 T Cell CD4 T Cell Treg T9 T Cell CD8 T Cell CD8 Naive - To confirm the cluster annotations, transcriptional profiles and corresponding annotations were compared to two publicly available scRNAseq datasets [See for example Refs. 29, 30]. A machine learning classifier was used to compare our annotations with those of a profile of PBMCs [See Ref 30] and tumor infiltrating immune cells [See for example Ref. 29]. It was seen that 96.5% of T cells from the PBMCs (clusters with at least 10 PBMC cells) and 94.1% from the tumor infiltrating immune cells T cell clusters dataset were correctly predicted using the classifier (
FIG. 2 panel (b),FIGS. 12A-B ). Cluster marker genes were compared and found to have a similarly high agreement of cluster annotations (FIG. 2 panel (b),FIGS. 12A-B ). The connections between the annotations herein and the published ones are shown in the network presented, and show an overall consensus in results with some refinement of cell subtype annotation between approaches (FIG. 13 ). As a final approach to validate our cell type annotations, 8 patients were profiled with both flow cytometry and scRNAseq. A high agreement in the total percentages of B cells and NK cells was found and a slightly lower agreement in the percentages of lymphocytes and monocytes with differences of 10% and 9%, respectively (FIG. 2 panels (c)-(d)). Further interrogation of the monocytes identified a cluster with a high percentage of activated platelet contamination. Without wishing to be bound by theory, this was likely due to activated platelets binding to the monocytes and partially explains the differences observed between the flow cytometry and scRNAseq analysis [See for example ref. 31]. This contaminated cluster was removed from further analysis. Overall, there was a similar level of major immune cell populations in the flow cytometry and scRNAseq analysis with differences likely due to the measurement of mRNA or protein. Additionally, flow cytometry benefits from high cell number throughput, allowing for the identification of rare immune populations, but lacks the resolution of scRNAseq (FIG. 14 ). No change in population frequencies of identified major subtypes (T cells, NK, monocytes, and B cells) was observed, as determined by scRNAseq and flow cytometry, after chemotherapy or PD-1i between responders and non-responders; however, at baseline, more monocytes and fewer NK cells in responders were detected by flow cytometry only (FIG. 15 ). - Activation of Responder T Cells After the Start of PD-1 Immunotherapy
- To capture information from signaling states of immune cells that is distinct from cell counts, pathway activity analysis within individual immune cells was performed using single sample Gene Set Enrichment Analysis (ssGSEA) [See for example. Ref 32]. Enrichment scores were calculated using C2 and Hallmark pathway signatures [See for example Refs. 33, 34]. Pathway differences before therapy, during chemotherapy and during the early-immunotherapy phase of the trial were analyzed using a random effects linear modeling framework. This allows partitioning of the molecular effects of chemotherapy from the effects of immunotherapy and simultaneously accounts for patient-specific variation in expression. Pathway changes specific to the immune cells of responders, and those that were common to both responder and non-responder were identified (
FIG. 2 e ). Overall, immune cell gene expression was not changed upon chemotherapy treatment (FIG. 2 e , left hand panel in red); however, specific changes common to all patients in NK, monocytes and T cells, including interferon (IFN) signaling after the start of PD-1i (FIG. 2 e , middle pane), as well as signaling changes specific only to responders were detected (FIG. 2 e , right hand panel in black). - Next, specific signaling pathway dynamics in subpopulations of T cells and monocytes were analyzed. Pathway activity was measured in every single cell as above, and pathways were categorized into key phenotypes, including interferon, inflammation, growth and differentiation signaling states. Interferon pathway activity in both CD4+ and CD8+ T-cells was strongly upregulated in responder patients following the initiation of PD-1i (C3-C5) (CD4: t=19.00, p<0.001, CD8 t=16.00, p<0.001) (
FIG. 3A ,FIG. 16 ). CD8+ T cells of non-responders show upregulation of interferon pathway activity signaling after the start of PD-1i while CD4+ T cells were not significantly increased (t=7.607 p<0.001). GSEA IFN pathway genes were significantly upregulated in the CD8+ and CD4+ T cells of responders (FIG. 3B ,FIG. 17 ). After the start of PD-1i, responders showed significantly higher upregulated gene expression of IFN-γ in CD8+ cells than non-responders (p<0.01) (FIG. 3B ) [also, see for example Ref. 35]. This translated to significant upregulation of IFN downstream signaling gene expression (IRF1/2/7 and STAT1/2 and interferon-stimulated gene (ISG) expression such as IFIT family members and GBPs in responder CD8+ and CD4+ T cells (data not shown). In contrast, non-responders showed significantly higher upregulation of SOCS1 and SOCS2 gene expression in CD4+ and CD8+ T cells (p<0.05). Without wishing to be bound by theory, because SOCS can repress IFN signaling, we concluded that CD4+ and CD8+ T cells of non-responders are unable to effectively induce IFN signaling upon PD-1i treatment. [See for example Ref. 35]. - Distinct inflammatory responses in the gene expression profile of responder T cells was identified (
FIG. 3A ). Responders' CD8+ T cells had a greater inflammatory response prior to the onset of the trial (t=5.14, p<0.001), although not after the two cycles of chemotherapy. The addition of PD-1i induced a significantly stronger inflammatory response in the CD8+ T cells of responders than in non-responders (t=3.8,p<0.001). This inflammation included significant upregulation of CD74, HLA-A/B/C and PSM genes, which are directly involved in the sorting and processing of major histocompatibility complex (MHC) class I and II (FIG. 3B ). In addition to MHC modulation, responder CD8+ and CD4+ T cells had significantly higher upregulation of NF-κB pathway genes. Specifically, expression of NFKB1 and MYD88 genes is upregulated significantly more in responders than in non-responders after the start of PD-1i while promoter (IKBKB) and inhibitor (NFKBIA) of NF-kB expression were upregulated and downregulated, respectively. NF-κB activation suggests an overall pro-survival state of these cells. Responder CD8+ and CD4+ T cells also upregulated chemokines that initiate immune cell recruitment (e.g. CCL3/4/5) (FIGS. 17A-C ). -
FIG. 17A presents results for gene expression data for the following genes, from top to bottom, ZFP36L2, ZBP1, XRCC6, XAF1, WARS, VAMP5, USP18, UBE2L6, UBA7, TYMP, TXNIP, TRIM26, TRIM25, TRIM22, TRIM21, TREVI14, TRAFD1, TNFSF10, TMEM140, TAP1, STAT2, STAT1, ST8SIA4, ST3GAL5, SSBP1, SRSF2, SRP9, SP110, SP100, SOCS3, SOCS1, SMAD4, SLC25A28, SKP1, SHFM1, SDCBP, SAMHD1, SAMD9L, SAMD9, RTP4, RNF213, RIPK2, RHOC, RBCK1, RBBP4, RARRES3, PTPN6, PTPN2, PTPN1, PSME2, PSME1, PSMB9, PSMB8, PSMB10, PSMA3, PPP5C, PPP3CA, POLR2B, PNPT1, PML, PMAIP1, PLSCR1, PDXK, PARP9, PARP14, PARP12, PARP1, OGFR, OASL, OAS3, OAS2, OAS1, NUP93, NUB1, NMI, NLRC5, NCOA7, MYD88, MX2, MX1, MT2A, MOV10, LY6E, LIPA, LGALS3BP, LAP3, JAK2, ISG20, ISG15, IRF9, IRF7, IRF3, IRF2, IRF1, IL4R, IL15RA, IL15, IFNAR2, IFITM3, IFITM2, IFITM1, IFIT5, IFIT3, IFIT2, IFIT1, IFIH1, IFI6, IFI44L, IFI44, IFI35, IFI16, HIF1A, HERC6, HERC5, HADHB, HADH, GCH1, GBP4, GBP2, GBP1, FAS, EPSTI1, EPS15, ELK4, ELF1, EIF4E3, EIF2B1, EIF2AK2, DTX3L, DHX58, DDX60, DDX58, DDX17, CYCS, CFH, CD74, CD164, CASP8, CASP1, BTG1, BST2, BBC3, BAG1, B2M, ATP6V0B, APOL6, APOL1, APOBEC3G, and ADAR. -
FIG. 17B presents results for gene expression data for the following genes, from top to bottom, ZFP36L2, ZBP1, XRCC6, XAF1, WARS, VAMP5, USP18, UBE2N, UBE2L6, UBE2E1, UBA7, UBA52, TYMP, TYK2, TXNIP, TRIM26, TRIM25, TRIM22, TRM21, TRIM14, TRAFD1, TPR, TNFSF10, TMEM140, TAP1, SUMO1, STAT3, STAT2, STAT1, ST8SIA4, ST3GAL5, SSBP1, SRSF2, SRP9, SP110, SP100, SOCS3, SOCS1, SMAD4, SLC25A28, SLAMF7, SKP1, SHFM1, SEH1L, SDCBP, SAMHD1, SAMD9L, SAMD9, RTP4, RPS27A, RNF213, RNASEL, RIPK2, RHOC, RBCK1, RBBP4, RARRES3, RANBP2, RAE1, PTPN6, PTPN2, PTPN1, PSME2, PSME1, PSMB9, PSMB8, PSMB10, PSMA3, PRKCD, PPP5C, PPP3CA, PPM1B, POM121, POLR2B, PNPT1, PML, PMAIP1, PLSCR1, PLCG1, PIN1, PIAS1, PDXK, PARP9, PARP14, PARP12, PARP1, OGFR, OASL, OAS3, OAS2, OAS1, NUPL2, NUPL1, NUP93, NUP88, NUP85, NUP62, NUP54, NUP50, NUP43, NUP37, NUP35, NUP214, NUP210, NUP205, NUP188, NUP155, NUP153, NUP133, NUP107, NUB1, NMI, NLRC5, NFKB1, NCOA7, NCAM1, MYD88, MX2, MX1, MT2A, MOV10, MAPK3, MAPK1, MAP2K6, LY6E, LIPA, LGALS3BP, LAP3, KPNB1, KPNA5, KPNA4, KPNA3, KPNA2, KPNA1, JAK2, JAK1, ISG20, ISG15, IRF9, IRF7, IRF3, IRF2, IRF1, IP6K2, IL4R, IL2RB, IL18BP, IL15RA, IL15, IFNGR2, IFNGR1, IFNG, IFNAR2, IFNAR1, IFITM3, IFITM2, IFITM1, IFIT5, IFIT3, IFIT2, IFIT1, IFIH1, IFI6, IFI44L, IFI44, IFI35, IFI16, ICAM1, HIF1A, HERC6, HERC5, HADHB, HADH, GCH1, GBP5, GBP4, GBP2, GBP1, FLNB, FAS, EPSTI1, EPS15, ELK4, ELF1, EIF4G3, EIF4G2, EIF4G1, EIF4E3, EIF4E2, EIF4E, EIF4A3, EIF4A2, EIF4A1, EIF2B1, EIF2AK2, DTX3L, DHX58, DDX60, DDX58, DDX17, CYCS, CISH, CFH, CEBPD, CD74, CD44, CD164, CASP8, CASP7, CASP3, CASP1, CAMK2D, BTG1, BST2, BBC3, BAG1, B2M, ATP6V0B, ARIH1, APOL6, APOL1, APOBEC3G, ADAR, and AAAS. -
FIG. 17C presents results for gene expression data for the following genes, from top to bottom, ZBTB16, YWHAZ, YWHAB, YES1, WWP1, WSB1, VPRBP, VHL, VAV1, UBR4, UBR2, UBR1, UBOX5, UBE4A, UBE3C, UBE3B, UBE3A, UBE2Z, UBE2W, UBE2V2, UBE2S, UBE2R2, UBE2Q2, UBE2Q1, UBE2O, UBE2N, UBE2M, UBE2L6, UBE2L3, UBE2K, UBE2J2, UBE2J1, UBE2H, UBE2G2, UBE2G1, UBE2F, UBE2E3, UBE2E1, UBE2D4, UBE2D3, UBE2D2, UBE2D1, UBE2B, UBE2A, UBA7, UBA6, UBA52, UBA5, UBA3, UBA2, UBA1, TYROBP, TYK2, TRIP12, TRIM37, TRIM32, TRIM21, TRIM11, TRAF6, TPP2, TPI1, TNIP1, TCEB2, TCEB1, TAP1, TAB2, STUB1, STMN1, STAT5A, STAT3, STAT1, SSX2IP, SPSB2, SOS1, SOCS3, SOCS1, SMURF2, SKP2, SKP1, SHC1, SH3BGRL, SERINC3, SEC61G, SEC61B, SEC61A1, SEC31A, SEC24D, SEC24C, SEC24B, SEC23A, SEC13, SAR1B, SAE1, RPS27A, RNF6, RNF41, RNF4, RNF34, RNF25, RNE220, RNE138, RNE123, RIPK2, RELA, RCHY1, RBX1, RBCK1, RAF1, PTPN6, PSMF1, PSME4, PSME2, PSME1, PSMD9, PMSD8, PSMD7, PSMD6, PSMD5, PSMD4, PSMD3, PSMD2, PSMD14, PSMD13, PSMD12, PSMD11, PSMD10, PSMD1, PSMC6, PSMC5, PSMC4, PSMC3, PSMC2, PSMC1, PSMB9, PSMB8, PSMB7, PSMB6, PSMB5, PSMB4, PSMB3, PSMB2, PSMB10, PSMB1, PSMA7, PSMA6, PSMA5, PSMA4, PSMA3, PSMA1, PRKACB, PLCG2, PJA2, PJA1, PIK3R3, PIK3R1, PIK3CD, PIK3CB, PIK3CA, PDIA3, PDCD1, PCNA, OAS3, OAS2, OAS1, NRAS, NPFPPS, NFKBIA, NCF4, MX1, MKRN1, MAP3K8, MAP3K7, LYN, LRSAM1, LRRC41, LRR1, LNPEP, LCK, KRAS, KLRK1, KLHL9, KLHL20, KIF22, KEAP1, JAK2, JAK1, ITM2B, ITGB1, ISG15, IL7R, IL6S1, IL12RB1, IKBKG, IKBKB, IFNG, IFITM1, IFIT3, IFIT1, IFIH1, IFI44, ID3, ID2, ICAM1, HUWE1, HSPA5, HRAS, HERC2, HECTD3, H2AFV, GRB2, GBP1, GAN, FYN, FTH1, FBXW7, FBW11, FBX06, FBXO44, FBXO4, FBXO3, ERAP1, DZIP3, DTX3L, DNAJA1, DDX60, DCTN6, DBI, CYBA, CXCR3, CUL5, CUL3, CUL2, CUL1, CTSS, CTSD, CTSB, CTSA, CST3, CHUK, CDKN2C, CDC34, CDC27, CDC26, CDC23, CDC16, CD74, CCR5, CCR2, CCL5, CCL4, CCL3, CBLB, CBL, CASP1, CANX, CALR, BLMH, B2M, ATPIF1, ATG7, ASB8, ASB7, ASB6, ASB1, ARIH2, ANAPC7, ANAPC5, ANAPC4, ANAPC2, ANAPC13, ANAPC11, ANAPC10, ANAPC1, ALAD, and AHNAK. - The upregulation of ubiquitin and vesicle trafficking gene expression (UBE and SEC family members) further suggests the increased overall activation of these cells. In contrast, non-responder T cells downregulated genes related to the NF-KB pathway (decreased IKBKB and increased NFKBIA) as well as genes related to migration of immune cells, indicating an inactive state. These results indicate that the signaling state dynamics of immune cells in the peripheral blood could captures signaling information relevant to tumor response to immunotherapy. Responder T cell signaling states differ from those of non-responders, with T cells in responders upregulating inflammation and IFN signaling that may reflect better recruitment and activation of immune cells and a potentially greater capacity to detect and kill cancer cells.
- Monocytes also exhibit different phenotypes in responders and non-responders but with signaling changes from those in T cells. Before treatment (C1), responder monocytes had significantly higher activation of three pathways representing related but distinct measures of monocyte developmental states: growth factor production (t=9.2, p<0.001), inflammation (t=6.1, p<0.001), and differentiation (t=6.3, p<0.001) (
FIG. 3D ). Chemotherapy decreased each of these pathway scores in both responders and non-responders, but responders experienced a significant reduction in all three pathways after PD-1i treatment (p<0.001 for each pathway) while non-responders showed a significant increase (p<0.001 for each pathway). - At C1, responder monocytes had higher expression of genes involved in the inhibition of NF-κB pathway (i.e. NFKBIZ and NFKBIA) than non-responders (p<0.001) (
FIG. 3D ,FIGS. 18A-C ). -
FIG. 18A presents results for gene expression data for the following genes, from top to bottom, ZSCAN16, ZNF217, ZNF107, ZFP36L2, ZFP36, ZFAND6, ZC3HAV1, ZBTB25, ZBTB20, WDR45, WDR37, VPS54, VOPP1, VEGFA, UGCG, UBE2H, UBAC2, TUBA4A, TTC39B, TSC22D1, TRIB1, TRA2B, TPP2, TP53INP1, TOP2B, TNFAIP3, TMEM64, THBS1, TCF12, TBC1D5, TBC1D15, TASP1, SUV420H1, STRN3, STAT5B, SOD2, SMAD1, SLC35B3, SIK3, SGMS1, SESN1, SEMA3C, SATB1, SAT1, SAMHD1, RNF125, RHOB, RGS2, RFX3, REEP3, RBL2, RBBP6, RB1, RAPGEF6, RABGAP1L, RAB8B, PTGS2, PTGER2, PSPC1, PSMA1, PPP3CC, PPP2R5C, PIP4K2A, PIM1, PIK3R1, PIK3IP1, PHTF2, PELI1, PDE4B, NUP153, NUDCD3, NSMCE2, NRBF2, NR4A2, NFKBIZ, NFIL3, NEK7, NCOA3, NCK2, MYC, MDFIC, MCL1, MBNL1, MAP4K4, MAP3K5, MAP3K1, MAN1A2, MAN1A1, MALT1, LTA4H, LRIF1, LRCH1, LATS2, L3MBTL3, KLF6, KLF3, KDM3A, KAT6B, JUNB, JUN, JMJD1C, JARID2, IRS2, IRF4, IRF2, IL7R, IGF1R, IFNAR2, IER3, ID2, IBTK, HIVEP2, HIF1A, HERPUD2, HEATR5A, HBS1L, GPRIN3, GPR183, GPHN, GLCCI1, GDI2, FOSL2, FOSB, FOS, FEM1C, FAS, FAM91A1, FAM76B, FAM3C, F2RL1, EXT1, EXOC6B, EVI5, ETS2, ETS1, ETNK1, ELK3, ELF1, EGR1, DUSP6, DUSP5, DOCK10, DNAJB4, DENND5A, CXCR4, CTSB, CREM, CPDX, CNOT6L, CNOT2, CITED2, CHD9, CELF2, CEBPD, CEBPB, CDKN1B, CDK19, CDK17, CDC42EP2, CD9, CCNG2, CBLB, CAST, C6orf62, C21orf91, BTN2A1, BTG2, BTG1, BTBD10, BCL6, BARD1, BAG3, BACH1, B3GNT2, ATP2B1, ATP1B3, ATF3, ATAD2B, ASXL2, ARL4A, ARID5B, ARHGEF3, ARHGAP5, ARHGAP15, AKAP13, ADM, ADD3, and ABT1. -
FIG. 18B presents results for gene expression data for the following genes, from top to bottom, ZFP36, XBP1, VEGFA, TYK2, TTC9, TSC22D2, TSC22D1, TRIB1, TNFAIP3, TNFAIP2, TLR7, TLR2, TLE3, TJP2, TIMP1, THBD, TGIF1, TGFBR1, SYK, STAT5B, STAT5A, STAT3, STAT1, ST3GAL4, SQSTM1, SPHK1, SOS1, SOCS3, SLC2A3, SLC2A14, SIAH2, SHC1, SELL, SAT1, SAMSN1, RUNX1, RPAGD, RPS6KB1, RPS6KA5, RPS6KA3, RNF217, RNF19B, RIPK2, RHOB, RELA, REL, RAF1, PTX3, PTPRE, PTPN6, PTPN11, PTK2B, PTGS2, PTGER2, PRKCB, PPP2R5D, PPP2CA, PPP1R15A, POU2F1, PMAIP1, PLIN2, PLEKHG3, PLEK, PLAUR, PIM1, PIK3R1, PIK3CA, PIAS3, PHTF2, PFKFB3, PF4, PDGFC, P2RX4, NUAK2, NOD1, NFKBIZ, NFKBIA, NFKB2, NFIL3, NDRG1, NCOA3, MYC, MXD1, MOB3B, MGLL, MFSD2A, MEF2C, MCL1, MARCKSL1, MAPKAPK2, MAPK9, MAPK8, MAPK3, MAPK14, MAPK1, MAP3K8, MAP2K6, MAP2K4, MAP2K3, MAP2K2, MAP2K1, LTB, LRRC8C, LDLR, KLF6, KLF2, KLF13, KLF10, JUNB, JUN, JAK3, JAK2, JAK1, ITGAV, IRS2, IRF8, IRF4, IRF1, IL8, IL7R, IL6ST, IL6R, IL4R, IL3RA, IL2RG, IL2RB, IL13RA1, IFNGR2, IFI16, IER5, IER3, IER2, ICAM1, HUWE1, HRAS, HK2, HES1, HCK, HBEGF, GUCY1B3, GRB2, GPR65, GNPTAB, GNG2, GFOD1, GCH1, GBP4, GALNT3, GALC, GADD45B, GABARAPL1, GAB2, G0S2, FPR3, FOSL2, FOSB, FOS, FGL2, FCER2, FAM126B, F2RL1, ETS2, ETS1, ELK1, EHD1, EGFR1, DUSP6, DUSP5, DUSP1, DOK2, DENND5A, DCPS, CXCR4, CTSZ, CST7, CSNK2A1, COTL1, CLEC4A, CKAP4, CISH, CFLAR, CEBPD, CEBPB, CDKN1C, CDKN1A, CD86, CD83, CD79B, CD44, CD14, CCR5, CCNL1, CCND2, CCL5, CCL4, CCL3, CBL, CAPG, CA2, C4orf32, BTG3, BTG2, BTG1, BIRC3, BIRC2, BHLHE40, BCL6, BCL2L1, BATF3, BATF, ATF3, ARL4A, ARID5B, ANTXR2, AKT1, AK3, AGER, and ABCA1. -
FIG. 18C presents results for gene expression data for the following genes, from top to bottom, ZFP36L2, ZFP36, ZFAND5, YRDC, VEGFA, VCL, USP12, UPP1, TSC22D1, TRIB1, TPM1, TOP1, TOB1, TNFRSF10B, TNFAIP3, TMEM176B, TMEM176A, TIPARP, TIMP1, TIAM1, THBS1, TFRC, STAT3, SRF, SRC, SPHK1, SPARC, SOS1, SOCS3, SMAD7, SLK, SLC20A1, SLC12A2, SIK1, SHC1, SGMS1, SGK1, SERPINB8, RUNX1, RPS6KA5, RPS6KA3, RPS6KA1, RHOA, RGS2, RBMS1, RASA1, RAPGEF1, RAP1B, RAP1A, RAF1, PXN, PVR, PTX3, PTPRE, PTPN11, PTK2B, PTK2, PTGS2, PTEN, PRKCA, PPP1R15A, PPBP, PNPLA8, PMAIP1, PLEKHO2, PLAUR, PIM1, PIK3R1, PIK3CG, PIK3CA, PFKFB3, PER2, PER1, PDPK1, PDLIM5, PALLD, OXSR1, NR4A2, NR4A1, NFKBIZ, NFKB1, NEDD9, NDRG1, NAB2, MYD88, MYC, MTM1, MPZL2, MIR22HG, MEG3, MEF2C, MCL1, MBNL2, MAPKAPK2, MAPK8, MAPK7, MAPK3, MAPK14, MAPK1, MAP4K1, MAP3K8, MAP2K3, MAP2K1, LYN, LRRFIP1, LRRC8C, LDLR, LBH, KLF6, KLF4, KLF10, KDM6B, KCNN4, KBTBD2, JUNB, JUN, JOSD1, JAK1, ITPRIP, ITGAV, IRS2, INPP1, IL8, IL6R, IL1B, IKZF1, IGF1R, IER5, IER3, IER2, HRAS, HOMER1, HK2, HGF, HES1, HBEGF, GRB2, GNG11, GK, GALNT7, GADD45B, GADD45A, GAB1, G0S2, FRS2, FOXP1, FOSL2, FOSB, FOS, F2RL1, EZR, ETS2, ETS1, EPHB2, ELK1, EHD4, EHD1, EGR1, DUSP7, DUSP6, DUSP5, DUSP2, DUSP10, DUSP1, DST, DNMBP, DNAJB1, CYP1B1, CXCR4, CSNK2A1, CSNK1E, CSNK1D, CRKL, CRK, CREB1, CLCF1, CITED4, CEBPB, CD55, CD44, CCNL1, CBL, CASP9, C12orf44, BTBD3, BIRC3, BHLHE40, BCL3, BCL10, B3GNT5, ATF3, ATF1, ARHGAP6, ARHGAP25, ARAP2, AKT2, AKT1, AKIRIN1, AEN, ADRB2, ADM, ADAM8, and ADAM17. - Moreover, responder monocytes had upregulated TNF (p<0.05) and TNFAIP (p<0.001) expression known to inhibit NF-κB activation. Both transcription factors (JUN and FOS), related to growth factor signaling molecules are expressed at higher levels in responders (both p<0.001). We also found significant upregulation of CXCR4, CCR and CCL family members in responder monocytes, which promote migration and the recruitment of other immune cells. [Also, see for example Ref. 37]. After the start of PD-1i, responder monocytes significantly downregulate inflammation and growth-related genes, while non-responders monocytes upregulate genes related to NF-κB activation (NFKB2, BIRC3, AKT1 or RELA). Both non-responders and responders upregulated ISGs (STAT, GBP, IRF, IFIT family members) after commencement of PD-1i, yet this upregulation was markedly greater in responders (p<0.001). In addition, MHC II genes were upregulated in non-responders and responders after the start of PD-1i; however, responders have significantly higher expression of HLA-DQ and HLA-DP while non-responders have higher expression of HLA-DR. Gene expression of HLA-DM protein, which is involved in the intracellular processing of antigen presentation, is upregulated in both responders and non-responders. Upregulation of more antigen presenting receptor genes (HLA) by responder monocytes may confer an increased ability to activate other immune cells. Monocytes show significant pre-treatment differences in signaling and divergent evolutionary trajectories in responders versus non-responders. Activation of monocytes after the start of PD-1i may reflect responses to the upregulation of IFN and cytokine gene expression observed in responder T cells.
- To evaluate the differences in differentiation and activation states of CD4+ T cells, CD8+ T cells, and monocytes between patients during treatment, major axes of phenotypic variation within each immune type from single-cell gene expression profiles were identified using pseudotime reconstruction (
FIG. 4 ). Naïve T cells are CCR7+/CD45RA+, the EM (Effector memory) T cells are CCR7−/CD45RA−, EMRA (Effector memory CD45RA+) T cells are CCR7−/CD45RA+, CM (Central memory) T cells are CCR7+/CD45RA−, from right to left, and on the x-axis C stands for cycle, 1 cycle is 14 days, C1 is the baseline, C3 is the chemotherapy mFOLOFX6 regimen, C5 and C8 are Chemotherapy including anti-PD-1 immunotherapy. The statistical significance is displayed as *P<0.05, **P<0.01 and ***P<0.001 (two-tailed unpaired t-test), and box plots represent the interquartile range (IQR), with the horizontal line indicating the median. Whiskers extend to the farthest data point within a maximum of 1.5×IQR. These phenotypic traits were verified using zinbwave and principal component analysis dimension reduction methods (FIG. 19 ). By overlaying these phenotypic scores onto the uniform manifold approximation and projection (UMAP), we further validated that these traits reflect major sources of variation within the immune cell types (FIG. 4 panel (a)). For both CD4+ and CD8+ T cells, the major axes of phenotypic gradient related to differentiation states. The CD4+ T cell phenotypic gradient captured a continuum of differentiation from naïve to effector helper T cells (FIG. 4 panel (a)). Canonical gene markers of T cell differentiation (e.g. CCR7 and S100A4) distinguished the naïve, central memory, and effector memory CD4+ sub-types (FIG. 4 panel (b)). The expected order of cell type differentiation aligned clearly with the continuous phenotype gradient (FIG. 4 panel (c)). Similarly, the CD8+ T cell phenotype gradient captured differentiation from naïve to highly cytotoxic cells. Naïve, central memory, effector memory, and effector memory CD45RA+ (EMRA) subtypes were identified. The strong agreement between CD8+ cell subtype classification and the cytotoxic phenotype scales reinforced the functional relevance of the T cell sub-types that were identified. - The distribution of T cell phenotypes in the peripheral blood population was assessed by calculating a phenotype score for each cell. Differences in the frequency of T cells with different scores were identified between responders and non-responders and over time. Before the trial (C1), responders had a higher frequency of undifferentiated (naïve) CD4+ T cells, while non-responders had more differentiated CD4+ T cells, especially CD4+EM cells (t=−7.5,p<0.001). This difference remained following the onset of chemotherapy (C3). However, after the addition of immunotherapy (C5) the CD4+ T cells of responders showed a significant shift towards increased differentiation (t=9.9,p<0.001) and in fact converged with non-responders (
FIG. 4 panel (d),FIG. 20 panel (a)). In CD8+ T cells, responders had a higher frequency of cytotoxic differentiated CD8+ cells than non-responders, both before and during treatment (FIG. 4 panel (d),FIG. 20 panel (b)) (F=16.8, p<0.001). With the addition of PD-1i, responder CD8+ T cells became more differentiated (t=3.9, p<0.001), while non-responder CD8+ T cells shifted to lower differentiation (t=−4.0,p<0.001). - In addition to the scRNAseq analyses, flow cytometry analysis using CD45RA and CCR7 as markers to discriminate memory from naïve T cells identified multiple significant differences in the CD4+ population. Responders had a higher frequency of CCR7+ CD45RA+ CD4+ naïve cells before and throughout treatment (
FIG. 4 panel (e),FIG. 9 ). CD45RA−/CCR7+ CD4+ CM cells were significantly more frequent in responders at the C1 and C3 time points but not after PD-1i treatment (C5). Conversely, CCR7−/CD45RA− CD4+ EM cells and CD45RA+/CCR7− CD4+ EMRA cells were significantly more frequent in non-responders at all time points. CD8+ subtypes showed no significant difference between responders and non-responders. - Responders Start Therapy with Exhausted Memory T Cells
- Due to pembrolizumab targeting the PD-1 receptor, the frequencies of PD-1+ cells by CD4+ and CD8+ subtype at C1 were evaluated and found that EM cells are the most frequent of PD1+ cells in both CD4+ and CD8+ cells (
FIG. 5 panel (a)). With the alternative exhaustion marker, CTLA-4, the frequency of CTLA-4+ cells within the CD4+ EM cells and CD4+ EMRA populations is higher in responders across all time points (FIG. 5 panel (b)). The data showed no difference of CTLA-4+ frequency among CD8+ subtypes; however, PD-1+ CD8+ EM cells were significantly more frequent in responders than non-responders before treatment (FIG. 5 panel (c)).FIG. 5 panels (a), (b), (c), and (e) show box plots representing the interquartile range (IQR), with the horizontal line indicating the median. Whiskers extend to the farthest data point within a maximum of 1.5×IQR. Because exhausted markers are also associated with a past or present activated function, patients with activated/exhausted T cell function (i.e., against cancer cells) are more likely to respond to therapy [See for example Refs. 38, 39]. - Across all treatment time points, PD-1 expression in CD8 and CD4 T cells differs between responders and non-responders. In both groups, PD-1+ CD8+ and PD-1+ CD8+EM cell frequencies significantly decrease upon commencement of PD-1i therapy. CD4+ and CD4+EM cell frequencies show a significant decrease only in the non-responder patients after the start of PD-1i (p<0.05) (
FIG. 5 panel (d)). This decrease of PD-1 levels by FACS may be explained by the internalization of the receptor after binding pembrolizumab, suggesting that PD-1+ CD8+ T cells, CD4+, and especially CD4+EM cells of non-responders are targeted by the drug. CD4+ EM cells express PD-1 and are found at a higher frequency in non-responders, suggesting that these cells may act as a collateral target of pembrolizumab. In addition, the frequency of PD-1+ T follicular helper cells (TFH), a population that highly expresses PD-1 [See for example Ref. 40], was higher in non-responders than responders at C1, suggesting that these cells could also, in a minority way due to their abundance compared to the CD4+EM, bind pembrolizumab reducing its availability to other cells (FIG. 5 panel (e)). InFIG. 5 panels (d), (e) the vertical bars indicate s.d. The statistical significance is displayed as *P<0.05, **P<0.01 and ***P<0.001 (two-tailed unpaired t-test). - Finally, at baseline, scRNAseq shows responder T cells express more genes associated with programmed cell death, including PMAIP1, SOCS3, BTG1 and several caspases (
FIGS. 16, 17A -C). These genes may signal hallmarks of an exhausted immune cell status. A category of pathways including all death related genes was created and data showed that responders show higher expression of these pathways than non-responders throughout treatment (FIG. 16 ). Combined with flow cytometry results, the data supported a conclusion that the exhausted status of circulating CD8+ and CD4+ T cells may be a useful criterion in assessing patient response to PD-1i. - The major axes of phenotypic variation in monocytes were associated with the distinction among classical monocytes (CD14), non-classical monocytes (FCGR3A=CD16), and dendritic cells (FCER1A) (
FIG. 6 panel (a)), as well as the interferon response genes (FIG. 6 panel (b)). Indeed, within both monocyte groups, the expression of interferon response genes was the major axis of monocyte subtype phenotypic variation. Cells with high interferon activation scores had higher expression of genes directly upregulated by IFN stimulation (e.g. IFIT1/3, IFITM3, IFI44L, PSME2, IFI6, ISG15) and MCHII production (e.g. HLA.DPA1, HLA.DPB1, and HLA.DMA). The monocyte interferon activation score was highest in the dendritic cells (FIG. 6 panels (a)-(b)). Cells with lowest scores had increased expression of genes related to proliferation (e.g. FOS, FOSB, and JUN), differentiation (e.g. BTG1, RGS2, and DDX17), inflammation (e.g. SELL, S100A12, and CD36) and migration (e.g. VCAN, MALAT1, VIM, and ZEB2). - Cells with the highest interferon activation score were prevalent in responder patients after the onset of the PD-1i (
FIG. 6 panel (b),FIG. 11B ). The distribution of interferon activation in non-responder monocytes of remained relatively constant between time points C1, C3, and C5. In contrast, responder monocytes showed a significant activation shift after the addition of PD-1i (C5) (t=15.463,p<0.001) (FIG. 6 panel (c)). The phenotype distribution of monocytes in responders shifted from having the lowest to the highest average level of interferon activation and WIC II gene expression (FIG. 21 ). - Next, the frequency of classical monocytes (CD14+/CD16−) was analyzed by flow cytometry, a measure shown to be useful for predicting response to PD-1i in melanoma cancer [See for example Ref 28]. At C1, responders had a higher frequency of classical monocytes, a difference abolished by the start of chemotherapy treatment (
FIG. 6 panel (d)). Contrary to the findings from scRNAseq analysis, data showed that responders have more CD86+ and HLADR+ classical monocytes than non-responders (FIG. 6 panel (d)). Indeed, scRNAseq showed a higher density of classical monocytes and a slightly higher upregulation of MHC II genes in non-responders at baseline. The data suggests MHC II gene expression and protein expression are inversely correlated. - Frequencies of CD4+EM and Classical Monocytes are Correlated with Overall Survival
- The relationship between the frequency of CD4+ EM cells as determined by flow cytometry and the overall survival after 12 months of treatment was analyzed (
FIG. 7 panel (a)). Data showed that 7 patients had an overall survival greater than 12 months when their frequency of CD4+ EM was below 40% at the C1 time point. Among these 7 patients, 6 were responders and 1 a non-responder. In contrast, 5 patients survived less than 12 months. Four were non-responders and show a frequency of CD4+ EM greater than 40%. Similarly, classical monocyte counts prior to therapy may also serve as a marker of response to immunotherapy (FIG. 7 panel (b)). - In order to test whether immune cell density and signaling states predict response to therapy, random effects logistic regression models were developed. Patients with a lower total PBMC density during the first five cycles of treatment were significantly more likely to respond to PD-1i (z=−3.01, p<0.001). Incorporating the frequencies of CD4+ T cell and classical monocyte immune sub-classes significantly improved the prediction of patient response (
FIG. 7 panel (c)). Patients with a lower CD4+ effector memory density were significantly more likely to respond to PD-1i therapy than would be expected given their PBMC density (z=−4.03, p<0.001). Patients with a relatively high proportion of classical monocytes were also significantly more likely to respond (z=2.76, p<0.01). By combining initial PBMC count and immune subclass frequencies, patient responses could be predicted with an overall 85% accuracy (FIG. 7 panel (c)). Differences in pathway activity signatures (GSEA scores) between responders and non-responders at baseline were assessed. Responsive patients had either: a) monocytes exhibiting a high inflammatory response or b) CD8+ T cells with high IFN signaling activation (z=3.18, p<0.001) (FIG. 7 panel (d)). These results indicate that patient PD-1i response could be predicted at early stages of therapy based on a low CD4+ EM T cell count and a high fraction of classical monocytes. Importantly, the signaling state of T cells and monocytes may contribute to outcomes. - Immune checkpoint inhibitors have great potential and are being increasingly used to treat a variety of cancers; however, only a minor proportion of patients have an objective response [See for example Ref 41]. To understand why some patients respond while others do not, the evolution of immune response to PD-1i using a combined scRNAseq and flow cytometry analysis of PBMCs was assessed. The data show state changes of immune populations during chemotherapy and immunotherapy and provide potential markers of therapy response, including the density of CD4+EM cells and classical monocytes. Moreover, measurements of T cell and monocyte signaling states before and during therapy in relation to patient responsiveness were determined. Based on all observed results, a model of circulating immune cell evolution during the treatment of GI cancer patients is provided (
FIG. 8 ), where treatment with PD-1i leads to activation of PD1-expressing exhausted T-cells, resulting in antitumor activity, cytokine release, and stimulation of the immune system. Before treatment, responders have more circulating CD4+ naïve cells, fewer CD4+ EM (Effector memory) cells and more CTLA4+ EM cells, more PD-1+CD8+ EM cells, fewer TFH, and more activated classical monocytes than non-responders. The exhausted state of responders' immune cells supports the hypothesis that T cells of responders were activated before treatment, possibly with tumor specificity, followed by exhaustion induced by cancer or stromal cells. In addition, responder monocytes have higher frequency than non-responders and upregulated TNF-α, NF-KB and growth factor pathways. An explanation for this behavior is that responder monocytes can have an immune suppressive function. Further, non-responders have low levels of exhausted cells and a large population of circulating differentiated cells (CD4+ EM). Also, in non-responders, an explanation for this behavior includes cancer cells directly or indirectly inhibiting the recruitment of tumor infiltrating cells and/or the function of cytotoxic immune cells. After chemotherapy and immunotherapy, T cells and monocytes of responders upregulate activation pathways including interferon signaling and MEW processing. The continuing excess of CTLA4+ CD4+ EM cells in responders and lack of a difference in PD-1+ CD8+ EM cells imply that PD-1i is protecting T cells leading to their activation along with recruitment and subsequent activation of other cancer-killing immune cells. In non-responders, CD4+ EM and TFH (Follicular helper) are high in frequency and express PD-1, and may act as a decoy for the PD-1i before it reaches cytotoxic CD8+ cells. Finally, non-responder monocytes upregulated NF-KB and TNF-α pathways after the start of PD-1i. An explanation for this behavior includes non-responder monocytes having an immune suppressive function similar to responder monocytes before treatment. - In particular, before treatment, responders exhibit a high abundance of exhausted PD1+ T-cells and classical monocytes show increased growth and inflammation signaling. This exhausted state may reflect prior tumor recognition, for example upon chemotherapy treatment and neoantigen presentation. No other immune cell populations show these signatures prior to immune therapy initiation. Following PD-1i treatment, monocytes change states that may reflect cancer cell recognition and immune cell activation. Further, memory T cell abundances in immunotherapy-responsive patients evolves and increases, with concurrent upregulation in IFN signaling. Overall, both abundance and frequency of CD4+EM and classical monocytes, as well as their signaling states, are associated with improved survival.
- After the start of PD-1i, the data showed that IFN signaling is highly upregulated in T cells and monocytes of responders. In particular, CD8+ T cells upregulate IFN-γ gene expression, a major cytokine associated with an overall activation of immune cells and to an anti-tumor effect [See for example Ref. 42]. However, the CD8+ T cells and monocytes of non-responders do not have a clear upregulation of the IFN signaling, indicating that these cells are not fully activated. This lack of IFN activation in circulating immune cells in non-responders may indicate these cells are not able to detect the cancer cells even with the help of PD-1i.
- Another potential mechanism of non-responsiveness to immunotherapy may be an imbalance of T cell subtype abundances. If chemotherapy response and subsequent cancer cell death releases antigen and promotion of T cell exhaustion, resistance to chemotherapy could be one mechanism explaining why non-responders have a low relative abundance of exhausted T cells. PD-1+ and CTLA4+ cells are commonly categorized as exhausted which also means that they potentially were or are activated against cancer cells [See for example Refs. 38 and 39]. The data demonstrated increased circulating PD-1+CD8+EM and CTLA4+CD4+EM (exhausted) T cells in responders at baseline and after a month of mFOLFOX6 therapy. In agreement, NSCLC patients with clinical benefit to immunotherapy also exhibited circulating PD-1+CD8+ T-cell with effector-like phenotype [See for example Ref. 44]. The low frequency of PD1+ CD8+ cells in non-responders before the start of PD-1i imply less potential PD-1 immunotherapy-targeted cells. Indeed, a recent study demonstrated that FOLFOX induces durable complete responses when combined with anti-PD-1 therapy in mouse colorectal cancer models [See for example Ref 43], in part due to recruitment of exhausted PD-1+CD8+ cells to the tumor. The data herein supports circulating exhausted T cells may reflect the presence of activated intra-tumoral T cells and therefore be a marker of immunotherapy response.
- An alternative possibility of non-response is that the PD-1 antibody availability to cytotoxic CD8+ is reduced in non-responders. For example, CD4+EM express PD-1 and have high relative abundance in non-responders at baseline. A high frequency of CD4+EM was also correlated with shorter PFS in NSCLC [See for example Ref. 45]. Some studies reveal that chemotherapy induces the proliferation of differentiated CD4+memory or EM cells in breast cancer or chronic lymphocytic leukemia patients [See for example Refs. 46-48]. Those studies found that PD-1 is highly expressed in those memory CD4+ cells [See for example Refs. 46, 48]. In the cohort studied herein, all non-responders had prior treatment and 70% had prior 5-FU/Oxaliplatin whereas only 25% of responders had prior treatment and 88% did not have prior 5-FU/Oxaliplatin and had, at baseline, more CD4+EM which expressing PD-1 compare to responders. The data suggests that long term chemotherapy increases the production of CD4+EM cells expressing PD-1 which could potentially diminish availability of pembrolizumab to tumor-specific CD8+ T cells through binding in the peripheral blood. Additionally, protected by anti-PD-1 therapy, CD4+ EM cells could actively secrete immune suppressive cytokines after activation. It does not appear as though any mechanistic research regarding CD4+EM cells under PD-1i treatment has been conducted but a high frequency of those cells were also found in melanoma patients non-responsive to anti-PD-1 therapy [See for example Ref. 28].
- Additional mechanisms include the possibility that non-responder cancer cells may have developed PD-1/PD-L1 independent avoidance of the immune system such as down regulation of MHC presentation, and that non-responders present less circulating naïve CD4+T cells and lower tumor-dependent activation and differentiation of these cells in response to antigen-presenting cells.
- At baseline, the data demonstrated increased classical monocytes (CD14+/CD16−) in responders, which correlated with longer survival. These results parallel findings in melanomas responsive to PD-1i [See for example Ref 28]. There were striking differences in signaling states of monocytes before and during PD-1i treatment. At baseline, responder monocytes inhibit the NF-κB pathway, upregulate TNF-induced gene expression, and express genes related to migration and recruitment of immune cells. The data showed that classical monocytes express more MHC class II receptor, HLADR, reflecting a potential antigen presentation function. These cells also express more CD86, which is a ligand of both CTLA-4, a protein associated with immunosuppressive function, and CD28, a costimulatory signal for activation of T cells. These results, taken along with the increased frequency of exhausted T cells, suggest that at baseline, monocytes of responders may have an immune suppressive function. However, after the start of PD-1i, responder monocytes upregulate expression of ISGs and MHC related genes showing an overall activation of these cells with potentially a costimulatory immune function. This phenotype could be the consequence of T cells high upregulation of IFN gene expression we have detected after the start of PD-1i. IFN could be used as a biomarker of early response to PD-1i and clearance of cancer. However, long-term exposure to IFN-γ is not necessarily beneficial to patients [See for example Ref 42]. In this trial, most responders eventually developed resistance to treatment by
cycle 9, (median PFS of responders was 8 months, data not shown). Relapses could be explained by cancer cells capacity to take advantage of IFN signaling to develop new resistance mechanisms [See for example Ref 42]. - Rapid and readily accessible predictive biomarkers can be used to target therapies to responsive patients, reducing adverse events and costs. A PBMC marker provides such access. Overall, the data showed that the density and signaling activity of circulating immune cells is dynamic. Differences in immune cells between patients that respond and do not respond to PD-1i are present prior to and following treatment, and reflect unique activation and differentiation states related to drug response. The fact that cell densities and signaling states of circulating classical monocytes and CD4+EM cells are correlated with better overall survival in melanoma and GI cancers, demonstrates the possibility of using blood-based biomarkers for predicting PD-1i response across multiple cancer types in which this treatment has been approved.
- Cryopreserved peripheral blood mononuclear cells (PBMC) samples from patients with advanced (
stage 3/4) gastrointestinal cancers (including colorectal, gastroesophageal, pancreatic and biliary cancers) were provided by the Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah, USA. Patients in this trial (NCT02268825), were treated with modified FOLFOX6 (mFOLOFX6) chemotherapy regimen consisting of 400 mg/m2 intravenous (IV) leucovorin, 400 mg/m2 IV fluorouracil (5-FU) bolus followed by 2400 mg/m2 IV over 46 hrs and 85 mg/m2 IV oxaliplatin (Eloxatin) every 2 weeks (i.e. 1 cycle) until disease progression, death, or completion of the study.Pembrolizumab 200 mg IV every two weeks was added to mFOLFOX6 atcycle 3, after 4 weeks of mFOLFOX. Every two weeks, and before starting treatment, patients' blood was collected and PBMCs were isolated and cryopreserved. Median of previous history of chemotherapy treatment for responders was 101 days and 42 days for non-responders (Table 1). Clinical response and disease assessment were measured by computed tomography scans and assessed according to RECIST1.1 and immune-related response criteria (irRC) every 12 weeks. The responders were classified as any patient with clinical benefit at 24 weeks after the start of the trial; this group includes patients with complete response (CR), partial response (PR) and stable disease (SD). The non-responder group includes patients with progressive disease (PD) at least 12 weeks after the start of the trial and maximum 24 weeks after the start of the trial. Progressive disease was defined by an increase in the tumor volume of at least 20% or appearance of new metastatic lesions. All human biological samples were collected after written informed consent of the patients was obtained and with approval of the local ethics committee in accordance to federal and institutional guidelines. Samples from 12 patients were used for flow cytometry immunophenotyping at cycle 1 (C1), C3, C5, C8 time points (period since prior chemotherapy). Samples from 13 patients were used for single cell (SC) RNA analysis at C1, C3 and C5 time points. Samples from eight patients were utilized for both FACS and SC RNA analysis. - PBMC samples were thawed at 37° C. and washed with PBS followed by 0.04% non-acetylated BSA in PBS. Samples were diluted to 1000 cells/μL and suspensions were loaded on a Chromium 10X Cell Instrument (10X Genomics). Approximately 1200 to 2000 cells were loaded per sample. Single-cell RNA sequencing libraries were prepared using the
Chromium Single Cell 3′ Library & Gel Bead Kit V2 protocol (10x Genomics). Libraries were sequenced on an Illumina HiSeq 2500 with 2×125 paired-end reads. Raw BCL sequencing files were processed by the Cell Ranger Single Cell Software Suite for demultiplexing, barcode assignment, alignment and UMI counting (support. 10xgenomics.com/single-cell-gene-expression/software/overview/welcome). Samples were aligned to hg19 using the STAR aligner [See for example Ref. 49]. Count tables were generated with a total of 71,545 cells and used as input into Seurat v2 [See for example Ref. 50]. We filtered out cells with fewer than 400 genes and high mitochondrial expression (cells with>10% of mitochondrial counts), resulting in 69,745 cells and 19,324 genes. Counts from remaining cells were log-transformed and normalized across samples. Two regressions were performed on the data set, the first to remove sequencing lane artifacts and the second to further reduce mitochondrial heterogeneity. No notable batch effects were found (FIGS. 11B-D ). - The top 1000 variable genes with 1480 non-overlapping known immune cell marker genes were used for PCA [See for example Refs. 51-53]. The data showed the first 25 PCs to be significant using Seurat's jackstraw analysis, which was then used for graph-based clustering and UMAP visualization [See for example Ref. 54]. To gain a better understanding of T cell subpopulations, initial T cell clusters were identified by CD3D, CD4 and CD8 expression and re-clustered. The same number of PCs were used for clustering along with 500 T cell specific variable genes and 273 known T cell markers [See for example Ref.53]. Differential expression markers for each cluster were generated using the MAST [See for example Ref. 55].
- Pathway enrichment scores were generated using the R package GSVA 1.30.0 [See for example Ref. 32]. The GSVA ssGSEA option was used to generate scores for all molecular Signatures Database C2 and Hallmark pathway signatures (version 5).
- Comparing Cluster Annotations in PD-1 Dataset with Public Data Sets
- Two methods were used to compare immune cell annotation in our study and in two public datasets [See for example Refs. 29,30]. First, the dataset herein was used to train classification learners and used the trained learners to predict immune cells from public data sets. The cluster labels annotated in public data sets were used as ground truth. The similarity of annotations was measured by the accuracy of prediction. Second, the similarity of annotation was measured by the number of shared markers between this study and public data sets. To match the clusters in two datasets, only clusters containing at least 10 cells in public data sets were used.
- PD-1 scRNAseq samples (N=69745) were used to train and evaluate the classifiers. ScRNAseq raw counts for PBMCs were downloaded from GEO accession GSE114727 [See for example Ref. 30] as a test data set. TPM values for tumor-infiltrating immune cells downloaded from GSE120575 See for example Ref. 29] were used as a second test data set.
- In PD-1 dataset, 500 samples were randomly selected from each cluster, except for T6. For clusters with less than 1000 cells, oversampling was performed for 50% of the cells in the cluster. In total, 17,000 cells were used as a training set. The rest of the samples were held out for validation. We repeated this procedure and generated 10 different training and 10 corresponding validation sets.
- Seurat was run on the training dataset to obtain the cluster-associated markers See for example Ref. 50]. Only positive markers were selected. For efficiency, only genes that were detected in a minimum fraction of 0.25 in either of the two populations (min.pct=0.25) and whose average expression was larger than 0.25 between clusters were selected (thresh.use=0.25). We ranked the candidate markers using adjusted p-values. The top 20 markers per cluster (410 unique genes) were selected as features in the machine learning process. A multi-class classification using MLR with the RandomForest classifier was performed See for example Ref 56].
- The lists of markers was downloaded from Azizi et al. and Sade-Feldman et al. See for example Refs. 29,30]. The markers in Azizi et al. were ranked by z-score and only those with absolute z-score greater than 1.95 were kept. Then, the number of shared marker genes between public data sets and top 20 markers was calculated for each cluster in our study.
- A network structure was used to visualize the similarity and hierarchy of our clusters and the ones in a breast cancer study. The rationale of inferring cluster B belongs to A is that: (1) A and B share a high number of markers. (2) A can pair more clusters than B. The network visualization workflow is shown in
FIGS. 13A-C . - Identifying Gene Set Expression Differences Between Responders and Non-Responders
- Differences in the gene set expression of immune cell types were examined between responder and non-responder patients (R). For each immune cell type, the changes in pathway (X) expression over time (T) and with the addition of the PD-1 inhibitor (P) were examined. A random effects model with the following linear predictor (η) and error structure was constructed for each pathway:
-
E(ssGSEA[X])i=β0+βR R+β T T+β TR RT+β PT PT+β PTR RPT+u i -
ssGSEA[X] i,c˜Normal(E(ssGSEA[X])i,σx 2) -
u i˜Normal(0,μui 2) - Initial differences in gene set expression between immune cells from responders and non-responders, at the pre-treatment time point (C1), were captured by the group-specific intercepts (β0 vs. βR). Differential trends in expression over the first 5 treatment cycles were described by the group specific slope terms of responders and non-responders (βT vs βTR). Differential effects of the addition of PD-1i on gene expression, over cycle C3-C5, were described by the group specific PD-1i treatment effect terms of responders and non-responders (βPT vs βPTR).
- Consistent and considerable background differences in gene expression occur between individuals and are independent of the impacts of therapy. This interpatient variability was accounted for by allowing the model intercept to vary among patients (ui). Significant differences in: A) initial pathway scores, B) temporal trend and C) PD-1i treatment effects between non-responders and responders were assessed using likelihood ratio tests. Multiple comparison corrections were made using Holm's p-value correction.
- Pathways exhibiting significant differences in PD-1i treatment effects between responders and non-responders were examined and found to reflect four major processes: a) interferon signaling b) inflammatory response, c) growth factor production and d) differentiation. The trends in immune cell expression were predicted by producing the expectation across all significant ssGSEA pathways reflecting each process. Separate predictions were made for each immune cell type and for responders and non-responders. Pathway scores were normalized to the average score of each cell type at the initial sample (C1).
- Major axes of phenotypic variation were identified separately for CD4+/CD8+ T cells and monocytes using Affinity-based pseudotime reconstruction of cell states [See for example Refs. 57, 58]. This allowed the description of continuous spectrums of cellular states, as is produced by differentiation and activation processes. It also allows complex nonlinear gene expression changes to be captured, despite the sparsity of transcripts (leading to dropout), the presence of normalization induced noise artifacts and the high levels of gene amplification noise that is present in all single cell datasets [See for example Ref. 59]. The full gene expression profile of the immune cell types was filtered to remove genes that had zero expression in more than 99% of cells. The first 150 principle components of this gene expression profile were then calculated and used to create a dissimilarity matrix (Euclidean distance) of gene expression between cells. Nearest neighbor distances were calculated for the 100 most similar cells and an exponential kernel was used to produce the local affinity matrix, which was normalized to give the Markov transition matrix between cells. The kernel decay rate (α) parameter was set to 10, to capture the local and global relatedness between cells (Parameter sensitivity was low but below 5 the global structure is lost and above 30 local structure is lost). Log transition probabilities were calculated and a reduce dimension embedding was created to visualize the first 5 major axes of phenotypic variation. Phenotypic axes were validated using comparisons to PCA, zinbwave, and UMAP dimension reduction [See for example Refs. 54, 60]. The same phenotypes were identified by all the dimension reduction techniques and the correspondence between the inferred phenotypic scores was high for all cell types. Random effects linear regression was used to test the statistical differences in immune population phenotype distributions between responders and non-responders, whilst accounting for patient-specific random effects.
- Response to PD1 therapy was predicted based on immune cell number and composition. Measurements of peripheral blood mononuclear cell density (cells μL−1) were obtained from blood draws, taken from each patient at each sampling time point (C1-C5). Immune cell subtype densities (Ns) were calculated for each patient sample, by multiplying the total PBMC density (N) by the proportion of scRNA sequenced cells belonging to each immune class.
- Total PBMC density (N) and the density of immune subclasses (Ns) were used to predict patient response, using random effects logistic regression models:Responsei˜Bern(logit−1(β0+βNN+βsNs+βSNNNs+uTime))
-
u Time˜Normal(0,σuTime 2) - A random effect of time (uTime) was included to account for the non-independence of patients' responses when predicted by the immune composition at different time points. Sample size corrected Akaike information criterion (AIC) was used to compare the ability of differing components of the total immune cell density in predicting patient responses.
- This assay was performed by the UCLA Immune Assessment Core. PBMCs were stained with two different antibody panels. The first panel was used to phenotype antigen presenting cells and B cells using: IgM BV421 (clone MHM-88), CD11b BV510 (clone ICRF44), CD303 BV605 (clone 201A), HLA-DR BV650 (clone L243), CD1c BV711 (clone L161), CD16 BV785 (clone 3G8), CD33 FITC (clone P67.6), CD86 PE (clone IT2.2), CD141 PE-CY7 (clone M80), CD3 PECF594 (OKT3), CD14 PCP-CY5 (HCD14), CD19 APC (SJ25C1), CD11c Alexa700 (Bu15), CD27 APC-CY7 (M-T271), CD15 BUV395 (HI98), CD56 BUV737 (NCAM16.2). The second panel was used to phenotype T cell lineage using: CCR10 BV421 (clone 1B5), CCR7 BV510 (clone G043H7), CTLA4 BV605 (clone BNI3), CD3 BV650 (clone OKT3), PD-1 BV711 (clone EH12.2H7), CD4 FITC (clone RPA-T4), FOXP3 PE (clone PCH101), CD45RA PCP-CY5 (clone HI100), CXCR5 APC (clone J252D4), HLA-DR Alexa700 (clone LN3), CD8 APC-CY7 (clone SK1), Ki67 BUV395 (clone B56), CD25 BUV737 (clone 2A3). An average of 0.3×106 cells per cocktail were stained for 20 min at 4° C. with LIVE/DEAD Fixable Blue Dead Cell Stain Kit (Invitrogen), diluted 1:1000 in PBS. Cells were then washed once with flow cytometry buffer (2% FBS in PBS) and stained with fluorochrome-conjugated antibodies (BioLegend, BD Biosciences, eBioscience) for 20 minutes at 4° C. Finally, the cells were washed and re-suspended in 200 μL FACS buffer. At least 100,000 lymphocyte events per sample were acquired using DIVA 8.0 software on an LSRFortessa Cell Analyzer (BD Biosciences). Data analysis was performed using FlowJo v10.5.0 (Tree Star) by gating on live cells based on forward versus side scatter profiles, then gating on singlets using forward scatter area versus height, followed by dead cell exclusion using Live/Dead exclusion stain, and then cell subset-specific gating.
- This assay was performed by the UCLA Immune Assessment Core. An average of 0.3×106 cells per cocktail were stained with 1:1000 LIVE/DEAD Fixable Blue Dead Cell Stain Kit (Invitrogen), diluted in PBS, for 20 min at 4° C. After washing with flow cytometry buffer (2% FBS in PBS), cells were stained for surface markers for 20 min at 4° C., washed again with FACS Buffer, then centrifuged at 1500 rpm for 5 minutes. Subsequently, cells were incubated for 45 minutes using FoxP3 fix/perm buffer (eBioscience) at 4° C. in the dark, washed twice with perm buffer (eBioscience), and centrifuged at 2000 rpm for 6 min. Antibodies specific to FoxP3, Ki67, and CTLA4 intracellular markers were then prepared in perm buffer and used to stain cells for 30 min at 4° C. Following two additional washes with perm buffer, cells were resuspended in flow cytometry buffer and 100,000 lymphocyte cell events per sample were collected using DIVA 8.0 software on an LSRFortessa Cell Analyzer (BD Biosciences). Data analysis was performed using FlowJo v10.5.0 (Tree Star) by gating on live cells based on forward versus side scatter profiles, then gating on singlets using forward scatter area versus height, followed by dead cell exclusion using Live/Dead exclusion stain, and then cell subset-specific gating.
- Additional analyses were performed in connection with the experiments described in Examples 1 and 2. Time courses of tumor burden and immune abundance (PBMC) were constructed for each patient (
FIG. 22 i ). Tumor burden was measured by combining information from cancer specific antigen biomarkers and RECIST 1.1 measurements of tumor size, using a Gaussian process latent variable model. The changes in patients' tumor burden and immune cell abundance during the trial were described mathematically by a dynamic model of cancer-immune cell interactions (FIG. 22 ii). This model describes the interactions between populations of tumor and immune cells within a patient, with tumor cells (T) being attacked by immune cells (I) and inducing increased immune cell recruitment. Chemotherapy (C) kills both tumor and immune cells, whilst PD-1 inhibitor immunotherapy (P) impacts immune proliferation, recruitment and cytotoxic tumor activity (FIG. 23A ). - Changes in tumor and immune cell abundance over time were accurately described by statistically fitting the mathematical model to the clinical data, using a Bayesian hierarchical approach (
FIG. 23B ). This captured the biological differences between tumor and immune populations of responders and non-responders and described the substantial variation between patients within response categories. Key biological rates were also estimated, including: a) how effectively immune cells attack the tumor and b) the impact of chemotherapy on tumor and immune populations. This identified the consistently improved ability of responder patients' immune cells to attack the tumor, compared to the non-responder (FIG. 23C ). - The time periods of most rapid growth and decline of the tumor and immune populations were determined by analyzing the population's relative growth rates (RGR=speed of population change, positive=growth, negative=decline) (
FIG. 23D-E ). The response dynamics (described below) were not dependent on the patient's cancer tissue type. The tumor burden of the responders declined more rapidly during the chemotherapy phase and continued to decline (negative RGR) over most of the rest of the time on trial (FIG. 23D ). The exception is a time window aroundday 100 when the immune population was still increasing but the chemotherapy effect was generally decreased. Once the immune cell abundance increased further, the tumor began to shrink once again. As a result, tumor burden of responders remained substantially below the pre-treatment level for the duration of the trial. Responders' PBMC's were also initially less abundant and more sensitive to chemotherapy (more negative RGR). However, their immune cell abundance was substantially boosted following the addition of immunotherapy (FIG. 23D ; spike in PBMC's RGR around days 48-100). Their immune abundance the stabilized at this level or even increased gradually during the rest of the trial (with an overall positive RGR). - In contrast, the tumor burden of patients non-responsive to immunotherapy declined very little during the pre-immunotherapy chemotherapy phase, and only marginally in the first weeks of immunotherapy. Subsequently, tumor growth accelerated, and the tumor burden returned to the pre-treatment level within just 80-150 days. Non-responders also exhibited a continual decline in immune cell number (negative RGR over most of the trial) and did not experience the immunotherapy induced boost in immune population growth following the addition of immunotherapy (no spike between days 48-100). Analysis of the fitted mathematical model showed that prior to immunotherapy, the responders' immune populations less effectively regulated tumor growth (
FIG. 23E ). However, after immunotherapy induced the growth spike in the responders' immune cell population, these immune cells became more effective at regulating the tumor growth. In contrast, the ability of immune cells to regulate tumor growth declined continually during the trial and very little benefit of immunotherapy could be detected. - We assessed the strength of tumor-immune cell interactions and the predictability of responsive to therapy, by fitting a coupled tumor-immune population model to clinical patient data. For each patient, a time series of tumor burden was first constructed, by combining RECIST 1.1 measurements, from CT scans, with information from tumor burden biomarkers (CA 19-9 and CEA), using a Gaussian process model [see, e.g., Ref. 69]. The RECIST1.1 data provides information about the absolute burden and the magnitude of changes during therapy, whilst blood biomarkers provides higher temporal resolution of the patterns of change. Gaussian process models probabilistically combine these tumor burden data sources, allowing inference of the most likely time course of tumor burden, given the available information.
- Gaussian processes latent variable models were fitted to each patients' tumor time course data. A Bayesian priors of nonlinear functions was constructed to describe a wide range of different kinds of fluctuation in tumor burden that could have occurred. Then, using the Markov chain Monte Carlo, we infer a posterior that represents our belief about the fluctuations that are likely to have occurred, conditioned on observed data. Specifically, a multidimensional Gaussian, F=(f1 . . . fx)˜N(μ,Σ),{indices i=1 . . . x}, was defined, with each of n dimensions describing the tumor burden at one of the time points at which either RECIST or blood biomarker data was available. The nonlinear function describing the tumor burden over time (f(t)) was then described as a Gaussian process: f(t)˜GP(m(x),k(x, x′)), {indices x},
- where m(x) is an n-vector and k(x, x′) is an n×n covariance matrix. The covariance of tumor burden at different time points was calculated, using a squared exponential covariance function:
-
k(x)i,j=η2exp(−ρ2Σd=1 D(x i,d −x j,d)2)+δi,jσ2 - Covariance function hyper-parameters (η,ρ) were estimated. To ensure a positive definite covariance matrix, σ2 was added to the diagonal elements, using δ as a Kronecker delta function with
value 1 if i=j, but 0 otherwise. The summation of squared Euclidean distances in time results in smooth changes in tumor burden over time. - RECIST1.1 assessments of the volume of tracked lesions within a given patient (RP) was assumed to be a lognormally distributed measurement of a fixed fraction of a patient's overall tumor burden: RP(t)˜LogNormal(fP(t),σR
P ) The two blood biomarkers were assumed to be produced by cancer cells at a constant rate, α, degrade at rate λ and to have a baseline production level within the healthy body of rate r. The dynamics of blood antigens can then be described as: -
- Applying steady state assumptions, the blood biomarkers were also expected to be lognormally distributed measurements such that:
-
M xP (t)˜LogNormal(βxP f P(t)+c xP ,σMxP ) - Bayesian sampling of these probabilistic models yielded overall time course estimates of tumor burden during the trial. Concurrent measurements of immune cell abundance and therapeutic dosages (immunotherapy and chemotherapy) were also curated.
- The dynamics of tumor and immune cell abundance were coupled with the immunotherapy and chemotherapy dosing schedules, using a patient specific tumor-immune population dynamic model. The model (Equ.1 below) describes the patient specific changes in tumor (T) and immune cell (I) abundance over time. Over short periods of time, the increase or decrease in tumor and immune cell abundance was measured by the populations relative growth rate (RGRT for tumor and RGRI for immune cells). Positive RGR values indicate population growth, whilst negative values show population decline. The data driven model decomposed this population growth rate into effects of different concurrent biological processes (described below). Tumor and immune cells interact in two main ways, with tumor cells being attacked by immune cells (α) and also inducing increased immune cell recruitment (λ). Therapeutic dosing also impacts the cell populations and the strength of their interactions, with chemotherapy (C) killing both tumor (
μT ) and immune cells (μI ), whilst PD-1i immunotherapy (P) influences immune proliferation (βr), recruitment (βλ) and cytotoxic tumor killing activity (βφ). Both tumor and immune cells experience density dependent population growth (γT & γI), reflecting competition for resources or growth stimulating molecules. This leads to the equations: -
- We simultaneously fitted this model to all of the patients' time course tumor and immune data, and accounted for the differing dosages and timings of therapy. To capture inter-patient biological differences, patient specific parameters were assumed to be drawn from a hyper-distribution of parameters, creating a hierarchical model structure. Observation error in the populations' growth rates were assumed to be T distributed, to account for occasional large observed changes in tumor or immune measurements. Model parameters were estimated using Bayesian inference, with Hamiltonian Monte Carlo in Stan [see, e.g., Ref 70].
- Immune cell phenotypes were related to the model estimates of: a) the effectiveness of immune cells at attacking tumor cells and b) the tumor cell sensitivity to chemotherapy. These biological estimates of immune and chemotherapy function (X) were regressed against the peripheral immune cell phenotypes identified in: i) the GSEA pathway analysis and ii) the pseudotime analysis of the major phenotypic variation within cell types. For each phenotype, the significance of the relationship between single cell peripheral immune phenotypes (Y) and immune/chemotherapy function (X) was assessed. A patient specific intercept was added to account for non-independence of cell phenotypes within a patient. The random effects regression model was:
-
Y i,p˜Norm(β0+βX X+u Time) -
u i˜Normal(0,σui 2) - The significance of the relationship between peripheral phenotypes and immune/chemotherapy function was assessed using a likelihood ratio test, with the sample size corrected for the non-independence of data points.
- The input data to the predator-prey mathematical model included a) clinical measurements of tumor burden including CT imaging estimates and cancer specific antigen levels obtained during the trial and b) peripheral blood mononuclear immune cell (PBMC) counts obtained from periodic blood tests. These two data types provide time courses of the size of the tumor and the concurrent immune populations within a specific patient.
- The first analysis involved looking across all available data on the size of the patients' tumor during the trial and estimating the most probable time course, using a Gaussian process latent variable model. The amount that a tumor grows or shrinks between two observation times is then assessed by a measurement called the relative growth rate. The same calculation can be made for the immune cell population size, to quantify how much the immune population is growing or shrinking over time.
-
-
- 1. Loos, M. et al. Clinical significance and regulation of the costimulatory molecule B7-H1 in pancreatic cancer. Cancer Lett 268, 98-109, doi:10.1016/j.canlet.2008.03.056 (2008).
- 2. Nomi, T. et al. Clinical significance and therapeutic potential of the programmed death-1 ligand/programmed death-1 pathway in human pancreatic cancer.
Clin Cancer Res 13, 2151-2157, doi:10.1158/1078-0432.CCR-06-2746 (2007). - 3. Ohigashi, Y. et al. Clinical significance of programmed death-1 ligand-1 and programmed death-1 ligand-2 expression in human esophageal cancer.
Clin Cancer Res 11, 2947-2953, doi:10.1158/1078-0432.CCR-04-1469 (2005). - 4. Oki, E. et al. Protein Expression of
Programmed Death 1Ligand 1 and HER2 in Gastric Carcinoma. Oncology 93, 387-394, doi:10.1159/000479231 (2017). - 5. Song, M. et al. PTEN loss increases PD-L1 protein expression and affects the correlation between PD-L1expression and clinical parameters in colorectal cancer. PLoS One 8, e65821, doi:10.1371/journal.pone.0065821 (2013).
- 6. Wang, L. et al. Clinical significance of B7-H1 and B7-1 expressions in pancreatic carcinoma. World J Surg 34, 1059-1065, doi:10.1007/s00268-010-0448-x (2010).
- 7. Ye, Y. et al. Interaction of B7-H1 on intrahepatic cholangiocarcinoma cells with PD-1 on tumor-infiltrating T cells as a mechanism of immune evasion.
J Surg Oncol 100, 500-504, doi:10.1002/jso.21376 (2009). - 8. Zhang, M. Y., Yang, Y. Y., Wang, X. H. & Li, X. F. [Expression of Bcl-2, PD-L1 and its clinical significance in colorectal cancer]. Sichuan Da Xue Xue Bao Yi Xue Ban 43, 827-829, 859 (2012).
- 9. Ansell, S. M. et al. PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma. N Engl J Med 372, 311-319, doi:10.1056/NEJMoa1411087 (2015).
- 10. Garon, E. B. et al. Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med 372, 2018-2028, doi:10.1056/NEJMoa1501824 (2015).
- 11. Nghiem, P. T. et al. PD-1 Blockade with Pembrolizumab in Advanced Merkel-Cell Carcinoma. N Engl J Med 374, 2542-2552, doi:10.1056/NEJMoa1603702 (2016).
- 12. Yuan, Y. et al. Complete regression of cutaneous metastases with systemic immune response in a patient with triple negative breast cancer receiving p53MVA vaccine with pembrolizumab.
Oncoimmunology 6, e1363138, doi:10.1080/2162402X.2017.1363138 (2017). - 13. Palucka, A. K. & Coussens, L. M. The Basis of Oncoimmunology. Cell 164, 1233-1247, doi:10.1016/j.cell.2016.01.049 (2016).
- 14. Lynch, T. J. et al. Ipilimumab in combination with paclitaxel and carboplatin as first-line treatment in stage IIIB/IV non-small-cell lung cancer: results from a randomized, double-blind, multicenter phase II study.
J Clin Oncol 30, 2046-2054, doi:10.1200/JCO.2011.38.4032 (2012). - 15. Reck, M. et al. Ipilimumab in combination with paclitaxel and carboplatin as first-line therapy in extensive-disease-small-cell lung cancer: results from a randomized, double-blind,
multicenter phase 2 trial. Ann Oncol 24, 75-83, doi:10.1093/annonc/mds213 (2013). - 16. Rizvi, N. A. et al. Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science 348, 124-128, doi:10.1126/science.aaa1348 (2015).
- 17. Samstein, R. M. et al. Tumor mutational load predicts survival after immunotherapy across multiple cancer types.
Nat Genet 51, 202-206, doi:10.1038/s41588-018-0312-8 (2019). - 18. Huang, A. C. et al. T-cell invigoration to tumour burden ratio associated with anti-PD-1 response. Nature 545, 60-65, doi:10.1038/nature22079 (2017).
- 19. Ayers, M. et al. IFN-gamma-related mRNA profile predicts clinical response to PD-1 blockade. J Clin Invest 127, 2930-2940, doi:10.1172/JCI91190 (2017).
- 20. Garris, C. S. et al. Successful Anti-PD-1 Cancer Immunotherapy Requires T Cell-Dendritic Cell Crosstalk Involving the Cytokines IFN-gamma and IL-12. Immunity 49, 1148-1161 e1147, doi:10.1016/j.immuni.2018.09.024 (2018).
- 21. Hamid, O. et al. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med 369, 134-144, doi:10.1056/NEJMoa1305133 (2013).
- 22. Topalian, S. L. et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 366, 2443-2454, doi:10.1056/NEJMoa1200690 (2012).
- 23. Powles, T. et al. MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer. Nature 515, 558-562, doi:10.1038/nature13904 (2014).
- 24. Llosa, N. J. et al. The vigorous immune microenvironment of microsatellite instable colon cancer is balanced by multiple counter-inhibitory checkpoints.
Cancer Discov 5, 43-51, doi:10.1158/2159-8290.CD-14-0863 (2015). - 25. Le, D. T. et al. Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. Science 357, 409-413, doi:10.1126/science.aan6733 (2017).
- 26. Grosso, J. et al. Association of tumor PD-L1 expression and immune biomarkers with clinical activity in patients (pts) with advanced solid tumors treated with nivolumab (anti-PD-1; BMS-936558; ONO-4538). Journal of Clinical Oncology 31, 3016-3016, doi:10.1200/jco.2013.31.15_suppl.3016 (2013).
- 27. Carbone, D. P. et al. First-Line Nivolumab in Stage IV or Recurrent Non-Small-Cell Lung Cancer. N Engl J Med 376, 2415-2426, doi:10.1056/NEJMoa1613493 (2017).
- 28. Krieg, C. et al. High-dimensional single-cell analysis predicts response to anti-PD-1 immunotherapy. Nat Med 24, 144-153, doi:10.1038/nm.4466 (2018).
- 29. Sade-Feldman, M. et al. Defining T Cell States Associated with Response to Checkpoint Immunotherapy in Melanoma. Cell 175, 998-1013 e1020, doi:10.1016/j.cell.2018.10.038 (2018).
- 30. Azizi, E. et al. Single-Cell Map of Diverse Immune Phenotypes in the Breast Tumor Microenvironment. Cell 174, 1293-1308 e1236, doi:10.1016/j.cell.2018.05.060 (2018).
- 31. Rinder, H. M., Bonan, J. L., Rinder, C. S., Ault, K. A. & Smith, B. R. Activated and unactivated platelet adhesion to monocytes and neutrophils. Blood 78, 1760-1769 (1991).
- 32. Hanzelmann, S., Castelo, R. & Guinney, J. GSVA: gene set variation analysis for microarray and RNA-seq data.
BMC Bioinformatics - 33. Liberzon, A. et al. The Molecular Signatures Database (MSigDB) hallmark gene set collection.
Cell Syst 1, 417-425, doi:10.1016/j.cels.2015.12.004 (2015). - 34. Liberzon, A. et al. Molecular signatures database (MSigDB) 3.0. Bioinformatics 27, 1739-1740, doi:10.1093/bioinformatics/btr260 (2011).
- 35. Wang, Y. et al. Negative feedback regulation of IFN-gamma pathway by IFN
regulatory factor 2 in esophageal cancers. Cancer Res 68, 1136-1143, doi:10.1158/0008-5472.CAN-07-5021 (2008). - 36. Schroder, K., Hertzog, P. J., Ravasi, T. & Hume, D. A. Interferon-gamma: an overview of signals, mechanisms and functions. J Leukoc Biol 75, 163-189, doi:10.1189/jlb.0603252 (2004).
- 37. Shi, C. & Pamer, E. G. Monocyte recruitment during infection and inflammation.
Nat Rev Immunol 11, 762-774, doi:10.1038/nri3070 (2011). - 38. Wherry, E. J. T cell exhaustion.
Nat Immunol 12, 492-499 (2011). - 39. Herbst, R. S. et al. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature 515, 563-567, doi:10.1038/nature14011 (2014).
- 40. Shi, J. et al. PD-1 Controls Follicular T Helper Cell Positioning and Function. Immunity 49, 264-274 e264, doi:10.1016/j.immuni.2018.06.012 (2018).
- 41. Sharma, P., Hu-Lieskovan, S., Wargo, J. A. & Ribas, A. Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy. Cell 168, 707-723, doi:10.1016/j.cell.2017.01.017 (2017).
- 42. Reading, J. L. & Quezada, S. A. Too Much of a Good Thing? Chronic IFN Fuels Resistance to Cancer Immunotherapy. Immunity 45, 1181-1183, doi:10.1016/j.immuni.2016.12.004 (2016).
- 43. Dosset, M. et al. PD-1/PD-L1 pathway: an adaptive immune resistance mechanism to immunogenic chemotherapy in colorectal cancer.
Oncoimmunology 7, e1433981, doi:10.1080/2162402X.2018.1433981 (2018). - 44. Kamphorst, A. O. et al. Proliferation of PD-1+ CD8 T cells in peripheral blood after PD-1-targeted therapy in lung cancer patients. Proc Natl
Acad Sci U S A 114, 4993-4998, doi:10.1073/pnas.1705327114 (2017). - 45. Yang, P., Ma, J., Yang, X. & Li, W. Peripheral CD4+ naive/memory ratio is an independent predictor of survival in non-small cell lung cancer.
Oncotarget 8, 83650-83659, doi:10.18632/oncotarget.19330 (2017). - 46. Peguillet, I. et al. High numbers of differentiated effector CD4 T cells are found in patients with cancer and correlate with clinical response after neoadjuvant therapy of breast cancer. Cancer Res 74, 2204-2216, doi:10.1158/0008-5472.CAN-13-2269 (2014).
- 47. Verma, R. et al. Lymphocyte depletion and repopulation after chemotherapy for primary breast cancer.
Breast Cancer Res - 48. Palma, M. et al. T cells in chronic lymphocytic leukemia display dysregulated expression of immune checkpoints and activation markers. Haematologica 102, 562-572, doi:10.3324/haematol.2016.151100 (2017).
- 49. Dobin, A. et al. STAR: ultrafast universal RNA-seq aligner.
Bioinformatics 29, 15-21, doi:10.1093/bioinformatics/bts635 (2013). - 50. Butler, A., Hoffman, P., Smibert, P., Papalexi, E. & Satija, R. Integrating single-cell transcriptomic data across different conditions, technologies, and species.
Nat Biotechnol 36, 411-420, doi:10.1038/nbt.4096 (2018). - 51. Tirosh, I. et al. Dissecting the multicellular ecosystem of metastatic melanoma by single-cell RNA-seq. Science 352, 189-196, doi:10.1126/science.aad0501 (2016).
- 52. Newman, A. M. et al. Robust enumeration of cell subsets from tissue expression profiles.
Nat Methods 12, 453-457, doi:10.1038/nmeth.3337 (2015). - 53. De Simone, M. et al. Transcriptional Landscape of Human Tissue Lymphocytes Unveils Uniqueness of Tumor-Infiltrating T Regulatory Cells. Immunity 45, 1135-1147, doi:10.1016/j.immuni.2016.10.021 (2016).
- 54. McInnes, L., Healy, J. & Melville, J. UMAP: Uniform Manifold Approximation and Projection for Dimension Reduction. arXiv e-prints (2018). ui.adsabs.harvard.edu/\#abs/2018arXiv180203426M.
- 55. Finak, G. et al. MAST: a flexible statistical framework for assessing transcriptional changes and characterizing heterogeneity in single-cell RNA sequencing data.
Genome Biology 16, 278, doi:10.1186/s13059-015-0844-5 (2015). - 56. Bischl, B. mlr: Machine Learning in R. Journal of Machine Learning Research (2016).
- 57. Moon, K. R. Manifold learning-based methods for analyzing single-cell RNA-sequencing data. Current Opinion in
Systems Biology 7, 36-46, doi:10.1016/j.coisb.2017.12.008 (2017). - 58. van Dijk, D. et al. Recovering Gene Interactions from Single-Cell Data Using Data Diffusion. Cell 174, 716-729 e727, doi:10.1016/j.cell.2018.05.061 (2018).
- 59. Moon, K. R. et al. Visualizing Transitions and Structure for Biological Data Exploration. bioRxiv, 120378, doi:10.1101/120378 (2018).
- 60. Risso, D., Perraudeau, F., Gribkova, S., Dudoit, S. & Vert, J. P. A general and flexible method for signal extraction from single-cell RNA-seq data.
Nat Commun 9, 284, doi:10.1038/s41467-017-02554-5 (2018). - 61. Sambrook, et al., Molecular Cloning: A Laboratory Manual (3rd Edition, 2001)
- 62. Sambrook, et al., Molecular Cloning: A Laboratory Manual (2nd Edition, 1989)
- 63. Maniatis et al., Molecular Cloning: A Laboratory Manual (1982); Ausubel et al.
- 64. Current Protocols in Molecular Biology (John Wiley and Sons, updated July 2008
- 65. Short Protocols in Molecular Biology: A Compendium of Methods from Current Protocols in Molecular Biology, Greene Pub. Associates and Wiley-Interscience
- 66. Glover, DNA Cloning: A Practical Approach, vol. I & II (IRL Press, Oxford, 1985)
- 67. Anand, Techniques for the Analysis of Complex Genomes, (Academic Press, New York, 1992)
- 68. Hames, B. S. Higgins, S.Transcription and Translation (Eds., 1984)
- 69. N. Lawrence, Probabilistic non-liner component analysis with Gaussian process latent variable models. Journal of
Machine Learning Research 6, 1783-1816 (2005). - 70. B. Carpenter, A. Gelman, M. D. Hoffman, D. Lee, B. Goodrich, M. Betancourt, M. Brubaker, J. Guo, P. Li, A. Riddell, Stan: A Probabilistic Programming Language. 2017 76, 32 (2017).
- In various aspects, the present disclosure provides the following illustrative embodiments.
-
Embodiment 1. A method comprising detecting one or more parameters in a sample of peripheral blood from a subject with cancer, comprising detecting: (i) gene expression in monocytes comprising (1) increased expression of one or more of NFKB1, MYD88, NFKBIA or NFKBIZ, (2) decreased expression of IKBKB, (3) increased expression of one or more of growth factor genes, and/or (4) increased expression of one or more TNF genes, compared to a control; (ii) a greater number of CD8+ differentiated cells, a greater number of CD4+ naive cells, fewer CD4+ differentiated cells, and fewer T follicular helper (TFH) cells compared to a control; or (iii) a lower density of total peripheral blood mononuclear cells, a lower density of CD4+ effector memory (EM) cells, and a higher density of classical monocytes compared to a control. -
Embodiment 2. A method of identifying a cancer of a subject as responsive to treatment with a PD-1 inhibitor, the method comprising detecting one or more parameters in a sample of peripheral blood from the subject, comprising detecting: (i) gene expression in monocytes comprising (1) increased expression of one or more of NFKB1, MYD88, NFKBIA or NFKBIZ, (2) decreased expression of IKBKB, (3) increased expression of one or more of growth factor genes, and/or (4) increased expression of one or more TNF genes, compared to a control; (ii) a greater number of CD8+ differentiated cells, a greater number of CD4+ naive cells, fewer CD4+ differentiated cells, and fewer T follicular helper (TFH) cells compared to a control; or (iii) a lower density of total peripheral blood mononuclear cells, a lower density of CD4+ effector memory (EM) cells, and a higher density of classical monocytes compared to a control. -
Embodiment 3. A method for treating cancer in a subject comprising: (a) detecting one or more parameters in a sample of peripheral blood from the subject, comprising detecting: (i) gene expression in monocytes comprising (1) increased expression of one or more of NFKB1, MYD88, NFKBIA or NFKBIZ, (2) decreased expression of IKBKB, (3) increased expression of one or more of growth factor genes, and/or (4) increased expression of one or more TNF genes, compared to a control; (ii) a greater number of CD8+ differentiated cells, a greater number of CD4+ naive cells, fewer CD4+ differentiated cells, and fewer T follicular helper (TFH) cells compared to a control; or (iii) a lower density of total peripheral blood mononuclear cells, a lower density of CD4+ effector memory (EM) cells, and a higher density of classical monocytes compared to a control; and (b) identifying the cancer as responsive to treatment with a PD-1 inhibitor if the cancer has one or more of the parameters (i)-(iii). -
Embodiment 4. The method of any one of embodiments 1-3, further comprising detecting one or more of the following parameters: (iv) increased expression in T cells of one or more cell death genes compared to a control; (v) greater number of CTLA4+CD4+ EM cells and PD-1+CD8+ cells compared to a control; (vi) greater number of classical, CD86+, and HLADR+ monocytes as measured by florescence-activated cell sorting (FACS) and compared to a control; and (vii) fewer CD4+EM cells and a greater number of CLT4+CD4+ EM cells as measured by FACS and compared to a control. -
Embodiment 5. The method of any one of embodiments 1-4, further comprising selecting a PD-1 inhibitor for administration to the subject, and optionally treating the subject with the PD-1 inhibitor, if one or more of the parameters (i) — (vii) is detected. -
Embodiment 6. The method ofembodiment 4, wherein two, three, four, five, six, or seven of the parameters (i)-(vii) are detected. -
Embodiment 7. The method ofembodiment 4, wherein all of the parameters (i)-(vii) are detected. -
Embodiment 8. The method ofembodiment 4, wherein all of the parameters (i)-(iii) are detected. -
Embodiment 9. The method of any one of embodiments 1-8, wherein the one or more growth factor genes comprise one or more of FOS, JUN, or JUNB. -
Embodiment 10. The method of any one of embodiments 1-9, wherein the one or more TNF genes comprise one or more of TNF, TNFAIP2, or TNFAIP3. -
Embodiment 11. The method of any one of embodiments 4-10, wherein the one or more cell death genes comprise one or more of CASP1, CASP3, CASP7, or CASP8. -
Embodiment 12. The method of any one of embodiments 1-11, further comprising selecting the subject for anticancer therapy if the cancer is not identified as responsive to treatment with a PD-1 inhibitor; and optionally administering the anticancer therapy to the subject. -
Embodiment 13. The method ofembodiment 12, wherein the anticancer therapy comprises one or more of radiation therapy, chemotherapy, surgery, or immunotherapy. -
Embodiment 14. The method of any one ofembodiments -
Embodiment 15. The method of any one of embodiments 2-14, wherein the PD-1 inhibitor is a PD-1 antibody. -
Embodiment 16. The method ofembodiment 15, wherein the PD-1 antibody is one or more of pembrolizumab, nivolumab, or cemiplimab. -
Embodiment 17. The method of any one of embodiments 1-16, further comprising treating the subject with an anticancer therapy other than a PD-1 inhibitor. -
Embodiment 18. The method of any one of embodiments 1-17, wherein the cancer is gastrointestinal cancer. -
Embodiment 19. The method ofembodiment 18, wherein the gastrointestinal cancer is selected from colorectal cancer, gastroesophogeal cancer, pancreatic cancer, and biliary cancer. -
Embodiment 20. The method of any one of embodiments 1-19, wherein detecting gene expression comprises one or more of single-cell RNA sequencing, single sample gene set enrichment analysis, Northern blotting, fluorescent in situ hybridization, reverse transcription polymerase chain reaction (RT-PCR), serial analysis of gene expression (SAGE), microarray, or tiling arrays. -
Embodiment 21. The method of any one of embodiments 1-20, wherein detecting a number of cells as fewer or greater than a control comprises one or more of single-cell RNA sequencing, affinity-based pseudotime reconstruction, flow cytometry or immunophenotyping. -
Embodiment 22. A method comprising detecting one or more parameters in a sample of peripheral blood from a subject with cancer previously treated with a PD-1 inhibitor, comprising detecting: (i) in T cells, (1) increased expression of one or more interferon type I or type II signaling genes, (2) increased expression one or more of NFKB1, MYD88, NFKBIA or NFKBIZ, (3) increased expression of one or more major histocompatibility complex (MHC) class I or class II processing genes, (4) increased expression of one or more of CCL3, CCL4, CCL5, and CCR5, (5) decreased expression of one or more of CXCR3 or CCR2 genes, (6) increased expression in CD8+ T cells of one or more cell death genes, (7) a greater number of differentiated CD8+ cells, and/or (8) fewer differentiated CD4+ cells compared to a control; or (ii) in monocytes, (1) increased expression of genes upregulated by IFN stimulation, and/or (2) increased expression of genes upregulated by major histocompatibility complex 2 (MHCII) production. -
Embodiment 23. A method of identifying a cancer of a subject previously treated with a PD-1 inhibitor as responsive to treatment with the PD-1 inhibitor, the method comprising detecting one or more parameters in a sample of peripheral blood from the subject, comprising detecting: (i) in T cells, (1) increased expression of one or more interferon type I or type II signaling genes, (2) increased expression one or more of NFKB1, MYD88, NFKBIA or NFKBIZ, (3) increased expression of one or more major histocompatibility complex (MHC) class I or class II processing genes, (4) increased expression of one or more of CCL3, CCL4, CCL5, and CCR5, (5) decreased expression of one or more of CXCR3 or CCR2 genes, (6) increased expression in CD8+ T cells of one or more cell death genes, (7) a greater number of differentiated CD8+ cells, and/or (8) fewer differentiated CD4+ cells compared to a control; or (ii) in monocytes, (1) increased expression of genes upregulated by IFN stimulation, and/or (2) increased expression of genes upregulated by major histocompatibility complex 2 (MHCII) production. - Embodiment 24. A method of monitoring response to PD-1 immunotherapy in a subject previously treated with a PD-1 inhibitor, the method comprising: (a) detecting one or more parameters in a sample of peripheral blood from the subject, comprising detecting: (i) in T cells, (1) increased expression of one or more interferon (IFN) type I or type II signaling genes, (2) increased expression one or more of NFKB1, MYD88, NFKBIA or NFKBIZ, (3) increased expression of one or more major histocompatibility complex (MHC) class I or class II processing genes, (4) increased expression of one or more of CCL3, CCL4, CCL5, and CCR5, (5) decreased expression of one or more of CXCR3 or CCR2 genes, (6) increased expression in CD8+ T cells of one or more cell death genes, (7) a greater number of differentiated CD8+ cells, and/or (8) fewer differentiated CD4+ cells compared to a control; or (ii) in monocytes, (1) increased expression of genes upregulated by IFN stimulation, and/or (2) increased expression of genes upregulated by major histocompatibility complex 2 (MHCII) production compared to a control; and (b) identifying the cancer as responsive to continued treatment with the PD-1 inhibitor if one or both of parameters (i) and (ii) are detected.
-
Embodiment 25. The method of any one of embodiments 22-24, wherein the IFN signaling genes comprise one or more genes ofFIGS. 17A-C , optionally including one or more of IFIT1/3, IFITM3, IFI44L, PSME2, IFI6, ISG15. - Embodiment 26. The method of any one of embodiments 22-25, wherein the MHC I processing genes comprise one or more of PIK3CD, PSMA7, PSMB8, PSMD9, HLA-A, HLA-B, or HLA-C.
- Embodiment 27. The method of any one of embodiments 22-26, wherein the MHC II processing genes comprise one or more of HLA-DQB1, HLA-DQA1, HLA-DPB1, HLA-DPA1, HLA-DRB1, HLA-DRA, HLA-DMB, or HLA-DMA.
-
Embodiment 28. The method of any one of embodiments 22-27, wherein detecting gene expression comprises one or more of single-cell RNA sequencing, single sample gene set enrichment analysis, Northern blotting, fluorescent in situ hybridization, reverse transcription polymerase chain reaction (RT-PCR), serial analysis of gene expression (SAGE), microarray, or tiling arrays. -
Embodiment 29. The method of any one of embodiments 22-28, wherein detecting a number of cells as fewer or greater than a control comprises one or more of single-cell RNA sequencing, affinity-based pseudotime reconstruction, flow cytometry or immunophenotyping. -
Embodiment 30. The method of any one of embodiments 22-29, further comprising administering one or more doses of a PD-1 inhibitor after the detecting. - Embodiment 31. The method of any one of embodiments 22-30, wherein the PD-1 inhibitor is a PD-1 antibody.
- Embodiment 32. The method of embodiment 31, wherein the PD-1 antibody comprises one or more of pembrolizumab, nivolumab, or cemiplimab.
- Embodiment 33. The method of any one of embodiments 22-32, further comprising selecting the subject for anticancer therapy if the cancer is not identified as responsive to continued treatment with the PD-1 inhibitor, and optionally administering the anticancer therapy to the subject.
- Embodiment 34. The method of embodiment 33, wherein the anticancer therapy comprises one or more of radiation therapy, chemotherapy, surgery, or immunotherapy.
-
Embodiment 35. The method of any one of embodiments 30-34, comprising administering the anticancer therapy to the subject. -
Embodiment 36. The method of any one of embodiments 22-35, wherein the cancer is gastrointestinal cancer. - Embodiment 37. The method of
embodiment 36, wherein the gastrointestinal cancer is selected from colorectal cancer, gastroesophogeal cancer, pancreatic cancer, and biliary cancer. -
Embodiment 38. A system comprising: (a) at least one processor; and (b) at least one memory including program code which when executed by the at least one memory provides operations for performing a method according to any of the preceding embodiments. -
Embodiment 39. The system ofembodiment 38, wherein the operations include: (i) collecting gene expression data associated with a subject; (ii) collecting cell density data associated with a subject; and (iii) providing, via a user interface, a prognosis for the subject based at least in part on detected gene expression and/or cell density. -
Embodiment 40. A method of monitoring response to PD-1 immunotherapy in a subject previously treated with a PD-1 inhibitor, the method comprising: (a) detecting an increase in peripheral blood mononuclear cells (PBMCs) in a sample of peripheral blood from the subject compared to a control; (b) detecting a reduced rate of tumor growth compared to a control, comprising measuring tumor size and/or a level of one or more tumor antigens; and, (c) identifying the cancer as responsive to continued treatment with the PD-1 inhibitor if both of parameters (a) and (b) are detected. - Embodiment 41. The method of
embodiment 40, further comprising administering one or more doses of a PD-1 inhibitor after the detecting. -
Embodiment 42. The method ofembodiment 40, further comprising selecting the subject for anticancer therapy if the cancer is not identified as responsive to continued treatment with the PD-1 inhibitor, and optionally administering the anticancer therapy to the subject.
Claims (19)
1-35. (canceled)
36. A method of detecting a parameter in a sample of peripheral blood from a subject with cancer, the method comprising detecting:
(i) gene expression in monocytes comprising:
(1) increased expression of TNF, FOS, JUN, JUNB, TNFAIP2, TNFAIP3, NFKB1, NFKBIA, NFKBIZ, or a combination of two or more thereof, compared to a control;
(2) decreased expression of IKBKB, compared to a control;
(3) increased expression of MYD88, compared to a control; or
(ii) a greater number of CD8+ differentiated cells, a greater number of CD4+ naive cells, fewer CD4+ differentiated cells, and fewer T follicular helper cells, compared to a control;
(iii) a lower density of total peripheral blood mononuclear cells, a lower density of CD4+ effector memory cells, and a higher density of classical monocytes, compared to a control;
(iv) gene expression in T cells comprising:
(1) increased expression of IFIT1/3, IFITM3, IFI44L, PSME2, IFI6, ISG15, or a combination of two or more thereof, compared to a control;
(2) increased expression of NFKB1, MYD88, NFKBIA, NFKBIZ, or a combination of two or more thereof, compared to a control;
(3) increased expression of PIK3CD, PSMA7, PSMB8, PSMD9, HLA-A, HLA-B, HLA-C, HLA-DQB1, HLA-DQA1, HLA-DPB1, HLA-DPA1, HLA-DRB1, HLA-DRA, HLA-DMB, HLA-DMA, or a combination of two or more thereof, compared to a control;
(4) increased expression of CCL3, CCL4, CCL5, CCR5, or a combination of two or more thereof, compared to a control;
(5) decreased expression of CXCR3, CCR2, or a combination thereof, compared to a control;
(6) increased expression in CD8+ T cells in a cell death gene selected from the group consisting of CASP1, CASP3, CASP7, CASP8, and a combination of two or more thereof, compared to a control;
(7) a greater number of differentiated CD8+ cells, compared to a control; or
(8) fewer differentiated CD4+ cells compared to a control; or
(v) gene expression in monocytes comprising:
(1) increased expression of genes upregulated by IFN stimulation, compared to a control; or
(2) increased expression of genes upregulated by major histocompatibility complex 2 (MCHII) production, compared to a control.
37. The method of claim 36 , wherein the cancer is a gastrointestinal cancer.
38. The method of claim 36 , wherein the cancer is colorectal cancer, gastroesophageal cancer, pancreatic cancer, or biliary cancer.
39. The method of claim 36 , wherein the subject was previously treated with a PD-1 inhibitor.
40. The method of claim 36 , wherein detecting gene expression comprises single-cell RNA sequencing, single sample gene set enrichment analysis, Northern blotting, fluorescent in situ hybridization, reverse transcription polymerase chain reaction, serial analysis of gene expression, microarray, or a tiling array.
41. The method of claim 36 , wherein detecting a number of cells as fewer or greater than a control comprises single-cell RNA sequencing, affinity-based pseudotime reconstruction, flow cytometry, or immunophenotyping.
42. A method of treating cancer in a subject in need thereof, the method comprising:
(A) detecting a parameter in a peripheral blood sample from the subject, comprising detecting:
(i) gene expression in monocytes comprising:
(1) increased expression of TNF, FOS, JUN, JUNB, TNFAIP2, TNFAIP3, NFKB1, NFKBIA, NFKBIZ, or a combination of two or more thereof, compared to a control;
(2) decreased expression of IKBKB, compared to a control;
(3) increased expression of MYD88, compared to a control; or
(ii) a greater number of CD8+ differentiated cells, a greater number of CD4+ naive cells, fewer CD4+ differentiated cells, and fewer T follicular helper cells, compared to a control;
(iii) a lower density of total peripheral blood mononuclear cells, a lower density of CD4+ effector memory cells, and a higher density of classical monocytes, compared to a control;
(iv) gene expression in T cells comprising:
(1) increased expression of IFIT1/3, IFITM3, IFI44L, PSME2, IFI6, ISG15, or a combination of two or more thereof, compared to a control;
(2) increased expression of NFKB1, MYD88, NFKBIA, NFKBIZ, or a combination of two or more thereof, compared to a control;
(3) increased expression of PIK3CD, PSMA7, PSMB8, PSMD9, HLA-A, HLA-B, HLA-C, HLA-DQB1, HLA-DQA1, HLA-DPB1, HLA-DPA1, HLA-DRB1, HLA-DRA, HLA-DMB, HLA-DMA, or a combination of two or more thereof, compared to a control;
(4) increased expression of CCL3, CCL4, CCL5, CCR5, or a combination of two or more thereof, compared to a control;
(5) decreased expression of CXCR3, CCR2, or a combination thereof, compared to a control;
(6) increased expression in CD8+ T cells in a cell death gene selected from the group consisting of CASP1, CASP3, CASP7, CASP8, and a combination of two or more thereof, compared to a control;
(7) a greater number of differentiated CD8+ cells, compared to a control; or
(8) fewer differentiated CD4+ cells compared to a control; or
(v) gene expression in monocytes comprising:
(1) increased expression of genes upregulated by IFN stimulation, compared to a control; or
(2) increased expression of genes upregulated by major histocompatibility complex 2 (MCHII) production, compared to a control; and
(B) administering to the subject an effective amount of a PD-1 inhibitor.
43. The method of claim 42 , wherein the cancer is a gastrointestinal cancer.
44. The method of claim 42 , wherein the cancer is colorectal cancer, gastroesophageal cancer, pancreatic cancer, or biliary cancer.
45. The method of claim 42 , wherein the subject was previously treated with a PD-1 inhibitor.
46. The method of claim 42 , wherein detecting gene expression comprises single-cell RNA sequencing, single sample gene set enrichment analysis, Northern blotting, fluorescent in situ hybridization, reverse transcription polymerase chain reaction, serial analysis of gene expression, microarray, or a tiling array.
47. The method of claim 42 , wherein detecting a number of cells as fewer or greater than a control comprises one or more of single-cell RNA sequencing, affinity-based pseudotime reconstruction, flow cytometry or immunophenotyping.
48. The method of claim 42 , wherein the PD-1 inhibitor is pembrolizumab, nivolumab, or cemiplimab.
49. A method of treating cancer in a subject in need thereof, the method comprising, in order:
(i) administering to the subject an effective amount of a PD-1 inhibitor, and thereafter;
(ii) detecting:
(a) an increase in peripheral blood mononuclear cells in a sample of peripheral blood from the subject, compared to a control;
(b) a reduced rate of tumor growth in the subject, compared to a control; or
(c) an increase in peripheral blood mononuclear cells in a sample of peripheral blood from the subject, compared to a control, and a reduced rate of tumor growth in the subject, compared to a control.
50. The method of claim 49 , further comprising administering to the subject an effective amount of a PD-1 inhibitor after step (ii).
51. The method of claim 49 , wherein the PD-1 inhibitor is pembrolizumab, nivolumab, or cemiplimab.
52. The method of claim 49 , wherein the cancer is a gastrointestinal cancer.
53. The method of claim 49 , wherein the cancer is colorectal cancer, gastroesophageal cancer, pancreatic cancer, or biliary cancer.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US18/325,497 US20230392215A1 (en) | 2019-12-02 | 2023-05-30 | Biomarkers for cancer immunotherapy outcomes |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962942714P | 2019-12-02 | 2019-12-02 | |
US17/110,067 US11708612B2 (en) | 2019-12-02 | 2020-12-02 | Biomarkers for cancer immunotherapy outcomes |
US18/325,497 US20230392215A1 (en) | 2019-12-02 | 2023-05-30 | Biomarkers for cancer immunotherapy outcomes |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US17/110,067 Continuation US11708612B2 (en) | 2019-12-02 | 2020-12-02 | Biomarkers for cancer immunotherapy outcomes |
Publications (1)
Publication Number | Publication Date |
---|---|
US20230392215A1 true US20230392215A1 (en) | 2023-12-07 |
Family
ID=76091574
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US17/110,067 Active 2040-12-25 US11708612B2 (en) | 2019-12-02 | 2020-12-02 | Biomarkers for cancer immunotherapy outcomes |
US18/325,497 Pending US20230392215A1 (en) | 2019-12-02 | 2023-05-30 | Biomarkers for cancer immunotherapy outcomes |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US17/110,067 Active 2040-12-25 US11708612B2 (en) | 2019-12-02 | 2020-12-02 | Biomarkers for cancer immunotherapy outcomes |
Country Status (1)
Country | Link |
---|---|
US (2) | US11708612B2 (en) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP4367268A1 (en) * | 2021-07-07 | 2024-05-15 | Evaxion Biotech A/S | Method for predicting response to cancer immunotherapy |
WO2023215571A1 (en) * | 2022-05-06 | 2023-11-09 | Memorial Sloan-Kettering Cancer Center | Integration of radiologic, pathologic, and genomic features for prediction of response to immunotherapy |
CN116497117A (en) * | 2022-09-19 | 2023-07-28 | 苏州系统医学研究所 | Application of MFSD2A as marker in preparation, screening or treatment of gastric cancer drugs |
-
2020
- 2020-12-02 US US17/110,067 patent/US11708612B2/en active Active
-
2023
- 2023-05-30 US US18/325,497 patent/US20230392215A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
US20210164054A1 (en) | 2021-06-03 |
US11708612B2 (en) | 2023-07-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11708612B2 (en) | Biomarkers for cancer immunotherapy outcomes | |
JP7401710B2 (en) | System and method for identifying cancer treatment from normalized biomarker scores | |
US9128096B2 (en) | Methods for determining cancer resistance to histone deacetylase inhibitors | |
US8445198B2 (en) | Methods, kits and devices for identifying biomarkers of treatment response and use thereof to predict treatment efficacy | |
JP5984324B2 (en) | Method and apparatus for identifying biomarkers of therapeutic response and use thereof for estimating therapeutic effect | |
US20200297728A1 (en) | Methods of treating cancer | |
KR20200096921A (en) | Adenosine pathway inhibitors for cancer treatment | |
JP2023534094A (en) | Cell-free RNA analysis method | |
US20220057400A1 (en) | Il-6 signaling and breast cancer | |
JP2022539019A (en) | PDL1 positive NK cell cancer treatment | |
US20180238886A1 (en) | Methods for treating hematological cancer and the use of biomarkers as a predictor for responsiveness to treatment compounds | |
US20220347278A1 (en) | Blood-based biomarkers and use thereof for treating cancer | |
WO2022082048A1 (en) | Methods of treating breast cancer | |
US20230175072A1 (en) | 3 flap okazaki fragments and uses thereof | |
JPWO2021257729A5 (en) | ||
WO2023275173A1 (en) | Inhibitors of bruton's tyrosine kinase and methods of their use | |
WO2022246000A1 (en) | Compositions and methods for determining dna methylation level in cancer | |
TW202328457A (en) | Compositions and methods for cell-free dna epigenetic gastrointestinal cancer detection and treatment | |
WO2022235701A1 (en) | Gene expression profiling methods and compositions for determining cancer and treatment thereof | |
CN117916596A (en) | Method for analyzing target molecules in biological fluid | |
WO2023076574A1 (en) | Tumor microenvironment types in breast cancer | |
WO2022165440A2 (en) | Treatment of neuroendocrine cancers | |
WO2022046792A2 (en) | Methods and compositions for genetic modulation of tumor microenvironments | |
WO2022183069A9 (en) | Development of prmt-targeting therapy to enhance egfr-targeting drug efficacy in nsclc |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |
|
AS | Assignment |
Owner name: CITY OF HOPE, CALIFORNIA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:BILD, ANDREA;GRIFFITHS, JASON I.;SIGNING DATES FROM 20191217 TO 20200227;REEL/FRAME:065804/0803 |